data_2ge4_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ge4 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 p . . . . . 0 N--CA 1.461 0.089 0 CA-C-O 120.919 0.39 . . . . 0.0 110.664 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.484 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 18.6 p90 -125.44 164.22 20.92 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.577 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.432 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 22.5 p90 -155.2 156.6 35.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.77 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 44.4 p -149.13 150.51 32.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.737 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.0 -162.98 23.26 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.245 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.99 153.5 51.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.543 -0.329 . . . . 0.0 110.584 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.97 149.41 47.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.181 0.515 . . . . 0.0 111.739 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.734 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.872 0.368 . . . . 0.0 111.193 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -173.91 -174.74 41.04 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.374 -0.917 . . . . 0.0 113.325 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.67 154.15 48.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.836 -0.182 . . . . 0.0 110.612 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -159.24 163.75 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.326 0.584 . . . . 0.0 112.112 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.25 161.16 30.65 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.27 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.432 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -158.0 165.08 33.57 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.711 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -120.16 134.93 55.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.517 -0.342 . . . . 0.0 110.409 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -95.05 125.77 39.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.337 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -92.94 -38.42 9.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.415 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -155.01 177.93 1.84 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.165 179.888 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.417 ' HB2' ' CD1' ' A' ' 48' ' ' TYR . 31.2 Cg_exo -60.14 -23.53 73.94 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.707 2.271 . . . . 0.0 113.644 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CD1' ' HB2' ' A' ' 47' ' ' PRO . 69.3 m-85 -127.59 2.31 6.17 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 26.9 m -137.77 115.94 13.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.844 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.44 179.83 19.9 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.51 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -129.03 151.41 49.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.522 0.201 . . . . 0.0 110.556 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -152.03 138.49 18.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.045 0.45 . . . . 0.0 111.789 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 1.3 ptm -126.72 156.8 40.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.919 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.37 159.78 30.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.593 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 12.4 t80 . . . . . 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.587 179.922 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.731 0.3 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -127.81 136.43 51.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.027 0.441 . . . . 0.0 110.844 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.0 pp -131.22 130.87 43.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.843 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.6 p -151.74 173.13 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.464 0.65 . . . . 0.0 111.874 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.56 141.24 39.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.905 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.8 mttp -108.02 126.98 53.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.493 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 20.9 mt -129.8 110.68 11.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.402 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.96 169.36 22.56 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.41 -0.9 . . . . 0.0 113.109 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 35.0 m-85 -123.72 137.67 29.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 110.548 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -84.43 99.4 0.75 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.707 2.271 . . . . 0.0 112.613 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.446 HG23 HD11 ' A' ' 87' ' ' ILE . 33.5 mt -81.28 -34.63 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.057 0.456 . . . . 0.0 110.442 179.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 27.9 m -148.0 164.78 32.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.184 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 -60.13 -27.66 67.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.478 0.18 . . . . 0.0 111.485 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.414 ' HB3' ' CZ ' ' A' ' 129' ' ' TYR . 1.6 m-20 -112.02 -33.78 6.17 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -178.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.1 tt -102.85 123.84 47.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.941 0.4 . . . . 0.0 111.716 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -135.69 164.14 28.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.261 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 1.7 pp -119.6 142.93 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.003 179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.431 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 6.7 m-85 -143.4 157.49 44.42 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.706 0.765 . . . . 0.0 112.715 -178.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.6 m -141.14 136.26 31.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 114.542 -1.208 . . . . 0.0 109.029 178.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.13 139.58 51.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.963 0.411 . . . . 0.0 111.384 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.0 mp -140.82 119.18 12.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.736 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -166.13 -141.84 3.26 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.296 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.44 23.35 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.317 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.8 ttt . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.991 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.408 ' CD1' ' N ' ' A' ' 123' ' ' PHE . 3.5 p90 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.781 0.324 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -142.18 164.2 30.8 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.252 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -149.04 141.95 9.42 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.122 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.25 -155.0 16.92 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 119.87 -1.157 . . . . 0.0 113.358 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 30.1 m -139.71 148.17 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.974 0.416 . . . . 0.0 111.25 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -124.51 132.2 53.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.642 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . 0.414 ' CZ ' ' HB3' ' A' ' 90' ' ' ASP . 45.0 t80 -128.27 148.33 50.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.418 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 116.37 32.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.818 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 7.8 tp -88.57 -36.58 9.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.402 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -162.36 165.09 16.14 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.854 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 132' ' ' THR . 11.7 Cg_endo -55.2 141.59 80.08 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.596 2.197 . . . . 0.0 112.074 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 58.54 19.01 6.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.531 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.474 HD11 HG22 ' A' ' 135' ' ' ILE . 31.1 mt -149.13 111.95 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 121.018 0.437 . . . . 0.0 111.718 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -124.42 156.13 37.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.836 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.6 m -142.83 136.26 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.5 ptt85 -146.15 157.94 43.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.253 0.549 . . . . 0.0 112.038 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 1.9 tt -128.18 139.86 52.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.596 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -147.35 158.18 43.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.177 0.513 . . . . 0.0 111.693 -179.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.869 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.118 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 17.8 m -136.73 157.54 46.52 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.331 0.586 . . . . 0.0 112.015 -179.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 10.9 tp -141.69 127.87 19.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.673 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.98 161.75 27.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.09 -1.052 . . . . 0.0 113.431 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.2 m -106.16 147.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 22.4 p -134.54 146.11 49.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.159 0.504 . . . . 0.0 111.608 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -113.61 131.63 56.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.786 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -108.54 117.12 33.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.955 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 4.0 t80 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.975 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 67.5 p . . . . . 0 N--CA 1.463 0.216 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 12.9 p90 -128.01 164.18 22.93 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.641 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.418 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 5.3 p90 -155.29 156.63 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 t -149.17 150.21 32.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.71 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.75 -161.94 22.24 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.465 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -130.46 159.38 37.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.537 -0.331 . . . . 0.0 110.608 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -142.26 150.05 40.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.216 0.532 . . . . 0.0 112.003 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 6.6 tt . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.548 179.129 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.793 0.33 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.18 -159.4 31.86 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.357 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -135.1 155.08 51.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.543 0.211 . . . . 0.0 110.668 179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -159.29 163.66 35.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.289 0.566 . . . . 0.0 111.907 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -140.61 158.84 26.24 Favored Glycine 0 N--CA 1.448 -0.544 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.35 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.418 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.67 150.13 21.75 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.509 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 6.9 m-85 -117.35 131.79 56.72 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -94.64 126.46 39.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.236 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.01 -36.9 7.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.769 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.436 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -152.76 179.21 1.32 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.154 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.436 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 39.3 Cg_exo -61.47 -26.89 81.62 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.684 2.256 . . . . 0.0 113.692 -179.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 11.3 p90 -124.53 4.11 8.31 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 -178.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.424 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 3.7 m -137.74 116.11 13.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.862 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.35 179.41 19.56 Favored Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.439 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -130.23 152.38 49.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.62 0.248 . . . . 0.0 110.767 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -150.38 136.71 18.77 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.09 0.471 . . . . 0.0 111.528 -179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 5.1 mpp? -132.35 114.39 14.32 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.327 179.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -119.09 164.02 13.23 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.431 -0.89 . . . . 0.0 113.39 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 17.9 p90 . . . . . 0 C--N 1.331 -0.221 0 CA-C-O 120.796 0.331 . . . . 0.0 110.828 179.983 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 30.9 m . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.735 0.302 . . . . 0.0 111.151 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.0 pm0 -131.72 139.33 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 7.7 tt -127.11 132.13 50.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.803 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -151.62 173.06 15.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.44 0.638 . . . . 0.0 111.978 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.54 141.44 39.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.862 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -108.83 126.44 53.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.874 0.369 . . . . 0.0 111.447 -179.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 2.4 mt -131.61 110.09 10.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.239 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.1 177.53 19.48 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.773 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.434 ' N ' ' CD1' ' A' ' 85' ' ' TYR . 3.4 m-85 -131.76 140.63 38.87 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.659 0.266 . . . . 0.0 110.475 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -87.56 106.72 0.61 Allowed 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.836 2.357 . . . . 0.0 112.826 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 26.4 pt -80.22 -33.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.433 ' CG2' ' CB ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -150.65 169.68 21.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.05 178.914 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -64.17 -23.31 67.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.079 0.399 . . . . 0.0 112.079 -179.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.42 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -110.94 -28.22 8.45 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 -178.708 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.433 ' CB ' ' CG2' ' A' ' 88' ' ' THR . 0.5 OUTLIER -109.34 126.37 53.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.138 0.494 . . . . 0.0 111.924 -179.086 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.24 152.52 50.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.001 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 12.0 tt -123.11 142.12 40.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.907 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.42 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 28.5 p90 -153.22 170.21 21.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.719 0.771 . . . . 0.0 113.021 -179.017 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 p -139.62 141.91 37.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.62 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 46.1 mtp180 -117.3 137.39 52.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.882 0.372 . . . . 0.0 111.067 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -139.86 120.03 13.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.856 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -141.06 3.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.338 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.17 151.89 23.78 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.591 -0.814 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 2.4 ppp? . . . . . 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.955 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.841 0.353 . . . . 0.0 110.818 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -151.94 149.48 28.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.21 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.91 138.65 7.44 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.075 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.38 -158.5 22.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 119.996 -1.097 . . . . 0.0 113.264 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 18.8 m -141.89 149.78 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.134 0.492 . . . . 0.0 111.474 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -125.27 131.37 53.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.504 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . 0.42 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 42.6 t80 -126.89 146.98 50.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.319 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.4 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.84 114.53 27.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.81 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -87.03 -39.18 12.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.009 0.433 . . . . 0.0 110.933 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -159.59 169.75 9.88 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.729 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.41 139.94 92.57 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.52 2.147 . . . . 0.0 112.214 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 59.71 17.72 6.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.842 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 tt -149.21 113.93 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.114 0.483 . . . . 0.0 111.721 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.71 157.86 40.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.084 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 3.2 t -124.9 141.11 52.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.534 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 25.0 mtt180 -135.16 134.59 40.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.124 0.488 . . . . 0.0 111.815 -179.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.3 tt -130.06 130.78 45.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.543 179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -153.53 169.42 23.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.392 0.615 . . . . 0.0 112.017 -179.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . 0.414 ' CZ ' ' HG ' ' A' ' 162' ' ' LEU . 4.1 m-85 . . . . . 0 C--N 1.327 -0.39 0 CA-C-N 115.21 -0.904 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.414 ' HG ' ' CZ ' ' A' ' 141' ' ' TYR . 7.2 tt . . . . . 0 C--O 1.23 0.055 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 28.3 t -132.69 154.2 50.39 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.199 0.523 . . . . 0.0 111.78 -179.267 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 8.0 tt -144.66 122.7 12.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.853 179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.12 163.83 26.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.245 -0.978 . . . . 0.0 113.24 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.8 m -105.06 146.83 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -135.14 143.42 46.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.096 0.474 . . . . 0.0 111.67 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -109.61 132.68 53.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.687 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.12 29.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.89 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.8 t80 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.893 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.8 p . . . . . 0 N--CA 1.462 0.166 0 CA-C-O 120.889 0.376 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.487 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 9.2 p-90 -126.68 164.58 20.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.561 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.433 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 2.8 p90 -155.34 158.35 38.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.966 179.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 t -149.14 149.54 31.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.401 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -169.68 -162.94 22.86 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.399 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.6 155.43 48.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.601 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.424 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 14.2 pttt -139.5 153.14 47.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.299 0.571 . . . . 0.0 112.276 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 48.3 tp . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.268 179.085 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.851 0.358 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.71 -162.78 35.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.306 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.86 155.1 45.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.717 -0.241 . . . . 0.0 110.7 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.424 ' CE1' ' HB3' ' A' ' 12' ' ' LYS . 27.3 p90 -159.13 157.72 31.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.304 0.573 . . . . 0.0 112.01 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -147.47 159.86 28.14 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.319 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.433 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -155.26 161.29 30.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 119.824 -1.179 . . . . 0.0 113.602 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 13.1 t80 -123.05 133.72 54.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.252 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -95.07 125.62 39.86 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.272 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 t -93.24 -37.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.961 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.425 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.1 t30 -153.92 178.32 1.66 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.424 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.4 Cg_exo -60.1 -25.97 81.24 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.679 2.252 . . . . 0.0 113.64 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.409 ' CD1' ' HB2' ' A' ' 47' ' ' PRO . 17.9 m-85 -127.46 3.99 6.24 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.425 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 4.3 m -138.04 115.06 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.819 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.65 -177.23 18.4 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.466 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.59 150.04 49.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.559 0.219 . . . . 0.0 110.629 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -146.57 134.25 21.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.039 0.447 . . . . 0.0 111.375 -179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -128.43 153.68 46.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.339 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.61 158.84 30.02 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.191 -1.004 . . . . 0.0 113.116 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 7.3 p90 . . . . . 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.863 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.684 0.278 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -130.22 140.43 50.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.048 0.451 . . . . 0.0 111.091 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -129.85 132.1 46.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.968 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.3 t -151.43 170.11 20.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.523 0.678 . . . . 0.0 112.09 -179.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.94 144.22 35.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.946 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -110.14 125.26 52.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -130.89 108.15 9.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.209 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.461 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -134.99 176.89 19.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.232 -0.985 . . . . 0.0 113.658 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 6.5 m-85 -128.07 140.18 37.52 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.661 0.267 . . . . 0.0 110.606 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -87.87 103.72 0.51 Allowed 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.772 2.315 . . . . 0.0 112.634 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 41.6 pt -82.14 -30.64 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.042 0.448 . . . . 0.0 110.337 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.47 167.31 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.177 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -64.94 -23.45 67.23 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.423 ' HB3' ' CE1' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -112.07 -37.31 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.02 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 15.3 tp -102.94 125.73 49.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.984 0.421 . . . . 0.0 111.656 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -133.54 161.02 35.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.186 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 2.6 pp -125.66 143.23 39.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.035 179.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.461 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 10.2 p90 -155.1 170.27 22.2 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.723 0.773 . . . . 0.0 113.003 -178.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.3 p -139.39 143.05 37.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.714 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 68.5 mtm180 -118.69 139.06 52.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.012 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 6.7 tp -141.25 120.84 13.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.1 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -164.8 -149.04 5.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.347 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.56 152.25 24.35 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.107 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.2 ptt? . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.829 0.347 . . . . 0.0 110.848 -179.889 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 t80 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -151.48 148.5 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.221 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.95 138.88 7.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.111 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.65 -156.96 20.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.002 -1.094 . . . . 0.0 113.299 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 28.9 m -141.54 147.9 21.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.043 0.449 . . . . 0.0 111.335 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.402 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 21.6 tt0 -124.05 132.11 53.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.703 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . 0.423 ' CE1' ' HB3' ' A' ' 90' ' ' ASP . 70.9 t80 -126.09 146.4 49.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.176 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.39 116.15 31.68 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.808 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.2 pt -92.8 -30.99 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.611 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.421 ' CG2' ' HD2' ' A' ' 133' ' ' PRO . 0.2 OUTLIER -147.13 169.27 9.65 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.499 179.916 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.421 ' HD2' ' CG2' ' A' ' 132' ' ' THR . 53.1 Cg_exo -55.91 -60.95 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.575 2.183 . . . . 0.0 112.843 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -98.05 23.85 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.708 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 4.3 mp -146.46 117.6 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.053 0.454 . . . . 0.0 111.651 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.12 161.86 29.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.082 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.9 p -135.93 140.59 44.14 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.407 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.65 144.04 32.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.237 0.542 . . . . 0.0 112.041 -179.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 2.6 tt -124.83 136.34 53.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.598 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -146.0 156.44 43.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.227 0.537 . . . . 0.0 111.807 -179.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.536 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 8.4 mp . . . . . 0 C--O 1.23 0.079 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 22.5 m -132.31 152.7 51.28 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.201 0.524 . . . . 0.0 111.627 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 2.7 tt -143.81 123.86 13.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.775 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.55 164.75 27.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.24 -0.981 . . . . 0.0 113.456 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.401 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 25.9 m -105.45 147.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 30.0 p -134.78 145.91 48.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.125 0.488 . . . . 0.0 111.761 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -112.12 131.96 55.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.738 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -108.51 116.79 32.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.025 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 3.1 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 -179.955 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.462 0.127 0 CA-C-O 120.957 0.408 . . . . 0.0 110.811 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 7.2 t90 -113.1 161.07 17.53 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.317 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.471 ' CZ ' ' HB2' ' A' ' 169' ' ' ARG . 0.1 OUTLIER -145.12 141.62 28.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 m -147.56 144.42 28.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.698 0.285 . . . . 0.0 111.189 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -173.82 -157.58 15.82 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.295 -0.955 . . . . 0.0 113.256 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -134.02 155.44 49.98 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.659 -0.271 . . . . 0.0 110.746 179.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.406 ' HB2' ' CD1' ' A' ' 40' ' ' PHE . 1.7 mmmm -139.16 153.15 47.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.147 0.498 . . . . 0.0 111.966 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 mp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.516 179.139 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.18 0 CA-C-O 120.79 0.329 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.01 -159.78 32.47 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.28 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.4 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -114.51 151.63 33.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.921 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.431 ' CD2' ' HA3' ' A' ' 54' ' ' GLY . 61.2 m-85 -151.23 149.88 29.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.03 0.443 . . . . 0.0 111.692 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.04 156.75 28.63 Favored Glycine 0 N--CA 1.45 -0.417 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -157.04 154.67 25.73 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 119.783 -1.199 . . . . 0.0 113.771 -179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -107.21 133.63 51.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.5 -0.35 . . . . 0.0 110.086 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -96.13 125.91 40.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.453 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.0 t -94.78 -36.44 6.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.493 ' HB2' HG21 ' A' ' 49' ' ' VAL . 0.8 OUTLIER -156.6 173.37 5.03 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.688 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.471 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 25.9 Cg_endo -62.82 -15.31 46.21 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 122.227 1.952 . . . . 0.0 113.551 -179.085 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -126.86 -4.76 6.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.493 HG21 ' HB2' ' A' ' 46' ' ' ASN . 11.6 m -139.07 117.48 12.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.97 -179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.6 -179.37 18.67 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.369 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -128.87 149.59 50.7 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.636 0.255 . . . . 0.0 110.414 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -149.37 137.01 20.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.004 0.43 . . . . 0.0 111.616 -179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -128.23 156.72 42.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.212 179.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.431 ' HA3' ' CD2' ' A' ' 40' ' ' PHE . . . -159.03 157.54 28.58 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.142 -1.028 . . . . 0.0 113.199 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 13.9 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-O 120.873 0.368 . . . . 0.0 110.841 -179.945 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 24.8 t . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.709 0.29 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -128.11 134.14 49.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.007 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 2.4 mt -128.92 130.28 46.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.842 179.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.7 p -151.38 173.1 14.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.461 0.648 . . . . 0.0 111.99 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -109.0 142.91 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.001 179.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -109.07 126.17 52.89 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.877 0.37 . . . . 0.0 111.479 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.0 mp -129.15 112.17 13.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.248 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -135.72 170.85 22.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.217 -0.992 . . . . 0.0 113.474 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -124.3 139.07 32.05 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.639 0.257 . . . . 0.0 110.517 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -85.31 100.04 0.68 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.708 2.272 . . . . 0.0 112.704 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.2 mp -80.36 -35.04 15.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.135 0.493 . . . . 0.0 110.309 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 27.8 m -148.62 164.88 32.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.164 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -60.71 -24.8 65.95 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.574 0.212 . . . . 0.0 111.574 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.441 ' CB ' ' CE2' ' A' ' 129' ' ' TYR . 10.8 m-20 -113.08 -33.52 6.0 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.087 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 6.8 tp -102.89 123.58 46.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.903 0.383 . . . . 0.0 111.793 -179.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -134.03 160.81 36.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.297 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -120.41 142.88 34.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.984 179.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.421 ' CE1' ' HB2' ' A' ' 128' ' ' GLU . 47.2 p90 -147.15 163.49 36.14 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.653 0.74 . . . . 0.0 112.872 -178.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -140.58 139.64 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.363 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.51 135.04 54.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.891 0.377 . . . . 0.0 111.003 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.37 118.21 11.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.836 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.86 -144.19 3.99 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.298 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -150.03 151.09 23.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.205 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 p90 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -156.17 150.82 25.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.207 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.45 139.3 7.75 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.126 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.37 -156.57 19.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.248 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 29.4 m -138.88 148.25 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.161 0.505 . . . . 0.0 111.267 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.421 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 40.1 tt0 -124.62 131.93 53.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.715 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . 0.441 ' CE2' ' CB ' ' A' ' 90' ' ' ASP . 48.8 t80 -127.9 147.59 50.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.239 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 117.0 34.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.859 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 29.6 pt -89.57 -33.59 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.069 0.462 . . . . 0.0 110.671 179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -147.37 174.58 3.29 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.52 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -54.17 -62.08 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.586 2.191 . . . . 0.0 112.75 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -100.15 31.52 3.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.629 -179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.4 HD11 ' N ' ' A' ' 135' ' ' ILE . 4.5 mp -145.99 115.52 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.952 0.406 . . . . 0.0 111.555 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.07 150.13 52.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.924 179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.31 141.66 51.95 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.641 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -134.2 140.48 46.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.104 0.478 . . . . 0.0 111.687 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.5 pp -132.68 130.54 40.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.511 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -151.68 168.21 25.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.301 0.572 . . . . 0.0 111.933 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . 0.442 ' CD1' ' N ' ' A' ' 141' ' ' TYR . 2.7 m-85 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.911 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.463 0.215 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.8 m -132.44 154.12 50.17 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.292 0.568 . . . . 0.0 111.891 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 2.6 mp -145.3 122.52 11.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.865 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -141.88 165.18 26.62 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.25 -0.976 . . . . 0.0 113.465 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.41 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 8.8 p -111.37 147.19 15.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' SER . . . . . 0.42 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 5.3 t -136.33 151.54 49.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.294 0.568 . . . . 0.0 112.175 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -119.49 133.63 55.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.838 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . 0.471 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 2.0 ttp180 -106.97 121.61 44.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.295 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 9.0 t80 . . . . . 0 C--N 1.33 -0.253 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.935 -179.961 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.46 0.061 0 CA-C-O 120.79 0.329 . . . . 0.0 110.455 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 35.7 p90 -127.92 164.16 22.89 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.798 -179.204 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.42 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 4.0 p90 -155.24 157.16 36.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.907 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.02 150.86 33.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.741 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.89 -164.93 27.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.332 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.53 154.14 49.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.628 -0.286 . . . . 0.0 110.568 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.416 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . 0.9 OUTLIER -138.32 150.48 46.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.186 0.517 . . . . 0.0 111.809 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.9 mp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.628 179.248 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.821 0.343 . . . . 0.0 111.256 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.62 -173.26 42.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.385 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 153.45 52.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.716 -0.242 . . . . 0.0 110.598 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 12' ' ' LYS . 6.2 p90 -159.42 166.33 31.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.225 0.536 . . . . 0.0 112.016 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -148.08 160.03 28.21 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.53 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.1 159.88 28.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.363 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -124.85 132.13 53.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.569 -0.315 . . . . 0.0 110.276 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -95.48 126.22 40.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.119 179.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.8 t -96.24 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.0 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.493 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 3.3 m-20 -103.54 171.27 5.28 Favored Pre-proline 0 C--N 1.332 -0.185 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.192 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.493 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 10.1 Cg_endo -51.52 128.8 27.15 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.683 2.255 . . . . 0.0 113.085 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.416 ' CE1' ' HG3' ' A' ' 86' ' ' PRO . 1.4 m-85 59.88 16.32 5.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.407 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.8 m -138.95 113.96 8.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.843 -0.343 . . . . 0.0 111.385 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.3 -172.86 14.48 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.777 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -130.3 154.31 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.561 0.22 . . . . 0.0 110.602 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -150.4 138.14 19.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.482 . . . . 0.0 111.733 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -130.46 113.53 14.41 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.261 179.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.03 159.65 14.14 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.406 -0.902 . . . . 0.0 113.189 -179.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 47.8 p90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 120.804 0.335 . . . . 0.0 110.846 179.975 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 31.1 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.706 0.289 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -130.29 137.34 49.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.075 0.464 . . . . 0.0 111.028 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -125.34 130.16 51.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.702 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.7 p -151.35 173.01 15.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.492 0.663 . . . . 0.0 111.924 -179.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.0 141.98 37.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.922 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -108.26 125.57 51.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.82 0.343 . . . . 0.0 111.403 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 2.4 tp -130.31 112.44 13.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.397 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.421 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.49 171.17 22.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.434 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -123.99 138.94 31.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.715 0.293 . . . . 0.0 110.598 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.416 ' HG3' ' CE1' ' A' ' 48' ' ' TYR . 95.1 Cg_endo -84.6 98.89 0.72 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.73 2.286 . . . . 0.0 112.675 -179.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 24.0 mm -79.06 -36.66 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.032 0.444 . . . . 0.0 110.365 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.51 164.45 34.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.177 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -60.61 -24.02 65.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.524 0.202 . . . . 0.0 111.314 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.423 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 2.7 m-20 -113.6 -35.06 5.34 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -102.86 123.48 46.59 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.944 0.402 . . . . 0.0 111.758 -179.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -133.69 161.25 35.19 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.292 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 2.7 pt -121.44 142.51 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.979 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.421 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 40.4 p90 -147.8 165.34 30.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.69 0.757 . . . . 0.0 112.895 -178.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -144.32 140.66 29.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.399 -1.273 . . . . 0.0 109.445 179.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.5 mtm-85 -118.81 137.44 53.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 111.18 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.403 ' HB3' ' CE1' ' A' ' 123' ' ' PHE . 0.5 OUTLIER -139.5 119.7 13.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.918 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -166.32 -141.6 3.19 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.352 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.34 150.58 22.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.55 -0.833 . . . . 0.0 113.251 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.8 ptp . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.945 -179.917 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.403 ' CE1' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.715 0.293 . . . . 0.0 110.752 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -155.41 146.57 22.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.325 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.2 138.94 7.55 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.188 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.21 -155.77 18.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.044 -1.074 . . . . 0.0 113.243 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 29.8 m -138.71 147.97 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.008 0.432 . . . . 0.0 111.258 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -124.77 132.2 53.38 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.692 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 34.7 t80 -125.87 145.95 50.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.047 -179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.404 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.86 115.58 29.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.952 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 21.4 pt -89.88 -33.11 5.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.036 0.446 . . . . 0.0 110.408 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.445 ' CG2' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -149.25 165.16 18.34 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.187 179.682 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.445 ' HD2' ' CG2' ' A' ' 132' ' ' THR . 9.6 Cg_endo -53.17 -56.25 2.93 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -95.75 17.07 15.8 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.426 ' HB ' ' OG1' ' A' ' 132' ' ' THR . 3.5 mp -144.3 120.61 4.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.061 0.458 . . . . 0.0 111.897 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.13 154.05 48.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.814 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.2 p -125.06 142.19 51.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.618 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 24.9 mtt180 -138.66 135.23 34.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.067 0.46 . . . . 0.0 111.873 -179.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.5 mp -124.67 133.89 53.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.574 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -151.76 167.63 27.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.307 0.575 . . . . 0.0 112.005 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . 0.444 ' N ' ' CD1' ' A' ' 141' ' ' TYR . 2.9 m-85 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.851 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.7 mp . . . . . 0 C--O 1.232 0.178 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -131.77 152.54 50.88 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.315 0.579 . . . . 0.0 111.861 -179.288 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 3.9 pp -142.45 122.54 13.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.673 179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.17 163.68 27.02 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.236 -0.983 . . . . 0.0 113.485 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.403 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 21.8 t -106.14 146.94 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.5 p -134.87 145.73 48.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.469 . . . . 0.0 111.739 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.5 m-85 -114.64 131.39 56.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.773 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.55 118.64 37.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.021 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.882 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.463 0.208 0 CA-C-O 121.076 0.465 . . . . 0.0 111.634 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.6 m-90 -125.19 166.67 16.04 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.562 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.487 ' N ' ' O ' ' A' ' 42' ' ' GLY . 1.5 p90 -155.62 163.03 40.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.16 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 m -149.22 152.75 36.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.519 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.401 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -171.49 -160.36 19.86 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 119.894 -1.146 . . . . 0.0 113.426 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.27 153.92 51.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.631 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.6 mmmp? -137.58 149.8 46.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.119 0.485 . . . . 0.0 111.567 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.1 mp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.662 179.272 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.888 0.375 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.21 -167.54 38.26 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.301 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.408 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -119.02 153.03 35.34 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.477 0.18 . . . . 0.0 110.75 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.427 ' CZ ' ' HA3' ' A' ' 54' ' ' GLY . 1.7 m-85 -154.72 142.69 20.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.158 0.504 . . . . 0.0 111.619 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -140.61 156.94 25.55 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.535 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -155.57 165.07 32.36 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.215 -0.993 . . . . 0.0 112.82 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 1.4 p90 -146.06 139.27 25.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.921 0.391 . . . . 0.0 111.373 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -94.96 124.67 39.14 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.533 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 10.9 m -98.49 -37.0 6.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.72 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.483 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.9 OUTLIER -149.39 170.11 8.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.359 -179.828 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.483 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 6.2 Cg_endo -48.64 120.5 5.3 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.826 2.351 . . . . 0.0 113.26 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.407 ' CD1' ' N ' ' A' ' 48' ' ' TYR . 0.9 OUTLIER 58.38 18.37 5.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.561 -0.745 . . . . 0.0 112.33 178.85 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.431 ' CG2' ' CB ' ' A' ' 46' ' ' ASN . 4.9 m -138.71 112.96 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.826 0.346 . . . . 0.0 111.451 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.45 -172.36 15.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . 0.418 ' HB2' ' CZ ' ' A' ' 43' ' ' TYR . 20.9 m-85 -128.38 151.43 49.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.662 0.268 . . . . 0.0 110.518 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -145.87 135.23 23.0 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.026 0.441 . . . . 0.0 111.47 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 15.1 ttp -129.73 154.71 46.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.331 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.427 ' HA3' ' CZ ' ' A' ' 40' ' ' PHE . . . -160.72 159.31 30.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.265 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.1 t80 . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.897 -179.983 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 N--CA 1.458 -0.071 0 CA-C-O 120.736 0.303 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -128.23 135.27 49.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 111.047 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -130.85 130.76 44.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.888 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.4 ' HA ' ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.37 173.05 14.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.492 0.663 . . . . 0.0 111.989 -179.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.75 144.35 35.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.986 178.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . 0.42 ' HE2' ' CD2' ' A' ' 94' ' ' TYR . 0.3 OUTLIER -110.24 125.29 52.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.381 . . . . 0.0 111.479 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 6.2 tp -130.64 110.06 11.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.263 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.444 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.02 175.29 20.95 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.71 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -129.09 139.87 36.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.694 0.283 . . . . 0.0 110.576 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -86.63 104.18 0.66 Allowed 'Trans proline' 0 N--CA 1.46 -0.465 0 C-N-CA 122.786 2.324 . . . . 0.0 112.736 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 40.3 pt -81.11 -33.75 13.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.162 0.506 . . . . 0.0 110.353 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.36 164.3 33.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.151 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -60.59 -25.09 65.96 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.448 ' CB ' ' CE2' ' A' ' 129' ' ' TYR . 1.0 OUTLIER -112.74 -30.85 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.104 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 13.4 tp -102.96 123.59 46.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.614 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -131.62 154.97 48.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.369 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 25.6 pt -123.07 142.62 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.873 179.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.444 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 19.3 p90 -152.83 170.15 21.05 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.752 0.786 . . . . 0.0 113.073 -178.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.4 p -141.5 142.5 33.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.295 -1.321 . . . . 0.0 109.53 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.14 137.49 52.93 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.964 0.412 . . . . 0.0 111.001 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.3 tt -139.77 119.25 13.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.814 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.4 ' HA3' ' HA ' ' A' ' 80' ' ' THR . . . -164.98 -144.52 4.08 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.233 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -152.9 152.6 24.24 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.491 -0.862 . . . . 0.0 113.292 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.3 ttt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.845 -179.904 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 9.6 t80 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.79 0.328 . . . . 0.0 110.816 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -152.14 147.1 26.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.249 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.6 138.82 7.62 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.14 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.1 -157.96 21.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.314 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 28.4 m -138.38 147.99 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.052 0.453 . . . . 0.0 111.255 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -125.35 131.1 53.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.777 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . 0.448 ' CE2' ' CB ' ' A' ' 90' ' ' ASP . 38.0 t80 -126.86 146.59 50.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.408 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.89 115.65 29.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 19.8 pt -89.27 -34.82 7.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.958 0.408 . . . . 0.0 110.7 179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.402 ' CG2' ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -146.65 172.98 4.59 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.555 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.402 ' CD ' ' CG2' ' A' ' 132' ' ' THR . 50.5 Cg_exo -54.4 -61.86 0.36 Allowed 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.517 2.145 . . . . 0.0 112.757 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -99.84 25.44 7.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.777 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 4.0 mp -144.24 116.06 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.979 0.419 . . . . 0.0 111.565 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -127.35 158.48 37.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.972 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 26.0 p -141.49 138.42 32.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.41 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.22 150.92 35.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.131 0.491 . . . . 0.0 111.944 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.3 mp -118.34 139.81 50.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.723 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.426 ' HG3' ' CZ ' ' A' ' 94' ' ' TYR . 0.1 OUTLIER -143.15 149.94 38.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 111.567 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 6.2 m-85 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.91 179.932 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.08 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 85.2 p -132.7 155.54 48.63 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.331 0.586 . . . . 0.0 111.885 -179.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -142.76 125.2 15.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.692 179.125 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.4 163.7 27.45 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.477 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.401 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 23.3 m -108.89 147.93 13.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 11.3 t -136.21 147.0 47.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.488 . . . . 0.0 111.852 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.746 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 3.0 ptm180 -108.2 119.13 38.6 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.103 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 179.994 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 N--CA 1.461 0.086 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.6 p-90 -124.52 163.87 20.96 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.523 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 42' ' ' GLY . 33.0 p90 -155.25 156.62 35.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.93 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 p -149.26 151.93 35.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.98 -160.73 21.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 119.904 -1.141 . . . . 0.0 113.32 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.412 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -127.11 154.45 44.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.524 -0.338 . . . . 0.0 110.512 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -142.21 146.08 34.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.083 0.468 . . . . 0.0 111.549 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.4 mp . . . . . 0 C--N 1.326 -0.429 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.374 178.96 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.999 0.428 . . . . 0.0 111.726 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.95 -173.29 42.37 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.606 -0.807 . . . . 0.0 113.295 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.412 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -130.55 154.22 48.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.876 -0.162 . . . . 0.0 110.57 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -159.23 161.65 36.09 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.281 0.562 . . . . 0.0 112.258 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -154.77 159.22 28.84 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.201 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 8' ' ' TYR . . . -157.77 165.1 33.46 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.796 -1.192 . . . . 0.0 113.563 -179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.5 m-85 -119.91 135.14 55.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.404 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -95.13 125.96 40.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.27 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.1 t -92.88 -37.57 8.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.874 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.437 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -153.6 179.32 1.32 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.125 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.437 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 35.2 Cg_exo -60.72 -26.1 82.3 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.689 2.259 . . . . 0.0 113.712 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.4 p90 -127.97 4.43 5.93 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 113.135 0.791 . . . . 0.0 113.135 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.401 HG11 ' CB ' ' A' ' 46' ' ' ASN . 9.1 p -139.52 115.72 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.601 -0.44 . . . . 0.0 111.718 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.4 -175.7 17.76 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.653 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -127.15 149.45 49.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.569 0.224 . . . . 0.0 110.44 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -147.76 136.82 22.17 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.085 0.469 . . . . 0.0 111.578 -179.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -128.22 155.27 44.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.231 179.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.34 158.37 29.47 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.213 -0.994 . . . . 0.0 113.197 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 30.5 p90 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.79 -179.978 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.0 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.718 0.295 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 -130.21 142.78 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.051 0.453 . . . . 0.0 111.08 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.7 131.34 43.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.84 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 p -151.46 173.0 15.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.495 0.664 . . . . 0.0 111.891 -179.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -110.29 142.41 41.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.963 179.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.62 127.25 53.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.969 0.414 . . . . 0.0 111.453 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.6 mp -129.73 111.22 12.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.303 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -133.55 169.79 22.61 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.266 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -121.69 137.4 27.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.613 0.244 . . . . 0.0 110.591 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -83.14 97.55 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.687 2.258 . . . . 0.0 112.63 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.404 HD11 HG21 ' A' ' 87' ' ' ILE . 31.1 mt -80.67 -35.67 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.048 0.451 . . . . 0.0 110.462 179.462 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 27.4 m -148.27 164.81 32.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.112 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -60.51 -27.34 67.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.522 0.201 . . . . 0.0 111.479 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 129' ' ' TYR . 73.8 m-20 -112.27 -34.9 5.77 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 15.1 tp -102.84 123.74 47.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.981 0.42 . . . . 0.0 111.688 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -135.39 164.19 28.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.348 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 1.3 pt -117.75 142.29 32.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.929 178.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.424 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 36.6 m-85 -144.72 159.14 43.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.686 0.755 . . . . 0.0 112.838 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.1 m -140.87 137.02 32.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.191 178.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 54.8 mtm180 -118.17 137.44 52.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.883 0.373 . . . . 0.0 111.277 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.3 tt -141.9 121.21 13.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.853 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.11 -146.25 4.71 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.273 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.23 156.05 26.71 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.612 -0.804 . . . . 0.0 113.179 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.765 0.317 . . . . 0.0 110.857 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 124' ' ' ALA . 40.2 t80 . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.79 0.328 . . . . 0.0 110.678 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.443 ' N ' ' CD1' ' A' ' 123' ' ' PHE . . . -158.27 148.02 19.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.313 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.98 140.0 8.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.124 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 175.36 -151.75 12.48 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.306 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 29.7 m -140.26 149.24 21.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.126 0.488 . . . . 0.0 111.357 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -125.39 132.37 52.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.631 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . 0.419 ' CZ ' ' HB3' ' A' ' 90' ' ' ASP . 39.6 t80 -125.54 146.2 49.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.213 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.405 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -97.91 115.4 28.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.929 179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.4 tt -88.5 -35.04 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.958 0.409 . . . . 0.0 110.561 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.401 ' CG2' ' HD2' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -150.49 172.41 5.32 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.426 179.631 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.401 ' HD2' ' CG2' ' A' ' 132' ' ' THR . 52.8 Cg_exo -53.23 -57.06 2.2 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.473 2.115 . . . . 0.0 112.488 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -102.89 31.8 4.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.515 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.16 114.23 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 111.743 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.09 154.23 46.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.919 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 26.1 p -129.0 140.59 51.57 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.411 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.2 ttm105 -137.39 135.1 36.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.947 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.3 tp -124.98 132.51 53.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.432 179.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.77 165.58 32.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.255 0.55 . . . . 0.0 111.886 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 8.6 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.948 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 95.4 p -130.28 153.04 49.05 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.231 0.538 . . . . 0.0 111.9 -179.301 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 3.0 tt -144.3 123.19 12.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.889 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.39 159.29 27.49 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.355 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 26.7 m -103.72 147.05 10.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 78.6 p -134.81 145.51 48.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.1 0.476 . . . . 0.0 111.785 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -112.19 132.06 55.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.675 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.51 116.25 31.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.009 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.95 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 N--CA 1.461 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.674 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.517 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.1 p90 -126.8 164.45 21.34 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.623 -179.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.421 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 26.5 p90 -155.26 157.05 36.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.018 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 p -149.13 151.19 33.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.739 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.6 -163.35 24.48 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.05 -1.071 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.49 153.47 50.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.556 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.4 ptmt -138.0 149.74 46.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.169 0.509 . . . . 0.0 111.81 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.1 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.637 179.27 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.815 0.34 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.17 -174.24 40.86 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.281 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.14 154.29 47.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.761 -0.22 . . . . 0.0 110.549 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -159.14 156.96 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.317 0.58 . . . . 0.0 112.101 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -150.29 159.06 27.95 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.244 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.421 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -157.12 164.98 33.09 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 119.793 -1.194 . . . . 0.0 113.498 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.517 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.6 m-85 -118.53 134.17 55.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.445 -0.378 . . . . 0.0 110.384 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 14.7 tt0 -95.79 126.44 41.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.238 179.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 25.1 t -94.75 -35.77 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.837 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.46 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.9 OUTLIER -155.67 172.77 5.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.866 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.46 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 23.1 Cg_endo -62.23 -15.87 47.26 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.222 1.948 . . . . 0.0 113.449 -179.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.421 ' CD1' ' HG2' ' A' ' 47' ' ' PRO . 39.9 m-85 -128.24 -4.03 5.57 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.43 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 4.0 m -139.45 116.93 11.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.566 -0.453 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.53 -175.65 16.83 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.456 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -128.97 149.56 50.76 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -148.85 138.03 21.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.127 0.489 . . . . 0.0 111.665 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 6.3 mtt -128.26 156.09 43.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.148 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.22 158.29 29.36 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.031 -1.081 . . . . 0.0 113.138 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 4.0 p90 . . . . . 0 C--N 1.331 -0.219 0 CA-C-O 120.89 0.376 . . . . 0.0 110.821 -179.994 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.732 0.301 . . . . 0.0 111.151 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 46.0 mt-30 -129.8 141.27 50.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.057 0.456 . . . . 0.0 111.039 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.0 pp -131.23 130.83 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.764 179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.5 p -151.71 173.03 15.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.475 0.655 . . . . 0.0 111.964 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.71 142.0 38.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.827 178.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -107.99 126.33 52.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.823 0.344 . . . . 0.0 111.554 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.4 tt -129.65 110.64 11.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.37 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.426 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.8 169.01 22.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.362 -0.923 . . . . 0.0 113.209 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.406 ' CD2' ' HD2' ' A' ' 86' ' ' PRO . 5.1 t80 -124.28 137.61 29.42 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.614 0.245 . . . . 0.0 110.65 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.406 ' HD2' ' CD2' ' A' ' 85' ' ' TYR . 98.5 Cg_endo -85.37 100.19 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.684 2.256 . . . . 0.0 112.633 -179.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.04 -34.2 12.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.053 0.454 . . . . 0.0 110.367 179.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.6 m -148.59 163.83 36.07 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.26 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.45 -24.96 67.73 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -111.42 -29.43 7.79 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.12 124.72 50.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 111.696 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -133.51 157.75 44.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.326 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 5.2 mt -117.04 141.71 34.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.888 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.426 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 16.8 m-85 -143.62 157.87 44.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.697 0.76 . . . . 0.0 112.721 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.6 p -141.83 137.05 31.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.52 -1.218 . . . . 0.0 108.987 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.413 ' CG ' ' CB ' ' A' ' 124' ' ' ALA . 0.4 OUTLIER -119.57 140.94 49.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.963 0.411 . . . . 0.0 111.467 -179.463 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.4 pp -142.17 120.68 12.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.816 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -164.96 -144.85 4.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.278 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.47 163.14 28.96 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.553 -0.832 . . . . 0.0 113.261 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 6.4 ttt . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.901 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 9.7 p90 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.796 0.332 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.413 ' CB ' ' CG ' ' A' ' 96' ' ' ARG . . . -141.38 162.15 36.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.235 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.31 141.98 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.078 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.27 -154.86 16.59 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 119.926 -1.131 . . . . 0.0 113.331 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 16.2 m -140.38 148.22 22.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.045 0.45 . . . . 0.0 111.441 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.52 132.6 49.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.649 179.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . . . . . . . . . 30.8 p90 -129.92 151.61 50.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.361 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -102.3 117.31 34.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.835 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 20.5 pt -88.96 -36.1 8.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.04 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -162.47 162.12 19.53 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.965 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.26 140.79 41.35 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.558 2.172 . . . . 0.0 112.222 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.54 19.53 6.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.587 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.505 HG21 HD11 ' A' ' 135' ' ' ILE . 32.2 mt -149.08 111.76 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.047 0.451 . . . . 0.0 111.633 -179.674 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.11 151.1 50.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.797 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.1 m -133.46 140.36 47.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.449 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 3.6 ptm180 -146.92 145.0 29.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.158 0.504 . . . . 0.0 111.886 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.0 pp -120.21 140.61 50.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.575 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -146.45 157.37 43.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.147 0.499 . . . . 0.0 111.63 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 2.7 p90 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.001 179.932 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 5.5 tp . . . . . 0 C--O 1.231 0.13 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 4.9 t -136.9 157.99 45.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.365 0.602 . . . . 0.0 112.132 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 1.1 tt -143.33 128.05 18.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.694 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.96 162.84 27.78 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.443 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 22.0 t -105.39 146.6 12.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.7 m -134.59 145.42 48.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.137 0.494 . . . . 0.0 111.614 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -113.83 131.53 56.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -108.66 117.73 34.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.976 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 45.4 p . . . . . 0 N--CA 1.462 0.156 0 CA-C-O 120.892 0.377 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 25.9 p-90 -128.38 162.81 26.24 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.667 -179.294 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.455 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 1.4 p90 -155.28 157.28 36.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.717 179.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.1 p -149.15 151.78 34.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.665 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.406 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.1 -165.65 27.79 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.392 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -128.79 152.45 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.539 -0.33 . . . . 0.0 110.252 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.05 150.47 45.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.327 0.585 . . . . 0.0 112.058 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.7 mp . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.675 178.727 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.075 0 CA-C-O 121.032 0.444 . . . . 0.0 111.73 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.68 179.65 44.04 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.28 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.26 153.24 47.17 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.55 -0.167 . . . . 0.0 110.55 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -159.38 165.69 32.71 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.349 0.595 . . . . 0.0 112.226 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -155.05 161.35 30.31 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.401 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.455 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -152.23 163.8 30.32 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 119.794 -1.193 . . . . 0.0 113.616 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.2 t80 -132.44 132.56 42.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.531 -0.335 . . . . 0.0 110.493 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -92.93 123.69 36.37 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.68 -43.83 12.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.813 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.506 ' HB2' ' HD2' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -152.06 165.19 18.01 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.411 -179.873 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.506 ' HD2' ' HB2' ' A' ' 46' ' ' ASN . 65.9 Cg_exo -40.12 123.09 1.28 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.904 2.403 . . . . 0.0 113.79 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 48' ' ' TYR . 0.8 OUTLIER 59.17 17.68 5.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.419 178.871 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 24.5 t -136.68 114.02 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.451 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.24 -177.35 19.96 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.568 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -124.89 152.11 44.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -147.12 134.85 21.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.059 0.456 . . . . 0.0 111.527 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 16.4 ttm -126.84 151.79 47.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.182 179.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -157.44 157.43 28.12 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.247 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 13.9 p90 . . . . . 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.348 . . . . 0.0 110.73 179.946 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.726 0.298 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -129.29 138.76 51.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.03 0.443 . . . . 0.0 111.029 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.1 mt -129.44 130.68 46.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.852 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.9 p -151.56 173.09 15.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.445 0.64 . . . . 0.0 111.997 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -108.28 142.18 38.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.85 -1.068 . . . . 0.0 109.896 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . 0.41 ' HD3' ' CD2' ' A' ' 94' ' ' TYR . 14.5 tttp -108.6 126.15 52.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.879 0.371 . . . . 0.0 111.488 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 5.2 mt -129.96 113.12 14.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.332 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.459 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -136.4 171.59 22.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.371 -0.918 . . . . 0.0 113.494 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -128.94 136.94 29.96 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 110.476 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -83.95 104.26 1.07 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.651 2.234 . . . . 0.0 112.946 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.1 mp -78.33 -36.52 20.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 121.173 0.511 . . . . 0.0 110.183 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.418 ' CG2' ' CB ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -150.91 169.64 21.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.957 179.119 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.1 -22.37 66.81 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -112.11 -29.05 7.74 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.418 ' CB ' ' CG2' ' A' ' 88' ' ' THR . 0.3 OUTLIER -109.68 125.53 52.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.099 0.476 . . . . 0.0 112.031 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -133.01 155.42 49.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.186 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 11.5 pt -117.47 141.25 37.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.933 179.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.459 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 24.5 m-85 -144.27 161.28 39.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 112.628 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -141.63 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.218 178.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -117.34 136.23 53.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.893 0.378 . . . . 0.0 111.287 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.7 tt -140.42 119.38 12.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.95 -143.96 3.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.349 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -149.9 152.58 24.49 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.299 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 7.3 ttm . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.701 0.286 . . . . 0.0 110.965 -179.962 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 t80 . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.77 0.319 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -150.63 146.79 26.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.176 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.79 139.44 7.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.24 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.74 -158.02 22.05 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.112 -1.042 . . . . 0.0 113.238 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 31.0 m -138.45 146.39 26.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.058 0.456 . . . . 0.0 111.241 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.416 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.2 OUTLIER -126.03 131.7 52.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.739 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . 0.406 ' CE2' ' OG1' ' A' ' 137' ' ' THR . 3.5 p90 -127.48 149.28 50.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.179 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.49 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.898 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 39.1 mt -88.91 -34.75 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.008 0.433 . . . . 0.0 110.744 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.88 174.56 3.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.675 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.8 -61.61 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.657 2.238 . . . . 0.0 112.75 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -101.17 30.17 4.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.643 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 4.4 mp -146.66 114.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.44 . . . . 0.0 111.609 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -127.05 156.34 41.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.994 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.406 ' OG1' ' CE2' ' A' ' 129' ' ' TYR . 3.5 p -141.77 139.07 32.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.474 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 4.4 ptp85 -148.94 148.32 29.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.178 0.514 . . . . 0.0 111.931 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -117.55 140.8 49.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.602 -0.726 . . . . 0.0 109.753 179.202 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -144.55 151.78 39.59 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.044 0.45 . . . . 0.0 111.561 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 8.1 p90 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.979 179.955 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 6.4 tp . . . . . 0 N--CA 1.462 0.148 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 10.3 t -130.51 154.37 47.86 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 121.255 0.55 . . . . 0.0 112.03 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 4.7 tt -145.25 123.98 12.59 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.771 179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -144.88 163.4 28.01 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.573 -179.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 29.3 m -105.29 146.99 11.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' SER . . . . . 0.406 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 2.8 m -134.96 147.21 49.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.204 0.526 . . . . 0.0 111.776 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -114.63 131.89 56.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.732 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 50.0 mtp180 -108.18 118.26 36.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.038 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.839 179.983 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 43' ' ' TYR . 74.5 p . . . . . 0 N--CA 1.461 0.116 0 CA-C-O 120.916 0.389 . . . . 0.0 110.752 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 8.0 t90 -119.09 137.49 53.54 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.286 -179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.422 ' CD1' ' HA ' ' A' ' 169' ' ' ARG . 3.9 m-85 -124.32 155.92 37.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.831 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.406 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 71.4 p -149.01 147.03 28.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.05 -163.06 23.45 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.174 -1.012 . . . . 0.0 113.364 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.48 153.99 50.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.647 -0.276 . . . . 0.0 110.611 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.426 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . 0.1 OUTLIER -137.12 149.88 47.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.157 0.503 . . . . 0.0 111.863 -179.401 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 tt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.678 179.216 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.111 0 CA-C-O 120.87 0.367 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.35 -173.12 40.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.284 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.04 153.4 48.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.813 -0.193 . . . . 0.0 110.694 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.426 ' CE1' ' HB2' ' A' ' 12' ' ' LYS . 23.6 p90 -159.42 169.02 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.186 0.517 . . . . 0.0 111.867 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.406 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -145.68 160.9 28.2 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.756 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 52' ' ' GLU . . . -148.46 124.65 1.9 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.043 -1.075 . . . . 0.0 113.222 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.418 ' CG ' ' O ' ' A' ' 6' ' ' THR . 8.4 t80 -104.53 129.51 52.57 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -94.51 124.81 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.776 0.322 . . . . 0.0 110.548 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.11 -38.1 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.453 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 0.8 OUTLIER -147.06 -179.92 1.04 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.073 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.453 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.5 Cg_exo -59.96 -35.77 92.25 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.476 2.117 . . . . 0.0 112.923 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -123.74 11.11 9.06 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.2 t -135.55 112.95 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.573 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.25 178.03 21.14 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.489 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -127.1 150.01 49.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.573 0.225 . . . . 0.0 110.533 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.41 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 0.9 OUTLIER -146.9 133.73 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.031 0.443 . . . . 0.0 111.429 -179.654 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 8.5 ttp -126.49 151.95 47.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.352 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -158.26 157.54 28.4 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.272 -0.966 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.2 p90 . . . . . 0 C--N 1.33 -0.269 0 CA-C-O 120.769 0.319 . . . . 0.0 110.811 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.1 p . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.687 0.279 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.405 ' HA ' ' HA ' ' A' ' 100' ' ' MET . 4.5 mt-30 -126.22 132.06 51.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.976 0.417 . . . . 0.0 110.985 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -133.83 129.98 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.624 179.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -152.07 173.1 15.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.518 0.675 . . . . 0.0 111.979 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -103.37 142.37 34.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.862 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . 0.421 ' HE2' ' CG ' ' A' ' 94' ' ' TYR . 3.4 tttm -109.14 124.59 51.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 111.389 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 9.1 mp -130.7 110.14 11.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.464 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.446 ' HA3' ' CD2' ' A' ' 94' ' ' TYR . . . -133.46 172.09 21.68 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.383 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -126.74 137.59 30.78 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.665 0.269 . . . . 0.0 110.509 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.4 102.05 0.73 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.721 2.281 . . . . 0.0 112.716 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 7.0 tp -82.46 -33.33 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.029 0.442 . . . . 0.0 110.312 179.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.35 165.24 32.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.222 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -66.08 -21.98 66.39 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.522 0.193 . . . . 0.0 111.522 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -111.34 -27.82 8.48 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.0 mt -115.97 127.73 55.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.952 0.406 . . . . 0.0 111.677 -179.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -134.96 161.83 34.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.147 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.43 HG22 HD11 ' A' ' 93' ' ' ILE . 29.4 pt -119.62 142.06 36.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.033 179.117 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.446 ' CD2' ' HA3' ' A' ' 84' ' ' GLY . 39.5 m-85 -143.92 158.99 43.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.621 0.724 . . . . 0.0 112.662 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -139.03 136.47 35.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.111 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.3 mtp85 -116.35 136.86 52.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.034 0.445 . . . . 0.0 111.183 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.8 mt -139.38 117.43 11.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.748 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -168.48 -142.38 3.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.327 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -144.27 145.23 14.59 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.054 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.405 ' HA ' ' HA ' ' A' ' 78' ' ' GLN . 9.6 ptm . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.207 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 18.8 p90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.786 0.327 . . . . 0.0 110.761 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -148.52 153.19 38.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.299 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.41 140.97 8.68 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.102 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 176.96 -154.2 15.49 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.402 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 31.0 m -139.59 146.98 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.07 0.462 . . . . 0.0 111.377 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -126.19 131.04 52.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.531 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -128.84 150.81 50.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.478 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.79 116.03 31.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.769 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 32.7 mt -86.69 -38.42 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.874 0.368 . . . . 0.0 110.948 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -162.19 166.34 14.3 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -55.87 140.21 85.1 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.617 2.211 . . . . 0.0 112.53 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 63.78 10.42 5.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.441 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 13.4 pt -149.32 117.01 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.117 0.484 . . . . 0.0 112.081 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -128.57 157.0 42.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.855 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.9 m -136.36 140.84 43.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.58 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -149.0 149.43 31.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.154 0.502 . . . . 0.0 111.788 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.4 pp -120.11 141.83 49.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -145.06 152.78 40.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.538 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 26.8 p90 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.014 -179.976 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 C--O 1.231 0.099 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 8.5 t -137.35 157.96 45.46 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 121.351 0.596 . . . . 0.0 112.093 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 5.6 mp -143.33 128.57 18.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.716 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -144.12 163.57 27.73 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.471 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.5 t -105.09 146.04 12.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 2.0 m -134.67 143.8 47.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.078 0.466 . . . . 0.0 111.657 -179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -111.23 131.72 54.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.699 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . 0.422 ' HA ' ' CD1' ' A' ' 8' ' ' TYR . 0.0 OUTLIER -107.19 118.8 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.149 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.944 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 20.7 ttt . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.857 0.36 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -74.04 152.14 88.51 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.83 175.67 7.85 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.555 2.17 . . . . 0.0 112.35 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.73 167.45 11.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -149.67 157.26 43.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.847 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.9 t30 66.25 41.56 3.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 p -123.9 171.67 9.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.664 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.484 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 18.6 p90 -125.44 164.22 20.92 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.577 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.432 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 22.5 p90 -155.2 156.6 35.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.77 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 44.4 p -149.13 150.51 32.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.737 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.0 -162.98 23.26 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.245 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.99 153.5 51.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.543 -0.329 . . . . 0.0 110.584 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.97 149.41 47.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.181 0.515 . . . . 0.0 111.739 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.21 124.31 10.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.734 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.424 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.25 174.18 28.02 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.093 -1.051 . . . . 0.0 113.463 -179.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.41 ' CZ ' ' HB2' ' A' ' 162' ' ' LEU . 12.1 p90 -121.4 147.54 45.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.8 0.333 . . . . 0.0 110.71 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.18 143.56 50.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.8 tm0? -66.38 -58.55 5.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.911 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.9 t80 -143.03 137.58 29.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -94.99 169.71 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.953 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -98.3 36.05 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.23 156.25 37.43 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -105.59 -30.87 4.46 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -94.19 97.22 10.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.811 0.338 . . . . 0.0 110.954 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.7 mt -110.24 127.67 67.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.064 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 m-80 -153.29 35.85 0.47 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -135.88 148.8 48.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.898 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.29 -31.58 26.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.952 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.82 149.89 15.29 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.69 -45.17 1.16 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.509 2.139 . . . . 0.0 112.295 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.8 p -127.48 -71.99 0.65 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.3 t-160 -147.89 -68.26 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -156.73 96.57 1.64 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -177.2 116.05 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -120.3 115.79 24.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.738 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 6.3 mt -84.0 133.78 34.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.46 148.72 19.73 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -123.18 158.4 30.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.872 0.368 . . . . 0.0 111.193 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -173.91 -174.74 41.04 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.374 -0.917 . . . . 0.0 113.325 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.67 154.15 48.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.836 -0.182 . . . . 0.0 110.612 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -159.24 163.75 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.326 0.584 . . . . 0.0 112.112 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.25 161.16 30.65 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.27 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.432 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -158.0 165.08 33.57 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.711 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -120.16 134.93 55.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.517 -0.342 . . . . 0.0 110.409 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -95.05 125.77 39.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.337 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -92.94 -38.42 9.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.415 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -155.01 177.93 1.84 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.165 179.888 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.417 ' HB2' ' CD1' ' A' ' 48' ' ' TYR . 31.2 Cg_exo -60.14 -23.53 73.94 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.707 2.271 . . . . 0.0 113.644 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CD1' ' HB2' ' A' ' 47' ' ' PRO . 69.3 m-85 -127.59 2.31 6.17 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 26.9 m -137.77 115.94 13.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.844 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.44 179.83 19.9 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.51 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -129.03 151.41 49.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.522 0.201 . . . . 0.0 110.556 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -152.03 138.49 18.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.045 0.45 . . . . 0.0 111.789 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 1.3 ptm -126.72 156.8 40.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.919 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.37 159.78 30.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.593 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.404 ' CD1' ' O ' ' A' ' 76' ' ' GLY . 12.4 t80 -154.53 140.54 18.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.587 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -84.98 112.2 20.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.15 -170.05 0.11 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 2.7 mp -149.81 147.77 28.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.894 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -131.74 123.61 3.74 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.467 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.44 177.09 4.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.851 0.358 . . . . 0.0 110.972 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 2.4 mmt -123.0 93.99 47.75 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.871 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -49.51 -27.11 13.56 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.582 2.188 . . . . 0.0 112.382 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -93.41 70.25 4.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.45 129.14 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.9 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -110.43 54.91 0.52 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 m -117.01 138.35 51.63 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.5 m -65.55 118.97 9.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.187 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -142.06 109.65 5.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.898 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -142.01 170.78 15.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.86 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.32 -48.35 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.53 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.45 -179.19 5.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.833 0.349 . . . . 0.0 111.05 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -142.98 113.23 7.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER 60.29 31.5 20.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -87.86 152.98 21.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.066 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -144.31 157.96 43.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.404 ' O ' ' CD1' ' A' ' 55' ' ' TYR . . . -154.94 143.57 10.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.592 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 25.4 t -154.78 159.12 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.731 0.3 . . . . 0.0 110.984 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -127.81 136.43 51.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.027 0.441 . . . . 0.0 110.844 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.0 pp -131.22 130.87 43.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.843 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.6 p -151.74 173.13 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.464 0.65 . . . . 0.0 111.874 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.56 141.24 39.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.905 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.8 mttp -108.02 126.98 53.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.493 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 20.9 mt -129.8 110.68 11.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.402 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.96 169.36 22.56 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.41 -0.9 . . . . 0.0 113.109 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 35.0 m-85 -123.72 137.67 29.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 110.548 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -84.43 99.4 0.75 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.707 2.271 . . . . 0.0 112.613 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.446 HG23 HD11 ' A' ' 87' ' ' ILE . 33.5 mt -81.28 -34.63 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.057 0.456 . . . . 0.0 110.442 179.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 27.9 m -148.0 164.78 32.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.184 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 -60.13 -27.66 67.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.478 0.18 . . . . 0.0 111.485 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.414 ' HB3' ' CZ ' ' A' ' 129' ' ' TYR . 1.6 m-20 -112.02 -33.78 6.17 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -178.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.1 tt -102.85 123.84 47.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.941 0.4 . . . . 0.0 111.716 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -135.69 164.14 28.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.261 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 1.7 pp -119.6 142.93 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.003 179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.431 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 6.7 m-85 -143.4 157.49 44.42 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.706 0.765 . . . . 0.0 112.715 -178.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.6 m -141.14 136.26 31.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 114.542 -1.208 . . . . 0.0 109.029 178.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.13 139.58 51.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.963 0.411 . . . . 0.0 111.384 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.0 mp -140.82 119.18 12.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.736 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -166.13 -141.84 3.26 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.296 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.44 23.35 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.317 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.8 ttt -103.79 122.87 46.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.4 m -96.88 128.86 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -132.7 133.88 44.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.93 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 7.9 ttm-85 -140.27 147.69 40.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.826 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -142.1 162.2 36.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.122 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -110.74 130.61 55.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.986 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.8 92.45 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 20.7 mttp 60.26 105.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -138.54 125.5 21.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.848 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.41 30.8 3.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 15.9 t 59.39 31.28 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.086 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.9 -32.64 12.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.971 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 94.28 72.18 1.16 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.489 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 6.5 mmtm -139.99 161.05 38.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.859 0.361 . . . . 0.0 110.863 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -128.42 158.5 38.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.899 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -117.74 -40.67 2.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.17 118.73 2.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.82 152.18 34.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -100.5 113.26 4.65 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.504 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.4 t -146.08 62.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.982 0.42 . . . . 0.0 111.076 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.8 m -105.87 102.18 37.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.69 139.11 32.0 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.508 2.139 . . . . 0.0 112.382 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 21.5 t -141.24 159.0 22.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.119 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.408 ' CD1' ' N ' ' A' ' 123' ' ' PHE . 3.5 p90 -137.18 164.02 29.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -142.18 164.2 30.8 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.252 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -149.04 141.95 9.42 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.122 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.25 -155.0 16.92 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 119.87 -1.157 . . . . 0.0 113.358 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 30.1 m -139.71 148.17 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.974 0.416 . . . . 0.0 111.25 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -124.51 132.2 53.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.642 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . 0.414 ' CZ ' ' HB3' ' A' ' 90' ' ' ASP . 45.0 t80 -128.27 148.33 50.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.418 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 116.37 32.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.818 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 7.8 tp -88.57 -36.58 9.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.402 ' CB ' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -162.36 165.09 16.14 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.854 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 132' ' ' THR . 11.7 Cg_endo -55.2 141.59 80.08 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.596 2.197 . . . . 0.0 112.074 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 58.54 19.01 6.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.531 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.474 HD11 HG22 ' A' ' 135' ' ' ILE . 31.1 mt -149.13 111.95 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 121.018 0.437 . . . . 0.0 111.718 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -124.42 156.13 37.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.836 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.6 m -142.83 136.26 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.5 ptt85 -146.15 157.94 43.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.253 0.549 . . . . 0.0 112.038 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 1.9 tt -128.18 139.86 52.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.596 179.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -147.35 158.18 43.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.177 0.513 . . . . 0.0 111.693 -179.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.478 ' HA ' ' O ' ' A' ' 161' ' ' MET . 19.3 m-85 -125.05 158.59 33.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.869 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 21.6 mt-30 -126.61 154.11 44.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -104.91 125.97 51.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 58.9 p -100.06 -31.43 11.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -95.43 78.54 3.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -175.82 37.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.6 pt -152.88 172.93 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 74.06 -76.46 1.05 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.444 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -141.1 135.88 31.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.869 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.57 125.92 30.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.07 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 -85.19 141.15 30.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.62 -59.7 2.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.899 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 3.1 pt -146.35 165.64 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.119 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 139.65 -123.37 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.562 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 39.8 p -71.07 143.92 50.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.857 0.36 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -93.06 139.11 23.0 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.855 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.25 85.68 0.83 Allowed 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.507 2.138 . . . . 0.0 112.275 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -145.46 35.9 1.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.816 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -174.76 128.04 0.31 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.887 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -151.08 -129.39 1.58 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.478 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 1.7 ttm -91.55 139.22 30.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.657 0.265 . . . . 0.0 110.934 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.41 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 0.8 OUTLIER -121.94 118.43 28.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.073 179.252 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.424 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 17.8 m -136.73 157.54 46.52 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.331 0.586 . . . . 0.0 112.015 -179.27 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 10.9 tp -141.69 127.87 19.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.673 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.98 161.75 27.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.09 -1.052 . . . . 0.0 113.431 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.2 m -106.16 147.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 22.4 p -134.54 146.11 49.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.159 0.504 . . . . 0.0 111.608 -179.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -113.61 131.63 56.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.786 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -108.54 117.12 33.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.955 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -107.66 131.4 54.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 136.5 57.15 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -83.83 -56.95 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.798 0.332 . . . . 0.0 110.89 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 66.08 -164.17 40.49 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -140.9 -51.39 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -106.92 -64.11 1.22 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.066 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.136 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 4.3 mtm . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.861 0.362 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -76.73 143.5 71.58 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.07 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.32 132.32 14.88 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.574 2.183 . . . . 0.0 112.37 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.67 -38.67 3.93 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.787 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' A' ' 44' ' ' GLN . 1.3 t70 -140.06 28.78 2.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -64.12 67.05 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.848 0.356 . . . . 0.0 111.777 -179.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.423 ' N ' ' O ' ' A' ' 4' ' ' ASP . 67.5 p -126.13 173.02 9.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.797 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 12.9 p90 -128.01 164.18 22.93 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.641 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.418 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 5.3 p90 -155.29 156.63 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 t -149.17 150.21 32.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.71 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.75 -161.94 22.24 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.465 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -130.46 159.38 37.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.537 -0.331 . . . . 0.0 110.608 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -142.26 150.05 40.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.216 0.532 . . . . 0.0 112.003 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 6.6 tt -149.24 125.98 11.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.548 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.2 174.36 27.92 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.011 -1.09 . . . . 0.0 113.745 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.446 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 2.9 m-85 -134.39 154.23 51.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.272 179.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.3 t -148.38 -169.23 3.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.836 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -74.57 151.57 39.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -107.7 91.55 3.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 13.3 m170 -104.09 103.14 12.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.878 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.29 132.39 5.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.895 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.0 157.72 17.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.974 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.403 ' O ' ' CD2' ' A' ' 23' ' ' PHE . . . 162.3 51.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.474 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' A' ' 22' ' ' GLY . 0.8 OUTLIER -174.75 137.97 0.47 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.806 0.336 . . . . 0.0 110.851 -179.971 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.7 pt -74.91 -30.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -125.21 150.55 46.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -138.37 179.64 6.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -101.22 -31.33 11.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 153.24 177.78 27.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.564 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.32 162.28 2.22 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.593 2.195 . . . . 0.0 112.285 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 p -105.21 178.67 4.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -167.23 33.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -119.57 -176.81 3.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -134.88 171.35 14.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 166.2 142.31 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.676 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.412 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 3.8 tt -156.47 -70.47 0.11 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.592 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 144.81 176.9 19.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.643 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -128.24 -176.9 3.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.793 0.33 . . . . 0.0 111.027 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.18 -159.4 31.86 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.357 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.42 ' HB2' ' CE2' ' A' ' 57' ' ' PHE . . . -135.1 155.08 51.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.543 0.211 . . . . 0.0 110.668 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -159.29 163.66 35.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.289 0.566 . . . . 0.0 111.907 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -140.61 158.84 26.24 Favored Glycine 0 N--CA 1.448 -0.544 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.35 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.418 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.67 150.13 21.75 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.509 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 6.9 m-85 -117.35 131.79 56.72 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' A' ' 4' ' ' ASP . 11.3 mt-30 -94.64 126.46 39.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.236 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.01 -36.9 7.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.769 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.436 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -152.76 179.21 1.32 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.154 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.436 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 39.3 Cg_exo -61.47 -26.89 81.62 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.684 2.256 . . . . 0.0 113.692 -179.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 11.3 p90 -124.53 4.11 8.31 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 -178.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.424 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 3.7 m -137.74 116.11 13.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.862 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.35 179.41 19.56 Favored Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.439 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -130.23 152.38 49.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.62 0.248 . . . . 0.0 110.767 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -150.38 136.71 18.77 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.09 0.471 . . . . 0.0 111.528 -179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 5.1 mpp? -132.35 114.39 14.32 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.327 179.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -119.09 164.02 13.23 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.431 -0.89 . . . . 0.0 113.39 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 17.9 p90 -152.43 156.19 39.0 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.796 0.331 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.0 153.88 22.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.42 ' CE2' ' HB2' ' A' ' 39' ' ' ALA . 1.1 m-85 -86.28 -71.87 0.52 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.825 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 9.5 mp 60.49 32.93 20.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.874 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 129.13 -99.11 0.46 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -139.23 168.58 19.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.752 0.31 . . . . 0.0 110.928 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -157.36 88.28 2.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.6 -175.62 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.541 2.16 . . . . 0.0 112.227 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -159.57 -45.15 0.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.913 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? -58.62 -30.82 67.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.966 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.68 141.79 9.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.496 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -176.98 172.77 1.95 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.821 0.343 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 12.2 m -90.01 144.68 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.135 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -153.17 -176.0 5.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.843 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -135.1 167.51 20.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.878 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.37 28.25 10.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.488 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . 59.81 177.99 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -93.56 154.38 17.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.7 mmtm -101.32 154.0 19.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.86 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.91 120.71 13.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.149 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -98.31 135.14 40.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -131.73 121.4 3.08 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.428 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 30.9 m -136.0 154.15 33.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.735 0.302 . . . . 0.0 111.151 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.0 pm0 -131.72 139.33 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 7.7 tt -127.11 132.13 50.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.803 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -151.62 173.06 15.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.44 0.638 . . . . 0.0 111.978 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.54 141.44 39.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.862 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -108.83 126.44 53.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.874 0.369 . . . . 0.0 111.447 -179.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 2.4 mt -131.61 110.09 10.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.239 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.42 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.1 177.53 19.48 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.773 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.434 ' N ' ' CD1' ' A' ' 85' ' ' TYR . 3.4 m-85 -131.76 140.63 38.87 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.659 0.266 . . . . 0.0 110.475 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -87.56 106.72 0.61 Allowed 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.836 2.357 . . . . 0.0 112.826 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 26.4 pt -80.22 -33.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.433 ' CG2' ' CB ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -150.65 169.68 21.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.05 178.914 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -64.17 -23.31 67.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.079 0.399 . . . . 0.0 112.079 -179.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.42 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -110.94 -28.22 8.45 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 -178.708 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.433 ' CB ' ' CG2' ' A' ' 88' ' ' THR . 0.5 OUTLIER -109.34 126.37 53.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.138 0.494 . . . . 0.0 111.924 -179.086 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.24 152.52 50.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.001 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 12.0 tt -123.11 142.12 40.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.907 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.42 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 28.5 p90 -153.22 170.21 21.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.719 0.771 . . . . 0.0 113.021 -179.017 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 p -139.62 141.91 37.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.62 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 46.1 mtp180 -117.3 137.39 52.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.882 0.372 . . . . 0.0 111.067 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -139.86 120.03 13.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.856 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -141.06 3.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.338 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.17 151.89 23.78 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.591 -0.814 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 2.4 ppp? -101.98 132.51 47.77 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.35 124.92 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -117.26 125.75 51.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -129.3 122.21 29.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -138.21 125.72 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.121 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -83.92 136.37 34.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.878 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -103.35 125.33 49.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.914 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 6.2 mtmp? -70.96 -46.07 63.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.9 p -166.15 32.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -74.4 -63.96 1.13 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.892 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 29.8 m -100.72 146.2 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -95.54 -33.38 12.43 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -76.32 -158.64 8.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -153.56 104.84 2.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.799 0.333 . . . . 0.0 110.929 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -139.13 83.93 1.98 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.827 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 60.3 178.29 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.796 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -168.83 33.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.4 m -146.15 109.17 4.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -84.21 123.64 6.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.548 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.6 m -131.07 150.0 34.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 2.7 m -171.56 149.22 2.41 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.06 158.94 54.93 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 6.0 m -159.02 141.71 5.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -117.65 158.88 23.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.818 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -151.94 149.48 28.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.21 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.91 138.65 7.44 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.075 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.38 -158.5 22.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 119.996 -1.097 . . . . 0.0 113.264 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 18.8 m -141.89 149.78 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.134 0.492 . . . . 0.0 111.474 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -125.27 131.37 53.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.504 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . 0.42 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 42.6 t80 -126.89 146.98 50.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.319 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.4 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.84 114.53 27.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.81 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -87.03 -39.18 12.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.009 0.433 . . . . 0.0 110.933 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -159.59 169.75 9.88 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.729 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.41 139.94 92.57 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.52 2.147 . . . . 0.0 112.214 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 59.71 17.72 6.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.842 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 tt -149.21 113.93 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.114 0.483 . . . . 0.0 111.721 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.71 157.86 40.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.084 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 3.2 t -124.9 141.11 52.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.534 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 25.0 mtt180 -135.16 134.59 40.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.124 0.488 . . . . 0.0 111.815 -179.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.3 tt -130.06 130.78 45.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.543 179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -153.53 169.42 23.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.392 0.615 . . . . 0.0 112.017 -179.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.465 ' HA ' ' O ' ' A' ' 161' ' ' MET . 4.1 m-85 -122.2 161.98 22.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.21 -0.904 . . . . 0.0 110.847 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -129.49 151.34 50.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -119.75 150.77 39.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -160.88 78.47 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.87 102.12 13.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.942 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 13.9 m-80 -127.58 78.93 1.86 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.882 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 5.9 pt -76.94 -30.74 18.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.055 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 69.07 -85.67 0.22 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.55 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -162.94 83.79 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.828 0.347 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -162.17 -170.18 2.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.082 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 2.7 t-160 -102.99 34.18 2.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.883 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.0 t -106.84 31.05 5.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 1.7 pt -67.14 116.24 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -166.16 104.78 0.23 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.507 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 3.4 t -112.7 128.7 56.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.59 146.34 32.31 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.46 -61.91 0.39 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.545 2.163 . . . . 0.0 112.214 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -152.17 77.82 1.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -151.58 35.71 0.56 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -96.12 -104.22 2.09 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.504 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.465 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 39.2 mtt -93.79 130.91 39.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.627 0.251 . . . . 0.0 110.902 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.414 ' HG ' ' CZ ' ' A' ' 141' ' ' TYR . 7.2 tt -120.95 119.1 31.61 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.437 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 28.3 t -132.69 154.2 50.39 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.199 0.523 . . . . 0.0 111.78 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 8.0 tt -144.66 122.7 12.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.853 179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.12 163.83 26.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.245 -0.978 . . . . 0.0 113.24 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.8 m -105.06 146.83 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -135.14 143.42 46.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.096 0.474 . . . . 0.0 111.67 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -109.61 132.68 53.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.687 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.12 29.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.89 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -84.43 133.08 34.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.893 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.7 149.87 23.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.548 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -83.76 -51.72 6.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 110.895 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 84.41 165.14 38.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.448 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -148.56 96.9 2.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.86 0.362 . . . . 0.0 110.867 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -139.93 131.84 27.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.073 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.112 179.952 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 7.8 mtm . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 120.817 0.342 . . . . 0.0 111.218 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.409 ' CB ' ' CD ' ' A' ' 2' ' ' PRO . . . -72.79 -61.21 1.67 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.409 ' CD ' ' CB ' ' A' ' 1' ' ' ALA . 58.5 Cg_endo -71.64 173.71 12.14 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.533 2.155 . . . . 0.0 112.387 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.6 tptp -176.89 -40.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.929 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -148.06 164.05 35.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.955 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m120 65.38 41.87 4.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.978 0.418 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.8 p -124.06 172.2 9.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.734 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.487 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 9.2 p-90 -126.68 164.58 20.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.561 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.433 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 2.8 p90 -155.34 158.35 38.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.966 179.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 t -149.14 149.54 31.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.401 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -169.68 -162.94 22.86 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.399 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.6 155.43 48.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.601 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.424 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 14.2 pttt -139.5 153.14 47.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.299 0.571 . . . . 0.0 112.276 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 48.3 tp -147.32 127.42 13.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.268 179.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.45 ' O ' ' HB3' ' A' ' 35' ' ' LEU . . . -148.15 174.5 27.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.743 -178.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.419 ' HA ' ' CB ' ' A' ' 35' ' ' LEU . 19.2 m-85 -143.52 149.75 37.93 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.268 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -144.28 -172.34 3.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.823 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -117.55 109.91 17.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -124.98 140.8 52.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.887 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -95.13 129.03 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.866 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -106.22 176.88 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.78 161.58 41.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.58 -28.63 2.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -131.14 123.85 29.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.844 0.354 . . . . 0.0 110.906 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -59.79 156.95 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.135 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.6 m-20 -162.53 -45.15 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 m120 60.67 35.62 19.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -105.79 159.73 15.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -132.12 63.71 0.62 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.504 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.75 -175.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.6 2.2 . . . . 0.0 112.314 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.42 -59.2 2.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -161.99 -178.96 6.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.935 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -131.34 -178.15 4.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.929 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.446 ' O ' ' HB2' ' A' ' 34' ' ' GLN . 56.4 t30 -171.84 118.85 0.42 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.927 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 33' ' ' ASN . 42.5 tt0 167.56 144.68 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.477 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.45 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 10.5 tt -158.08 -71.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.513 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 144.89 -179.69 21.86 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.397 -0.906 . . . . 0.0 112.624 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -123.61 -176.97 3.59 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.851 0.358 . . . . 0.0 111.0 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.71 -162.78 35.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.306 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.86 155.1 45.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.717 -0.241 . . . . 0.0 110.7 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.424 ' CE1' ' HB3' ' A' ' 12' ' ' LYS . 27.3 p90 -159.13 157.72 31.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.304 0.573 . . . . 0.0 112.01 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -147.47 159.86 28.14 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.319 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.433 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -155.26 161.29 30.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 119.824 -1.179 . . . . 0.0 113.602 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 13.1 t80 -123.05 133.72 54.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.252 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -95.07 125.62 39.86 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.272 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 t -93.24 -37.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.961 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.425 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.1 t30 -153.92 178.32 1.66 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.424 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.4 Cg_exo -60.1 -25.97 81.24 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.679 2.252 . . . . 0.0 113.64 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.409 ' CD1' ' HB2' ' A' ' 47' ' ' PRO . 17.9 m-85 -127.46 3.99 6.24 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.425 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 4.3 m -138.04 115.06 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.819 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.65 -177.23 18.4 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.466 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.59 150.04 49.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.559 0.219 . . . . 0.0 110.629 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -146.57 134.25 21.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.039 0.447 . . . . 0.0 111.375 -179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -128.43 153.68 46.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.339 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.61 158.84 30.02 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.191 -1.004 . . . . 0.0 113.116 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 7.3 p90 -159.17 161.81 36.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.4 t0 -93.21 124.62 37.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.98 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -108.37 128.59 54.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mt -94.01 -66.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 143.56 146.04 4.49 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.573 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 83.4 mtt180 -151.32 157.6 42.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' MET . . . . . 0.408 ' CB ' ' CD ' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -64.74 -60.9 7.25 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.942 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.408 ' CD ' ' CB ' ' A' ' 61' ' ' MET . 58.3 Cg_endo -71.77 145.6 46.42 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.425 2.083 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -67.63 -53.79 25.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -78.13 -47.65 17.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.887 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 126.49 41.56 0.32 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.446 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.5 m 60.2 175.9 0.09 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.834 0.349 . . . . 0.0 110.834 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.6 -47.24 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -102.1 31.58 3.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.95 -54.7 2.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.839 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.15 82.79 0.32 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.552 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.92 90.77 1.31 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 111.057 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.45 165.17 11.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tttt -131.05 -60.99 0.95 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -175.27 148.07 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.108 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 7.4 tt0 -117.95 117.22 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.916 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.419 ' HA3' ' CE2' ' A' ' 102' ' ' PHE . . . -134.19 124.01 3.43 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.476 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 31.3 m -142.83 162.78 17.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.684 0.278 . . . . 0.0 111.137 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -130.22 140.43 50.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.048 0.451 . . . . 0.0 111.091 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -129.85 132.1 46.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.968 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.3 t -151.43 170.11 20.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.523 0.678 . . . . 0.0 112.09 -179.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.94 144.22 35.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.946 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -110.14 125.26 52.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -130.89 108.15 9.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.209 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.461 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -134.99 176.89 19.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.232 -0.985 . . . . 0.0 113.658 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 6.5 m-85 -128.07 140.18 37.52 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.661 0.267 . . . . 0.0 110.606 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -87.87 103.72 0.51 Allowed 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.772 2.315 . . . . 0.0 112.634 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 41.6 pt -82.14 -30.64 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.042 0.448 . . . . 0.0 110.337 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.47 167.31 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.177 179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -64.94 -23.45 67.23 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.423 ' HB3' ' CE1' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -112.07 -37.31 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.02 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 15.3 tp -102.94 125.73 49.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.984 0.421 . . . . 0.0 111.656 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -133.54 161.02 35.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.186 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 2.6 pp -125.66 143.23 39.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.035 179.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.461 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 10.2 p90 -155.1 170.27 22.2 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.723 0.773 . . . . 0.0 113.003 -178.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.3 p -139.39 143.05 37.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.714 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 68.5 mtm180 -118.69 139.06 52.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.012 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 6.7 tp -141.25 120.84 13.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.1 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -164.8 -149.04 5.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.347 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.56 152.25 24.35 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.107 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.2 ptt? -106.52 141.19 38.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.829 0.347 . . . . 0.0 110.848 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 5.0 m -126.01 108.52 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.12 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.419 ' CE2' ' HA3' ' A' ' 76' ' ' GLY . 4.5 m-85 -118.2 111.9 19.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.848 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 -114.36 124.73 52.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . 0.411 ' HB2' ' CE1' ' A' ' 115' ' ' HIS . . . -109.56 140.93 42.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.109 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.37 156.79 20.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.64 129.06 22.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -163.47 31.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.4 m -142.08 -54.66 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -154.6 147.02 23.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.908 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.56 106.5 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -67.73 -35.97 79.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.861 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -114.47 -120.13 3.45 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.459 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -156.78 -65.18 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 0.0 110.953 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -73.78 147.75 43.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . 0.411 ' CE1' ' HB2' ' A' ' 104' ' ' ALA . 0.4 OUTLIER -122.06 124.21 43.42 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.841 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -106.82 139.79 40.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 47.2 p -107.46 154.57 21.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -91.06 111.86 4.03 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.473 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.5 t -152.13 113.17 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.808 0.337 . . . . 0.0 111.191 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.3 m -177.21 163.24 1.48 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.59 168.44 21.33 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.636 2.224 . . . . 0.0 112.316 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 5.8 m -158.93 121.81 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.222 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -102.13 156.48 17.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.823 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -151.48 148.5 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.221 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.95 138.88 7.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.111 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.65 -156.96 20.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.002 -1.094 . . . . 0.0 113.299 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 28.9 m -141.54 147.9 21.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.043 0.449 . . . . 0.0 111.335 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.402 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 21.6 tt0 -124.05 132.11 53.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.703 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . 0.423 ' CE1' ' HB3' ' A' ' 90' ' ' ASP . 70.9 t80 -126.09 146.4 49.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.176 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.39 116.15 31.68 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.808 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.2 pt -92.8 -30.99 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.611 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.421 ' CG2' ' HD2' ' A' ' 133' ' ' PRO . 0.2 OUTLIER -147.13 169.27 9.65 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.499 179.916 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.421 ' HD2' ' CG2' ' A' ' 132' ' ' THR . 53.1 Cg_exo -55.91 -60.95 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.575 2.183 . . . . 0.0 112.843 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -98.05 23.85 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.708 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 4.3 mp -146.46 117.6 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.053 0.454 . . . . 0.0 111.651 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.12 161.86 29.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.082 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 80.9 p -135.93 140.59 44.14 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.407 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.65 144.04 32.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.237 0.542 . . . . 0.0 112.041 -179.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 2.6 tt -124.83 136.34 53.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.598 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -146.0 156.44 43.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.227 0.537 . . . . 0.0 111.807 -179.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 161' ' ' MET . 3.1 m-85 -121.17 143.06 49.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.536 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.06 145.48 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -104.31 142.93 33.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.945 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -109.7 -30.66 7.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.3 t30 62.04 152.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -168.98 -43.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.4 mp -61.24 -43.65 96.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.161 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 158.53 -111.08 0.47 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.538 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -124.74 102.32 7.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.77 0.319 . . . . 0.0 110.876 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 160.96 15.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 8.9 m80 -127.55 80.68 1.97 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 38.9 p -137.45 132.39 33.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.874 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 2.7 tt -79.28 -30.86 14.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -111.71 133.2 11.31 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.51 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 20.8 p -77.32 157.0 30.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.791 0.329 . . . . 0.0 110.872 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.9 mmt85 -87.18 145.77 38.72 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -74.58 128.22 11.65 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.62 2.213 . . . . 0.0 112.377 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 58.98 45.72 14.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.953 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -112.88 -43.62 3.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -118.32 -110.78 2.48 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.514 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.473 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 2.4 mtp -102.38 130.84 49.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.596 0.236 . . . . 0.0 110.892 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 8.4 mp -120.8 118.98 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.12 179.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 22.5 m -132.31 152.7 51.28 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.201 0.524 . . . . 0.0 111.627 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 2.7 tt -143.81 123.86 13.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.775 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.55 164.75 27.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.24 -0.981 . . . . 0.0 113.456 -179.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.401 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 25.9 m -105.45 147.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 30.0 p -134.78 145.91 48.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.125 0.488 . . . . 0.0 111.761 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -112.12 131.96 55.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.738 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -108.51 116.79 32.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.025 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -84.36 150.2 25.52 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -148.01 52.12 0.55 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.24 79.7 1.59 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 135.07 140.15 4.17 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.485 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -151.62 -50.93 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.873 0.368 . . . . 0.0 110.877 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -149.22 -67.56 0.22 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.07 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.1 -179.974 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 5.0 ptp . . . . . 0 N--CA 1.488 1.441 0 CA-C-O 120.856 0.36 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -98.37 150.13 36.42 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.041 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.8 68.6 1.71 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.528 2.152 . . . . 0.0 112.297 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 30.1 mtmt -149.36 166.35 29.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -87.88 -79.21 0.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 67.23 42.09 2.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.8 p -123.48 165.66 16.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.811 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 7.2 t90 -113.1 161.07 17.53 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.317 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.471 ' CZ ' ' HB2' ' A' ' 169' ' ' ARG . 0.1 OUTLIER -145.12 141.62 28.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 m -147.56 144.42 28.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.698 0.285 . . . . 0.0 111.189 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -173.82 -157.58 15.82 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.295 -0.955 . . . . 0.0 113.256 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -134.02 155.44 49.98 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.659 -0.271 . . . . 0.0 110.746 179.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.406 ' HB2' ' CD1' ' A' ' 40' ' ' PHE . 1.7 mmmm -139.16 153.15 47.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.147 0.498 . . . . 0.0 111.966 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 mp -148.9 128.21 12.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.516 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.459 ' O ' ' HB3' ' A' ' 35' ' ' LEU . . . -148.24 174.48 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.024 -1.084 . . . . 0.0 113.694 -178.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.43 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 3.8 m-85 -134.1 156.83 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 2.5 t -131.21 164.9 24.54 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.86 0.362 . . . . 0.0 110.915 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 62.87 73.69 0.45 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -83.18 168.15 17.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.822 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -173.11 93.37 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.867 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -127.31 -48.77 1.43 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 26.9 m -80.98 146.52 30.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.893 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 70.24 -157.07 53.52 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -176.15 88.6 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.804 0.335 . . . . 0.0 110.824 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.9 mp -128.26 113.39 30.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.157 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 11.2 m-20 -169.83 151.6 4.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -132.08 31.58 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.887 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -136.38 -47.03 0.63 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.898 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.9 -152.29 18.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.455 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.94 109.03 2.25 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.146 . . . . 0.0 112.308 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 49.4 m -153.35 -54.7 0.11 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -126.58 115.42 19.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.929 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -143.46 88.22 1.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.929 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 63.59 130.76 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.948 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 166.6 142.66 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.459 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 14.7 tp -156.51 -72.14 0.1 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.5 179.742 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 145.57 177.65 20.48 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.319 -0.943 . . . . 0.0 112.621 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.04 -176.94 3.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.79 0.329 . . . . 0.0 110.974 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.01 -159.78 32.47 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.28 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.4 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -114.51 151.63 33.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.921 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.431 ' CD2' ' HA3' ' A' ' 54' ' ' GLY . 61.2 m-85 -151.23 149.88 29.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.03 0.443 . . . . 0.0 111.692 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.04 156.75 28.63 Favored Glycine 0 N--CA 1.45 -0.417 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -157.04 154.67 25.73 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 119.783 -1.199 . . . . 0.0 113.771 -179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -107.21 133.63 51.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.5 -0.35 . . . . 0.0 110.086 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -96.13 125.91 40.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.453 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.0 t -94.78 -36.44 6.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.493 ' HB2' HG21 ' A' ' 49' ' ' VAL . 0.8 OUTLIER -156.6 173.37 5.03 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.688 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.471 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 25.9 Cg_endo -62.82 -15.31 46.21 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 122.227 1.952 . . . . 0.0 113.551 -179.085 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -126.86 -4.76 6.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.493 HG21 ' HB2' ' A' ' 46' ' ' ASN . 11.6 m -139.07 117.48 12.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.97 -179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.6 -179.37 18.67 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.369 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -128.87 149.59 50.7 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.636 0.255 . . . . 0.0 110.414 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -149.37 137.01 20.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.004 0.43 . . . . 0.0 111.616 -179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -128.23 156.72 42.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.212 179.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.431 ' HA3' ' CD2' ' A' ' 40' ' ' PHE . . . -159.03 157.54 28.58 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.142 -1.028 . . . . 0.0 113.199 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.405 ' CD2' ' O ' ' A' ' 76' ' ' GLY . 13.9 t80 -138.73 141.3 38.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.873 0.368 . . . . 0.0 110.841 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -129.01 129.0 44.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.927 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -95.07 116.6 28.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 10.9 mt -122.98 158.51 30.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.971 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -92.12 -88.47 1.49 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.469 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 12.7 ttm180 -101.48 147.75 26.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 0.0 110.842 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 1.1 mmt -85.25 160.57 54.23 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -36.12 11.62 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.513 2.142 . . . . 0.0 112.371 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 51.2 t80 -92.48 79.73 4.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.45 137.57 58.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.88 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -164.21 -42.3 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.435 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.1 t -171.36 111.91 0.34 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.876 0.37 . . . . 0.0 110.936 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.81 106.49 12.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.111 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -106.27 90.85 3.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.865 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -90.7 149.45 22.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -141.95 -115.99 1.18 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -99.2 31.23 3.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.857 0.36 . . . . 0.0 111.097 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -175.78 -169.45 0.34 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 2.4 tmtt? -144.24 159.92 41.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.31 135.16 57.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -94.78 100.03 12.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.817 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.405 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -113.86 107.43 1.89 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.508 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 24.8 t -111.53 159.13 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.709 0.29 . . . . 0.0 110.952 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -128.11 134.14 49.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.007 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 2.4 mt -128.92 130.28 46.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.842 179.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.7 p -151.38 173.1 14.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.461 0.648 . . . . 0.0 111.99 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -109.0 142.91 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.001 179.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -109.07 126.17 52.89 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.877 0.37 . . . . 0.0 111.479 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.0 mp -129.15 112.17 13.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.248 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -135.72 170.85 22.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.217 -0.992 . . . . 0.0 113.474 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -124.3 139.07 32.05 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.639 0.257 . . . . 0.0 110.517 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -85.31 100.04 0.68 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.708 2.272 . . . . 0.0 112.704 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.2 mp -80.36 -35.04 15.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.135 0.493 . . . . 0.0 110.309 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 27.8 m -148.62 164.88 32.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.164 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -60.71 -24.8 65.95 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.574 0.212 . . . . 0.0 111.574 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.441 ' CB ' ' CE2' ' A' ' 129' ' ' TYR . 10.8 m-20 -113.08 -33.52 6.0 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.087 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 6.8 tp -102.89 123.58 46.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.903 0.383 . . . . 0.0 111.793 -179.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -134.03 160.81 36.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.297 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -120.41 142.88 34.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.984 179.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.421 ' CE1' ' HB2' ' A' ' 128' ' ' GLU . 47.2 p90 -147.15 163.49 36.14 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.653 0.74 . . . . 0.0 112.872 -178.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -140.58 139.64 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.363 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.51 135.04 54.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.891 0.377 . . . . 0.0 111.003 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.37 118.21 11.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.836 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.86 -144.19 3.99 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.298 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -150.03 151.09 23.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.205 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -102.54 128.61 49.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 11.9 p -104.52 129.87 56.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.034 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -116.55 115.57 26.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 6.7 mtp85 -105.56 126.29 51.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -125.43 135.59 52.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.085 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -81.95 155.15 25.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -163.51 151.87 13.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.833 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 4.6 mttm -96.75 80.23 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.03 -71.87 0.54 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -107.25 140.2 40.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.7 m -98.9 31.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -75.25 -35.97 61.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 98.67 -33.48 6.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.497 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 33.9 mttt -134.95 110.26 8.99 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.836 0.35 . . . . 0.0 110.873 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -115.72 175.78 5.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 10.6 m170 -107.43 36.54 2.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -119.35 98.69 6.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -152.53 150.29 29.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -76.44 142.11 27.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.531 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.4 m -157.28 139.36 5.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.84 0.352 . . . . 0.0 111.122 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -163.67 137.0 4.28 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.927 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -54.68 159.77 8.36 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.502 2.135 . . . . 0.0 112.336 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 15.3 m -158.06 134.77 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.095 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.404 ' CZ ' ' O ' ' A' ' 143' ' ' PHE . 5.0 p90 -121.25 162.44 20.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -156.17 150.82 25.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.207 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.45 139.3 7.75 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.126 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.37 -156.57 19.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.248 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 29.4 m -138.88 148.25 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.161 0.505 . . . . 0.0 111.267 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.421 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 40.1 tt0 -124.62 131.93 53.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.715 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . 0.441 ' CE2' ' CB ' ' A' ' 90' ' ' ASP . 48.8 t80 -127.9 147.59 50.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.239 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 117.0 34.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.859 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 29.6 pt -89.57 -33.59 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.069 0.462 . . . . 0.0 110.671 179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -147.37 174.58 3.29 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.52 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -54.17 -62.08 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.586 2.191 . . . . 0.0 112.75 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -100.15 31.52 3.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.629 -179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.4 HD11 ' N ' ' A' ' 135' ' ' ILE . 4.5 mp -145.99 115.52 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.952 0.406 . . . . 0.0 111.555 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.07 150.13 52.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.924 179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.31 141.66 51.95 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.641 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -134.2 140.48 46.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.104 0.478 . . . . 0.0 111.687 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.5 pp -132.68 130.54 40.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.511 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -151.68 168.21 25.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.301 0.572 . . . . 0.0 111.933 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.494 ' HA ' ' O ' ' A' ' 161' ' ' MET . 2.7 m-85 -131.8 159.28 38.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.911 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -141.57 165.06 28.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.404 ' O ' ' CZ ' ' A' ' 123' ' ' PHE . 0.7 OUTLIER -132.21 163.0 29.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 14.3 p -105.87 -178.53 3.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.1 121.61 33.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.967 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -128.57 173.74 10.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 4.6 mt 62.9 147.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.085 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -88.01 145.47 19.26 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.494 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -63.77 129.66 41.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.809 0.338 . . . . 0.0 110.957 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -172.39 -63.88 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.14 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -131.01 -60.26 0.97 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 48.6 p -73.71 116.38 14.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.877 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.1 pt -134.26 31.0 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.115 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -95.56 -177.35 37.05 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.453 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 62.7 p -96.91 125.78 41.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.808 0.337 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 1.8 mtt180 -122.15 135.77 25.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.19 108.82 2.8 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.487 2.125 . . . . 0.0 112.307 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.51 -60.43 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 21.3 t-20 -129.98 108.96 10.5 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.0 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -100.93 124.83 8.38 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.415 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.494 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.5 OUTLIER -94.1 115.91 28.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.622 0.249 . . . . 0.0 110.947 -179.957 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -121.41 120.44 35.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.006 179.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.412 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 1.8 m -132.44 154.12 50.17 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.292 0.568 . . . . 0.0 111.891 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 2.6 mp -145.3 122.52 11.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.865 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -141.88 165.18 26.62 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.25 -0.976 . . . . 0.0 113.465 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.41 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 8.8 p -111.37 147.19 15.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' SER . . . . . 0.42 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 5.3 t -136.33 151.54 49.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.294 0.568 . . . . 0.0 112.175 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -119.49 133.63 55.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.838 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . 0.471 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 2.0 ttp180 -106.97 121.61 44.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.295 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -69.06 154.86 41.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.935 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -135.6 -140.27 4.16 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -111.83 86.49 2.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.883 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -138.31 60.44 0.59 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.461 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -150.23 116.61 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . 60.52 106.44 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.043 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.105 179.962 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 1.6 mtt . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 120.867 0.365 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . 59.97 84.43 0.2 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 149.31 64.32 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.563 2.176 . . . . 0.0 112.269 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -110.7 113.61 26.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.897 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -173.42 100.25 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 24.4 m-80 59.31 -135.06 0.86 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.61 -0.268 . . . . 0.0 110.327 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 4.1 t -117.35 150.95 37.99 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.79 0.329 . . . . 0.0 110.455 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 35.7 p90 -127.92 164.16 22.89 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.798 -179.204 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.42 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 4.0 p90 -155.24 157.16 36.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.907 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.02 150.86 33.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.741 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.89 -164.93 27.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.332 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.53 154.14 49.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.628 -0.286 . . . . 0.0 110.568 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.416 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . 0.9 OUTLIER -138.32 150.48 46.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.186 0.517 . . . . 0.0 111.809 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.9 mp -148.63 127.08 12.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.628 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.15 174.11 27.95 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.481 -179.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -129.8 157.88 40.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 110.643 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.17 124.75 15.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.991 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -118.1 128.01 54.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.845 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -122.12 161.61 22.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -112.99 -169.55 1.5 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -123.41 111.63 16.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.0 p -78.54 106.59 10.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.941 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.63 129.23 4.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.49 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 60.56 98.83 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.872 0.368 . . . . 0.0 110.92 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 33.0 mt -108.41 135.21 47.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -142.46 165.08 28.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -136.77 82.53 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -75.56 -35.53 60.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 131.77 -81.3 0.32 Allowed Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.515 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.12 63.19 2.0 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.566 2.177 . . . . 0.0 112.334 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.5 m -100.74 143.02 31.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.905 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -105.63 101.48 10.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.854 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -96.63 -68.65 0.79 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 45.3 t30 -91.0 129.04 37.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.854 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -121.17 125.16 46.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.693 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 13.2 tp -96.04 136.36 36.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.147 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.46 156.8 23.26 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.378 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -130.67 162.44 29.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.821 0.343 . . . . 0.0 111.256 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.62 -173.26 42.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.385 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 153.45 52.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.716 -0.242 . . . . 0.0 110.598 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 12' ' ' LYS . 6.2 p90 -159.42 166.33 31.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.225 0.536 . . . . 0.0 112.016 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -148.08 160.03 28.21 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.53 179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.1 159.88 28.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.363 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -124.85 132.13 53.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.569 -0.315 . . . . 0.0 110.276 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -95.48 126.22 40.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.119 179.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.8 t -96.24 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.0 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.493 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 3.3 m-20 -103.54 171.27 5.28 Favored Pre-proline 0 C--N 1.332 -0.185 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.192 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.493 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 10.1 Cg_endo -51.52 128.8 27.15 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.683 2.255 . . . . 0.0 113.085 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.416 ' CE1' ' HG3' ' A' ' 86' ' ' PRO . 1.4 m-85 59.88 16.32 5.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.407 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 2.8 m -138.95 113.96 8.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.843 -0.343 . . . . 0.0 111.385 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.3 -172.86 14.48 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.777 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -130.3 154.31 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.561 0.22 . . . . 0.0 110.602 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -150.4 138.14 19.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.482 . . . . 0.0 111.733 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -130.46 113.53 14.41 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.261 179.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.03 159.65 14.14 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.406 -0.902 . . . . 0.0 113.189 -179.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -153.11 150.31 28.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.804 0.335 . . . . 0.0 110.846 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -103.81 144.34 31.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.936 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.2 127.35 7.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.8 tp -124.85 141.13 52.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.813 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -105.99 -170.57 23.31 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.582 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 5.7 mtp85 -142.92 -68.14 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.888 0.375 . . . . 0.0 110.912 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 5.8 tpt -146.3 81.43 9.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.03 63.55 1.95 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.493 2.129 . . . . 0.0 112.293 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -168.15 96.72 0.42 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.33 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.877 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 105.17 142.67 11.42 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.545 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.14 79.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.774 0.321 . . . . 0.0 110.956 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 19.3 m -130.85 129.35 63.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -99.08 -40.86 7.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.915 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -123.39 175.84 6.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.66 80.25 0.12 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.466 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.58 76.9 1.54 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.822 0.344 . . . . 0.0 111.127 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -104.67 -48.93 3.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.902 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.5 mmmt -75.83 176.31 7.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.06 152.03 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.071 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -105.84 107.39 18.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.407 ' HA3' ' CD1' ' A' ' 102' ' ' PHE . . . -142.69 145.96 16.44 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.559 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 31.1 m -144.12 163.99 14.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.706 0.289 . . . . 0.0 111.044 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -130.29 137.34 49.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.075 0.464 . . . . 0.0 111.028 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -125.34 130.16 51.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.702 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.7 p -151.35 173.01 15.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.492 0.663 . . . . 0.0 111.924 -179.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.0 141.98 37.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.922 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -108.26 125.57 51.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.82 0.343 . . . . 0.0 111.403 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 2.4 tp -130.31 112.44 13.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.397 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.421 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.49 171.17 22.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.434 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -123.99 138.94 31.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.715 0.293 . . . . 0.0 110.598 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.416 ' HG3' ' CE1' ' A' ' 48' ' ' TYR . 95.1 Cg_endo -84.6 98.89 0.72 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.73 2.286 . . . . 0.0 112.675 -179.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 24.0 mm -79.06 -36.66 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.032 0.444 . . . . 0.0 110.365 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.51 164.45 34.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.177 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -60.61 -24.02 65.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.524 0.202 . . . . 0.0 111.314 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.423 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 2.7 m-20 -113.6 -35.06 5.34 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -102.86 123.48 46.59 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.944 0.402 . . . . 0.0 111.758 -179.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -133.69 161.25 35.19 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.292 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 2.7 pt -121.44 142.51 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.979 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.421 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 40.4 p90 -147.8 165.34 30.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.69 0.757 . . . . 0.0 112.895 -178.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -144.32 140.66 29.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.399 -1.273 . . . . 0.0 109.445 179.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.5 mtm-85 -118.81 137.44 53.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 111.18 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.403 ' HB3' ' CE1' ' A' ' 123' ' ' PHE . 0.5 OUTLIER -139.5 119.7 13.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.918 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -166.32 -141.6 3.19 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.352 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.34 150.58 22.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.55 -0.833 . . . . 0.0 113.251 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.8 ptp -101.86 157.33 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.945 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.4 m -141.38 101.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.407 ' CD1' ' HA3' ' A' ' 76' ' ' GLY . 1.2 t80 -96.33 124.52 40.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.958 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 25.0 mtt85 -122.15 131.08 53.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -126.89 142.16 51.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.055 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -91.37 120.55 32.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.1 m 60.29 93.82 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.948 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -157.55 158.08 34.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.941 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.88 145.45 45.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 23.5 t30 -128.87 170.74 13.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.13 158.04 41.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.108 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -74.5 -31.61 62.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.887 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.67 -30.23 68.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.483 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 11.1 mmtp -110.73 130.75 55.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.34 . . . . 0.0 110.891 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -101.21 31.3 3.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -160.4 120.39 2.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -60.36 -31.28 70.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 t -74.16 126.42 30.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -89.33 135.05 12.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 17.1 m -139.52 155.49 25.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.886 0.374 . . . . 0.0 111.189 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.3 m -177.31 153.9 1.05 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.862 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -52.59 147.05 31.81 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.547 2.165 . . . . 0.0 112.346 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 21.9 t -140.71 116.31 7.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.204 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.403 ' CE1' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -115.2 157.91 23.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.752 179.832 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -155.41 146.57 22.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.325 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.2 138.94 7.55 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.188 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.21 -155.77 18.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.044 -1.074 . . . . 0.0 113.243 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 29.8 m -138.71 147.97 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.008 0.432 . . . . 0.0 111.258 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -124.77 132.2 53.38 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.692 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 34.7 t80 -125.87 145.95 50.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.047 -179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.404 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.86 115.58 29.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.952 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 21.4 pt -89.88 -33.11 5.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.036 0.446 . . . . 0.0 110.408 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.445 ' CG2' ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -149.25 165.16 18.34 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.187 179.682 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.445 ' HD2' ' CG2' ' A' ' 132' ' ' THR . 9.6 Cg_endo -53.17 -56.25 2.93 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -95.75 17.07 15.8 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.426 ' HB ' ' OG1' ' A' ' 132' ' ' THR . 3.5 mp -144.3 120.61 4.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.061 0.458 . . . . 0.0 111.897 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.13 154.05 48.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.814 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.2 p -125.06 142.19 51.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.618 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 24.9 mtt180 -138.66 135.23 34.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.067 0.46 . . . . 0.0 111.873 -179.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.5 mp -124.67 133.89 53.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.574 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -151.76 167.63 27.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.307 0.575 . . . . 0.0 112.005 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.477 ' HA ' ' O ' ' A' ' 161' ' ' MET . 2.9 m-85 -122.57 159.5 27.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.851 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -159.98 115.93 2.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.984 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -92.42 162.62 14.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.901 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 62.5 m -92.75 108.36 19.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 25.2 m-20 -77.66 168.84 19.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -161.78 32.37 0.13 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 1.6 pp -98.13 31.7 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.114 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -128.19 -101.71 1.08 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.451 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -73.58 120.1 18.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.835 0.35 . . . . 0.0 110.856 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.96 9.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.162 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 3.1 t-160 60.55 35.26 20.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.41 160.54 21.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.7 mt -71.32 -38.72 70.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.058 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 100.06 93.2 2.1 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.521 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 81.5 p -75.87 157.02 33.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.781 0.324 . . . . 0.0 110.944 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -100.88 97.98 7.73 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.24 104.1 1.34 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.489 2.126 . . . . 0.0 112.298 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -98.72 31.8 2.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -175.26 96.76 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.9 -154.9 20.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.477 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 10.3 mmm 61.96 -82.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.537 0.208 . . . . 0.0 110.932 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.7 mp -120.65 118.18 29.47 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.457 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 0.3 OUTLIER -131.77 152.54 50.88 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.315 0.579 . . . . 0.0 111.861 -179.288 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 3.9 pp -142.45 122.54 13.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.673 179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.17 163.68 27.02 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.236 -0.983 . . . . 0.0 113.485 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.403 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 21.8 t -106.14 146.94 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.5 p -134.87 145.73 48.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.469 . . . . 0.0 111.739 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.5 m-85 -114.64 131.39 56.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.773 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.55 118.64 37.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.021 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -100.84 120.29 39.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.882 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.34 -74.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -78.87 85.46 4.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.815 0.341 . . . . 0.0 110.91 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -144.89 54.94 0.56 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.503 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -95.91 155.07 16.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.833 0.349 . . . . 0.0 110.932 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -60.0 127.39 31.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.136 179.966 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 12.8 mtp . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.72 0.295 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -175.35 89.05 0.3 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.43 138.0 41.21 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.599 2.199 . . . . 0.0 112.308 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.56 141.58 31.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -166.55 32.71 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -121.0 59.23 0.94 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.911 0.386 . . . . 0.0 110.399 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.1 173.26 11.41 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.634 -178.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.6 m-90 -125.19 166.67 16.04 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.562 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.487 ' N ' ' O ' ' A' ' 42' ' ' GLY . 1.5 p90 -155.62 163.03 40.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.16 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 m -149.22 152.75 36.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.519 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.401 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -171.49 -160.36 19.86 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 119.894 -1.146 . . . . 0.0 113.426 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.27 153.92 51.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.631 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.6 mmmp? -137.58 149.8 46.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.119 0.485 . . . . 0.0 111.567 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.1 mp -148.56 126.36 11.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.662 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.14 174.12 27.94 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.445 -179.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -128.63 156.47 43.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.856 0.36 . . . . 0.0 110.763 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -129.28 158.93 37.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.851 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 61.55 44.69 8.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 9.0 t80 -98.94 97.14 8.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.875 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -115.47 143.35 45.44 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.843 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -167.86 33.6 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.89 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.1 t -107.87 -31.92 7.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -71.87 1.05 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.553 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.8 160.85 14.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -92.57 165.07 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.088 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 11.8 t30 60.63 166.62 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.902 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -73.52 100.11 3.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -158.82 123.52 4.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -104.63 150.44 17.18 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.454 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.32 -45.59 1.24 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.577 2.185 . . . . 0.0 112.319 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 39.0 p -145.07 -58.54 0.35 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.902 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -106.89 131.25 54.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.877 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -95.66 -177.52 4.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 17.8 p-10 -78.16 146.51 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.835 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -119.65 127.3 52.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.723 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -94.27 135.2 35.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.07 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.97 157.4 23.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.335 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -138.64 164.94 28.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.888 0.375 . . . . 0.0 111.32 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.21 -167.54 38.26 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.301 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.408 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -119.02 153.03 35.34 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.477 0.18 . . . . 0.0 110.75 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.427 ' CZ ' ' HA3' ' A' ' 54' ' ' GLY . 1.7 m-85 -154.72 142.69 20.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.158 0.504 . . . . 0.0 111.619 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -140.61 156.94 25.55 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.535 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -155.57 165.07 32.36 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.215 -0.993 . . . . 0.0 112.82 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 1.4 p90 -146.06 139.27 25.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.921 0.391 . . . . 0.0 111.373 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -94.96 124.67 39.14 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.533 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 10.9 m -98.49 -37.0 6.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.72 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.483 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.9 OUTLIER -149.39 170.11 8.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.359 -179.828 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.483 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 6.2 Cg_endo -48.64 120.5 5.3 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.826 2.351 . . . . 0.0 113.26 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.407 ' CD1' ' N ' ' A' ' 48' ' ' TYR . 0.9 OUTLIER 58.38 18.37 5.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.561 -0.745 . . . . 0.0 112.33 178.85 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.431 ' CG2' ' CB ' ' A' ' 46' ' ' ASN . 4.9 m -138.71 112.96 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.826 0.346 . . . . 0.0 111.451 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.45 -172.36 15.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . 0.418 ' HB2' ' CZ ' ' A' ' 43' ' ' TYR . 20.9 m-85 -128.38 151.43 49.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.662 0.268 . . . . 0.0 110.518 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -145.87 135.23 23.0 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.026 0.441 . . . . 0.0 111.47 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 15.1 ttp -129.73 154.71 46.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.331 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.427 ' HA3' ' CZ ' ' A' ' 40' ' ' PHE . . . -160.72 159.31 30.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.265 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.1 t80 -140.76 148.89 41.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -113.54 119.33 37.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -122.53 -66.25 1.04 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.847 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.6 178.5 1.26 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.816 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -165.99 -49.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.449 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 20.6 mtt85 -130.24 136.48 49.24 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.842 0.353 . . . . 0.0 110.901 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 1.9 mtm -72.65 -60.69 1.92 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.66 109.89 2.88 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.537 2.158 . . . . 0.0 112.319 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -69.82 -55.74 9.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.856 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.55 31.34 20.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.879 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 135.57 122.74 2.24 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 33.8 p -109.9 105.9 15.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.816 0.341 . . . . 0.0 110.928 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.6 m -109.96 31.06 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.135 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -83.3 101.96 11.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.906 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -75.4 -36.5 60.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.77 52.14 1.22 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -101.42 -59.7 1.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.341 . . . . 0.0 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -129.73 -175.32 3.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 2.2 tmtm? -174.38 -41.26 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . 60.47 173.83 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.08 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -137.42 124.14 21.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.964 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -121.71 101.02 0.75 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.516 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 24.7 t -106.93 153.96 7.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.736 0.303 . . . . 0.0 111.051 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -128.23 135.27 49.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 111.047 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -130.85 130.76 44.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.888 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.4 ' HA ' ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.37 173.05 14.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.492 0.663 . . . . 0.0 111.989 -179.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.75 144.35 35.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.986 178.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . 0.42 ' HE2' ' CD2' ' A' ' 94' ' ' TYR . 0.3 OUTLIER -110.24 125.29 52.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.381 . . . . 0.0 111.479 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 6.2 tp -130.64 110.06 11.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.263 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.444 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.02 175.29 20.95 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.71 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -129.09 139.87 36.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.694 0.283 . . . . 0.0 110.576 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -86.63 104.18 0.66 Allowed 'Trans proline' 0 N--CA 1.46 -0.465 0 C-N-CA 122.786 2.324 . . . . 0.0 112.736 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 40.3 pt -81.11 -33.75 13.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.162 0.506 . . . . 0.0 110.353 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.36 164.3 33.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.151 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -60.59 -25.09 65.96 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.448 ' CB ' ' CE2' ' A' ' 129' ' ' TYR . 1.0 OUTLIER -112.74 -30.85 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.104 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 13.4 tp -102.96 123.59 46.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.614 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -131.62 154.97 48.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.369 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 25.6 pt -123.07 142.62 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.873 179.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.444 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 19.3 p90 -152.83 170.15 21.05 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.752 0.786 . . . . 0.0 113.073 -178.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.4 p -141.5 142.5 33.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.295 -1.321 . . . . 0.0 109.53 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.14 137.49 52.93 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.964 0.412 . . . . 0.0 111.001 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.3 tt -139.77 119.25 13.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.814 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.4 ' HA3' ' HA ' ' A' ' 80' ' ' THR . . . -164.98 -144.52 4.08 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.233 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -152.9 152.6 24.24 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.491 -0.862 . . . . 0.0 113.292 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.3 ttt -101.99 157.78 16.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.845 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 11.2 p -139.01 124.4 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.062 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -125.52 125.22 42.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -124.13 146.8 48.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.99 147.76 24.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.132 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -101.04 105.01 16.17 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.894 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.8 p -72.66 143.09 48.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 -44.71 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 6.8 t -139.16 -49.32 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.859 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -166.57 143.39 4.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 5.6 m -147.81 174.59 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.139 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 16.2 t80 -68.57 -35.96 78.11 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.944 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -113.5 -174.48 18.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.473 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 2.6 tttt -169.47 35.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.898 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -151.69 153.19 33.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 1.4 t-160 -61.37 85.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.38 -60.55 1.64 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.2 p 57.67 106.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.017 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.55 130.58 18.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.491 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.6 m -149.19 157.77 6.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.869 0.366 . . . . 0.0 111.206 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 26.9 t -177.5 143.91 0.53 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.74 161.52 4.44 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.493 2.129 . . . . 0.0 112.3 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 27.8 m -155.65 140.73 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.091 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -121.49 156.41 32.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.816 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -152.14 147.1 26.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.249 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.6 138.82 7.62 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.14 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.1 -157.96 21.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.314 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 28.4 m -138.38 147.99 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.052 0.453 . . . . 0.0 111.255 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -125.35 131.1 53.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.777 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . 0.448 ' CE2' ' CB ' ' A' ' 90' ' ' ASP . 38.0 t80 -126.86 146.59 50.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.408 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.89 115.65 29.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 19.8 pt -89.27 -34.82 7.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.958 0.408 . . . . 0.0 110.7 179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.402 ' CG2' ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -146.65 172.98 4.59 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.555 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.402 ' CD ' ' CG2' ' A' ' 132' ' ' THR . 50.5 Cg_exo -54.4 -61.86 0.36 Allowed 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.517 2.145 . . . . 0.0 112.757 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -99.84 25.44 7.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.777 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 4.0 mp -144.24 116.06 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.979 0.419 . . . . 0.0 111.565 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -127.35 158.48 37.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.972 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 26.0 p -141.49 138.42 32.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.41 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.22 150.92 35.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.131 0.491 . . . . 0.0 111.944 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.3 mp -118.34 139.81 50.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.723 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.426 ' HG3' ' CZ ' ' A' ' 94' ' ' TYR . 0.1 OUTLIER -143.15 149.94 38.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 111.567 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 161' ' ' MET . 6.2 m-85 -121.21 157.25 30.67 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.91 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -120.45 137.46 54.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.964 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -89.38 113.0 24.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.823 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 23.0 m -102.81 146.99 27.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 11.4 t30 60.31 109.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -147.66 82.06 1.52 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.8 mp -133.4 124.17 48.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.175 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -99.65 111.74 4.28 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.395 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -170.85 -179.19 2.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.934 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.32 89.39 0.06 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -70.24 138.34 51.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 46.4 p -76.18 -59.17 2.88 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.823 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 2.7 tt -91.28 -30.85 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.069 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 67.85 87.95 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 10.9 m -118.41 128.03 54.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 0.0 110.908 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 2.9 ttp85 -109.46 97.89 29.37 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.898 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 135.21 52.4 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.469 2.112 . . . . 0.0 112.388 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.88 -51.09 20.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.897 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -145.93 127.06 14.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.893 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -67.08 -100.85 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.486 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 2.1 mtm -108.6 140.75 41.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.68 0.276 . . . . 0.0 110.888 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -121.97 117.41 26.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.089 179.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.43 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 85.2 p -132.7 155.54 48.63 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.331 0.586 . . . . 0.0 111.885 -179.244 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -142.76 125.2 15.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.692 179.125 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.4 163.7 27.45 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.477 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.401 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 23.3 m -108.89 147.93 13.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 11.3 t -136.21 147.0 47.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.488 . . . . 0.0 111.852 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.746 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 3.0 ptm180 -108.2 119.13 38.6 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.103 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -82.16 154.75 25.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 159.11 -81.44 0.15 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.501 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 60.41 34.97 20.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.893 0.377 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -132.16 160.88 23.78 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.48 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 60.48 170.39 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.319 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -104.45 -34.26 8.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.141 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.108 -179.964 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 2.9 mtt . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.806 0.336 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -175.62 102.0 0.25 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.039 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.49 114.7 3.37 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.45 2.1 . . . . 0.0 112.242 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.5 tttp -108.05 -31.16 8.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.013 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -146.72 157.51 43.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.037 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 65.65 41.37 4.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.941 0.401 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -123.35 169.32 11.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.712 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.6 p-90 -124.52 163.87 20.96 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.523 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 42' ' ' GLY . 33.0 p90 -155.25 156.62 35.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.93 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 p -149.26 151.93 35.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.98 -160.73 21.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 119.904 -1.141 . . . . 0.0 113.32 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.412 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -127.11 154.45 44.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.524 -0.338 . . . . 0.0 110.512 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -142.21 146.08 34.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.083 0.468 . . . . 0.0 111.549 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.408 ' HA ' ' O ' ' A' ' 36' ' ' GLY . 1.4 mp -143.24 119.18 10.62 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.374 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.534 ' O ' ' HB2' ' A' ' 15' ' ' PHE . . . -149.52 168.56 29.77 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.012 -1.089 . . . . 0.0 113.914 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.534 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 0.3 OUTLIER 170.84 -92.53 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 122.979 0.512 . . . . 0.0 110.19 178.554 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.404 ' O ' ' N ' ' A' ' 34' ' ' GLN . 0.3 OUTLIER -177.58 128.28 0.14 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 110.985 179.662 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -151.18 84.14 1.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -127.24 145.8 50.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 60.1 -179.66 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.933 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -147.0 31.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 m 60.4 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.934 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -130.74 -128.27 2.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.558 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -108.49 35.58 3.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.867 0.365 . . . . 0.0 110.918 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.5 pt -103.98 -30.49 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -150.91 136.22 17.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -132.51 -67.05 0.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 32.1 m-20 -107.36 77.39 1.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.878 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -173.28 -148.97 6.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.467 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.57 123.61 12.56 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.597 2.198 . . . . 0.0 112.325 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -64.94 167.42 7.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -97.45 -176.31 3.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -148.73 100.59 3.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.937 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 31.1 m-20 -132.63 85.0 2.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.856 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.446 ' O ' ' HB3' ' A' ' 15' ' ' PHE . 8.9 mm100 -123.61 179.15 4.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.701 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.401 ' HA ' ' CB ' ' A' ' 15' ' ' PHE . 0.4 OUTLIER -148.99 136.45 20.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.47 -179.927 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 13' ' ' LEU . . . -123.79 149.37 16.88 Favored Glycine 0 C--N 1.331 0.264 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.189 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.38 153.02 46.75 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.999 0.428 . . . . 0.0 111.726 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.95 -173.29 42.37 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.606 -0.807 . . . . 0.0 113.295 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.412 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -130.55 154.22 48.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.876 -0.162 . . . . 0.0 110.57 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -159.23 161.65 36.09 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.281 0.562 . . . . 0.0 112.258 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -154.77 159.22 28.84 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.201 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 8' ' ' TYR . . . -157.77 165.1 33.46 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.796 -1.192 . . . . 0.0 113.563 -179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.5 m-85 -119.91 135.14 55.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.404 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -95.13 125.96 40.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.27 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.1 t -92.88 -37.57 8.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.874 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.437 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -153.6 179.32 1.32 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.125 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.437 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 35.2 Cg_exo -60.72 -26.1 82.3 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.689 2.259 . . . . 0.0 113.712 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.4 p90 -127.97 4.43 5.93 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 113.135 0.791 . . . . 0.0 113.135 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.401 HG11 ' CB ' ' A' ' 46' ' ' ASN . 9.1 p -139.52 115.72 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.601 -0.44 . . . . 0.0 111.718 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.4 -175.7 17.76 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.653 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -127.15 149.45 49.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.569 0.224 . . . . 0.0 110.44 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -147.76 136.82 22.17 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.085 0.469 . . . . 0.0 111.578 -179.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -128.22 155.27 44.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.231 179.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.34 158.37 29.47 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.213 -0.994 . . . . 0.0 113.197 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -159.12 167.37 29.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.79 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.42 154.09 22.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.982 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -100.69 169.71 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.961 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.2 tt 60.48 92.56 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -155.74 -103.8 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.512 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.45 137.35 47.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.874 0.369 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -174.04 87.2 0.36 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.06 149.79 65.47 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.351 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -115.02 35.46 4.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.861 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.61 -53.74 20.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.919 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 153.07 -28.0 0.8 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.557 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 42.8 t 61.03 110.39 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.798 0.333 . . . . 0.0 110.925 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 29.4 m -124.36 31.01 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.142 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -134.66 116.87 15.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -86.07 126.8 34.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.36 -155.81 8.56 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.465 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -81.59 -44.27 17.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 111.079 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 1.6 t80 60.72 46.01 9.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -97.5 38.22 1.29 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.986 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -93.87 -167.49 1.7 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER 62.9 -169.01 0.19 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.841 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -112.07 132.8 11.03 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.532 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.93 157.55 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.718 0.295 . . . . 0.0 111.044 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 -130.21 142.78 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.051 0.453 . . . . 0.0 111.08 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.7 131.34 43.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.84 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 p -151.46 173.0 15.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.495 0.664 . . . . 0.0 111.891 -179.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -110.29 142.41 41.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.963 179.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.62 127.25 53.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.969 0.414 . . . . 0.0 111.453 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.6 mp -129.73 111.22 12.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.303 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -133.55 169.79 22.61 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.266 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -121.69 137.4 27.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.613 0.244 . . . . 0.0 110.591 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -83.14 97.55 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.687 2.258 . . . . 0.0 112.63 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.404 HD11 HG21 ' A' ' 87' ' ' ILE . 31.1 mt -80.67 -35.67 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.048 0.451 . . . . 0.0 110.462 179.462 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 27.4 m -148.27 164.81 32.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.112 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -60.51 -27.34 67.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.522 0.201 . . . . 0.0 111.479 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 129' ' ' TYR . 73.8 m-20 -112.27 -34.9 5.77 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 15.1 tp -102.84 123.74 47.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.981 0.42 . . . . 0.0 111.688 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -135.39 164.19 28.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.348 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 1.3 pt -117.75 142.29 32.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.929 178.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.424 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 36.6 m-85 -144.72 159.14 43.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.686 0.755 . . . . 0.0 112.838 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.1 m -140.87 137.02 32.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.191 178.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 54.8 mtm180 -118.17 137.44 52.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.883 0.373 . . . . 0.0 111.277 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.3 tt -141.9 121.21 13.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.853 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.11 -146.25 4.71 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.273 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.23 156.05 26.71 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.612 -0.804 . . . . 0.0 113.179 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.97 158.86 15.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.765 0.317 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 12.1 m -145.83 118.2 2.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -126.93 115.22 18.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -131.43 127.13 36.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.889 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -131.62 126.61 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.092 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -104.25 152.05 22.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 6.5 m -144.88 -49.79 0.26 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.907 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.07 149.64 40.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 49.7 m -103.47 136.19 43.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -127.53 -45.28 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 18.3 t 69.02 -67.14 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.218 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -60.14 -31.21 69.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -103.0 125.79 8.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.484 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 8.5 mttp -104.21 105.37 15.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 19.6 m120 -104.78 136.91 43.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -104.59 90.76 3.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -119.14 36.53 4.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.874 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.88 118.55 31.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.9 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -77.78 126.02 7.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.553 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 20.7 t -146.69 139.34 19.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.776 0.322 . . . . 0.0 111.148 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -164.65 164.69 13.29 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.76 157.08 63.38 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.595 2.197 . . . . 0.0 112.253 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 21.5 t -145.42 97.56 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.225 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 124' ' ' ALA . 40.2 t80 -98.65 156.56 16.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.678 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.443 ' N ' ' CD1' ' A' ' 123' ' ' PHE . . . -158.27 148.02 19.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.313 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.98 140.0 8.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.124 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 175.36 -151.75 12.48 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.306 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 29.7 m -140.26 149.24 21.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.126 0.488 . . . . 0.0 111.357 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -125.39 132.37 52.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.631 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . 0.419 ' CZ ' ' HB3' ' A' ' 90' ' ' ASP . 39.6 t80 -125.54 146.2 49.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.213 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.405 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -97.91 115.4 28.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.929 179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.4 tt -88.5 -35.04 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.958 0.409 . . . . 0.0 110.561 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.401 ' CG2' ' HD2' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -150.49 172.41 5.32 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.426 179.631 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.401 ' HD2' ' CG2' ' A' ' 132' ' ' THR . 52.8 Cg_exo -53.23 -57.06 2.2 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.473 2.115 . . . . 0.0 112.488 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -102.89 31.8 4.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.515 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.16 114.23 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 111.743 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.09 154.23 46.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.919 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 26.1 p -129.0 140.59 51.57 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.411 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.2 ttm105 -137.39 135.1 36.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.947 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.3 tp -124.98 132.51 53.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.432 179.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.77 165.58 32.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.255 0.55 . . . . 0.0 111.886 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 161' ' ' MET . 8.6 p90 -129.73 162.8 27.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.948 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.93 115.94 2.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -92.69 139.38 30.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 8.8 t -98.18 152.32 19.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -98.13 35.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -89.27 109.52 20.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 24.4 mt -133.69 -49.42 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -149.21 -46.86 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.457 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -133.23 -68.19 0.59 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.914 0.387 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . 59.92 169.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -67.04 115.67 7.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 60.47 162.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.879 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 2.8 pp -152.73 174.0 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.192 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 171.96 -112.14 0.43 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.538 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 32.1 p -110.8 140.65 45.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.838 0.351 . . . . 0.0 110.959 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.8 mtt180 -70.7 147.02 94.25 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.59 151.61 52.84 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.547 2.165 . . . . 0.0 112.284 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -117.01 30.22 7.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.903 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -177.49 82.69 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.89 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -149.57 -156.22 7.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.484 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.448 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER 59.98 -84.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.425 0.155 . . . . 0.0 110.938 -179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -120.75 117.87 28.57 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.257 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.437 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 95.4 p -130.28 153.04 49.05 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.231 0.538 . . . . 0.0 111.9 -179.301 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 3.0 tt -144.3 123.19 12.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.889 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.39 159.29 27.49 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.355 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 26.7 m -103.72 147.05 10.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 78.6 p -134.81 145.51 48.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.1 0.476 . . . . 0.0 111.785 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -112.19 132.06 55.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.675 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.51 116.25 31.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.009 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -108.75 134.18 51.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -174.47 59.65 0.12 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.453 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -112.48 96.37 5.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 64.45 -153.98 48.53 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.484 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -131.42 -54.74 1.02 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 110.935 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -107.54 33.41 4.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.076 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.996 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 3.0 tpt . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.808 0.337 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -146.28 152.95 47.77 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.119 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.78 116.47 4.58 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.547 2.165 . . . . 0.0 112.34 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.91 83.53 2.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -64.46 117.81 7.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -68.51 -124.95 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.482 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.8 m -119.47 155.27 32.38 Favored 'General case' 0 N--CA 1.461 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.674 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.517 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.1 p90 -126.8 164.45 21.34 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.623 -179.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.421 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 26.5 p90 -155.26 157.05 36.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.018 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 p -149.13 151.19 33.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.739 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.6 -163.35 24.48 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.05 -1.071 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.49 153.47 50.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.556 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.4 ptmt -138.0 149.74 46.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.169 0.509 . . . . 0.0 111.81 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.1 tt -149.29 125.3 10.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.637 179.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.14 174.2 27.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.239 -0.982 . . . . 0.0 113.58 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.447 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 3.1 m-85 -115.11 144.59 43.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.72 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -154.35 -168.3 2.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.9 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 61.79 84.76 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -113.79 85.72 2.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -104.22 174.0 6.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.992 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -93.46 127.49 39.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.8 p -113.39 -47.63 3.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.886 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.87 50.35 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -106.47 -176.73 3.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.787 0.327 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.9 mp -126.81 -45.2 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -158.65 161.47 37.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -72.27 87.38 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.929 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -155.99 110.63 2.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.96 -150.0 17.44 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.517 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.62 97.17 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.527 2.151 . . . . 0.0 112.315 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.7 t -82.6 152.04 26.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.985 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -176.78 37.69 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.861 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -85.15 -40.83 16.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -93.18 164.68 13.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.58 124.04 45.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.425 HD11 ' CE2' ' A' ' 15' ' ' PHE . 8.5 tt -85.63 132.61 34.13 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.979 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.81 138.17 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -118.18 159.22 23.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.815 0.34 . . . . 0.0 111.198 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.17 -174.24 40.86 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.281 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.14 154.29 47.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.761 -0.22 . . . . 0.0 110.549 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -159.14 156.96 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.317 0.58 . . . . 0.0 112.101 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -150.29 159.06 27.95 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.244 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.421 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -157.12 164.98 33.09 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 119.793 -1.194 . . . . 0.0 113.498 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.517 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.6 m-85 -118.53 134.17 55.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.445 -0.378 . . . . 0.0 110.384 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 14.7 tt0 -95.79 126.44 41.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.238 179.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 25.1 t -94.75 -35.77 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.837 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.46 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.9 OUTLIER -155.67 172.77 5.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.866 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.46 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 23.1 Cg_endo -62.23 -15.87 47.26 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.222 1.948 . . . . 0.0 113.449 -179.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.421 ' CD1' ' HG2' ' A' ' 47' ' ' PRO . 39.9 m-85 -128.24 -4.03 5.57 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.43 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 4.0 m -139.45 116.93 11.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.566 -0.453 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.53 -175.65 16.83 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.456 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -128.97 149.56 50.76 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -148.85 138.03 21.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.127 0.489 . . . . 0.0 111.665 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 6.3 mtt -128.26 156.09 43.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.148 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.22 158.29 29.36 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.031 -1.081 . . . . 0.0 113.138 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -156.74 158.61 37.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.89 0.376 . . . . 0.0 110.821 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 25.3 p-10 -90.52 128.29 36.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -92.75 -38.38 11.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 12.3 tp 68.81 -67.22 0.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.047 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 166.26 93.41 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.469 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.31 103.2 9.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.892 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -139.86 88.36 12.12 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -68.99 131.21 21.81 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.544 2.163 . . . . 0.0 112.29 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -60.23 -72.6 0.11 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.929 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.91 35.99 0.07 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.91 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 140.67 162.81 9.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.418 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.6 m -107.32 154.04 21.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.881 0.372 . . . . 0.0 110.839 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 13.9 m -135.5 -46.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.112 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -134.24 93.02 3.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 60.58 158.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 175.05 -56.64 0.12 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.05 114.47 4.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.135 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -65.25 125.67 25.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.928 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -78.16 -32.49 50.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -97.54 104.87 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.069 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -95.96 152.88 18.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.884 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -139.91 123.56 2.48 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.525 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t -140.56 156.24 23.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.732 0.301 . . . . 0.0 111.151 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 46.0 mt-30 -129.8 141.27 50.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.057 0.456 . . . . 0.0 111.039 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 4.0 pp -131.23 130.83 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.764 179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.5 p -151.71 173.03 15.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.475 0.655 . . . . 0.0 111.964 -179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.71 142.0 38.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.827 178.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -107.99 126.33 52.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.823 0.344 . . . . 0.0 111.554 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.4 tt -129.65 110.64 11.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.37 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.426 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.8 169.01 22.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.362 -0.923 . . . . 0.0 113.209 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.406 ' CD2' ' HD2' ' A' ' 86' ' ' PRO . 5.1 t80 -124.28 137.61 29.42 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.614 0.245 . . . . 0.0 110.65 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.406 ' HD2' ' CD2' ' A' ' 85' ' ' TYR . 98.5 Cg_endo -85.37 100.19 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.684 2.256 . . . . 0.0 112.633 -179.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -82.04 -34.2 12.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.053 0.454 . . . . 0.0 110.367 179.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 23.6 m -148.59 163.83 36.07 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.26 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.45 -24.96 67.73 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -111.42 -29.43 7.79 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.12 124.72 50.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 111.696 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -133.51 157.75 44.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.326 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 5.2 mt -117.04 141.71 34.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.888 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.426 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 16.8 m-85 -143.62 157.87 44.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.697 0.76 . . . . 0.0 112.721 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.6 p -141.83 137.05 31.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.52 -1.218 . . . . 0.0 108.987 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.413 ' CG ' ' CB ' ' A' ' 124' ' ' ALA . 0.4 OUTLIER -119.57 140.94 49.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.963 0.411 . . . . 0.0 111.467 -179.463 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 1.4 pp -142.17 120.68 12.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.816 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -164.96 -144.85 4.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.278 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.47 163.14 28.96 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.553 -0.832 . . . . 0.0 113.261 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 6.4 ttt -101.97 144.74 30.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.901 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 5.1 m -122.74 122.08 65.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.135 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -109.75 125.32 52.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -109.87 106.84 16.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -106.73 128.4 54.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.088 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.84 124.73 28.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.852 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 4.4 t -88.8 156.6 18.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.89 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 11.0 mtpp -150.65 -49.35 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 60.0 m -110.66 115.67 29.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -127.77 89.24 2.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 12.3 m -138.34 -46.98 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -101.0 -35.9 9.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 144.31 132.48 2.56 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -157.5 -174.37 4.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 110.862 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -80.25 135.25 36.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 3.4 t60 -142.22 -47.56 0.35 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.899 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.44 167.07 15.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.875 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.1 p -82.34 139.19 34.26 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.998 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.95 129.66 9.28 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.66 159.98 12.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.858 0.361 . . . . 0.0 111.105 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.1 m -176.92 88.62 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.04 132.19 23.92 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.627 2.218 . . . . 0.0 112.327 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 15.5 m -148.31 175.33 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.062 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 9.7 p90 -146.71 164.05 33.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.967 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.413 ' CB ' ' CG ' ' A' ' 96' ' ' ARG . . . -141.38 162.15 36.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.235 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.31 141.98 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.078 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.27 -154.86 16.59 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 119.926 -1.131 . . . . 0.0 113.331 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 16.2 m -140.38 148.22 22.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.045 0.45 . . . . 0.0 111.441 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.52 132.6 49.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.649 179.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . . . . . . . . . 30.8 p90 -129.92 151.61 50.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.361 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -102.3 117.31 34.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.835 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 20.5 pt -88.96 -36.1 8.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.04 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -162.47 162.12 19.53 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.965 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.26 140.79 41.35 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.558 2.172 . . . . 0.0 112.222 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.54 19.53 6.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.587 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.505 HG21 HD11 ' A' ' 135' ' ' ILE . 32.2 mt -149.08 111.76 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.047 0.451 . . . . 0.0 111.633 -179.674 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.11 151.1 50.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.797 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.1 m -133.46 140.36 47.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.449 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 3.6 ptm180 -146.92 145.0 29.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.158 0.504 . . . . 0.0 111.886 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.0 pp -120.21 140.61 50.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.575 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -146.45 157.37 43.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.147 0.499 . . . . 0.0 111.63 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.456 ' HA ' ' O ' ' A' ' 161' ' ' MET . 2.7 p90 -137.84 164.84 27.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.001 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -128.9 143.99 51.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -106.75 153.8 21.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.895 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 20.5 m 60.48 94.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -133.27 -52.74 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -131.69 86.56 2.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.8 pp -143.65 153.68 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.095 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -78.9 -81.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -62.56 138.75 58.55 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 0.0 110.88 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.94 -51.94 9.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.063 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -86.31 135.68 33.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 38.5 p -134.47 165.78 24.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.891 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 24.5 mt -134.9 111.31 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 114.98 -173.65 14.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.46 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -130.9 109.67 10.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.89 149.12 65.02 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -52.44 145.74 35.64 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.603 2.202 . . . . 0.0 112.319 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -168.37 -57.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.4 m120 60.59 91.05 0.06 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -59.33 -91.83 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.456 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 8.8 mtm -119.73 132.82 55.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.663 0.268 . . . . 0.0 110.876 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 5.5 tp -122.25 118.97 29.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.085 179.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.432 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 4.9 t -136.9 157.99 45.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.365 0.602 . . . . 0.0 112.132 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 1.1 tt -143.33 128.05 18.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.694 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.96 162.84 27.78 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.443 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 22.0 t -105.39 146.6 12.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.7 m -134.59 145.42 48.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.137 0.494 . . . . 0.0 111.614 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -113.83 131.53 56.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -108.66 117.73 34.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.976 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -102.04 172.2 7.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 119.32 170.31 14.54 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.484 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.5 mm-40 60.62 35.61 19.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -69.96 -47.18 48.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.545 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -85.98 138.97 31.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.928 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -106.15 31.24 5.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.098 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -179.996 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.809 0.337 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -113.9 87.64 12.95 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.104 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.84 99.09 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.601 2.2 . . . . 0.0 112.29 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.88 160.74 14.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -130.26 -174.68 3.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.901 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.424 ' HA ' ' CE1' ' A' ' 43' ' ' TYR . 2.0 m120 65.31 41.67 4.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.961 0.41 . . . . 0.0 110.812 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 45.4 p -121.97 168.86 11.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.72 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 25.9 p-90 -128.38 162.81 26.24 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.667 -179.294 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.455 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 1.4 p90 -155.28 157.28 36.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.717 179.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.1 p -149.15 151.78 34.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.665 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.406 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.1 -165.65 27.79 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.392 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -128.79 152.45 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.539 -0.33 . . . . 0.0 110.252 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.05 150.47 45.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.327 0.585 . . . . 0.0 112.058 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.403 ' HA ' ' O ' ' A' ' 36' ' ' GLY . 1.7 mp -139.05 116.91 11.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.675 178.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.527 ' O ' ' HB2' ' A' ' 15' ' ' PHE . . . -149.45 165.5 29.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 119.734 -1.222 . . . . 0.0 114.375 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.527 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 0.7 OUTLIER 171.11 -90.82 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.022 0.529 . . . . 0.0 110.272 178.495 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.451 ' H ' ' HB3' ' A' ' 15' ' ' PHE . 1.4 m -177.54 125.75 0.13 Allowed 'General case' 0 C--N 1.335 -0.045 0 CA-C-O 120.845 0.355 . . . . 0.0 110.946 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -135.34 -52.92 0.78 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -173.36 162.6 4.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.9 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -123.49 128.26 49.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.05 -66.91 0.7 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 102.56 2.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.868 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -134.67 -67.88 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.43 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -133.36 143.71 49.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.816 0.341 . . . . 0.0 110.895 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.7 mt -67.52 90.91 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.052 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -107.62 123.96 49.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -130.41 36.54 3.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -121.03 31.18 6.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.64 91.53 0.44 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.16 -38.26 70.84 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.258 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -145.81 100.02 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.841 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -97.81 -36.23 10.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -154.11 137.84 16.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.903 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 59.6 m-20 -136.92 92.59 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.91 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.444 ' O ' ' HB3' ' A' ' 15' ' ' PHE . 1.1 mm100 -125.03 -179.9 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 3.6 pp -147.41 137.28 22.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.364 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.417 ' N ' ' HB2' ' A' ' 15' ' ' PHE . . . -124.27 155.76 18.19 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.961 -0.637 . . . . 0.0 112.252 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -130.74 149.58 52.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.032 0.444 . . . . 0.0 111.73 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.68 179.65 44.04 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.28 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.26 153.24 47.17 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.55 -0.167 . . . . 0.0 110.55 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -159.38 165.69 32.71 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.349 0.595 . . . . 0.0 112.226 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -155.05 161.35 30.31 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.401 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.455 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -152.23 163.8 30.32 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 119.794 -1.193 . . . . 0.0 113.616 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.2 t80 -132.44 132.56 42.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.531 -0.335 . . . . 0.0 110.493 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -92.93 123.69 36.37 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.68 -43.83 12.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.813 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.506 ' HB2' ' HD2' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -152.06 165.19 18.01 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.411 -179.873 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.506 ' HD2' ' HB2' ' A' ' 46' ' ' ASN . 65.9 Cg_exo -40.12 123.09 1.28 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.904 2.403 . . . . 0.0 113.79 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 48' ' ' TYR . 0.8 OUTLIER 59.17 17.68 5.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.419 178.871 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 24.5 t -136.68 114.02 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.451 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.24 -177.35 19.96 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.568 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -124.89 152.11 44.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -147.12 134.85 21.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.059 0.456 . . . . 0.0 111.527 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 16.4 ttm -126.84 151.79 47.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.182 179.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -157.44 157.43 28.12 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.247 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -156.52 167.14 31.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.348 . . . . 0.0 110.73 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.26 145.37 26.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -94.47 87.98 5.33 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.804 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.5 mt -104.5 33.13 3.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 96.77 91.95 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 13.1 ttm180 -123.01 -49.68 1.95 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.828 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 5.9 ttt -143.83 84.8 9.54 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.02 164.26 35.46 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.609 2.206 . . . . 0.0 112.309 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -95.08 101.66 13.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -148.49 31.24 0.82 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.881 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.81 -82.04 1.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 m -146.1 93.19 2.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -112.82 153.66 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -121.29 80.72 1.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -96.46 -175.66 3.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 174.48 -151.33 12.49 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.503 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -174.39 152.1 1.7 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.868 0.366 . . . . 0.0 111.043 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -137.95 -56.96 0.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.8 mtmt -105.28 154.02 20.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . 60.15 85.67 0.1 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.111 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.59 144.43 35.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.416 ' HA3' ' CE2' ' A' ' 102' ' ' PHE . . . -132.65 122.69 3.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.503 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.4 t -137.93 159.28 33.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.078 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -129.29 138.76 51.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.03 0.443 . . . . 0.0 111.029 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.1 mt -129.44 130.68 46.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.852 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.9 p -151.56 173.09 15.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.445 0.64 . . . . 0.0 111.997 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -108.28 142.18 38.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.85 -1.068 . . . . 0.0 109.896 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . 0.41 ' HD3' ' CD2' ' A' ' 94' ' ' TYR . 14.5 tttp -108.6 126.15 52.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.879 0.371 . . . . 0.0 111.488 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 5.2 mt -129.96 113.12 14.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.332 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.459 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -136.4 171.59 22.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.371 -0.918 . . . . 0.0 113.494 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -128.94 136.94 29.96 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 110.476 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -83.95 104.26 1.07 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.651 2.234 . . . . 0.0 112.946 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.1 mp -78.33 -36.52 20.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 121.173 0.511 . . . . 0.0 110.183 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.418 ' CG2' ' CB ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -150.91 169.64 21.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.957 179.119 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.1 -22.37 66.81 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -112.11 -29.05 7.74 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.418 ' CB ' ' CG2' ' A' ' 88' ' ' THR . 0.3 OUTLIER -109.68 125.53 52.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.099 0.476 . . . . 0.0 112.031 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -133.01 155.42 49.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.186 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 11.5 pt -117.47 141.25 37.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.933 179.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.459 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 24.5 m-85 -144.27 161.28 39.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 112.628 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -141.63 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.218 178.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -117.34 136.23 53.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.893 0.378 . . . . 0.0 111.287 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.7 tt -140.42 119.38 12.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.95 -143.96 3.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.349 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -149.9 152.58 24.49 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.299 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 7.3 ttm -102.16 126.85 49.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.701 0.286 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.5 m -107.05 122.11 60.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.416 ' CE2' ' HA3' ' A' ' 76' ' ' GLY . 1.4 t80 -125.39 133.16 52.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.892 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.99 109.14 6.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.907 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -142.98 122.75 13.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.125 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -107.65 124.51 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.883 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 m -98.83 31.73 2.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 60.32 31.59 20.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.915 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.5 p -114.65 149.55 36.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 7.2 m-20 -102.55 35.56 2.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.886 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 21.5 t 62.64 101.3 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -97.59 24.14 7.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.76 28.48 42.41 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.507 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 5.5 mtpp -145.24 -48.34 0.23 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.788 0.328 . . . . 0.0 110.939 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 38.3 t30 -65.85 104.73 1.14 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.855 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -69.27 -45.92 68.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.921 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 5.1 t0 60.48 172.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p 53.59 78.34 0.15 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -82.63 103.65 2.45 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.513 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 m -138.05 118.0 15.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.81 0.338 . . . . 0.0 111.105 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -156.99 155.2 27.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.882 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 158.19 57.45 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.581 2.187 . . . . 0.0 112.303 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 21.6 t -152.01 125.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.171 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -106.88 155.56 19.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -150.63 146.79 26.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.176 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.79 139.44 7.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.24 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.74 -158.02 22.05 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.112 -1.042 . . . . 0.0 113.238 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 31.0 m -138.45 146.39 26.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.058 0.456 . . . . 0.0 111.241 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.416 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.2 OUTLIER -126.03 131.7 52.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.739 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . 0.406 ' CE2' ' OG1' ' A' ' 137' ' ' THR . 3.5 p90 -127.48 149.28 50.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.179 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.49 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.898 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 39.1 mt -88.91 -34.75 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.008 0.433 . . . . 0.0 110.744 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.88 174.56 3.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.675 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.8 -61.61 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.657 2.238 . . . . 0.0 112.75 -179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -101.17 30.17 4.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.643 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 4.4 mp -146.66 114.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.44 . . . . 0.0 111.609 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -127.05 156.34 41.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.994 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.406 ' OG1' ' CE2' ' A' ' 129' ' ' TYR . 3.5 p -141.77 139.07 32.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.474 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 4.4 ptp85 -148.94 148.32 29.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.178 0.514 . . . . 0.0 111.931 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -117.55 140.8 49.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.602 -0.726 . . . . 0.0 109.753 179.202 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -144.55 151.78 39.59 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.044 0.45 . . . . 0.0 111.561 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.445 ' HA ' ' O ' ' A' ' 161' ' ' MET . 8.1 p90 -124.95 161.83 25.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.979 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -138.63 176.08 9.0 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -124.08 135.63 53.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.3 m -95.35 -31.4 13.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -102.49 159.37 15.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.895 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -176.53 -40.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.8 tt -120.05 -41.64 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.091 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 67.12 98.85 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.461 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -107.14 79.45 1.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.827 0.346 . . . . 0.0 110.902 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -172.92 109.7 0.19 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 20.9 m170 60.58 -176.28 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 51.5 p -98.95 31.61 2.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.933 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 23.8 mt -118.78 -51.0 3.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.31 158.82 6.12 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.503 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 2.9 t -106.07 145.47 31.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.896 0.379 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -102.54 138.53 19.68 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.93 113.1 3.45 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.472 2.115 . . . . 0.0 112.303 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -82.97 -31.74 27.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -166.07 112.99 0.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -59.73 166.27 9.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.415 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.445 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER -60.84 136.18 58.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.612 0.244 . . . . 0.0 110.91 -179.938 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 6.4 tp -118.81 118.57 31.94 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.417 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 10.3 t -130.51 154.37 47.86 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 121.255 0.55 . . . . 0.0 112.03 -179.151 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 4.7 tt -145.25 123.98 12.59 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.771 179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -144.88 163.4 28.01 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.573 -179.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 29.3 m -105.29 146.99 11.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' SER . . . . . 0.406 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 2.8 m -134.96 147.21 49.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.204 0.526 . . . . 0.0 111.776 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -114.63 131.89 56.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.732 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 50.0 mtp180 -108.18 118.26 36.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.038 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -98.95 173.56 6.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -145.57 -142.08 3.75 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.515 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -162.04 -168.36 1.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 110.785 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 129.09 73.96 0.16 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.559 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -91.02 152.26 20.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.847 0.356 . . . . 0.0 110.878 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -88.88 -54.14 4.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.1 -179.977 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 5.3 ttt . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 120.844 0.354 . . . . 0.0 111.182 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -175.1 89.05 0.31 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.11 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.53 -61.35 0.54 Allowed 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.591 2.194 . . . . 0.0 112.293 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.5 mmtm -153.46 -76.38 0.12 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.65 -83.23 0.06 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.756 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.2 t30 67.41 42.8 2.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.809 0.337 . . . . 0.0 110.954 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 43' ' ' TYR . 74.5 p -123.49 160.69 26.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.752 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 8.0 t90 -119.09 137.49 53.54 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.286 -179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.422 ' CD1' ' HA ' ' A' ' 169' ' ' ARG . 3.9 m-85 -124.32 155.92 37.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.831 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.406 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 71.4 p -149.01 147.03 28.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.05 -163.06 23.45 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.174 -1.012 . . . . 0.0 113.364 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.48 153.99 50.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.647 -0.276 . . . . 0.0 110.611 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.426 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . 0.1 OUTLIER -137.12 149.88 47.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.157 0.503 . . . . 0.0 111.863 -179.401 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 tt -149.1 124.06 10.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.678 179.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.2 174.26 27.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.171 -1.014 . . . . 0.0 113.577 -179.196 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.45 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 3.7 m-85 -116.73 145.84 43.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.796 0.331 . . . . 0.0 110.638 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.5 p -139.15 -167.95 2.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 62.28 117.27 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.979 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -138.15 -52.19 0.61 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 60.13 170.51 0.08 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -141.08 -48.44 0.41 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.84 172.69 6.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.924 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.31 -160.07 24.04 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -102.62 85.41 2.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.6 mt -120.1 137.27 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.042 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -64.62 119.03 9.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.931 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 60.61 166.67 0.08 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.87 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -95.97 155.91 16.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.7 73.09 1.26 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.545 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.21 -35.01 61.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.588 2.192 . . . . 0.0 112.306 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 60.64 82.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 60.42 102.74 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -149.99 86.71 1.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.1 p30 -137.36 176.39 8.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.956 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -118.67 118.74 32.45 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.797 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.415 ' HB3' ' CD2' ' A' ' 15' ' ' PHE . 0.5 OUTLIER -83.32 131.9 35.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.922 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.18 142.7 13.97 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.449 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.2 158.55 25.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 111.173 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.35 -173.12 40.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.284 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.04 153.4 48.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.813 -0.193 . . . . 0.0 110.694 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.426 ' CE1' ' HB2' ' A' ' 12' ' ' LYS . 23.6 p90 -159.42 169.02 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.186 0.517 . . . . 0.0 111.867 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.406 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -145.68 160.9 28.2 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.756 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 52' ' ' GLU . . . -148.46 124.65 1.9 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.043 -1.075 . . . . 0.0 113.222 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.418 ' CG ' ' O ' ' A' ' 6' ' ' THR . 8.4 t80 -104.53 129.51 52.57 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -94.51 124.81 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.776 0.322 . . . . 0.0 110.548 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.11 -38.1 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.453 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 0.8 OUTLIER -147.06 -179.92 1.04 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.073 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.453 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.5 Cg_exo -59.96 -35.77 92.25 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.476 2.117 . . . . 0.0 112.923 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -123.74 11.11 9.06 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.2 t -135.55 112.95 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.573 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.25 178.03 21.14 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.489 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -127.1 150.01 49.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.573 0.225 . . . . 0.0 110.533 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.41 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 0.9 OUTLIER -146.9 133.73 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.031 0.443 . . . . 0.0 111.429 -179.654 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 8.5 ttp -126.49 151.95 47.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.352 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -158.26 157.54 28.4 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.272 -0.966 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -156.49 158.68 37.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.769 0.319 . . . . 0.0 110.811 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 22.2 p-10 -100.29 128.73 46.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -148.23 95.86 2.53 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.937 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.1 tt -112.21 153.4 27.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 91.91 65.01 1.13 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.43 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -87.74 -31.41 19.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.722 0.296 . . . . 0.0 110.848 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.6 148.1 87.26 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.6 164.0 37.12 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.455 2.103 . . . . 0.0 112.321 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -176.95 -66.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.954 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.7 mttt -75.91 161.87 28.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -62.95 175.96 7.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 5.0 m -98.59 35.48 1.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 0.0 110.873 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.1 m -99.84 176.57 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.075 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -144.93 33.3 1.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.956 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.2 m-20 -95.16 117.64 30.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 137.85 -158.46 24.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.531 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -129.46 141.1 51.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.832 0.348 . . . . 0.0 111.081 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -169.48 90.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 21.8 ttmt -100.64 107.61 19.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -150.97 106.31 3.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.073 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -118.79 141.33 48.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -155.16 114.32 0.61 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.547 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.1 p -148.64 140.59 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.687 0.279 . . . . 0.0 110.951 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.405 ' HA ' ' HA ' ' A' ' 100' ' ' MET . 4.5 mt-30 -126.22 132.06 51.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.976 0.417 . . . . 0.0 110.985 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -133.83 129.98 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.624 179.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -152.07 173.1 15.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.518 0.675 . . . . 0.0 111.979 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -103.37 142.37 34.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.862 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . 0.421 ' HE2' ' CG ' ' A' ' 94' ' ' TYR . 3.4 tttm -109.14 124.59 51.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 111.389 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 9.1 mp -130.7 110.14 11.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.464 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.446 ' HA3' ' CD2' ' A' ' 94' ' ' TYR . . . -133.46 172.09 21.68 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.383 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -126.74 137.59 30.78 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.665 0.269 . . . . 0.0 110.509 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.4 102.05 0.73 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.721 2.281 . . . . 0.0 112.716 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 7.0 tp -82.46 -33.33 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.029 0.442 . . . . 0.0 110.312 179.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.35 165.24 32.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.222 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -66.08 -21.98 66.39 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.522 0.193 . . . . 0.0 111.522 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -111.34 -27.82 8.48 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.0 mt -115.97 127.73 55.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.952 0.406 . . . . 0.0 111.677 -179.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -134.96 161.83 34.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.147 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.43 HD11 HG22 ' A' ' 93' ' ' ILE . 29.4 pt -119.62 142.06 36.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.033 179.117 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.446 ' CD2' ' HA3' ' A' ' 84' ' ' GLY . 39.5 m-85 -143.92 158.99 43.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.621 0.724 . . . . 0.0 112.662 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -139.03 136.47 35.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.111 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.3 mtp85 -116.35 136.86 52.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.034 0.445 . . . . 0.0 111.183 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.8 mt -139.38 117.43 11.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.748 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -168.48 -142.38 3.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.327 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.501 ' HA2' ' O ' ' A' ' 120' ' ' SER . . . -144.27 145.23 14.59 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.054 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.405 ' HA ' ' HA ' ' A' ' 78' ' ' GLN . 9.6 ptm -128.03 117.96 22.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.207 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.9 m -93.16 117.31 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.006 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -132.02 111.03 11.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.84 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.6 124.12 19.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -136.4 156.15 49.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.057 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -132.95 133.04 42.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.848 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.2 p -146.53 114.36 6.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.912 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.59 -177.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 m -60.33 132.79 55.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.872 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.76 -179.91 3.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 15.3 t 59.84 29.18 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -115.54 -36.06 4.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 166.1 41.66 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.538 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -99.58 134.16 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.847 0.356 . . . . 0.0 110.903 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -105.17 31.35 4.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -67.59 -177.44 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.843 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -149.67 122.95 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.043 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.3 -176.54 3.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.871 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.88 106.12 1.0 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 45.3 t -57.08 -74.86 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.654 0.264 . . . . 0.0 110.985 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' SER . . . . . 0.501 ' O ' ' HA2' ' A' ' 99' ' ' GLY . 0.6 OUTLIER 177.08 -67.8 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.37 179.553 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.477 ' CD ' ' CB ' ' A' ' 120' ' ' SER . 77.3 Cg_exo -38.03 112.13 0.11 Allowed 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.889 2.393 . . . . 0.0 113.192 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 6.8 m -153.04 151.44 11.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 0.0 111.318 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 18.8 p90 -137.7 164.09 29.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.761 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -148.52 153.19 38.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.299 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.41 140.97 8.68 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.102 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 176.96 -154.2 15.49 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.402 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 31.0 m -139.59 146.98 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.07 0.462 . . . . 0.0 111.377 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -126.19 131.04 52.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.531 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -128.84 150.81 50.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.478 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.79 116.03 31.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.769 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 32.7 mt -86.69 -38.42 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.874 0.368 . . . . 0.0 110.948 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -162.19 166.34 14.3 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -55.87 140.21 85.1 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.617 2.211 . . . . 0.0 112.53 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 63.78 10.42 5.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.441 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 13.4 pt -149.32 117.01 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.117 0.484 . . . . 0.0 112.081 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -128.57 157.0 42.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.855 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.9 m -136.36 140.84 43.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.58 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -149.0 149.43 31.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.154 0.502 . . . . 0.0 111.788 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 4.4 pp -120.11 141.83 49.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -145.06 152.78 40.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.538 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' TYR . . . . . 0.46 ' HA ' ' O ' ' A' ' 161' ' ' MET . 26.8 p90 -130.48 164.66 24.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.014 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -135.71 125.2 25.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -95.2 162.6 13.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.854 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.1 p -114.9 -38.65 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 51.4 m-80 -110.54 115.06 28.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.92 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -146.0 125.84 13.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 18.8 pt -112.41 -39.67 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 177.67 -50.42 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -73.34 141.83 47.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.805 0.336 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -157.03 146.71 20.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.035 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 28.4 m-70 -105.27 165.74 10.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.6 m -131.18 -46.26 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.7 mt -72.71 -51.34 28.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.1 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -105.38 93.06 0.87 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.577 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 8.4 m -130.99 105.6 7.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.796 0.331 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -99.43 149.04 35.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.93 88.64 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.587 2.191 . . . . 0.0 112.323 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -101.44 -40.73 6.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -167.92 92.77 0.37 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -175.19 -149.26 7.18 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.529 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER -133.56 132.44 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.639 0.257 . . . . 0.0 110.916 179.983 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 2.8 mt -122.28 118.57 28.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.122 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.431 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 8.5 t -137.35 157.96 45.46 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 121.351 0.596 . . . . 0.0 112.093 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 5.6 mp -143.33 128.57 18.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.716 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -144.12 163.57 27.73 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.471 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 21.5 t -105.09 146.04 12.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 2.0 m -134.67 143.8 47.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.078 0.466 . . . . 0.0 111.657 -179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -111.23 131.72 54.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.699 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . 0.422 ' HA ' ' CD1' ' A' ' 8' ' ' TYR . 0.0 OUTLIER -107.19 118.8 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.149 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -85.88 165.07 17.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -139.1 110.72 0.73 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.516 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -60.22 -36.32 77.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 0.0 110.904 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 148.5 59.52 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.478 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -121.89 145.88 47.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.901 0.382 . . . . 0.0 110.845 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -108.32 -35.76 6.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.106 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 179.968 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 p . . . . . 0 N--CA 1.461 0.089 0 CA-C-O 120.919 0.39 . . . . 0.0 110.664 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 18.6 p90 -125.44 164.22 20.92 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.577 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.424 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 22.5 p90 -155.2 156.6 35.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.77 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 44.4 p -149.13 150.51 32.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.737 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.0 -162.98 23.26 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.245 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.99 153.5 51.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.543 -0.329 . . . . 0.0 110.584 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.97 149.41 47.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.181 0.515 . . . . 0.0 111.739 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.734 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.872 0.368 . . . . 0.0 111.193 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -173.91 -174.74 41.04 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.374 -0.917 . . . . 0.0 113.325 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.67 154.15 48.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.836 -0.182 . . . . 0.0 110.612 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -159.24 163.75 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.326 0.584 . . . . 0.0 112.112 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.25 161.16 30.65 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.27 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.424 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -158.0 165.08 33.57 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.711 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -120.16 134.93 55.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.517 -0.342 . . . . 0.0 110.409 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 5.9 mt-30 -95.05 125.77 39.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.337 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -92.94 -38.42 9.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.418 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.0 OUTLIER -155.01 177.93 1.84 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.165 179.888 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.415 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.2 Cg_exo -60.14 -23.53 73.94 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.707 2.271 . . . . 0.0 113.644 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.415 ' CD1' ' HB2' ' A' ' 47' ' ' PRO . 69.3 m-85 -127.59 2.31 6.17 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.517 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.9 m -137.77 115.94 13.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.844 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.44 179.83 19.9 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.51 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -129.03 151.41 49.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.522 0.201 . . . . 0.0 110.556 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -152.03 138.49 18.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.045 0.45 . . . . 0.0 111.789 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 1.3 ptm -126.72 156.8 40.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.919 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.37 159.78 30.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.593 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 12.4 t80 . . . . . 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.587 179.922 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 78' ' ' GLN . 25.4 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.731 0.3 . . . . 0.0 110.984 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.491 ' N ' HG12 ' A' ' 77' ' ' VAL . 6.5 tt0 -127.81 136.43 51.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.027 0.441 . . . . 0.0 110.844 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.611 ' O ' HD12 ' A' ' 79' ' ' LEU . 4.0 pp -131.22 130.87 43.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.843 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.414 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.6 p -151.74 173.13 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.464 0.65 . . . . 0.0 111.874 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.56 141.24 39.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.905 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.8 mttp -108.02 126.98 53.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.493 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 20.9 mt -129.8 110.68 11.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.402 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.44 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.96 169.36 22.56 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.41 -0.9 . . . . 0.0 113.109 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.729 ' HB2' HD11 ' A' ' 93' ' ' ILE . 35.0 m-85 -123.72 137.67 29.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 110.548 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -84.43 99.4 0.75 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.707 2.271 . . . . 0.0 112.613 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 33.5 mt -81.28 -34.63 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.057 0.456 . . . . 0.0 110.442 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.435 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.9 m -148.0 164.78 32.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.184 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.435 ' N ' HG22 ' A' ' 88' ' ' THR . 58.6 m-20 -60.13 -27.66 67.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.478 0.18 . . . . 0.0 111.485 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.434 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 1.6 m-20 -112.02 -33.78 6.17 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -178.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.1 tt -102.85 123.84 47.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.941 0.4 . . . . 0.0 111.716 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -135.69 164.14 28.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.261 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.981 HG22 HG12 ' A' ' 127' ' ' VAL . 1.7 pp -119.6 142.93 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.003 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.44 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 6.7 m-85 -143.4 157.49 44.42 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.706 0.765 . . . . 0.0 112.715 -178.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 124' ' ' ALA . 91.6 m -141.14 136.26 31.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 114.542 -1.208 . . . . 0.0 109.029 178.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.826 ' CG ' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -118.13 139.58 51.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.963 0.411 . . . . 0.0 111.384 -179.543 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.0 mp -140.82 119.18 12.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.736 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.414 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -166.13 -141.84 3.26 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.296 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.44 23.35 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.317 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.8 ttt . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.991 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.408 ' CD1' ' N ' ' A' ' 123' ' ' PHE . 3.5 p90 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.781 0.324 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.826 ' HB3' ' CG ' ' A' ' 96' ' ' ARG . . . -142.18 164.2 30.8 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.252 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -149.04 141.95 9.42 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.122 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.4 ' HA3' ' O ' ' A' ' 139' ' ' LEU . . . 177.25 -155.0 16.92 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 119.87 -1.157 . . . . 0.0 113.358 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.981 HG12 HG22 ' A' ' 93' ' ' ILE . 30.1 m -139.71 148.17 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.974 0.416 . . . . 0.0 111.25 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -124.51 132.2 53.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.642 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.434 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 45.0 t80 -128.27 148.33 50.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.418 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 116.37 32.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.818 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 7.8 tp -88.57 -36.58 9.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.467 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -162.36 165.09 16.14 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.854 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.467 ' HD2' HG22 ' A' ' 132' ' ' THR . 11.7 Cg_endo -55.2 141.59 80.08 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.596 2.197 . . . . 0.0 112.074 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 58.54 19.01 6.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.531 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 31.1 mt -149.13 111.95 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 121.018 0.437 . . . . 0.0 111.718 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.577 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -124.42 156.13 37.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.836 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.6 m -142.83 136.26 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.5 ptt85 -146.15 157.94 43.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.253 0.549 . . . . 0.0 112.038 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.839 HD12 HD13 ' A' ' 164' ' ' LEU . 1.9 tt -128.18 139.86 52.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.596 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.472 ' N ' HD23 ' A' ' 139' ' ' LEU . 38.6 mt-10 -147.35 158.18 43.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.177 0.513 . . . . 0.0 111.693 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.869 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.421 HD12 ' N ' ' A' ' 162' ' ' LEU . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.118 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 17.8 m -136.73 157.54 46.52 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.331 0.586 . . . . 0.0 112.015 -179.27 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' LEU . . . . . 0.839 HD13 HD12 ' A' ' 139' ' ' LEU . 10.9 tp -141.69 127.87 19.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.673 179.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.98 161.75 27.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.09 -1.052 . . . . 0.0 113.431 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.2 m -106.16 147.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' SER . . . . . 0.577 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 22.4 p -134.54 146.11 49.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.159 0.504 . . . . 0.0 111.608 -179.388 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -113.61 131.63 56.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.786 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -108.54 117.12 33.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.955 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 4.0 t80 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.975 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 67.5 p . . . . . 0 N--CA 1.463 0.216 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 12.9 p90 -128.01 164.18 22.93 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.641 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.415 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 5.3 p90 -155.29 156.63 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.417 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 3.3 t -149.17 150.21 32.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.71 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.416 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.75 -161.94 22.24 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.465 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -130.46 159.38 37.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.537 -0.331 . . . . 0.0 110.608 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -142.26 150.05 40.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.216 0.532 . . . . 0.0 112.003 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.798 ' HG ' ' HB2' ' A' ' 37' ' ' ALA . 6.6 tt . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.548 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.798 ' HB2' ' HG ' ' A' ' 13' ' ' LEU . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.793 0.33 . . . . 0.0 111.027 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.18 -159.4 31.86 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.357 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -135.1 155.08 51.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.543 0.211 . . . . 0.0 110.668 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -159.29 163.66 35.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.289 0.566 . . . . 0.0 111.907 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -140.61 158.84 26.24 Favored Glycine 0 N--CA 1.448 -0.544 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.35 179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.415 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.67 150.13 21.75 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.509 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 6.9 m-85 -117.35 131.79 56.72 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -94.64 126.46 39.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.236 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.01 -36.9 7.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.769 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.453 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 0.2 OUTLIER -152.76 179.21 1.32 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.154 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.436 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 39.3 Cg_exo -61.47 -26.89 81.62 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.684 2.256 . . . . 0.0 113.692 -179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.79 ' O ' HD23 ' A' ' 83' ' ' LEU . 11.3 p90 -124.53 4.11 8.31 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 -178.593 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.453 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 3.7 m -137.74 116.11 13.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.862 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.35 179.41 19.56 Favored Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.439 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -130.23 152.38 49.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.62 0.248 . . . . 0.0 110.767 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.408 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 13.0 mt-10 -150.38 136.71 18.77 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.09 0.471 . . . . 0.0 111.528 -179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' MET . . . . . 0.449 ' HG2' HD12 ' A' ' 79' ' ' LEU . 5.1 mpp? -132.35 114.39 14.32 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.327 179.567 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -119.09 164.02 13.23 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.431 -0.89 . . . . 0.0 113.39 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.636 ' HB3' HG12 ' A' ' 77' ' ' VAL . 17.9 p90 . . . . . 0 C--N 1.331 -0.221 0 CA-C-O 120.796 0.331 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 55' ' ' TYR . 30.9 m . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.735 0.302 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.0 pm0 -131.72 139.33 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.449 HD12 ' HG2' ' A' ' 53' ' ' MET . 7.7 tt -127.11 132.13 50.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.803 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -151.62 173.06 15.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.44 0.638 . . . . 0.0 111.978 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.54 141.44 39.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.862 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -108.83 126.44 53.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.874 0.369 . . . . 0.0 111.447 -179.416 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.79 HD23 ' O ' ' A' ' 48' ' ' TYR . 2.4 mt -131.61 110.09 10.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.239 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.1 177.53 19.48 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.773 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 85' ' ' TYR . 3.4 m-85 -131.76 140.63 38.87 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.659 0.266 . . . . 0.0 110.475 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -87.56 106.72 0.61 Allowed 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.836 2.357 . . . . 0.0 112.826 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 1.003 HD11 HD22 ' A' ' 91' ' ' LEU . 26.4 pt -80.22 -33.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.23 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.749 HG22 HG13 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -150.65 169.68 21.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.05 178.914 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -64.17 -23.31 67.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.079 0.399 . . . . 0.0 112.079 -179.161 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.446 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -110.94 -28.22 8.45 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 -178.708 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 1.003 HD22 HD11 ' A' ' 87' ' ' ILE . 0.5 OUTLIER -109.34 126.37 53.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.138 0.494 . . . . 0.0 111.924 -179.086 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.24 152.52 50.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.001 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 12.0 tt -123.11 142.12 40.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.907 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.439 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 28.5 p90 -153.22 170.21 21.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.719 0.771 . . . . 0.0 113.021 -179.017 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 p -139.62 141.91 37.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.62 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.613 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 46.1 mtp180 -117.3 137.39 52.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.882 0.372 . . . . 0.0 111.067 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.636 HD23 ' N ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -139.86 120.03 13.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.856 -179.924 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -141.06 3.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.338 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.17 151.89 23.78 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.591 -0.814 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 2.4 ppp? . . . . . 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.955 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.841 0.353 . . . . 0.0 110.818 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.613 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -151.94 149.48 28.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.21 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.91 138.65 7.44 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.075 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.38 -158.5 22.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 119.996 -1.097 . . . . 0.0 113.264 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 18.8 m -141.89 149.78 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.134 0.492 . . . . 0.0 111.474 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -125.27 131.37 53.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.504 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.446 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 42.6 t80 -126.89 146.98 50.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.319 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.4 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.84 114.53 27.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.81 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -87.03 -39.18 12.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.009 0.433 . . . . 0.0 110.933 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.726 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -159.59 169.75 9.88 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.729 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.726 ' CD ' HG22 ' A' ' 132' ' ' THR . 32.0 Cg_exo -58.41 139.94 92.57 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.52 2.147 . . . . 0.0 112.214 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 59.71 17.72 6.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.842 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.45 ' O ' HG23 ' A' ' 135' ' ' ILE . 1.8 tt -149.21 113.93 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.114 0.483 . . . . 0.0 111.721 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.71 157.86 40.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.084 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 3.2 t -124.9 141.11 52.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.534 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 25.0 mtt180 -135.16 134.59 40.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.124 0.488 . . . . 0.0 111.815 -179.35 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.939 HD12 HD12 ' A' ' 164' ' ' LEU . 4.3 tt -130.06 130.78 45.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.543 179.044 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.526 ' N ' HD23 ' A' ' 139' ' ' LEU . 0.9 OUTLIER -153.53 169.42 23.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.392 0.615 . . . . 0.0 112.017 -179.08 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 141' ' ' TYR . . . . . 0.416 ' CZ ' ' HG ' ' A' ' 162' ' ' LEU . 4.1 m-85 . . . . . 0 C--N 1.327 -0.39 0 CA-C-N 115.21 -0.904 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.523 HD23 ' C ' ' A' ' 162' ' ' LEU . 7.2 tt . . . . . 0 C--O 1.23 0.055 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 28.3 t -132.69 154.2 50.39 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.199 0.523 . . . . 0.0 111.78 -179.267 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' LEU . . . . . 0.939 HD12 HD12 ' A' ' 139' ' ' LEU . 8.0 tt -144.66 122.7 12.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.853 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.12 163.83 26.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.245 -0.978 . . . . 0.0 113.24 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.8 m -105.06 146.83 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' SER . . . . . 0.416 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 0.9 OUTLIER -135.14 143.42 46.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.096 0.474 . . . . 0.0 111.67 -179.505 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -109.61 132.68 53.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.687 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.12 29.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.89 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.8 t80 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.893 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.8 p . . . . . 0 N--CA 1.462 0.166 0 CA-C-O 120.889 0.376 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 9.2 p-90 -126.68 164.58 20.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.561 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.425 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 2.8 p90 -155.34 158.35 38.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.966 179.693 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 t -149.14 149.54 31.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -169.68 -162.94 22.86 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.399 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.6 155.43 48.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.601 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.425 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 14.2 pttt -139.5 153.14 47.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.299 0.571 . . . . 0.0 112.276 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.011 HD13 ' HB2' ' A' ' 37' ' ' ALA . 48.3 tp . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.268 179.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 1.011 ' HB2' HD13 ' A' ' 13' ' ' LEU . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.851 0.358 . . . . 0.0 111.0 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.71 -162.78 35.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.306 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.86 155.1 45.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.717 -0.241 . . . . 0.0 110.7 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.425 ' CE1' ' HB3' ' A' ' 12' ' ' LYS . 27.3 p90 -159.13 157.72 31.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.304 0.573 . . . . 0.0 112.01 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -147.47 159.86 28.14 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.319 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.425 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -155.26 161.29 30.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 119.824 -1.179 . . . . 0.0 113.602 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 13.1 t80 -123.05 133.72 54.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.252 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -95.07 125.62 39.86 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.272 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 t -93.24 -37.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.961 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.474 ' HB2' HG23 ' A' ' 49' ' ' VAL . 1.1 t30 -153.92 178.32 1.66 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.424 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.4 Cg_exo -60.1 -25.97 81.24 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.679 2.252 . . . . 0.0 113.64 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CE1' ' HB2' ' A' ' 47' ' ' PRO . 17.9 m-85 -127.46 3.99 6.24 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.474 HG23 ' HB2' ' A' ' 46' ' ' ASN . 4.3 m -138.04 115.06 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.819 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.65 -177.23 18.4 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.466 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.59 150.04 49.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.559 0.219 . . . . 0.0 110.629 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -146.57 134.25 21.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.039 0.447 . . . . 0.0 111.375 -179.699 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -128.43 153.68 46.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.339 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.61 158.84 30.02 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.191 -1.004 . . . . 0.0 113.116 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 7.3 p90 . . . . . 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.863 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.684 0.278 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -130.22 140.43 50.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.048 0.451 . . . . 0.0 111.091 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -129.85 132.1 46.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.968 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.423 ' HB ' ' HA3' ' A' ' 98' ' ' GLY . 1.3 t -151.43 170.11 20.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.523 0.678 . . . . 0.0 112.09 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.94 144.22 35.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.946 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -110.14 125.26 52.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -130.89 108.15 9.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.209 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.479 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -134.99 176.89 19.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.232 -0.985 . . . . 0.0 113.658 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.564 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.5 m-85 -128.07 140.18 37.52 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.661 0.267 . . . . 0.0 110.606 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -87.87 103.72 0.51 Allowed 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.772 2.315 . . . . 0.0 112.634 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 41.6 pt -82.14 -30.64 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.042 0.448 . . . . 0.0 110.337 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.404 ' OG1' ' HB3' ' A' ' 91' ' ' LEU . 0.2 OUTLIER -150.47 167.31 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.177 179.297 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -64.94 -23.45 67.23 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.447 ' HB3' ' CE1' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -112.07 -37.31 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.02 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.404 ' HB3' ' OG1' ' A' ' 88' ' ' THR . 15.3 tp -102.94 125.73 49.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.984 0.421 . . . . 0.0 111.656 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -133.54 161.02 35.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.186 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.051 HG22 HG12 ' A' ' 127' ' ' VAL . 2.6 pp -125.66 143.23 39.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.035 179.123 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.479 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 10.2 p90 -155.1 170.27 22.2 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.723 0.773 . . . . 0.0 113.003 -178.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.3 p -139.39 143.05 37.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.714 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.67 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 68.5 mtm180 -118.69 139.06 52.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.012 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 6.7 tp -141.25 120.84 13.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.1 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.423 ' HA3' ' HB ' ' A' ' 80' ' ' THR . . . -164.8 -149.04 5.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.56 152.25 24.35 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.107 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.2 ptt? . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.829 0.347 . . . . 0.0 110.848 -179.889 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 t80 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.67 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -151.48 148.5 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.221 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.95 138.88 7.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.111 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.65 -156.96 20.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.002 -1.094 . . . . 0.0 113.299 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 1.051 HG12 HG22 ' A' ' 93' ' ' ILE . 28.9 m -141.54 147.9 21.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.043 0.449 . . . . 0.0 111.335 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.421 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 21.6 tt0 -124.05 132.11 53.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.703 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.447 ' CE1' ' HB3' ' A' ' 90' ' ' ASP . 70.9 t80 -126.09 146.4 49.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.176 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.39 116.15 31.68 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.808 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.598 HD11 HG22 ' A' ' 135' ' ' ILE . 2.2 pt -92.8 -30.99 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.611 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.816 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.2 OUTLIER -147.13 169.27 9.65 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.499 179.916 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.816 ' HD2' HG22 ' A' ' 132' ' ' THR . 53.1 Cg_exo -55.91 -60.95 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.575 2.183 . . . . 0.0 112.843 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLU . . . . . 0.608 ' C ' HD12 ' A' ' 135' ' ' ILE . 9.8 tt0 -98.05 23.85 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.708 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.608 HD12 ' C ' ' A' ' 134' ' ' GLU . 4.3 mp -146.46 117.6 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.053 0.454 . . . . 0.0 111.651 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.12 161.86 29.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.082 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.816 HG22 HG12 ' A' ' 166' ' ' VAL . 80.9 p -135.93 140.59 44.14 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.407 179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.65 144.04 32.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.237 0.542 . . . . 0.0 112.041 -179.251 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.621 HD12 ' CD1' ' A' ' 164' ' ' LEU . 2.6 tt -124.83 136.34 53.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.598 178.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.462 ' N ' HD23 ' A' ' 139' ' ' LEU . 16.8 mt-10 -146.0 156.44 43.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.227 0.537 . . . . 0.0 111.807 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.536 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 8.4 mp . . . . . 0 C--O 1.23 0.079 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 22.5 m -132.31 152.7 51.28 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.201 0.524 . . . . 0.0 111.627 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' LEU . . . . . 0.621 ' CD1' HD12 ' A' ' 139' ' ' LEU . 2.7 tt -143.81 123.86 13.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.775 179.259 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' GLY . . . . . 0.425 ' N ' HD23 ' A' ' 164' ' ' LEU . . . -143.55 164.75 27.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.24 -0.981 . . . . 0.0 113.456 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.816 HG12 HG22 ' A' ' 137' ' ' THR . 25.9 m -105.45 147.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 167' ' ' SER . . . . . 0.414 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 30.0 p -134.78 145.91 48.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.125 0.488 . . . . 0.0 111.761 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -112.12 131.96 55.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.738 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -108.51 116.79 32.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.025 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 3.1 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 -179.955 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.462 0.127 0 CA-C-O 120.957 0.408 . . . . 0.0 110.811 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 7.2 t90 -113.1 161.07 17.53 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.317 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.467 ' CZ ' ' HB2' ' A' ' 169' ' ' ARG . 0.1 OUTLIER -145.12 141.62 28.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 m -147.56 144.42 28.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.698 0.285 . . . . 0.0 111.189 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -173.82 -157.58 15.82 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.295 -0.955 . . . . 0.0 113.256 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -134.02 155.44 49.98 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.659 -0.271 . . . . 0.0 110.746 179.685 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.467 ' C ' HD12 ' A' ' 13' ' ' LEU . 1.7 mmmm -139.16 153.15 47.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.147 0.498 . . . . 0.0 111.966 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HG ' ' HB1' ' A' ' 37' ' ' ALA . 2.7 mp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.516 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.603 ' HB1' ' HG ' ' A' ' 13' ' ' LEU . . . . . . . . 0 C--O 1.232 0.18 0 CA-C-O 120.79 0.329 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.01 -159.78 32.47 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.28 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.4 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -114.51 151.63 33.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.921 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.447 ' CD2' ' HA3' ' A' ' 54' ' ' GLY . 61.2 m-85 -151.23 149.88 29.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.03 0.443 . . . . 0.0 111.692 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.04 156.75 28.63 Favored Glycine 0 N--CA 1.45 -0.417 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -157.04 154.67 25.73 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 119.783 -1.199 . . . . 0.0 113.771 -179.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 24.9 t80 -107.21 133.63 51.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.5 -0.35 . . . . 0.0 110.086 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -96.13 125.91 40.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.453 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.0 t -94.78 -36.44 6.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.484 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -156.6 173.37 5.03 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.688 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.484 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 25.9 Cg_endo -62.82 -15.31 46.21 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 122.227 1.952 . . . . 0.0 113.551 -179.085 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -126.86 -4.76 6.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.6 m -139.07 117.48 12.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.97 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.6 -179.37 18.67 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.369 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -128.87 149.59 50.7 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.636 0.255 . . . . 0.0 110.414 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -149.37 137.01 20.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.004 0.43 . . . . 0.0 111.616 -179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' MET . . . . . 0.43 ' HG2' HD23 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -128.23 156.72 42.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.212 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.447 ' HA3' ' CD2' ' A' ' 40' ' ' PHE . . . -159.03 157.54 28.58 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.142 -1.028 . . . . 0.0 113.199 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.646 ' HD2' HG22 ' A' ' 77' ' ' VAL . 13.9 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-O 120.873 0.368 . . . . 0.0 110.841 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.646 HG22 ' HD2' ' A' ' 55' ' ' TYR . 24.8 t . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.709 0.29 . . . . 0.0 110.952 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.489 ' N ' HG12 ' A' ' 77' ' ' VAL . 6.7 tt0 -128.11 134.14 49.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.007 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.43 HD23 ' HG2' ' A' ' 53' ' ' MET . 2.4 mt -128.92 130.28 46.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.842 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.7 p -151.38 173.1 14.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.461 0.648 . . . . 0.0 111.99 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -109.0 142.91 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.001 179.049 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -109.07 126.17 52.89 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.877 0.37 . . . . 0.0 111.479 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.0 mp -129.15 112.17 13.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.248 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.72 170.85 22.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.217 -0.992 . . . . 0.0 113.474 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.745 ' HB2' HD11 ' A' ' 93' ' ' ILE . 3.1 m-85 -124.3 139.07 32.05 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.639 0.257 . . . . 0.0 110.517 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -85.31 100.04 0.68 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.708 2.272 . . . . 0.0 112.704 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 1.024 HD11 HG23 ' A' ' 93' ' ' ILE . 1.2 mp -80.36 -35.04 15.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.135 0.493 . . . . 0.0 110.309 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.438 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.8 m -148.62 164.88 32.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.164 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.438 ' N ' HG22 ' A' ' 88' ' ' THR . 1.9 t70 -60.71 -24.8 65.95 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.574 0.212 . . . . 0.0 111.574 -179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.441 ' CB ' ' CE2' ' A' ' 129' ' ' TYR . 10.8 m-20 -113.08 -33.52 6.0 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.087 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 6.8 tp -102.89 123.58 46.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.903 0.383 . . . . 0.0 111.793 -179.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.684 ' HA ' HD12 ' A' ' 87' ' ' ILE . 72.6 m-20 -134.03 160.81 36.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.297 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.036 HG22 HG12 ' A' ' 127' ' ' VAL . 1.0 OUTLIER -120.41 142.88 34.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.984 179.099 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.438 ' CE1' ' HB2' ' A' ' 128' ' ' GLU . 47.2 p90 -147.15 163.49 36.14 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.653 0.74 . . . . 0.0 112.872 -178.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -140.58 139.64 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.363 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.495 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -116.51 135.04 54.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.891 0.377 . . . . 0.0 111.003 -179.748 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.37 118.21 11.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.836 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.86 -144.19 3.99 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.298 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -150.03 151.09 23.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.205 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 p90 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.495 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -156.17 150.82 25.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.207 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.45 139.3 7.75 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.126 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.37 -156.57 19.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.248 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 1.036 HG12 HG22 ' A' ' 93' ' ' ILE . 29.4 m -138.88 148.25 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.161 0.505 . . . . 0.0 111.267 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.438 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 40.1 tt0 -124.62 131.93 53.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.715 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.441 ' CE2' ' CB ' ' A' ' 90' ' ' ASP . 48.8 t80 -127.9 147.59 50.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.239 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 117.0 34.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.859 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.834 HD11 ' CG2' ' A' ' 135' ' ' ILE . 29.6 pt -89.57 -33.59 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.069 0.462 . . . . 0.0 110.671 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.7 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -147.37 174.58 3.29 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.52 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.7 ' CD ' HG22 ' A' ' 132' ' ' THR . 50.7 Cg_exo -54.17 -62.08 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.586 2.191 . . . . 0.0 112.75 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLU . . . . . 0.478 ' C ' HD12 ' A' ' 135' ' ' ILE . 12.2 tt0 -100.15 31.52 3.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.629 -179.312 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.834 ' CG2' HD11 ' A' ' 131' ' ' ILE . 4.5 mp -145.99 115.52 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.952 0.406 . . . . 0.0 111.555 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.528 ' O ' HG23 ' A' ' 166' ' ' VAL . . . -131.07 150.13 52.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.924 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.31 141.66 51.95 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.641 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.404 ' HD2' ' HB2' ' A' ' 167' ' ' SER . 0.2 OUTLIER -134.2 140.48 46.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.104 0.478 . . . . 0.0 111.687 -179.515 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.5 pp -132.68 130.54 40.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.511 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -151.68 168.21 25.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.301 0.572 . . . . 0.0 111.933 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' TYR . . . . . 0.676 ' CE2' HD23 ' A' ' 162' ' ' LEU . 2.7 m-85 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.911 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.676 HD23 ' CE2' ' A' ' 141' ' ' TYR . 0.5 OUTLIER . . . . . 0 N--CA 1.463 0.215 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.8 m -132.44 154.12 50.17 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.292 0.568 . . . . 0.0 111.891 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 2.6 mp -145.3 122.52 11.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.865 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -141.88 165.18 26.62 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.25 -0.976 . . . . 0.0 113.465 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 136' ' ' ALA . 8.8 p -111.37 147.19 15.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 167' ' ' SER . . . . . 0.438 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 5.3 t -136.33 151.54 49.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.294 0.568 . . . . 0.0 112.175 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -119.49 133.63 55.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.838 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 2.0 ttp180 -106.97 121.61 44.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.295 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 9.0 t80 . . . . . 0 C--N 1.33 -0.253 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.935 -179.961 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.704 HG23 ' HB2' ' A' ' 44' ' ' GLN . 4.1 t . . . . . 0 N--CA 1.46 0.061 0 CA-C-O 120.79 0.329 . . . . 0.0 110.455 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 35.7 p90 -127.92 164.16 22.89 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.798 -179.204 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.417 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 4.0 p90 -155.24 157.16 36.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.907 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.402 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 0.8 OUTLIER -149.02 150.86 33.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.741 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.89 -164.93 27.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.332 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.53 154.14 49.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.628 -0.286 . . . . 0.0 110.568 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.459 ' C ' HD12 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -138.32 150.48 46.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.186 0.517 . . . . 0.0 111.809 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.479 HD12 ' N ' ' A' ' 13' ' ' LEU . 1.9 mp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.628 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.821 0.343 . . . . 0.0 111.256 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.62 -173.26 42.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.385 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 153.45 52.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.716 -0.242 . . . . 0.0 110.598 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.413 ' CE1' ' HB2' ' A' ' 12' ' ' LYS . 6.2 p90 -159.42 166.33 31.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.225 0.536 . . . . 0.0 112.016 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -148.08 160.03 28.21 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.53 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.417 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.1 159.88 28.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.363 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -124.85 132.13 53.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.569 -0.315 . . . . 0.0 110.276 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLN . . . . . 0.704 ' HB2' HG23 ' A' ' 6' ' ' THR . 1.7 mt-30 -95.48 126.22 40.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.119 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.8 t -96.24 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.0 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.496 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 3.3 m-20 -103.54 171.27 5.28 Favored Pre-proline 0 C--N 1.332 -0.185 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.192 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.496 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 10.1 Cg_endo -51.52 128.8 27.15 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.683 2.255 . . . . 0.0 113.085 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.419 ' CE1' ' HG3' ' A' ' 86' ' ' PRO . 1.4 m-85 59.88 16.32 5.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.407 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 47' ' ' PRO . 2.8 m -138.95 113.96 8.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.843 -0.343 . . . . 0.0 111.385 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.3 -172.86 14.48 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.777 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -130.3 154.31 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.561 0.22 . . . . 0.0 110.602 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -150.4 138.14 19.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.482 . . . . 0.0 111.733 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -130.46 113.53 14.41 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.261 179.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.03 159.65 14.14 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.406 -0.902 . . . . 0.0 113.189 -179.136 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.559 ' HB3' HG12 ' A' ' 77' ' ' VAL . 47.8 p90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 120.804 0.335 . . . . 0.0 110.846 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.559 HG12 ' HB3' ' A' ' 55' ' ' TYR . 31.1 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.706 0.289 . . . . 0.0 111.044 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -130.29 137.34 49.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.075 0.464 . . . . 0.0 111.028 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.433 HD23 ' N ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -125.34 130.16 51.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.702 179.315 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.408 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.7 p -151.35 173.01 15.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.492 0.663 . . . . 0.0 111.924 -179.101 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.0 141.98 37.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.922 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -108.26 125.57 51.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.82 0.343 . . . . 0.0 111.403 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.417 ' CD1' HG12 ' A' ' 49' ' ' VAL . 2.4 tp -130.31 112.44 13.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.397 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.449 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.49 171.17 22.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.434 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.487 ' HB2' HD11 ' A' ' 93' ' ' ILE . 29.4 m-85 -123.99 138.94 31.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.715 0.293 . . . . 0.0 110.598 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.419 ' HG3' ' CE1' ' A' ' 48' ' ' TYR . 95.1 Cg_endo -84.6 98.89 0.72 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.73 2.286 . . . . 0.0 112.675 -179.7 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 24.0 mm -79.06 -36.66 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.032 0.444 . . . . 0.0 110.365 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.51 164.45 34.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.177 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -60.61 -24.02 65.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.524 0.202 . . . . 0.0 111.314 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.447 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 2.7 m-20 -113.6 -35.06 5.34 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -102.86 123.48 46.59 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.944 0.402 . . . . 0.0 111.758 -179.164 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -133.69 161.25 35.19 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.292 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.035 HG22 HG12 ' A' ' 127' ' ' VAL . 2.7 pt -121.44 142.51 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.979 179.123 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.449 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 40.4 p90 -147.8 165.34 30.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.69 0.757 . . . . 0.0 112.895 -178.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -144.32 140.66 29.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.399 -1.273 . . . . 0.0 109.445 179.08 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.712 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 45.5 mtm-85 -118.81 137.44 53.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 111.18 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.42 ' HB3' ' CE1' ' A' ' 123' ' ' PHE . 0.5 OUTLIER -139.5 119.7 13.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.918 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.408 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -166.32 -141.6 3.19 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.352 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.34 150.58 22.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.55 -0.833 . . . . 0.0 113.251 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.8 ptp . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.945 -179.917 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.42 ' CE1' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.715 0.293 . . . . 0.0 110.752 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.712 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -155.41 146.57 22.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.325 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.2 138.94 7.55 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.188 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.21 -155.77 18.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.044 -1.074 . . . . 0.0 113.243 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 1.035 HG12 HG22 ' A' ' 93' ' ' ILE . 29.8 m -138.71 147.97 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.008 0.432 . . . . 0.0 111.258 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -124.77 132.2 53.38 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.692 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.447 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 34.7 t80 -125.87 145.95 50.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.047 -179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.404 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.86 115.58 29.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.952 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.476 HD11 HG22 ' A' ' 135' ' ' ILE . 21.4 pt -89.88 -33.11 5.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.036 0.446 . . . . 0.0 110.408 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.698 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -149.25 165.16 18.34 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.187 179.682 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.698 ' HD2' HG22 ' A' ' 132' ' ' THR . 9.6 Cg_endo -53.17 -56.25 2.93 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -95.75 17.07 15.8 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.476 HG22 HD11 ' A' ' 131' ' ' ILE . 3.5 mp -144.3 120.61 4.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.061 0.458 . . . . 0.0 111.897 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.53 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -131.13 154.05 48.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.814 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.2 p -125.06 142.19 51.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.618 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.537 ' O ' HD12 ' A' ' 139' ' ' LEU . 24.9 mtt180 -138.66 135.23 34.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.067 0.46 . . . . 0.0 111.873 -179.377 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 138' ' ' ARG . 8.5 mp -124.67 133.89 53.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.574 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -151.76 167.63 27.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.307 0.575 . . . . 0.0 112.005 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' TYR . . . . . 0.589 ' HE2' HD23 ' A' ' 162' ' ' LEU . 2.9 m-85 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.851 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.589 HD23 ' HE2' ' A' ' 141' ' ' TYR . 1.7 mp . . . . . 0 C--O 1.232 0.178 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -131.77 152.54 50.88 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.315 0.579 . . . . 0.0 111.861 -179.288 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' LEU . . . . . 0.63 ' O ' HD12 ' A' ' 164' ' ' LEU . 3.9 pp -142.45 122.54 13.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.673 179.096 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.17 163.68 27.02 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.236 -0.983 . . . . 0.0 113.485 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.53 HG13 ' O ' ' A' ' 136' ' ' ALA . 21.8 t -106.14 146.94 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.5 p -134.87 145.73 48.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.469 . . . . 0.0 111.739 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.5 m-85 -114.64 131.39 56.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.773 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.55 118.64 37.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.021 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.882 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.449 HG22 ' H ' ' A' ' 7' ' ' TRP . 0.2 OUTLIER . . . . . 0 N--CA 1.463 0.208 0 CA-C-O 121.076 0.465 . . . . 0.0 111.634 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.6 m-90 -125.19 166.67 16.04 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.562 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.487 ' N ' ' O ' ' A' ' 42' ' ' GLY . 1.5 p90 -155.62 163.03 40.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.16 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 m -149.22 152.75 36.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.519 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -171.49 -160.36 19.86 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 119.894 -1.146 . . . . 0.0 113.426 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.27 153.92 51.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.631 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.46 ' C ' HD12 ' A' ' 13' ' ' LEU . 1.6 mmmp? -137.58 149.8 46.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.119 0.485 . . . . 0.0 111.567 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.467 HD12 ' N ' ' A' ' 13' ' ' LEU . 2.1 mp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.662 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.888 0.375 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.21 -167.54 38.26 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.301 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.408 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -119.02 153.03 35.34 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.477 0.18 . . . . 0.0 110.75 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 54' ' ' GLY . 1.7 m-85 -154.72 142.69 20.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.158 0.504 . . . . 0.0 111.619 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -140.61 156.94 25.55 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.535 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -155.57 165.07 32.36 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.215 -0.993 . . . . 0.0 112.82 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 1.4 p90 -146.06 139.27 25.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.921 0.391 . . . . 0.0 111.373 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -94.96 124.67 39.14 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.533 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 10.9 m -98.49 -37.0 6.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.72 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.485 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.9 OUTLIER -149.39 170.11 8.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.359 -179.828 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.485 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 6.2 Cg_endo -48.64 120.5 5.3 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.826 2.351 . . . . 0.0 113.26 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.514 ' O ' HD12 ' A' ' 83' ' ' LEU . 0.9 OUTLIER 58.38 18.37 5.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.561 -0.745 . . . . 0.0 112.33 178.85 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.431 ' CG2' ' CB ' ' A' ' 46' ' ' ASN . 4.9 m -138.71 112.96 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.826 0.346 . . . . 0.0 111.451 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.45 -172.36 15.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PHE . . . . . 0.439 ' HB2' ' CZ ' ' A' ' 43' ' ' TYR . 20.9 m-85 -128.38 151.43 49.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.662 0.268 . . . . 0.0 110.518 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -145.87 135.23 23.0 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.026 0.441 . . . . 0.0 111.47 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 15.1 ttp -129.73 154.71 46.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.331 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 40' ' ' PHE . . . -160.72 159.31 30.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.265 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.603 ' HD2' HG22 ' A' ' 77' ' ' VAL . 22.1 t80 . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.603 HG22 ' HD2' ' A' ' 55' ' ' TYR . 24.7 t . . . . . 0 N--CA 1.458 -0.071 0 CA-C-O 120.736 0.303 . . . . 0.0 111.051 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -128.23 135.27 49.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 111.047 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -130.85 130.76 44.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.888 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.409 ' HA ' ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.37 173.05 14.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.492 0.663 . . . . 0.0 111.989 -179.106 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.75 144.35 35.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.986 178.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' LYS . . . . . 0.411 ' HE2' ' CD2' ' A' ' 94' ' ' TYR . 0.3 OUTLIER -110.24 125.29 52.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.381 . . . . 0.0 111.479 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.514 HD12 ' O ' ' A' ' 48' ' ' TYR . 6.2 tp -130.64 110.06 11.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.263 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.466 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.02 175.29 20.95 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.71 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -129.09 139.87 36.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.694 0.283 . . . . 0.0 110.576 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -86.63 104.18 0.66 Allowed 'Trans proline' 0 N--CA 1.46 -0.465 0 C-N-CA 122.786 2.324 . . . . 0.0 112.736 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.436 HD11 ' HG ' ' A' ' 91' ' ' LEU . 40.3 pt -81.11 -33.75 13.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.162 0.506 . . . . 0.0 110.353 179.141 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.36 164.3 33.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.151 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -60.59 -25.09 65.96 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.451 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 1.0 OUTLIER -112.74 -30.85 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.104 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.436 ' HG ' HD11 ' A' ' 87' ' ' ILE . 13.4 tp -102.96 123.59 46.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.614 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -131.62 154.97 48.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.369 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.05 HG22 HG12 ' A' ' 127' ' ' VAL . 25.6 pt -123.07 142.62 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.873 179.043 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.466 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 19.3 p90 -152.83 170.15 21.05 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.752 0.786 . . . . 0.0 113.073 -178.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.4 p -141.5 142.5 33.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.295 -1.321 . . . . 0.0 109.53 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.474 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -118.14 137.49 52.93 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.964 0.412 . . . . 0.0 111.001 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.684 HD12 ' CE2' ' A' ' 123' ' ' PHE . 1.3 tt -139.77 119.25 13.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.814 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.409 ' HA3' ' HA ' ' A' ' 80' ' ' THR . . . -164.98 -144.52 4.08 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.233 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -152.9 152.6 24.24 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.491 -0.862 . . . . 0.0 113.292 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.3 ttt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.845 -179.904 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.684 ' CE2' HD12 ' A' ' 97' ' ' LEU . 9.6 t80 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.79 0.328 . . . . 0.0 110.816 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.483 ' HB1' ' OE1' ' A' ' 140' ' ' GLU . . . -152.14 147.1 26.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.249 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.6 138.82 7.62 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.14 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.1 -157.96 21.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.314 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 1.05 HG12 HG22 ' A' ' 93' ' ' ILE . 28.4 m -138.38 147.99 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.052 0.453 . . . . 0.0 111.255 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -125.35 131.1 53.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.777 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.451 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 38.0 t80 -126.86 146.59 50.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.408 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.89 115.65 29.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.807 HD11 HG22 ' A' ' 135' ' ' ILE . 19.8 pt -89.27 -34.82 7.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.958 0.408 . . . . 0.0 110.7 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.726 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -146.65 172.98 4.59 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.555 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.726 ' CD ' HG22 ' A' ' 132' ' ' THR . 50.5 Cg_exo -54.4 -61.86 0.36 Allowed 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.517 2.145 . . . . 0.0 112.757 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -99.84 25.44 7.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.777 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.807 HG22 HD11 ' A' ' 131' ' ' ILE . 4.0 mp -144.24 116.06 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.979 0.419 . . . . 0.0 111.565 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -127.35 158.48 37.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.972 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.788 HG22 HG12 ' A' ' 166' ' ' VAL . 26.0 p -141.49 138.42 32.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.41 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.22 150.92 35.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.131 0.491 . . . . 0.0 111.944 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.949 HD21 HD23 ' A' ' 164' ' ' LEU . 8.3 mp -118.34 139.81 50.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.723 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.483 ' OE1' ' HB1' ' A' ' 124' ' ' ALA . 0.1 OUTLIER -143.15 149.94 38.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 111.567 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 141' ' ' TYR . . . . . 0.644 ' HE2' HD23 ' A' ' 162' ' ' LEU . 6.2 m-85 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.91 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.644 HD23 ' HE2' ' A' ' 141' ' ' TYR . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.08 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 85.2 p -132.7 155.54 48.63 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.331 0.586 . . . . 0.0 111.885 -179.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' LEU . . . . . 0.949 HD23 HD21 ' A' ' 139' ' ' LEU . 0.1 OUTLIER -142.76 125.2 15.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.692 179.125 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.4 163.7 27.45 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.477 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.788 HG12 HG22 ' A' ' 137' ' ' THR . 23.3 m -108.89 147.93 13.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.419 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 11.3 t -136.21 147.0 47.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.488 . . . . 0.0 111.852 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.746 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 3.0 ptm180 -108.2 119.13 38.6 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.103 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 179.994 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 N--CA 1.461 0.086 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.6 p-90 -124.52 163.87 20.96 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.523 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.42 ' CZ ' ' HA3' ' A' ' 42' ' ' GLY . 33.0 p90 -155.25 156.62 35.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.93 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 p -149.26 151.93 35.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.98 -160.73 21.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 119.904 -1.141 . . . . 0.0 113.32 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -127.11 154.45 44.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.524 -0.338 . . . . 0.0 110.512 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -142.21 146.08 34.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.083 0.468 . . . . 0.0 111.549 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.4 mp . . . . . 0 C--N 1.326 -0.429 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.374 178.96 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.999 0.428 . . . . 0.0 111.726 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.95 -173.29 42.37 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.606 -0.807 . . . . 0.0 113.295 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -130.55 154.22 48.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.876 -0.162 . . . . 0.0 110.57 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -159.23 161.65 36.09 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.281 0.562 . . . . 0.0 112.258 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -154.77 159.22 28.84 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.201 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CZ ' ' A' ' 8' ' ' TYR . . . -157.77 165.1 33.46 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.796 -1.192 . . . . 0.0 113.563 -179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.505 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.5 m-85 -119.91 135.14 55.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.404 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -95.13 125.96 40.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.27 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.1 t -92.88 -37.57 8.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.874 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.437 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -153.6 179.32 1.32 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.125 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.437 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 35.2 Cg_exo -60.72 -26.1 82.3 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.689 2.259 . . . . 0.0 113.712 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.4 p90 -127.97 4.43 5.93 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 113.135 0.791 . . . . 0.0 113.135 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 49' ' ' VAL . 9.1 p -139.52 115.72 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.601 -0.44 . . . . 0.0 111.718 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.4 -175.7 17.76 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.653 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -127.15 149.45 49.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.569 0.224 . . . . 0.0 110.44 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -147.76 136.82 22.17 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.085 0.469 . . . . 0.0 111.578 -179.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -128.22 155.27 44.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.231 179.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.34 158.37 29.47 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.213 -0.994 . . . . 0.0 113.197 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 30.5 p90 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.79 -179.978 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 78' ' ' GLN . 11.0 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.718 0.295 . . . . 0.0 111.044 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.466 ' N ' HG22 ' A' ' 77' ' ' VAL . 6.1 tt0 -130.21 142.78 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.051 0.453 . . . . 0.0 111.08 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.7 131.34 43.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.84 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.41 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.4 p -151.46 173.0 15.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.495 0.664 . . . . 0.0 111.891 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -110.29 142.41 41.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.963 179.03 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.62 127.25 53.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.969 0.414 . . . . 0.0 111.453 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.6 mp -129.73 111.22 12.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.303 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.436 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -133.55 169.79 22.61 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.266 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.481 ' HB3' HD11 ' A' ' 93' ' ' ILE . 2.5 t80 -121.69 137.4 27.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.613 0.244 . . . . 0.0 110.591 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -83.14 97.55 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.687 2.258 . . . . 0.0 112.63 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.456 HD11 HG12 ' A' ' 93' ' ' ILE . 31.1 mt -80.67 -35.67 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.048 0.451 . . . . 0.0 110.462 179.462 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.434 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.4 m -148.27 164.81 32.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.112 179.677 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.434 ' N ' HG22 ' A' ' 88' ' ' THR . 1.6 t70 -60.51 -27.34 67.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.522 0.201 . . . . 0.0 111.479 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.442 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 73.8 m-20 -112.27 -34.9 5.77 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 15.1 tp -102.84 123.74 47.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.981 0.42 . . . . 0.0 111.688 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -135.39 164.19 28.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.348 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.037 HG22 HG12 ' A' ' 127' ' ' VAL . 1.3 pt -117.75 142.29 32.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.929 178.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.436 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 36.6 m-85 -144.72 159.14 43.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.686 0.755 . . . . 0.0 112.838 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.697 HG23 ' O ' ' A' ' 124' ' ' ALA . 91.1 m -140.87 137.02 32.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.191 178.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.588 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 54.8 mtm180 -118.17 137.44 52.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.883 0.373 . . . . 0.0 111.277 -179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.3 tt -141.9 121.21 13.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.853 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.41 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -165.11 -146.25 4.71 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.273 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.23 156.05 26.71 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.612 -0.804 . . . . 0.0 113.179 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.765 0.317 . . . . 0.0 110.857 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 124' ' ' ALA . 40.2 t80 . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.79 0.328 . . . . 0.0 110.678 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.697 ' O ' HG23 ' A' ' 95' ' ' THR . . . -158.27 148.02 19.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.313 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.98 140.0 8.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.124 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 175.36 -151.75 12.48 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.306 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 1.037 HG12 HG22 ' A' ' 93' ' ' ILE . 29.7 m -140.26 149.24 21.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.126 0.488 . . . . 0.0 111.357 -179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -125.39 132.37 52.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.631 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.442 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 39.6 t80 -125.54 146.2 49.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.213 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.405 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -97.91 115.4 28.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.929 179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.4 tt -88.5 -35.04 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.958 0.409 . . . . 0.0 110.561 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.711 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -150.49 172.41 5.32 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.426 179.631 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.711 ' CD ' HG22 ' A' ' 132' ' ' THR . 52.8 Cg_exo -53.23 -57.06 2.2 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.473 2.115 . . . . 0.0 112.488 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -102.89 31.8 4.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.515 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.16 114.23 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 111.743 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.4 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -129.09 154.23 46.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.919 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.839 HG22 HG12 ' A' ' 166' ' ' VAL . 26.1 p -129.0 140.59 51.57 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.411 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.2 ttm105 -137.39 135.1 36.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.947 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.579 HD13 HD12 ' A' ' 164' ' ' LEU . 3.3 tp -124.98 132.51 53.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.432 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.77 165.58 32.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.255 0.55 . . . . 0.0 111.886 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 8.6 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.948 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' SER . . . . . 0.423 ' O ' HD12 ' A' ' 139' ' ' LEU . 95.4 p -130.28 153.04 49.05 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.231 0.538 . . . . 0.0 111.9 -179.301 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' LEU . . . . . 0.579 HD12 HD13 ' A' ' 139' ' ' LEU . 3.0 tt -144.3 123.19 12.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.889 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.39 159.29 27.49 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.355 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.839 HG12 HG22 ' A' ' 137' ' ' THR . 26.7 m -103.72 147.05 10.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' SER . . . . . 0.4 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 78.6 p -134.81 145.51 48.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.1 0.476 . . . . 0.0 111.785 -179.335 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -112.19 132.06 55.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.675 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.51 116.25 31.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.009 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.95 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 N--CA 1.461 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.674 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.544 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.1 p90 -126.8 164.45 21.34 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.623 -179.267 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.412 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 26.5 p90 -155.26 157.05 36.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.018 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 p -149.13 151.19 33.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.739 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.6 -163.35 24.48 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.05 -1.071 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.49 153.47 50.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.556 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.4 ptmt -138.0 149.74 46.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.169 0.509 . . . . 0.0 111.81 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 37' ' ' ALA . 9.1 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.637 179.27 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.545 ' HB2' HD12 ' A' ' 13' ' ' LEU . . . . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.815 0.34 . . . . 0.0 111.198 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.17 -174.24 40.86 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.281 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.14 154.29 47.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.761 -0.22 . . . . 0.0 110.549 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -159.14 156.96 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.317 0.58 . . . . 0.0 112.101 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -150.29 159.06 27.95 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.244 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.412 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -157.12 164.98 33.09 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 119.793 -1.194 . . . . 0.0 113.498 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.6 m-85 -118.53 134.17 55.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.445 -0.378 . . . . 0.0 110.384 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 14.7 tt0 -95.79 126.44 41.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.238 179.395 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.443 HG21 ' CE2' ' A' ' 51' ' ' PHE . 25.1 t -94.75 -35.77 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.837 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.51 ' HB2' HG23 ' A' ' 49' ' ' VAL . 0.6 OUTLIER -155.67 172.77 5.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.866 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.472 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 23.1 Cg_endo -62.23 -15.87 47.26 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.222 1.948 . . . . 0.0 113.449 -179.26 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CD1' ' HG2' ' A' ' 47' ' ' PRO . 39.9 m-85 -128.24 -4.03 5.57 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.51 HG23 ' HB2' ' A' ' 46' ' ' ASN . 4.0 m -139.45 116.93 11.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.566 -0.453 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.53 -175.65 16.83 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.456 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 45' ' ' VAL . 85.0 m-85 -128.97 149.56 50.76 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -148.85 138.03 21.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.127 0.489 . . . . 0.0 111.665 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 6.3 mtt -128.26 156.09 43.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.148 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.22 158.29 29.36 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.031 -1.081 . . . . 0.0 113.138 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 4.0 p90 . . . . . 0 C--N 1.331 -0.219 0 CA-C-O 120.89 0.376 . . . . 0.0 110.821 -179.994 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 78' ' ' GLN . 21.4 t . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.732 0.301 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.43 ' N ' HG12 ' A' ' 77' ' ' VAL . 46.0 mt-30 -129.8 141.27 50.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.057 0.456 . . . . 0.0 111.039 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.608 ' O ' HD12 ' A' ' 79' ' ' LEU . 4.0 pp -131.23 130.83 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.764 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.408 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.71 173.03 15.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.475 0.655 . . . . 0.0 111.964 -179.178 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.71 142.0 38.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.827 178.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -107.99 126.33 52.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.823 0.344 . . . . 0.0 111.554 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.4 tt -129.65 110.64 11.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.37 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.438 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.8 169.01 22.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.362 -0.923 . . . . 0.0 113.209 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.406 ' CD2' ' HD2' ' A' ' 86' ' ' PRO . 5.1 t80 -124.28 137.61 29.42 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.614 0.245 . . . . 0.0 110.65 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.406 ' HD2' ' CD2' ' A' ' 85' ' ' TYR . 98.5 Cg_endo -85.37 100.19 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.684 2.256 . . . . 0.0 112.633 -179.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.418 HG22 ' O ' ' A' ' 91' ' ' LEU . 1.0 OUTLIER -82.04 -34.2 12.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.053 0.454 . . . . 0.0 110.367 179.333 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.413 HG22 ' N ' ' A' ' 89' ' ' ASP . 23.6 m -148.59 163.83 36.07 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.26 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.413 ' N ' HG22 ' A' ' 88' ' ' THR . 1.0 OUTLIER -62.45 -24.96 67.73 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.418 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -111.42 -29.43 7.79 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.502 HD23 ' HB3' ' A' ' 129' ' ' TYR . 93.7 mt -108.12 124.72 50.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 111.696 -179.344 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -133.51 157.75 44.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.326 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 5.2 mt -117.04 141.71 34.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.888 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.438 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 16.8 m-85 -143.62 157.87 44.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.697 0.76 . . . . 0.0 112.721 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.6 p -141.83 137.05 31.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.52 -1.218 . . . . 0.0 108.987 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.883 ' CG ' ' HB3' ' A' ' 124' ' ' ALA . 0.4 OUTLIER -119.57 140.94 49.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.963 0.411 . . . . 0.0 111.467 -179.463 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.715 ' O ' HD12 ' A' ' 97' ' ' LEU . 1.4 pp -142.17 120.68 12.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.816 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.408 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -164.96 -144.85 4.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.278 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.47 163.14 28.96 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.553 -0.832 . . . . 0.0 113.261 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 6.4 ttt . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.901 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 9.7 p90 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.796 0.332 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.883 ' HB3' ' CG ' ' A' ' 96' ' ' ARG . . . -141.38 162.15 36.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.235 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.31 141.98 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.078 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 139' ' ' LEU . . . 177.27 -154.86 16.59 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 119.926 -1.131 . . . . 0.0 113.331 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 16.2 m -140.38 148.22 22.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.045 0.45 . . . . 0.0 111.441 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.402 ' CB ' ' HB3' ' A' ' 138' ' ' ARG . 0.0 OUTLIER -127.52 132.6 49.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.649 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.502 ' HB3' HD23 ' A' ' 91' ' ' LEU . 30.8 p90 -129.92 151.61 50.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.361 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -102.3 117.31 34.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.835 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.537 ' O ' HG23 ' A' ' 132' ' ' THR . 20.5 pt -88.96 -36.1 8.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.04 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.537 HG23 ' O ' ' A' ' 131' ' ' ILE . 0.8 OUTLIER -162.47 162.12 19.53 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.965 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.26 140.79 41.35 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.558 2.172 . . . . 0.0 112.222 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.54 19.53 6.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.587 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 32.2 mt -149.08 111.76 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.047 0.451 . . . . 0.0 111.633 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.54 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -129.11 151.1 50.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.797 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.1 m -133.46 140.36 47.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.449 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.402 ' HB3' ' CB ' ' A' ' 128' ' ' GLU . 3.6 ptm180 -146.92 145.0 29.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.158 0.504 . . . . 0.0 111.886 -179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.403 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 4.0 pp -120.21 140.61 50.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.575 179.053 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -146.45 157.37 43.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.147 0.499 . . . . 0.0 111.63 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 2.7 p90 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.001 179.932 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 5.5 tp . . . . . 0 C--O 1.231 0.13 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 4.9 t -136.9 157.99 45.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.365 0.602 . . . . 0.0 112.132 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 1.1 tt -143.33 128.05 18.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.694 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.96 162.84 27.78 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.443 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 136' ' ' ALA . 22.0 t -105.39 146.6 12.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.381 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.7 m -134.59 145.42 48.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.137 0.494 . . . . 0.0 111.614 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -113.83 131.53 56.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -108.66 117.73 34.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.976 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 45.4 p . . . . . 0 N--CA 1.462 0.156 0 CA-C-O 120.892 0.377 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 25.9 p-90 -128.38 162.81 26.24 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.667 -179.294 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.45 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 1.4 p90 -155.28 157.28 36.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.717 179.356 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.1 p -149.15 151.78 34.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.665 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.429 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.1 -165.65 27.79 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.392 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -128.79 152.45 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.539 -0.33 . . . . 0.0 110.252 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.447 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -139.05 150.47 45.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.327 0.585 . . . . 0.0 112.058 -179.208 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.447 HD12 ' O ' ' A' ' 12' ' ' LYS . 1.7 mp . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.675 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.075 0 CA-C-O 121.032 0.444 . . . . 0.0 111.73 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.68 179.65 44.04 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.28 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.26 153.24 47.17 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.55 -0.167 . . . . 0.0 110.55 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -159.38 165.69 32.71 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.349 0.595 . . . . 0.0 112.226 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -155.05 161.35 30.31 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.401 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.45 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -152.23 163.8 30.32 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 119.794 -1.193 . . . . 0.0 113.616 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.2 t80 -132.44 132.56 42.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.531 -0.335 . . . . 0.0 110.493 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -92.93 123.69 36.37 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.68 -43.83 12.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.813 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.539 ' ND2' ' HB ' ' A' ' 49' ' ' VAL . 3.1 p-10 -152.06 165.19 18.01 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.411 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.534 ' HD2' ' HB2' ' A' ' 46' ' ' ASN . 65.9 Cg_exo -40.12 123.09 1.28 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.904 2.403 . . . . 0.0 113.79 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 48' ' ' TYR . 0.8 OUTLIER 59.17 17.68 5.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.419 178.871 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.539 ' HB ' ' ND2' ' A' ' 46' ' ' ASN . 24.5 t -136.68 114.02 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.451 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.24 -177.35 19.96 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.568 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -124.89 152.11 44.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -147.12 134.85 21.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.059 0.456 . . . . 0.0 111.527 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' MET . . . . . 0.409 ' CE ' HD21 ' A' ' 79' ' ' LEU . 16.4 ttm -126.84 151.79 47.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.182 179.433 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -157.44 157.43 28.12 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.247 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 13.9 p90 . . . . . 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.348 . . . . 0.0 110.73 179.946 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 78' ' ' GLN . 21.4 t . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.726 0.298 . . . . 0.0 111.078 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.489 ' N ' HG12 ' A' ' 77' ' ' VAL . 3.0 tt0 -129.29 138.76 51.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.03 0.443 . . . . 0.0 111.029 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.409 HD21 ' CE ' ' A' ' 53' ' ' MET . 6.1 mt -129.44 130.68 46.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.852 179.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.9 p -151.56 173.09 15.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.445 0.64 . . . . 0.0 111.997 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -108.28 142.18 38.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.85 -1.068 . . . . 0.0 109.896 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -108.6 126.15 52.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.879 0.371 . . . . 0.0 111.488 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 5.2 mt -129.96 113.12 14.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.332 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.471 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -136.4 171.59 22.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.371 -0.918 . . . . 0.0 113.494 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -128.94 136.94 29.96 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 110.476 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -83.95 104.26 1.07 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.651 2.234 . . . . 0.0 112.946 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 1.063 HD11 HG23 ' A' ' 93' ' ' ILE . 1.1 mp -78.33 -36.52 20.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 121.173 0.511 . . . . 0.0 110.183 179.172 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.733 HG23 ' H ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -150.91 169.64 21.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.957 179.119 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.1 -22.37 66.81 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -112.11 -29.05 7.74 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.733 ' H ' HG23 ' A' ' 88' ' ' THR . 0.3 OUTLIER -109.68 125.53 52.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.099 0.476 . . . . 0.0 112.031 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.518 ' HA ' HD12 ' A' ' 87' ' ' ILE . 4.3 m-20 -133.01 155.42 49.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.186 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.063 HG23 HD11 ' A' ' 87' ' ' ILE . 11.5 pt -117.47 141.25 37.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.933 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.471 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 24.5 m-85 -144.27 161.28 39.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 112.628 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -141.63 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.218 178.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.76 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 75.7 mtp180 -117.34 136.23 53.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.893 0.378 . . . . 0.0 111.287 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.7 tt -140.42 119.38 12.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.95 -143.96 3.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.349 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -149.9 152.58 24.49 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.299 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 7.3 ttm . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.701 0.286 . . . . 0.0 110.965 -179.962 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 t80 . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.77 0.319 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.76 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -150.63 146.79 26.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.176 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.79 139.44 7.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.24 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.74 -158.02 22.05 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.112 -1.042 . . . . 0.0 113.238 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 1.034 HG12 HG22 ' A' ' 93' ' ' ILE . 31.0 m -138.45 146.39 26.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.058 0.456 . . . . 0.0 111.241 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.429 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.2 OUTLIER -126.03 131.7 52.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.739 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 129' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 129' ' ' TYR . 3.5 p90 -127.48 149.28 50.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.179 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.49 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.898 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.438 HD11 ' OG1' ' A' ' 137' ' ' THR . 39.1 mt -88.91 -34.75 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.008 0.433 . . . . 0.0 110.744 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.704 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -148.88 174.56 3.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.675 179.835 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.704 ' CD ' HG22 ' A' ' 132' ' ' THR . 51.2 Cg_exo -53.8 -61.61 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.657 2.238 . . . . 0.0 112.75 -179.609 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLU . . . . . 0.597 ' C ' HD12 ' A' ' 135' ' ' ILE . 2.4 mt-10 -101.17 30.17 4.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.643 -179.31 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.597 HD12 ' C ' ' A' ' 134' ' ' GLU . 4.4 mp -146.66 114.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.44 . . . . 0.0 111.609 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -127.05 156.34 41.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.994 179.739 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' THR . . . . . 1.076 HG22 HG12 ' A' ' 166' ' ' VAL . 3.5 p -141.77 139.07 32.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.474 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.41 ' HB3' ' CB ' ' A' ' 128' ' ' GLU . 4.4 ptp85 -148.94 148.32 29.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.178 0.514 . . . . 0.0 111.931 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.498 HD23 HD12 ' A' ' 164' ' ' LEU . 0.3 OUTLIER -117.55 140.8 49.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.602 -0.726 . . . . 0.0 109.753 179.202 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -144.55 151.78 39.59 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.044 0.45 . . . . 0.0 111.561 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 8.1 p90 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.979 179.955 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 6.4 tp . . . . . 0 N--CA 1.462 0.148 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 10.3 t -130.51 154.37 47.86 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 121.255 0.55 . . . . 0.0 112.03 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' LEU . . . . . 0.597 HD23 ' N ' ' A' ' 165' ' ' GLY . 4.7 tt -145.25 123.98 12.59 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.771 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' GLY . . . . . 0.597 ' N ' HD23 ' A' ' 164' ' ' LEU . . . -144.88 163.4 28.01 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.573 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 1.076 HG12 HG22 ' A' ' 137' ' ' THR . 29.3 m -105.29 146.99 11.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.38 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 167' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 2.8 m -134.96 147.21 49.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.204 0.526 . . . . 0.0 111.776 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -114.63 131.89 56.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.732 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 50.0 mtp180 -108.18 118.26 36.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.038 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.839 179.983 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 43' ' ' TYR . 74.5 p . . . . . 0 N--CA 1.461 0.116 0 CA-C-O 120.916 0.389 . . . . 0.0 110.752 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.0 t90 -119.09 137.49 53.54 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.286 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.429 ' CD1' ' HA ' ' A' ' 169' ' ' ARG . 3.9 m-85 -124.32 155.92 37.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.831 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.441 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 71.4 p -149.01 147.03 28.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.05 -163.06 23.45 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.174 -1.012 . . . . 0.0 113.364 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.48 153.99 50.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.647 -0.276 . . . . 0.0 110.611 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.43 ' HB2' ' CD1' ' A' ' 40' ' ' PHE . 0.1 OUTLIER -137.12 149.88 47.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.157 0.503 . . . . 0.0 111.863 -179.401 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 tt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.678 179.216 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.111 0 CA-C-O 120.87 0.367 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.35 -173.12 40.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.284 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.04 153.4 48.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.813 -0.193 . . . . 0.0 110.694 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.43 ' CD1' ' HB2' ' A' ' 12' ' ' LYS . 23.6 p90 -159.42 169.02 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.186 0.517 . . . . 0.0 111.867 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -145.68 160.9 28.2 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.756 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 52' ' ' GLU . . . -148.46 124.65 1.9 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.043 -1.075 . . . . 0.0 113.222 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.4 t80 -104.53 129.51 52.57 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -94.51 124.81 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.776 0.322 . . . . 0.0 110.548 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.11 -38.1 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.453 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 0.4 OUTLIER -147.06 -179.92 1.04 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.073 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.453 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.5 Cg_exo -59.96 -35.77 92.25 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.476 2.117 . . . . 0.0 112.923 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -123.74 11.11 9.06 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.2 t -135.55 112.95 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.573 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.25 178.03 21.14 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.489 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -127.1 150.01 49.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.573 0.225 . . . . 0.0 110.533 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.433 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 0.9 OUTLIER -146.9 133.73 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.031 0.443 . . . . 0.0 111.429 -179.654 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' MET . . . . . 0.804 ' HG3' HD12 ' A' ' 79' ' ' LEU . 8.5 ttp -126.49 151.95 47.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.352 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -158.26 157.54 28.4 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.272 -0.966 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.2 p90 . . . . . 0 C--N 1.33 -0.269 0 CA-C-O 120.769 0.319 . . . . 0.0 110.811 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.1 p . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.687 0.279 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 100' ' ' MET . 4.5 mt-30 -126.22 132.06 51.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.976 0.417 . . . . 0.0 110.985 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.804 HD12 ' HG3' ' A' ' 53' ' ' MET . 0.3 OUTLIER -133.83 129.98 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.624 179.266 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -152.07 173.1 15.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.518 0.675 . . . . 0.0 111.979 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -103.37 142.37 34.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.862 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' LYS . . . . . 0.511 ' C ' HD12 ' A' ' 83' ' ' LEU . 3.4 tttm -109.14 124.59 51.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 111.389 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.511 HD12 ' C ' ' A' ' 82' ' ' LYS . 9.1 mp -130.7 110.14 11.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.464 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.451 ' HA3' ' CD2' ' A' ' 94' ' ' TYR . . . -133.46 172.09 21.68 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.383 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -126.74 137.59 30.78 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.665 0.269 . . . . 0.0 110.509 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.4 102.05 0.73 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.721 2.281 . . . . 0.0 112.716 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 91' ' ' LEU . 7.0 tp -82.46 -33.33 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.029 0.442 . . . . 0.0 110.312 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.35 165.24 32.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.222 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -66.08 -21.98 66.39 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.522 0.193 . . . . 0.0 111.522 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -111.34 -27.82 8.48 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.407 ' O ' HG22 ' A' ' 87' ' ' ILE . 3.0 mt -115.97 127.73 55.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.952 0.406 . . . . 0.0 111.677 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -134.96 161.83 34.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.147 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.998 HG22 HG12 ' A' ' 127' ' ' VAL . 29.4 pt -119.62 142.06 36.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.033 179.117 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.451 ' CD2' ' HA3' ' A' ' 84' ' ' GLY . 39.5 m-85 -143.92 158.99 43.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.621 0.724 . . . . 0.0 112.662 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -139.03 136.47 35.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.111 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.436 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 1.3 mtp85 -116.35 136.86 52.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.034 0.445 . . . . 0.0 111.183 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.482 HD23 ' CB ' ' A' ' 123' ' ' PHE . 8.8 mt -139.38 117.43 11.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.748 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -168.48 -142.38 3.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.327 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -144.27 145.23 14.59 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.054 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.42 ' HA ' ' HA ' ' A' ' 78' ' ' GLN . 9.6 ptm . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.207 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.482 ' CB ' HD23 ' A' ' 97' ' ' LEU . 18.8 p90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.786 0.327 . . . . 0.0 110.761 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.436 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -148.52 153.19 38.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.299 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.41 140.97 8.68 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.102 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 176.96 -154.2 15.49 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.402 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.998 HG12 HG22 ' A' ' 93' ' ' ILE . 31.0 m -139.59 146.98 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.07 0.462 . . . . 0.0 111.377 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.417 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.7 OUTLIER -126.19 131.04 52.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.531 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 129' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -128.84 150.81 50.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.478 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.79 116.03 31.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.769 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 32.7 mt -86.69 -38.42 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.874 0.368 . . . . 0.0 110.948 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.778 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -162.19 166.34 14.3 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.894 -179.978 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.778 ' HD2' HG22 ' A' ' 132' ' ' THR . 49.8 Cg_exo -55.87 140.21 85.1 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.617 2.211 . . . . 0.0 112.53 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 63.78 10.42 5.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.441 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.522 HD11 ' HB ' ' A' ' 132' ' ' THR . 13.4 pt -149.32 117.01 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.117 0.484 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.563 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -128.57 157.0 42.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.855 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.9 m -136.36 140.84 43.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.58 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -149.0 149.43 31.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.154 0.502 . . . . 0.0 111.788 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.423 ' O ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -120.11 141.83 49.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -145.06 152.78 40.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.538 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 26.8 p90 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.014 -179.976 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 C--O 1.231 0.099 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 163' ' ' SER . . . . . 0.468 ' C ' HD12 ' A' ' 164' ' ' LEU . 8.5 t -137.35 157.96 45.46 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 121.351 0.596 . . . . 0.0 112.093 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' LEU . . . . . 0.468 HD12 ' C ' ' A' ' 163' ' ' SER . 5.6 mp -143.33 128.57 18.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.716 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -144.12 163.57 27.73 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.471 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.563 HG13 ' O ' ' A' ' 136' ' ' ALA . 21.5 t -105.09 146.04 12.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 167' ' ' SER . . . . . 0.402 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 2.0 m -134.67 143.8 47.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.078 0.466 . . . . 0.0 111.657 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -111.23 131.72 54.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.699 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.429 ' HA ' ' CD1' ' A' ' 8' ' ' TYR . 0.0 OUTLIER -107.19 118.8 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.149 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.944 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 20.7 ttt . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.857 0.36 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -74.04 152.14 88.51 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.83 175.67 7.85 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.555 2.17 . . . . 0.0 112.35 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.73 167.45 11.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -149.67 157.26 43.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.847 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.9 t30 66.25 41.56 3.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 p -123.9 171.67 9.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.664 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 18.6 p90 -125.44 164.22 20.92 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.577 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.424 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 22.5 p90 -155.2 156.6 35.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.77 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 44.4 p -149.13 150.51 32.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.737 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.0 -162.98 23.26 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.245 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.99 153.5 51.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.543 -0.329 . . . . 0.0 110.584 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.97 149.41 47.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.181 0.515 . . . . 0.0 111.739 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.21 124.31 10.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.734 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.25 174.18 28.02 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.093 -1.051 . . . . 0.0 113.463 -179.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.765 ' CE2' HD13 ' A' ' 162' ' ' LEU . 12.1 p90 -121.4 147.54 45.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.8 0.333 . . . . 0.0 110.71 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.18 143.56 50.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.8 tm0? -66.38 -58.55 5.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.911 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.9 t80 -143.03 137.58 29.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 13.8 t-80 -94.99 169.71 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.953 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -98.3 36.05 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.23 156.25 37.43 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -105.59 -30.87 4.46 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -94.19 97.22 10.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.811 0.338 . . . . 0.0 110.954 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.7 mt -110.24 127.67 67.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.064 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -153.29 35.85 0.47 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -135.88 148.8 48.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.898 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.29 -31.58 26.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.952 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.82 149.89 15.29 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.69 -45.17 1.16 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.509 2.139 . . . . 0.0 112.295 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.8 p -127.48 -71.99 0.65 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.3 t-160 -147.89 -68.26 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -156.73 96.57 1.64 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -177.2 116.05 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -120.3 115.79 24.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.738 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 6.3 mt -84.0 133.78 34.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.46 148.72 19.73 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -123.18 158.4 30.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.872 0.368 . . . . 0.0 111.193 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -173.91 -174.74 41.04 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.374 -0.917 . . . . 0.0 113.325 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.67 154.15 48.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.836 -0.182 . . . . 0.0 110.612 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -159.24 163.75 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.326 0.584 . . . . 0.0 112.112 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.25 161.16 30.65 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.27 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.424 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -158.0 165.08 33.57 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.711 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -120.16 134.93 55.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.517 -0.342 . . . . 0.0 110.409 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 5.9 mt-30 -95.05 125.77 39.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.337 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -92.94 -38.42 9.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.418 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.0 OUTLIER -155.01 177.93 1.84 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.165 179.888 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.415 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.2 Cg_exo -60.14 -23.53 73.94 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.707 2.271 . . . . 0.0 113.644 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.415 ' CD1' ' HB2' ' A' ' 47' ' ' PRO . 69.3 m-85 -127.59 2.31 6.17 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.517 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.9 m -137.77 115.94 13.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.844 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.44 179.83 19.9 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.51 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -129.03 151.41 49.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.522 0.201 . . . . 0.0 110.556 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -152.03 138.49 18.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.045 0.45 . . . . 0.0 111.789 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 1.3 ptm -126.72 156.8 40.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.919 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.37 159.78 30.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.593 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.404 ' CE1' ' O ' ' A' ' 76' ' ' GLY . 12.4 t80 -154.53 140.54 18.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.587 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -84.98 112.2 20.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.47 ' O ' HD12 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -67.15 -170.05 0.11 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 57' ' ' PHE . 2.7 mp -149.81 147.77 28.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.894 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -131.74 123.61 3.74 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.467 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.44 177.09 4.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.851 0.358 . . . . 0.0 110.972 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 2.4 mmt -123.0 93.99 47.75 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.871 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -49.51 -27.11 13.56 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.582 2.188 . . . . 0.0 112.382 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -93.41 70.25 4.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.45 129.14 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.9 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -110.43 54.91 0.52 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 m -117.01 138.35 51.63 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.474 ' O ' HG23 ' A' ' 67' ' ' VAL . 30.5 m -65.55 118.97 9.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.187 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -142.06 109.65 5.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.898 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -142.01 170.78 15.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.86 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.32 -48.35 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.53 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.45 -179.19 5.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.833 0.349 . . . . 0.0 111.05 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -142.98 113.23 7.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER 60.29 31.5 20.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -87.86 152.98 21.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.066 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -144.31 157.96 43.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.404 ' O ' ' CE1' ' A' ' 55' ' ' TYR . . . -154.94 143.57 10.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.592 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 78' ' ' GLN . 25.4 t -154.78 159.12 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.731 0.3 . . . . 0.0 110.984 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.491 ' N ' HG12 ' A' ' 77' ' ' VAL . 6.5 tt0 -127.81 136.43 51.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.027 0.441 . . . . 0.0 110.844 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.611 ' O ' HD12 ' A' ' 79' ' ' LEU . 4.0 pp -131.22 130.87 43.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.843 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.414 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.6 p -151.74 173.13 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.464 0.65 . . . . 0.0 111.874 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.56 141.24 39.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.905 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.8 mttp -108.02 126.98 53.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.493 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 20.9 mt -129.8 110.68 11.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.402 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.44 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.96 169.36 22.56 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.41 -0.9 . . . . 0.0 113.109 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.729 ' HB2' HD11 ' A' ' 93' ' ' ILE . 35.0 m-85 -123.72 137.67 29.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 110.548 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -84.43 99.4 0.75 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.707 2.271 . . . . 0.0 112.613 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 33.5 mt -81.28 -34.63 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.057 0.456 . . . . 0.0 110.442 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.435 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.9 m -148.0 164.78 32.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.184 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.435 ' N ' HG22 ' A' ' 88' ' ' THR . 58.6 m-20 -60.13 -27.66 67.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.478 0.18 . . . . 0.0 111.485 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.434 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 1.6 m-20 -112.02 -33.78 6.17 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -178.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.1 tt -102.85 123.84 47.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.941 0.4 . . . . 0.0 111.716 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -135.69 164.14 28.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.261 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.981 HG22 HG12 ' A' ' 127' ' ' VAL . 1.7 pp -119.6 142.93 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.003 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.44 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 6.7 m-85 -143.4 157.49 44.42 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.706 0.765 . . . . 0.0 112.715 -178.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 124' ' ' ALA . 91.6 m -141.14 136.26 31.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 114.542 -1.208 . . . . 0.0 109.029 178.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.826 ' CG ' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -118.13 139.58 51.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.963 0.411 . . . . 0.0 111.384 -179.543 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.0 mp -140.82 119.18 12.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.736 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.414 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -166.13 -141.84 3.26 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.296 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.44 23.35 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.317 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.8 ttt -103.79 122.87 46.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 77' ' ' VAL . 7.4 m -96.88 128.86 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -132.7 133.88 44.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.93 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 7.9 ttm-85 -140.27 147.69 40.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.826 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -142.1 162.2 36.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.122 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -110.74 130.61 55.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.986 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.8 92.45 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 20.7 mttp 60.26 105.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -138.54 125.5 21.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.848 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.41 30.8 3.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.585 HG12 ' O ' ' A' ' 110' ' ' VAL . 15.9 t 59.39 31.28 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.086 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.9 -32.64 12.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.971 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 94.28 72.18 1.16 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.489 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 6.5 mmtm -139.99 161.05 38.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.859 0.361 . . . . 0.0 110.863 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -128.42 158.5 38.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.899 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -117.74 -40.67 2.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.17 118.73 2.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.82 152.18 34.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -100.5 113.26 4.65 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.504 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.4 t -146.08 62.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.982 0.42 . . . . 0.0 111.076 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' SER . . . . . 0.505 ' O ' HG23 ' A' ' 122' ' ' VAL . 1.8 m -105.87 102.18 37.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.69 139.11 32.0 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.508 2.139 . . . . 0.0 112.382 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 120' ' ' SER . 21.5 t -141.24 159.0 22.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.119 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.484 ' N ' HG12 ' A' ' 122' ' ' VAL . 3.5 p90 -137.18 164.02 29.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.826 ' HB3' ' CG ' ' A' ' 96' ' ' ARG . . . -142.18 164.2 30.8 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.252 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -149.04 141.95 9.42 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.122 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.4 ' HA3' ' O ' ' A' ' 139' ' ' LEU . . . 177.25 -155.0 16.92 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 119.87 -1.157 . . . . 0.0 113.358 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.981 HG12 HG22 ' A' ' 93' ' ' ILE . 30.1 m -139.71 148.17 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.974 0.416 . . . . 0.0 111.25 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -124.51 132.2 53.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.642 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.434 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 45.0 t80 -128.27 148.33 50.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.418 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 116.37 32.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.818 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 7.8 tp -88.57 -36.58 9.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.467 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -162.36 165.09 16.14 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.854 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.467 ' HD2' HG22 ' A' ' 132' ' ' THR . 11.7 Cg_endo -55.2 141.59 80.08 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.596 2.197 . . . . 0.0 112.074 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 58.54 19.01 6.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.531 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 31.1 mt -149.13 111.95 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 121.018 0.437 . . . . 0.0 111.718 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.577 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -124.42 156.13 37.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.836 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.6 m -142.83 136.26 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.5 ptt85 -146.15 157.94 43.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.253 0.549 . . . . 0.0 112.038 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.839 HD12 HD13 ' A' ' 164' ' ' LEU . 1.9 tt -128.18 139.86 52.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.596 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.472 ' N ' HD23 ' A' ' 139' ' ' LEU . 38.6 mt-10 -147.35 158.18 43.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.177 0.513 . . . . 0.0 111.693 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 161' ' ' MET . 19.3 m-85 -125.05 158.59 33.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.869 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLN . . . . . 0.435 ' OE1' HG11 ' A' ' 122' ' ' VAL . 21.6 mt-30 -126.61 154.11 44.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -104.91 125.97 51.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 58.9 p -100.06 -31.43 11.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -95.43 78.54 3.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -175.82 37.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.6 pt -152.88 172.93 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 74.06 -76.46 1.05 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.444 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -141.1 135.88 31.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.869 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.57 125.92 30.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.07 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 -85.19 141.15 30.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.62 -59.7 2.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.899 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 3.1 pt -146.35 165.64 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.119 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 139.65 -123.37 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.562 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 39.8 p -71.07 143.92 50.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.857 0.36 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -93.06 139.11 23.0 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.855 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.25 85.68 0.83 Allowed 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.507 2.138 . . . . 0.0 112.275 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -145.46 35.9 1.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.816 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -174.76 128.04 0.31 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.887 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -151.08 -129.39 1.58 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.491 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 1.7 ttm -91.55 139.22 30.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.657 0.265 . . . . 0.0 110.934 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.765 HD13 ' CE2' ' A' ' 15' ' ' PHE . 0.8 OUTLIER -121.94 118.43 28.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.073 179.252 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.433 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 17.8 m -136.73 157.54 46.52 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.331 0.586 . . . . 0.0 112.015 -179.27 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' LEU . . . . . 0.839 HD13 HD12 ' A' ' 139' ' ' LEU . 10.9 tp -141.69 127.87 19.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.673 179.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.98 161.75 27.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.09 -1.052 . . . . 0.0 113.431 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.2 m -106.16 147.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' SER . . . . . 0.577 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 22.4 p -134.54 146.11 49.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.159 0.504 . . . . 0.0 111.608 -179.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -113.61 131.63 56.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.786 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -108.54 117.12 33.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.955 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -107.66 131.4 54.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 136.5 57.15 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -83.83 -56.95 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.798 0.332 . . . . 0.0 110.89 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 66.08 -164.17 40.49 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -140.9 -51.39 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -106.92 -64.11 1.22 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.066 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.136 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 4.3 mtm . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.861 0.362 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -76.73 143.5 71.58 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.07 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.32 132.32 14.88 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.574 2.183 . . . . 0.0 112.37 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.67 -38.67 3.93 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.787 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.466 ' O ' ' N ' ' A' ' 6' ' ' THR . 1.3 t70 -140.06 28.78 2.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -64.12 67.05 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.848 0.356 . . . . 0.0 111.777 -179.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.466 ' N ' ' O ' ' A' ' 4' ' ' ASP . 67.5 p -126.13 173.02 9.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.797 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 12.9 p90 -128.01 164.18 22.93 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.641 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.415 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 5.3 p90 -155.29 156.63 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.417 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 3.3 t -149.17 150.21 32.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.71 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.416 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.75 -161.94 22.24 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.465 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -130.46 159.38 37.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.537 -0.331 . . . . 0.0 110.608 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -142.26 150.05 40.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.216 0.532 . . . . 0.0 112.003 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.798 ' HG ' ' HB2' ' A' ' 37' ' ' ALA . 6.6 tt -149.24 125.98 11.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.548 179.129 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.455 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.2 174.36 27.92 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.011 -1.09 . . . . 0.0 113.745 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 2.9 m-85 -134.39 154.23 51.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.272 179.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.592 ' HB2' HD12 ' A' ' 35' ' ' LEU . 10.3 t -148.38 -169.23 3.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.836 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -74.57 151.57 39.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -107.7 91.55 3.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -104.09 103.14 12.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.878 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.29 132.39 5.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.895 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.0 157.72 17.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.974 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.403 ' O ' ' CD2' ' A' ' 23' ' ' PHE . . . 162.3 51.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.474 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' A' ' 22' ' ' GLY . 0.8 OUTLIER -174.75 137.97 0.47 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.806 0.336 . . . . 0.0 110.851 -179.971 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.7 pt -74.91 -30.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -125.21 150.55 46.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -138.37 179.64 6.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -101.22 -31.33 11.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 153.24 177.78 27.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.564 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.32 162.28 2.22 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.593 2.195 . . . . 0.0 112.285 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 p -105.21 178.67 4.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -167.23 33.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -119.57 -176.81 3.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -134.88 171.35 14.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 166.2 142.31 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.676 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.592 HD12 ' HB2' ' A' ' 16' ' ' SER . 3.8 tt -156.47 -70.47 0.11 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.592 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 144.81 176.9 19.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.643 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.798 ' HB2' ' HG ' ' A' ' 13' ' ' LEU . . . -128.24 -176.9 3.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.793 0.33 . . . . 0.0 111.027 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.18 -159.4 31.86 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.357 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -135.1 155.08 51.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.543 0.211 . . . . 0.0 110.668 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -159.29 163.66 35.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.289 0.566 . . . . 0.0 111.907 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -140.61 158.84 26.24 Favored Glycine 0 N--CA 1.448 -0.544 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.35 179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.415 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.67 150.13 21.75 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.509 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 6.9 m-85 -117.35 131.79 56.72 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' A' ' 4' ' ' ASP . 11.3 mt-30 -94.64 126.46 39.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.236 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.01 -36.9 7.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.769 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.453 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.0 OUTLIER -152.76 179.21 1.32 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.154 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.436 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 39.3 Cg_exo -61.47 -26.89 81.62 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.684 2.256 . . . . 0.0 113.692 -179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.79 ' O ' HD23 ' A' ' 83' ' ' LEU . 11.3 p90 -124.53 4.11 8.31 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 -178.593 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.453 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 3.7 m -137.74 116.11 13.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.862 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.35 179.41 19.56 Favored Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.439 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -130.23 152.38 49.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.62 0.248 . . . . 0.0 110.767 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.408 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 13.0 mt-10 -150.38 136.71 18.77 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.09 0.471 . . . . 0.0 111.528 -179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' MET . . . . . 0.449 ' HG2' HD12 ' A' ' 79' ' ' LEU . 5.1 mpp? -132.35 114.39 14.32 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.327 179.567 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -119.09 164.02 13.23 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.431 -0.89 . . . . 0.0 113.39 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.636 ' HB3' HG12 ' A' ' 77' ' ' VAL . 17.9 p90 -152.43 156.19 39.0 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.796 0.331 . . . . 0.0 110.828 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.675 ' HB3' HD13 ' A' ' 58' ' ' LEU . 8.2 m-20 -85.0 153.88 22.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -86.28 -71.87 0.52 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.825 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.675 HD13 ' HB3' ' A' ' 56' ' ' ASP . 9.5 mp 60.49 32.93 20.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.874 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 129.13 -99.11 0.46 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -139.23 168.58 19.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.752 0.31 . . . . 0.0 110.928 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -157.36 88.28 2.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.6 -175.62 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.541 2.16 . . . . 0.0 112.227 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -159.57 -45.15 0.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.913 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? -58.62 -30.82 67.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.966 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.68 141.79 9.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.496 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -176.98 172.77 1.95 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.821 0.343 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 12.2 m -90.01 144.68 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.135 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -153.17 -176.0 5.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.843 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -135.1 167.51 20.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.878 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.37 28.25 10.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.488 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . 59.81 177.99 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -93.56 154.38 17.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.7 mmtm -101.32 154.0 19.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.86 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.91 120.71 13.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.149 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 -98.31 135.14 40.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -131.73 121.4 3.08 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.428 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 55' ' ' TYR . 30.9 m -136.0 154.15 33.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.735 0.302 . . . . 0.0 111.151 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.0 pm0 -131.72 139.33 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.449 HD12 ' HG2' ' A' ' 53' ' ' MET . 7.7 tt -127.11 132.13 50.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.803 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -151.62 173.06 15.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.44 0.638 . . . . 0.0 111.978 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.54 141.44 39.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.862 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -108.83 126.44 53.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.874 0.369 . . . . 0.0 111.447 -179.416 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.79 HD23 ' O ' ' A' ' 48' ' ' TYR . 2.4 mt -131.61 110.09 10.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.239 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.1 177.53 19.48 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.773 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 85' ' ' TYR . 3.4 m-85 -131.76 140.63 38.87 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.659 0.266 . . . . 0.0 110.475 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -87.56 106.72 0.61 Allowed 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.836 2.357 . . . . 0.0 112.826 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 1.003 HD11 HD22 ' A' ' 91' ' ' LEU . 26.4 pt -80.22 -33.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.23 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.749 HG22 HG13 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -150.65 169.68 21.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.05 178.914 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -64.17 -23.31 67.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.079 0.399 . . . . 0.0 112.079 -179.161 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.446 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -110.94 -28.22 8.45 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 -178.708 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 1.003 HD22 HD11 ' A' ' 87' ' ' ILE . 0.5 OUTLIER -109.34 126.37 53.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.138 0.494 . . . . 0.0 111.924 -179.086 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.24 152.52 50.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.001 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 12.0 tt -123.11 142.12 40.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.907 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.439 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 28.5 p90 -153.22 170.21 21.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.719 0.771 . . . . 0.0 113.021 -179.017 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 p -139.62 141.91 37.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.62 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.613 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 46.1 mtp180 -117.3 137.39 52.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.882 0.372 . . . . 0.0 111.067 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.636 HD23 ' N ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -139.86 120.03 13.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.856 -179.924 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -141.06 3.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.338 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.17 151.89 23.78 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.591 -0.814 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 2.4 ppp? -101.98 132.51 47.77 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.35 124.92 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.407 ' HE1' ' HB2' ' A' ' 104' ' ' ALA . 6.8 t80 -117.26 125.75 51.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -129.3 122.21 29.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ALA . . . . . 0.407 ' HB2' ' HE1' ' A' ' 102' ' ' PHE . . . -138.21 125.72 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.121 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -83.92 136.37 34.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.878 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -103.35 125.33 49.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.914 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 6.2 mtmp? -70.96 -46.07 63.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.9 p -166.15 32.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -74.4 -63.96 1.13 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.892 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 29.8 m -100.72 146.2 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -95.54 -33.38 12.43 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -76.32 -158.64 8.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -153.56 104.84 2.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.799 0.333 . . . . 0.0 110.929 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -139.13 83.93 1.98 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.827 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 60.3 178.29 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.796 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -168.83 33.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.4 m -146.15 109.17 4.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -84.21 123.64 6.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.548 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.6 m -131.07 150.0 34.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 2.7 m -171.56 149.22 2.41 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.539 ' O ' HG13 ' A' ' 122' ' ' VAL . 55.5 Cg_endo -70.06 158.94 54.93 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.539 HG13 ' O ' ' A' ' 121' ' ' PRO . 6.0 m -159.02 141.71 5.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -117.65 158.88 23.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.818 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.613 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -151.94 149.48 28.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.21 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.91 138.65 7.44 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.075 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.38 -158.5 22.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 119.996 -1.097 . . . . 0.0 113.264 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 18.8 m -141.89 149.78 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.134 0.492 . . . . 0.0 111.474 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -125.27 131.37 53.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.504 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.446 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 42.6 t80 -126.89 146.98 50.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.319 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.4 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.84 114.53 27.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.81 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -87.03 -39.18 12.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.009 0.433 . . . . 0.0 110.933 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.726 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -159.59 169.75 9.88 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.729 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.726 ' CD ' HG22 ' A' ' 132' ' ' THR . 32.0 Cg_exo -58.41 139.94 92.57 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.52 2.147 . . . . 0.0 112.214 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 59.71 17.72 6.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.842 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.45 ' O ' HG23 ' A' ' 135' ' ' ILE . 1.8 tt -149.21 113.93 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.114 0.483 . . . . 0.0 111.721 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.71 157.86 40.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.084 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 3.2 t -124.9 141.11 52.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.534 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 25.0 mtt180 -135.16 134.59 40.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.124 0.488 . . . . 0.0 111.815 -179.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.939 HD12 HD12 ' A' ' 164' ' ' LEU . 4.3 tt -130.06 130.78 45.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.543 179.044 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.526 ' N ' HD23 ' A' ' 139' ' ' LEU . 0.9 OUTLIER -153.53 169.42 23.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.392 0.615 . . . . 0.0 112.017 -179.08 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.477 ' HA ' ' O ' ' A' ' 161' ' ' MET . 4.1 m-85 -122.2 161.98 22.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.21 -0.904 . . . . 0.0 110.847 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -129.49 151.34 50.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -119.75 150.77 39.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -160.88 78.47 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.87 102.12 13.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.942 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 13.9 m-80 -127.58 78.93 1.86 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.882 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 5.9 pt -76.94 -30.74 18.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.055 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 69.07 -85.67 0.22 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.55 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -162.94 83.79 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.828 0.347 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -162.17 -170.18 2.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.082 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 2.7 t-160 -102.99 34.18 2.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.883 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.0 t -106.84 31.05 5.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 1.7 pt -67.14 116.24 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -166.16 104.78 0.23 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.507 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 3.4 t -112.7 128.7 56.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.59 146.34 32.31 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.46 -61.91 0.39 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.545 2.163 . . . . 0.0 112.214 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -152.17 77.82 1.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -151.58 35.71 0.56 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -96.12 -104.22 2.09 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.504 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.477 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 39.2 mtt -93.79 130.91 39.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.627 0.251 . . . . 0.0 110.902 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.523 HD23 ' C ' ' A' ' 162' ' ' LEU . 7.2 tt -120.95 119.1 31.61 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.455 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 28.3 t -132.69 154.2 50.39 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.199 0.523 . . . . 0.0 111.78 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' LEU . . . . . 0.939 HD12 HD12 ' A' ' 139' ' ' LEU . 8.0 tt -144.66 122.7 12.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.853 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.12 163.83 26.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.245 -0.978 . . . . 0.0 113.24 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.8 m -105.06 146.83 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' SER . . . . . 0.416 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 0.9 OUTLIER -135.14 143.42 46.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.096 0.474 . . . . 0.0 111.67 -179.505 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -109.61 132.68 53.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.687 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.12 29.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.89 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -84.43 133.08 34.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.893 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.7 149.87 23.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.548 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -83.76 -51.72 6.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 110.895 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 84.41 165.14 38.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.448 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -148.56 96.9 2.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.86 0.362 . . . . 0.0 110.867 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -139.93 131.84 27.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.073 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.112 179.952 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 7.8 mtm . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 120.817 0.342 . . . . 0.0 111.218 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.741 ' HB3' ' HD3' ' A' ' 2' ' ' PRO . . . -72.79 -61.21 1.67 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.741 ' HD3' ' HB3' ' A' ' 1' ' ' ALA . 58.5 Cg_endo -71.64 173.71 12.14 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.533 2.155 . . . . 0.0 112.387 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.6 tptp -176.89 -40.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.929 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -148.06 164.05 35.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.955 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m120 65.38 41.87 4.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.978 0.418 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.8 p -124.06 172.2 9.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.734 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 9.2 p-90 -126.68 164.58 20.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.561 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.425 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 2.8 p90 -155.34 158.35 38.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.966 179.693 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 t -149.14 149.54 31.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -169.68 -162.94 22.86 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.399 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.6 155.43 48.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.601 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.425 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 14.2 pttt -139.5 153.14 47.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.299 0.571 . . . . 0.0 112.276 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.011 HD13 ' HB2' ' A' ' 37' ' ' ALA . 48.3 tp -147.32 127.42 13.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.268 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.462 ' O ' ' HB3' ' A' ' 35' ' ' LEU . . . -148.15 174.5 27.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.743 -178.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.425 ' HA ' ' CB ' ' A' ' 35' ' ' LEU . 19.2 m-85 -143.52 149.75 37.93 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.268 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -144.28 -172.34 3.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.823 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -117.55 109.91 17.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -124.98 140.8 52.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.887 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -95.13 129.03 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.866 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -106.22 176.88 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.78 161.58 41.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.58 -28.63 2.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -131.14 123.85 29.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.844 0.354 . . . . 0.0 110.906 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -59.79 156.95 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.135 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.6 m-20 -162.53 -45.15 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 m120 60.67 35.62 19.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -105.79 159.73 15.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -132.12 63.71 0.62 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.504 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.75 -175.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.6 2.2 . . . . 0.0 112.314 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.42 -59.2 2.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -161.99 -178.96 6.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.935 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -131.34 -178.15 4.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.929 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.463 ' O ' ' HB2' ' A' ' 34' ' ' GLN . 56.4 t30 -171.84 118.85 0.42 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.927 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 33' ' ' ASN . 42.5 tt0 167.56 144.68 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.477 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.462 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 10.5 tt -158.08 -71.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.513 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 144.89 -179.69 21.86 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.397 -0.906 . . . . 0.0 112.624 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 1.011 ' HB2' HD13 ' A' ' 13' ' ' LEU . . . -123.61 -176.97 3.59 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.851 0.358 . . . . 0.0 111.0 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.71 -162.78 35.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.306 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.86 155.1 45.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.717 -0.241 . . . . 0.0 110.7 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.425 ' CE1' ' HB3' ' A' ' 12' ' ' LYS . 27.3 p90 -159.13 157.72 31.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.304 0.573 . . . . 0.0 112.01 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -147.47 159.86 28.14 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.319 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.425 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -155.26 161.29 30.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 119.824 -1.179 . . . . 0.0 113.602 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 13.1 t80 -123.05 133.72 54.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.252 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -95.07 125.62 39.86 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.272 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 t -93.24 -37.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.961 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.474 ' HB2' HG23 ' A' ' 49' ' ' VAL . 1.1 t30 -153.92 178.32 1.66 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.424 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.4 Cg_exo -60.1 -25.97 81.24 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.679 2.252 . . . . 0.0 113.64 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CE1' ' HB2' ' A' ' 47' ' ' PRO . 17.9 m-85 -127.46 3.99 6.24 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.474 HG23 ' HB2' ' A' ' 46' ' ' ASN . 4.3 m -138.04 115.06 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.819 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.65 -177.23 18.4 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.466 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.59 150.04 49.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.559 0.219 . . . . 0.0 110.629 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -146.57 134.25 21.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.039 0.447 . . . . 0.0 111.375 -179.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -128.43 153.68 46.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.339 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.61 158.84 30.02 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.191 -1.004 . . . . 0.0 113.116 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 7.3 p90 -159.17 161.81 36.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.4 t0 -93.21 124.62 37.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.98 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -108.37 128.59 54.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mt -94.01 -66.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 143.56 146.04 4.49 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.573 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 83.4 mtt180 -151.32 157.6 42.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' MET . . . . . 0.408 ' CB ' ' CD ' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -64.74 -60.9 7.25 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.942 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.408 ' CD ' ' CB ' ' A' ' 61' ' ' MET . 58.3 Cg_endo -71.77 145.6 46.42 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.425 2.083 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -67.63 -53.79 25.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -78.13 -47.65 17.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.887 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 126.49 41.56 0.32 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.446 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.5 m 60.2 175.9 0.09 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.834 0.349 . . . . 0.0 110.834 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.6 -47.24 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -102.1 31.58 3.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.95 -54.7 2.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.839 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.15 82.79 0.32 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.552 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.92 90.77 1.31 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 111.057 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.45 165.17 11.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tttt -131.05 -60.99 0.95 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -175.27 148.07 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.108 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 7.4 tt0 -117.95 117.22 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.916 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.43 ' HA3' ' CE2' ' A' ' 102' ' ' PHE . . . -134.19 124.01 3.43 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.476 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 31.3 m -142.83 162.78 17.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.684 0.278 . . . . 0.0 111.137 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -130.22 140.43 50.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.048 0.451 . . . . 0.0 111.091 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -129.85 132.1 46.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.968 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.423 ' HB ' ' HA3' ' A' ' 98' ' ' GLY . 1.3 t -151.43 170.11 20.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.523 0.678 . . . . 0.0 112.09 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.94 144.22 35.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.946 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -110.14 125.26 52.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -130.89 108.15 9.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.209 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.479 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -134.99 176.89 19.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.232 -0.985 . . . . 0.0 113.658 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.564 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.5 m-85 -128.07 140.18 37.52 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.661 0.267 . . . . 0.0 110.606 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -87.87 103.72 0.51 Allowed 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.772 2.315 . . . . 0.0 112.634 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 41.6 pt -82.14 -30.64 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.042 0.448 . . . . 0.0 110.337 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.404 ' OG1' ' HB3' ' A' ' 91' ' ' LEU . 0.2 OUTLIER -150.47 167.31 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.177 179.297 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -64.94 -23.45 67.23 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.447 ' HB3' ' CE1' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -112.07 -37.31 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.02 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.404 ' HB3' ' OG1' ' A' ' 88' ' ' THR . 15.3 tp -102.94 125.73 49.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.984 0.421 . . . . 0.0 111.656 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -133.54 161.02 35.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.186 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.051 HG22 HG12 ' A' ' 127' ' ' VAL . 2.6 pp -125.66 143.23 39.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.035 179.123 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.479 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 10.2 p90 -155.1 170.27 22.2 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.723 0.773 . . . . 0.0 113.003 -178.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.3 p -139.39 143.05 37.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.714 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.67 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 68.5 mtm180 -118.69 139.06 52.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.012 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 6.7 tp -141.25 120.84 13.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.1 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.423 ' HA3' ' HB ' ' A' ' 80' ' ' THR . . . -164.8 -149.04 5.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.56 152.25 24.35 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.107 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.2 ptt? -106.52 141.19 38.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.829 0.347 . . . . 0.0 110.848 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 5.0 m -126.01 108.52 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.12 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.43 ' CE2' ' HA3' ' A' ' 76' ' ' GLY . 4.5 m-85 -118.2 111.9 19.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.848 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 -114.36 124.73 52.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -109.56 140.93 42.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.109 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.37 156.79 20.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.64 129.06 22.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -163.47 31.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.4 m -142.08 -54.66 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -154.6 147.02 23.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.908 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.56 106.5 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -67.73 -35.97 79.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.861 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -114.47 -120.13 3.45 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.459 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -156.78 -65.18 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 0.0 110.953 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -73.78 147.75 43.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -122.06 124.21 43.42 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.841 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -106.82 139.79 40.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 47.2 p -107.46 154.57 21.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -91.06 111.86 4.03 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.473 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.5 t -152.13 113.17 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.808 0.337 . . . . 0.0 111.191 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.3 m -177.21 163.24 1.48 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.536 ' O ' HG13 ' A' ' 122' ' ' VAL . 54.4 Cg_endo -69.59 168.44 21.33 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.636 2.224 . . . . 0.0 112.316 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.536 HG13 ' O ' ' A' ' 121' ' ' PRO . 5.8 m -158.93 121.81 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.222 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -102.13 156.48 17.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.823 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.67 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -151.48 148.5 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.221 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.95 138.88 7.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.111 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.65 -156.96 20.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.002 -1.094 . . . . 0.0 113.299 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 1.051 HG12 HG22 ' A' ' 93' ' ' ILE . 28.9 m -141.54 147.9 21.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.043 0.449 . . . . 0.0 111.335 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.421 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 21.6 tt0 -124.05 132.11 53.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.703 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.447 ' CE1' ' HB3' ' A' ' 90' ' ' ASP . 70.9 t80 -126.09 146.4 49.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.176 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.39 116.15 31.68 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.808 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.598 HD11 HG22 ' A' ' 135' ' ' ILE . 2.2 pt -92.8 -30.99 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.611 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.816 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.2 OUTLIER -147.13 169.27 9.65 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.499 179.916 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.816 ' HD2' HG22 ' A' ' 132' ' ' THR . 53.1 Cg_exo -55.91 -60.95 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.575 2.183 . . . . 0.0 112.843 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLU . . . . . 0.608 ' C ' HD12 ' A' ' 135' ' ' ILE . 9.8 tt0 -98.05 23.85 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.708 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.608 HD12 ' C ' ' A' ' 134' ' ' GLU . 4.3 mp -146.46 117.6 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.053 0.454 . . . . 0.0 111.651 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.12 161.86 29.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.082 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.816 HG22 HG12 ' A' ' 166' ' ' VAL . 80.9 p -135.93 140.59 44.14 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.407 179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.65 144.04 32.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.237 0.542 . . . . 0.0 112.041 -179.251 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.621 HD12 ' CD1' ' A' ' 164' ' ' LEU . 2.6 tt -124.83 136.34 53.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.598 178.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.462 ' N ' HD23 ' A' ' 139' ' ' LEU . 16.8 mt-10 -146.0 156.44 43.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.227 0.537 . . . . 0.0 111.807 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.486 ' HA ' ' O ' ' A' ' 161' ' ' MET . 3.1 m-85 -121.17 143.06 49.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.536 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.06 145.48 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -104.31 142.93 33.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.945 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -109.7 -30.66 7.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.3 t30 62.04 152.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -168.98 -43.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.527 ' H ' HD12 ' A' ' 147' ' ' ILE . 3.4 mp -61.24 -43.65 96.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.161 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 158.53 -111.08 0.47 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.538 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -124.74 102.32 7.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.77 0.319 . . . . 0.0 110.876 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 160.96 15.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 8.9 m80 -127.55 80.68 1.97 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 38.9 p -137.45 132.39 33.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.874 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 2.7 tt -79.28 -30.86 14.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -111.71 133.2 11.31 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.51 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 20.8 p -77.32 157.0 30.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.791 0.329 . . . . 0.0 110.872 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.9 mmt85 -87.18 145.77 38.72 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -74.58 128.22 11.65 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.62 2.213 . . . . 0.0 112.377 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 58.98 45.72 14.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.953 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -112.88 -43.62 3.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -118.32 -110.78 2.48 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.514 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 2.4 mtp -102.38 130.84 49.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.596 0.236 . . . . 0.0 110.892 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 8.4 mp -120.8 118.98 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.12 179.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.411 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 22.5 m -132.31 152.7 51.28 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.201 0.524 . . . . 0.0 111.627 -179.354 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' LEU . . . . . 0.621 ' CD1' HD12 ' A' ' 139' ' ' LEU . 2.7 tt -143.81 123.86 13.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.775 179.259 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' GLY . . . . . 0.425 ' N ' HD23 ' A' ' 164' ' ' LEU . . . -143.55 164.75 27.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.24 -0.981 . . . . 0.0 113.456 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.816 HG12 HG22 ' A' ' 137' ' ' THR . 25.9 m -105.45 147.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 167' ' ' SER . . . . . 0.414 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 30.0 p -134.78 145.91 48.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.125 0.488 . . . . 0.0 111.761 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -112.12 131.96 55.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.738 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -108.51 116.79 32.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.025 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -84.36 150.2 25.52 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -148.01 52.12 0.55 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.24 79.7 1.59 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 135.07 140.15 4.17 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.485 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -151.62 -50.93 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.873 0.368 . . . . 0.0 110.877 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -149.22 -67.56 0.22 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.07 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.1 -179.974 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 5.0 ptp . . . . . 0 N--CA 1.488 1.441 0 CA-C-O 120.856 0.36 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -98.37 150.13 36.42 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.041 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.8 68.6 1.71 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.528 2.152 . . . . 0.0 112.297 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 30.1 mtmt -149.36 166.35 29.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -87.88 -79.21 0.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 67.23 42.09 2.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.8 p -123.48 165.66 16.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.811 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 7.2 t90 -113.1 161.07 17.53 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.317 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.467 ' CZ ' ' HB2' ' A' ' 169' ' ' ARG . 0.1 OUTLIER -145.12 141.62 28.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 m -147.56 144.42 28.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.698 0.285 . . . . 0.0 111.189 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -173.82 -157.58 15.82 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.295 -0.955 . . . . 0.0 113.256 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -134.02 155.44 49.98 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.659 -0.271 . . . . 0.0 110.746 179.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.467 ' C ' HD12 ' A' ' 13' ' ' LEU . 1.7 mmmm -139.16 153.15 47.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.147 0.498 . . . . 0.0 111.966 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HG ' ' HB1' ' A' ' 37' ' ' ALA . 2.7 mp -148.9 128.21 12.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.516 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 35' ' ' LEU . . . -148.24 174.48 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.024 -1.084 . . . . 0.0 113.694 -178.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.43 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 3.8 m-85 -134.1 156.83 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.852 ' HB2' HD13 ' A' ' 35' ' ' LEU . 2.5 t -131.21 164.9 24.54 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.86 0.362 . . . . 0.0 110.915 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 62.87 73.69 0.45 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -83.18 168.15 17.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.822 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -173.11 93.37 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.867 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -127.31 -48.77 1.43 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 26.9 m -80.98 146.52 30.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.893 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 70.24 -157.07 53.52 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -176.15 88.6 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.804 0.335 . . . . 0.0 110.824 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.9 mp -128.26 113.39 30.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.157 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -169.83 151.6 4.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -132.08 31.58 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.887 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -136.38 -47.03 0.63 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.898 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.9 -152.29 18.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.455 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.94 109.03 2.25 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.146 . . . . 0.0 112.308 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 49.4 m -153.35 -54.7 0.11 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -126.58 115.42 19.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.929 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -143.46 88.22 1.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.929 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 63.59 130.76 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.948 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 166.6 142.66 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.852 HD13 ' HB2' ' A' ' 16' ' ' SER . 14.7 tp -156.51 -72.14 0.1 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.5 179.742 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 145.57 177.65 20.48 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.319 -0.943 . . . . 0.0 112.621 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.603 ' HB1' ' HG ' ' A' ' 13' ' ' LEU . . . -127.04 -176.94 3.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.79 0.329 . . . . 0.0 110.974 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.01 -159.78 32.47 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.28 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.4 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -114.51 151.63 33.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.921 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.447 ' CD2' ' HA3' ' A' ' 54' ' ' GLY . 61.2 m-85 -151.23 149.88 29.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.03 0.443 . . . . 0.0 111.692 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.04 156.75 28.63 Favored Glycine 0 N--CA 1.45 -0.417 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -157.04 154.67 25.73 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 119.783 -1.199 . . . . 0.0 113.771 -179.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 24.9 t80 -107.21 133.63 51.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.5 -0.35 . . . . 0.0 110.086 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -96.13 125.91 40.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.453 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.0 t -94.78 -36.44 6.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.484 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.8 OUTLIER -156.6 173.37 5.03 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.688 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.484 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 25.9 Cg_endo -62.82 -15.31 46.21 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 122.227 1.952 . . . . 0.0 113.551 -179.085 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -126.86 -4.76 6.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.6 m -139.07 117.48 12.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.97 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.6 -179.37 18.67 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.369 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -128.87 149.59 50.7 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.636 0.255 . . . . 0.0 110.414 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -149.37 137.01 20.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.004 0.43 . . . . 0.0 111.616 -179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' MET . . . . . 0.43 ' HG2' HD23 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -128.23 156.72 42.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.212 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.447 ' HA3' ' CD2' ' A' ' 40' ' ' PHE . . . -159.03 157.54 28.58 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.142 -1.028 . . . . 0.0 113.199 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.646 ' HD2' HG22 ' A' ' 77' ' ' VAL . 13.9 t80 -138.73 141.3 38.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.873 0.368 . . . . 0.0 110.841 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -129.01 129.0 44.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.927 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -95.07 116.6 28.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 10.9 mt -122.98 158.51 30.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.971 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -92.12 -88.47 1.49 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.469 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 12.7 ttm180 -101.48 147.75 26.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 0.0 110.842 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 1.1 mmt -85.25 160.57 54.23 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -36.12 11.62 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.513 2.142 . . . . 0.0 112.371 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 51.2 t80 -92.48 79.73 4.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.45 137.57 58.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.88 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -164.21 -42.3 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.435 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.1 t -171.36 111.91 0.34 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.876 0.37 . . . . 0.0 110.936 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.81 106.49 12.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.111 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -106.27 90.85 3.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.865 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -90.7 149.45 22.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -141.95 -115.99 1.18 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -99.2 31.23 3.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.857 0.36 . . . . 0.0 111.097 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -175.78 -169.45 0.34 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 2.4 tmtt? -144.24 159.92 41.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.31 135.16 57.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -94.78 100.03 12.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.817 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.405 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -113.86 107.43 1.89 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.508 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.646 HG22 ' HD2' ' A' ' 55' ' ' TYR . 24.8 t -111.53 159.13 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.709 0.29 . . . . 0.0 110.952 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.489 ' N ' HG12 ' A' ' 77' ' ' VAL . 6.7 tt0 -128.11 134.14 49.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.007 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.43 HD23 ' HG2' ' A' ' 53' ' ' MET . 2.4 mt -128.92 130.28 46.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.842 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.7 p -151.38 173.1 14.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.461 0.648 . . . . 0.0 111.99 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -109.0 142.91 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.001 179.049 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -109.07 126.17 52.89 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.877 0.37 . . . . 0.0 111.479 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.0 mp -129.15 112.17 13.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.248 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.72 170.85 22.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.217 -0.992 . . . . 0.0 113.474 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.745 ' HB2' HD11 ' A' ' 93' ' ' ILE . 3.1 m-85 -124.3 139.07 32.05 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.639 0.257 . . . . 0.0 110.517 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -85.31 100.04 0.68 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.708 2.272 . . . . 0.0 112.704 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 1.024 HD11 HG23 ' A' ' 93' ' ' ILE . 1.2 mp -80.36 -35.04 15.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.135 0.493 . . . . 0.0 110.309 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.438 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.8 m -148.62 164.88 32.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.164 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.438 ' N ' HG22 ' A' ' 88' ' ' THR . 1.9 t70 -60.71 -24.8 65.95 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.574 0.212 . . . . 0.0 111.574 -179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.441 ' CB ' ' CE2' ' A' ' 129' ' ' TYR . 10.8 m-20 -113.08 -33.52 6.0 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.087 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 6.8 tp -102.89 123.58 46.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.903 0.383 . . . . 0.0 111.793 -179.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.684 ' HA ' HD12 ' A' ' 87' ' ' ILE . 72.6 m-20 -134.03 160.81 36.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.297 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.036 HG22 HG12 ' A' ' 127' ' ' VAL . 1.0 OUTLIER -120.41 142.88 34.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.984 179.099 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.438 ' CE1' ' HB2' ' A' ' 128' ' ' GLU . 47.2 p90 -147.15 163.49 36.14 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.653 0.74 . . . . 0.0 112.872 -178.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -140.58 139.64 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.363 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.495 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -116.51 135.04 54.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.891 0.377 . . . . 0.0 111.003 -179.748 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.37 118.21 11.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.836 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.86 -144.19 3.99 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.298 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -150.03 151.09 23.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.205 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -102.54 128.61 49.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 11.9 p -104.52 129.87 56.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.034 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -116.55 115.57 26.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 6.7 mtp85 -105.56 126.29 51.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -125.43 135.59 52.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.085 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -81.95 155.15 25.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -163.51 151.87 13.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.833 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 4.6 mttm -96.75 80.23 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.03 -71.87 0.54 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -107.25 140.2 40.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.7 m -98.9 31.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -75.25 -35.97 61.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 98.67 -33.48 6.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.497 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 33.9 mttt -134.95 110.26 8.99 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.836 0.35 . . . . 0.0 110.873 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -115.72 175.78 5.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 10.6 m170 -107.43 36.54 2.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -119.35 98.69 6.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -152.53 150.29 29.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.476 ' O ' HG13 ' A' ' 119' ' ' VAL . . . -76.44 142.11 27.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.531 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.476 HG13 ' O ' ' A' ' 118' ' ' GLY . 8.4 m -157.28 139.36 5.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.84 0.352 . . . . 0.0 111.122 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' SER . . . . . 0.404 ' HA ' ' HD3' ' A' ' 121' ' ' PRO . 0.3 OUTLIER -163.67 137.0 4.28 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.927 -180.0 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.486 ' O ' HG13 ' A' ' 122' ' ' VAL . 52.8 Cg_exo -54.68 159.77 8.36 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.502 2.135 . . . . 0.0 112.336 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 ' O ' ' A' ' 121' ' ' PRO . 15.3 m -158.06 134.77 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.095 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.404 ' CZ ' ' O ' ' A' ' 143' ' ' PHE . 5.0 p90 -121.25 162.44 20.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.495 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -156.17 150.82 25.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.207 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.45 139.3 7.75 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.126 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.37 -156.57 19.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.248 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 1.036 HG12 HG22 ' A' ' 93' ' ' ILE . 29.4 m -138.88 148.25 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.161 0.505 . . . . 0.0 111.267 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.438 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 40.1 tt0 -124.62 131.93 53.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.715 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.441 ' CE2' ' CB ' ' A' ' 90' ' ' ASP . 48.8 t80 -127.9 147.59 50.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.239 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 117.0 34.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.859 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.834 HD11 ' CG2' ' A' ' 135' ' ' ILE . 29.6 pt -89.57 -33.59 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.069 0.462 . . . . 0.0 110.671 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.7 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -147.37 174.58 3.29 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.52 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.7 ' CD ' HG22 ' A' ' 132' ' ' THR . 50.7 Cg_exo -54.17 -62.08 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.586 2.191 . . . . 0.0 112.75 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLU . . . . . 0.478 ' C ' HD12 ' A' ' 135' ' ' ILE . 12.2 tt0 -100.15 31.52 3.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.629 -179.312 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.834 ' CG2' HD11 ' A' ' 131' ' ' ILE . 4.5 mp -145.99 115.52 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.952 0.406 . . . . 0.0 111.555 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.528 ' O ' HG23 ' A' ' 166' ' ' VAL . . . -131.07 150.13 52.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.924 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.31 141.66 51.95 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.641 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.404 ' HD2' ' HB2' ' A' ' 167' ' ' SER . 0.2 OUTLIER -134.2 140.48 46.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.104 0.478 . . . . 0.0 111.687 -179.515 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.5 pp -132.68 130.54 40.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.511 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -151.68 168.21 25.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.301 0.572 . . . . 0.0 111.933 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.676 ' CE2' HD23 ' A' ' 162' ' ' LEU . 2.7 m-85 -131.8 159.28 38.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.911 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -141.57 165.06 28.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.404 ' O ' ' CZ ' ' A' ' 123' ' ' PHE . 0.7 OUTLIER -132.21 163.0 29.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 14.3 p -105.87 -178.53 3.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.1 121.61 33.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.967 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -128.57 173.74 10.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 4.6 mt 62.9 147.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.085 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -88.01 145.47 19.26 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.494 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -63.77 129.66 41.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.809 0.338 . . . . 0.0 110.957 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -172.39 -63.88 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.14 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -131.01 -60.26 0.97 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 48.6 p -73.71 116.38 14.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.877 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.1 pt -134.26 31.0 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.115 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -95.56 -177.35 37.05 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.453 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 62.7 p -96.91 125.78 41.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.808 0.337 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 1.8 mtt180 -122.15 135.77 25.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.19 108.82 2.8 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.487 2.125 . . . . 0.0 112.307 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.51 -60.43 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 21.3 t-20 -129.98 108.96 10.5 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.0 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -100.93 124.83 8.38 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.415 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.507 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.5 OUTLIER -94.1 115.91 28.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.622 0.249 . . . . 0.0 110.947 -179.957 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.676 HD23 ' CE2' ' A' ' 141' ' ' TYR . 0.5 OUTLIER -121.41 120.44 35.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.006 179.196 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.422 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 1.8 m -132.44 154.12 50.17 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.292 0.568 . . . . 0.0 111.891 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 2.6 mp -145.3 122.52 11.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.865 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -141.88 165.18 26.62 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.25 -0.976 . . . . 0.0 113.465 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 136' ' ' ALA . 8.8 p -111.37 147.19 15.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' SER . . . . . 0.438 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 5.3 t -136.33 151.54 49.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.294 0.568 . . . . 0.0 112.175 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -119.49 133.63 55.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.838 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 2.0 ttp180 -106.97 121.61 44.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.295 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -69.06 154.86 41.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.935 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -135.6 -140.27 4.16 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -111.83 86.49 2.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.883 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -138.31 60.44 0.59 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.461 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -150.23 116.61 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . 60.52 106.44 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.043 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.105 179.962 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 1.6 mtt . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 120.867 0.365 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . 59.97 84.43 0.2 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 149.31 64.32 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.563 2.176 . . . . 0.0 112.269 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -110.7 113.61 26.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.897 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -173.42 100.25 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 16.8 m120 59.31 -135.06 0.86 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.61 -0.268 . . . . 0.0 110.327 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.704 HG23 ' HB2' ' A' ' 44' ' ' GLN . 4.1 t -117.35 150.95 37.99 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.79 0.329 . . . . 0.0 110.455 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 35.7 p90 -127.92 164.16 22.89 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.798 -179.204 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.417 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 4.0 p90 -155.24 157.16 36.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.907 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.402 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 0.8 OUTLIER -149.02 150.86 33.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.741 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.89 -164.93 27.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.332 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.53 154.14 49.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.628 -0.286 . . . . 0.0 110.568 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.459 ' C ' HD12 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -138.32 150.48 46.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.186 0.517 . . . . 0.0 111.809 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.479 HD12 ' N ' ' A' ' 13' ' ' LEU . 1.9 mp -148.63 127.08 12.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.628 179.248 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.15 174.11 27.95 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.481 -179.202 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.547 ' CE1' HD13 ' A' ' 162' ' ' LEU . 21.0 p90 -129.8 157.88 40.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 110.643 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.17 124.75 15.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.991 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -118.1 128.01 54.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.845 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -122.12 161.61 22.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -112.99 -169.55 1.5 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -123.41 111.63 16.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.0 p -78.54 106.59 10.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.941 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.63 129.23 4.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.49 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 60.56 98.83 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.872 0.368 . . . . 0.0 110.92 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 33.0 mt -108.41 135.21 47.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -142.46 165.08 28.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -136.77 82.53 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -75.56 -35.53 60.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 131.77 -81.3 0.32 Allowed Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.515 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.12 63.19 2.0 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.566 2.177 . . . . 0.0 112.334 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.5 m -100.74 143.02 31.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.905 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -105.63 101.48 10.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.854 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -96.63 -68.65 0.79 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 45.3 t30 -91.0 129.04 37.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.854 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -121.17 125.16 46.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.693 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.424 HD12 ' HB3' ' A' ' 15' ' ' PHE . 13.2 tp -96.04 136.36 36.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.147 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.46 156.8 23.26 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.378 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -130.67 162.44 29.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.821 0.343 . . . . 0.0 111.256 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.62 -173.26 42.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.385 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 153.45 52.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.716 -0.242 . . . . 0.0 110.598 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.413 ' CE1' ' HB2' ' A' ' 12' ' ' LYS . 6.2 p90 -159.42 166.33 31.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.225 0.536 . . . . 0.0 112.016 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -148.08 160.03 28.21 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.53 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.417 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.1 159.88 28.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.363 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -124.85 132.13 53.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.569 -0.315 . . . . 0.0 110.276 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.704 ' HB2' HG23 ' A' ' 6' ' ' THR . 1.7 mt-30 -95.48 126.22 40.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.119 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.8 t -96.24 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.0 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.496 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 3.3 m-20 -103.54 171.27 5.28 Favored Pre-proline 0 C--N 1.332 -0.185 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.192 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.496 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 10.1 Cg_endo -51.52 128.8 27.15 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.683 2.255 . . . . 0.0 113.085 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.419 ' CE1' ' HG3' ' A' ' 86' ' ' PRO . 1.4 m-85 59.88 16.32 5.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.407 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 47' ' ' PRO . 2.8 m -138.95 113.96 8.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.843 -0.343 . . . . 0.0 111.385 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.3 -172.86 14.48 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.777 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -130.3 154.31 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.561 0.22 . . . . 0.0 110.602 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -150.4 138.14 19.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.482 . . . . 0.0 111.733 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -130.46 113.53 14.41 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.261 179.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.03 159.65 14.14 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.406 -0.902 . . . . 0.0 113.189 -179.136 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.559 ' HB3' HG12 ' A' ' 77' ' ' VAL . 47.8 p90 -153.11 150.31 28.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.804 0.335 . . . . 0.0 110.846 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -103.81 144.34 31.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.936 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.2 127.35 7.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.8 tp -124.85 141.13 52.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.813 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -105.99 -170.57 23.31 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.582 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 5.7 mtp85 -142.92 -68.14 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.888 0.375 . . . . 0.0 110.912 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 5.8 tpt -146.3 81.43 9.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.03 63.55 1.95 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.493 2.129 . . . . 0.0 112.293 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -168.15 96.72 0.42 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.33 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.877 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 105.17 142.67 11.42 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.545 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.14 79.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.774 0.321 . . . . 0.0 110.956 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 19.3 m -130.85 129.35 63.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -99.08 -40.86 7.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.915 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -123.39 175.84 6.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.66 80.25 0.12 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.466 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.58 76.9 1.54 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.822 0.344 . . . . 0.0 111.127 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -104.67 -48.93 3.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.902 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.5 mmmt -75.83 176.31 7.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.06 152.03 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.071 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -105.84 107.39 18.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 102' ' ' PHE . . . -142.69 145.96 16.44 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.559 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.559 HG12 ' HB3' ' A' ' 55' ' ' TYR . 31.1 m -144.12 163.99 14.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.706 0.289 . . . . 0.0 111.044 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -130.29 137.34 49.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.075 0.464 . . . . 0.0 111.028 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.433 HD23 ' N ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -125.34 130.16 51.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.702 179.315 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.408 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.7 p -151.35 173.01 15.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.492 0.663 . . . . 0.0 111.924 -179.101 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.0 141.98 37.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.922 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -108.26 125.57 51.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.82 0.343 . . . . 0.0 111.403 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.417 ' CD1' HG12 ' A' ' 49' ' ' VAL . 2.4 tp -130.31 112.44 13.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.397 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.449 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.49 171.17 22.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.434 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.487 ' HB2' HD11 ' A' ' 93' ' ' ILE . 29.4 m-85 -123.99 138.94 31.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.715 0.293 . . . . 0.0 110.598 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.419 ' HG3' ' CE1' ' A' ' 48' ' ' TYR . 95.1 Cg_endo -84.6 98.89 0.72 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.73 2.286 . . . . 0.0 112.675 -179.7 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 24.0 mm -79.06 -36.66 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.032 0.444 . . . . 0.0 110.365 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.51 164.45 34.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.177 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -60.61 -24.02 65.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.524 0.202 . . . . 0.0 111.314 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.447 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 2.7 m-20 -113.6 -35.06 5.34 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -102.86 123.48 46.59 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.944 0.402 . . . . 0.0 111.758 -179.164 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -133.69 161.25 35.19 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.292 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.035 HG22 HG12 ' A' ' 127' ' ' VAL . 2.7 pt -121.44 142.51 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.979 179.123 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.449 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 40.4 p90 -147.8 165.34 30.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.69 0.757 . . . . 0.0 112.895 -178.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -144.32 140.66 29.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.399 -1.273 . . . . 0.0 109.445 179.08 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.712 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 45.5 mtm-85 -118.81 137.44 53.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 111.18 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.42 ' HB3' ' CE1' ' A' ' 123' ' ' PHE . 0.5 OUTLIER -139.5 119.7 13.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.918 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.408 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -166.32 -141.6 3.19 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.352 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.505 ' HA2' HG23 ' A' ' 122' ' ' VAL . . . -151.34 150.58 22.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.55 -0.833 . . . . 0.0 113.251 -179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.8 ptp -101.86 157.33 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.945 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.712 HG12 HG12 ' A' ' 119' ' ' VAL . 3.4 m -141.38 101.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 76' ' ' GLY . 1.2 t80 -96.33 124.52 40.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.958 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 25.0 mtt85 -122.15 131.08 53.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -126.89 142.16 51.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.055 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -91.37 120.55 32.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.1 m 60.29 93.82 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.948 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -157.55 158.08 34.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.941 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.88 145.45 45.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 23.5 t30 -128.87 170.74 13.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.13 158.04 41.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.108 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -74.5 -31.61 62.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.887 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.67 -30.23 68.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.483 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 11.1 mmtp -110.73 130.75 55.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.34 . . . . 0.0 110.891 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -101.21 31.3 3.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -160.4 120.39 2.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -60.36 -31.28 70.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 t -74.16 126.42 30.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -89.33 135.05 12.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.712 HG12 HG12 ' A' ' 101' ' ' VAL . 17.1 m -139.52 155.49 25.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.886 0.374 . . . . 0.0 111.189 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.3 m -177.31 153.9 1.05 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.862 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -52.59 147.05 31.81 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.547 2.165 . . . . 0.0 112.346 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.505 HG23 ' HA2' ' A' ' 99' ' ' GLY . 21.9 t -140.71 116.31 7.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.204 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.42 ' CE1' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -115.2 157.91 23.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.752 179.832 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.712 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -155.41 146.57 22.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.325 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.2 138.94 7.55 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.188 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.21 -155.77 18.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.044 -1.074 . . . . 0.0 113.243 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 1.035 HG12 HG22 ' A' ' 93' ' ' ILE . 29.8 m -138.71 147.97 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.008 0.432 . . . . 0.0 111.258 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -124.77 132.2 53.38 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.692 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.447 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 34.7 t80 -125.87 145.95 50.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.047 -179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.404 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.86 115.58 29.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.952 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.476 HD11 HG22 ' A' ' 135' ' ' ILE . 21.4 pt -89.88 -33.11 5.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.036 0.446 . . . . 0.0 110.408 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.698 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -149.25 165.16 18.34 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.187 179.682 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.698 ' HD2' HG22 ' A' ' 132' ' ' THR . 9.6 Cg_endo -53.17 -56.25 2.93 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -95.75 17.07 15.8 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.476 HG22 HD11 ' A' ' 131' ' ' ILE . 3.5 mp -144.3 120.61 4.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.061 0.458 . . . . 0.0 111.897 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.53 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -131.13 154.05 48.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.814 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.2 p -125.06 142.19 51.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.618 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.537 ' O ' HD12 ' A' ' 139' ' ' LEU . 24.9 mtt180 -138.66 135.23 34.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.067 0.46 . . . . 0.0 111.873 -179.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 138' ' ' ARG . 8.5 mp -124.67 133.89 53.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.574 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -151.76 167.63 27.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.307 0.575 . . . . 0.0 112.005 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.589 ' HE2' HD23 ' A' ' 162' ' ' LEU . 2.9 m-85 -122.57 159.5 27.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.851 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -159.98 115.93 2.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.984 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -92.42 162.62 14.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.901 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 62.5 m -92.75 108.36 19.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 25.2 m-20 -77.66 168.84 19.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -161.78 32.37 0.13 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.46 ' O ' HD12 ' A' ' 147' ' ' ILE . 1.6 pp -98.13 31.7 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.114 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -128.19 -101.71 1.08 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.451 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -73.58 120.1 18.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.835 0.35 . . . . 0.0 110.856 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.96 9.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.162 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 3.1 t-160 60.55 35.26 20.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.41 160.54 21.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.7 mt -71.32 -38.72 70.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.058 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 100.06 93.2 2.1 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.521 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 81.5 p -75.87 157.02 33.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.781 0.324 . . . . 0.0 110.944 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -100.88 97.98 7.73 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.24 104.1 1.34 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.489 2.126 . . . . 0.0 112.298 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -98.72 31.8 2.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -175.26 96.76 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.9 -154.9 20.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.791 ' HB3' HD12 ' A' ' 162' ' ' LEU . 10.3 mmm 61.96 -82.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.537 0.208 . . . . 0.0 110.932 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.791 HD12 ' HB3' ' A' ' 161' ' ' MET . 1.7 mp -120.65 118.18 29.47 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.15 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.475 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 0.3 OUTLIER -131.77 152.54 50.88 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.315 0.579 . . . . 0.0 111.861 -179.288 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 164' ' ' LEU . . . . . 0.63 ' O ' HD12 ' A' ' 164' ' ' LEU . 3.9 pp -142.45 122.54 13.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.673 179.096 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.17 163.68 27.02 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.236 -0.983 . . . . 0.0 113.485 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.53 HG13 ' O ' ' A' ' 136' ' ' ALA . 21.8 t -106.14 146.94 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.5 p -134.87 145.73 48.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.469 . . . . 0.0 111.739 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.5 m-85 -114.64 131.39 56.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.773 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.55 118.64 37.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.021 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -100.84 120.29 39.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.882 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.34 -74.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -78.87 85.46 4.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.815 0.341 . . . . 0.0 110.91 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -144.89 54.94 0.56 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.503 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -95.91 155.07 16.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.833 0.349 . . . . 0.0 110.932 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -60.0 127.39 31.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.136 179.966 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 12.8 mtp . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.72 0.295 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -175.35 89.05 0.3 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.43 138.0 41.21 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.599 2.199 . . . . 0.0 112.308 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.56 141.58 31.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -166.55 32.71 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -121.0 59.23 0.94 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.911 0.386 . . . . 0.0 110.399 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.449 HG22 ' H ' ' A' ' 7' ' ' TRP . 0.2 OUTLIER -132.1 173.26 11.41 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.634 -178.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.6 m-90 -125.19 166.67 16.04 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.562 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.487 ' N ' ' O ' ' A' ' 42' ' ' GLY . 1.5 p90 -155.62 163.03 40.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.16 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 m -149.22 152.75 36.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.519 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -171.49 -160.36 19.86 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 119.894 -1.146 . . . . 0.0 113.426 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.27 153.92 51.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.631 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.46 ' C ' HD12 ' A' ' 13' ' ' LEU . 1.6 mmmp? -137.58 149.8 46.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.119 0.485 . . . . 0.0 111.567 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.467 HD12 ' N ' ' A' ' 13' ' ' LEU . 2.1 mp -148.56 126.36 11.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.662 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.441 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.14 174.12 27.94 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.445 -179.186 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.8 ' HB3' HD12 ' A' ' 35' ' ' LEU . 18.2 p90 -128.63 156.47 43.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.856 0.36 . . . . 0.0 110.763 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -129.28 158.93 37.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.851 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 61.55 44.69 8.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 9.0 t80 -98.94 97.14 8.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.875 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -115.47 143.35 45.44 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.843 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -167.86 33.6 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.89 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.1 t -107.87 -31.92 7.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -71.87 1.05 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.553 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.8 160.85 14.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -92.57 165.07 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.088 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 11.8 t30 60.63 166.62 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.902 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -73.52 100.11 3.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -158.82 123.52 4.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -104.63 150.44 17.18 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.454 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.32 -45.59 1.24 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.577 2.185 . . . . 0.0 112.319 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 39.0 p -145.07 -58.54 0.35 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.902 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -106.89 131.25 54.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.877 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -95.66 -177.52 4.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 17.8 p-10 -78.16 146.51 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.835 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -119.65 127.3 52.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.723 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.8 HD12 ' HB3' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -94.27 135.2 35.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.07 -179.868 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.97 157.4 23.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.335 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -138.64 164.94 28.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.888 0.375 . . . . 0.0 111.32 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.21 -167.54 38.26 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.301 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.408 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -119.02 153.03 35.34 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.477 0.18 . . . . 0.0 110.75 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 54' ' ' GLY . 1.7 m-85 -154.72 142.69 20.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.158 0.504 . . . . 0.0 111.619 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -140.61 156.94 25.55 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.535 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -155.57 165.07 32.36 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.215 -0.993 . . . . 0.0 112.82 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 1.4 p90 -146.06 139.27 25.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.921 0.391 . . . . 0.0 111.373 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -94.96 124.67 39.14 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.533 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 10.9 m -98.49 -37.0 6.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.72 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.485 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.9 OUTLIER -149.39 170.11 8.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.359 -179.828 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.485 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 6.2 Cg_endo -48.64 120.5 5.3 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.826 2.351 . . . . 0.0 113.26 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.514 ' O ' HD12 ' A' ' 83' ' ' LEU . 0.9 OUTLIER 58.38 18.37 5.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.561 -0.745 . . . . 0.0 112.33 178.85 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.431 ' CG2' ' CB ' ' A' ' 46' ' ' ASN . 4.9 m -138.71 112.96 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.826 0.346 . . . . 0.0 111.451 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.45 -172.36 15.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.439 ' HB2' ' CZ ' ' A' ' 43' ' ' TYR . 20.9 m-85 -128.38 151.43 49.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.662 0.268 . . . . 0.0 110.518 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -145.87 135.23 23.0 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.026 0.441 . . . . 0.0 111.47 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 15.1 ttp -129.73 154.71 46.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.331 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 40' ' ' PHE . . . -160.72 159.31 30.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.265 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.603 ' HD2' HG22 ' A' ' 77' ' ' VAL . 22.1 t80 -140.76 148.89 41.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.897 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -113.54 119.33 37.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -122.53 -66.25 1.04 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.847 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.6 178.5 1.26 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.816 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -165.99 -49.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.449 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 20.6 mtt85 -130.24 136.48 49.24 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.842 0.353 . . . . 0.0 110.901 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 1.9 mtm -72.65 -60.69 1.92 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.66 109.89 2.88 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.537 2.158 . . . . 0.0 112.319 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -69.82 -55.74 9.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.856 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.55 31.34 20.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.879 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 135.57 122.74 2.24 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 33.8 p -109.9 105.9 15.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.816 0.341 . . . . 0.0 110.928 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.6 m -109.96 31.06 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.135 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -83.3 101.96 11.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.906 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -75.4 -36.5 60.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.77 52.14 1.22 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -101.42 -59.7 1.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.341 . . . . 0.0 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -129.73 -175.32 3.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 2.2 tmtm? -174.38 -41.26 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . 60.47 173.83 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.08 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -137.42 124.14 21.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.964 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -121.71 101.02 0.75 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.516 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.603 HG22 ' HD2' ' A' ' 55' ' ' TYR . 24.7 t -106.93 153.96 7.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.736 0.303 . . . . 0.0 111.051 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -128.23 135.27 49.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 111.047 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -130.85 130.76 44.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.888 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.409 ' HA ' ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.37 173.05 14.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.492 0.663 . . . . 0.0 111.989 -179.106 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.75 144.35 35.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.986 178.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' LYS . . . . . 0.411 ' HE2' ' CD2' ' A' ' 94' ' ' TYR . 0.3 OUTLIER -110.24 125.29 52.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.381 . . . . 0.0 111.479 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.514 HD12 ' O ' ' A' ' 48' ' ' TYR . 6.2 tp -130.64 110.06 11.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.263 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.466 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.02 175.29 20.95 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.71 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -129.09 139.87 36.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.694 0.283 . . . . 0.0 110.576 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -86.63 104.18 0.66 Allowed 'Trans proline' 0 N--CA 1.46 -0.465 0 C-N-CA 122.786 2.324 . . . . 0.0 112.736 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.436 HD11 ' HG ' ' A' ' 91' ' ' LEU . 40.3 pt -81.11 -33.75 13.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.162 0.506 . . . . 0.0 110.353 179.141 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.36 164.3 33.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.151 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -60.59 -25.09 65.96 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.451 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 1.0 OUTLIER -112.74 -30.85 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.104 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.436 ' HG ' HD11 ' A' ' 87' ' ' ILE . 13.4 tp -102.96 123.59 46.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.614 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -131.62 154.97 48.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.369 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.05 HG22 HG12 ' A' ' 127' ' ' VAL . 25.6 pt -123.07 142.62 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.873 179.043 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.466 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 19.3 p90 -152.83 170.15 21.05 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.752 0.786 . . . . 0.0 113.073 -178.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.4 p -141.5 142.5 33.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.295 -1.321 . . . . 0.0 109.53 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.474 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -118.14 137.49 52.93 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.964 0.412 . . . . 0.0 111.001 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.684 HD12 ' CE2' ' A' ' 123' ' ' PHE . 1.3 tt -139.77 119.25 13.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.814 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.469 ' O ' HG22 ' A' ' 122' ' ' VAL . . . -164.98 -144.52 4.08 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.233 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -152.9 152.6 24.24 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.491 -0.862 . . . . 0.0 113.292 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.3 ttt -101.99 157.78 16.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.845 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.428 ' O ' HG13 ' A' ' 101' ' ' VAL . 11.2 p -139.01 124.4 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.062 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -125.52 125.22 42.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -124.13 146.8 48.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.99 147.76 24.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.132 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -101.04 105.01 16.17 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.894 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.8 p -72.66 143.09 48.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 -44.71 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 6.8 t -139.16 -49.32 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.859 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -166.57 143.39 4.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.745 HG23 ' O ' ' A' ' 112' ' ' GLY . 5.6 m -147.81 174.59 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 16.2 t80 -68.57 -35.96 78.11 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.944 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.745 ' O ' HG23 ' A' ' 110' ' ' VAL . . . -113.5 -174.48 18.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.473 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 2.6 tttt -169.47 35.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.898 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -151.69 153.19 33.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 1.4 t-160 -61.37 85.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.38 -60.55 1.64 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.2 p 57.67 106.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.017 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.55 130.58 18.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.491 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.405 HG12 ' HA ' ' A' ' 101' ' ' VAL . 21.6 m -149.19 157.77 6.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.869 0.366 . . . . 0.0 111.206 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 26.9 t -177.5 143.91 0.53 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.74 161.52 4.44 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.493 2.129 . . . . 0.0 112.3 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 98' ' ' GLY . 27.8 m -155.65 140.73 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.091 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.684 ' CE2' HD12 ' A' ' 97' ' ' LEU . 9.6 t80 -121.49 156.41 32.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.816 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.483 ' HB1' ' OE1' ' A' ' 140' ' ' GLU . . . -152.14 147.1 26.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.249 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.6 138.82 7.62 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.14 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.1 -157.96 21.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.314 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 1.05 HG12 HG22 ' A' ' 93' ' ' ILE . 28.4 m -138.38 147.99 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.052 0.453 . . . . 0.0 111.255 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -125.35 131.1 53.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.777 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.451 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 38.0 t80 -126.86 146.59 50.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.408 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.89 115.65 29.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.807 HD11 HG22 ' A' ' 135' ' ' ILE . 19.8 pt -89.27 -34.82 7.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.958 0.408 . . . . 0.0 110.7 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.726 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -146.65 172.98 4.59 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.555 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.726 ' CD ' HG22 ' A' ' 132' ' ' THR . 50.5 Cg_exo -54.4 -61.86 0.36 Allowed 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.517 2.145 . . . . 0.0 112.757 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -99.84 25.44 7.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.777 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.807 HG22 HD11 ' A' ' 131' ' ' ILE . 4.0 mp -144.24 116.06 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.979 0.419 . . . . 0.0 111.565 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -127.35 158.48 37.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.972 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.788 HG22 HG12 ' A' ' 166' ' ' VAL . 26.0 p -141.49 138.42 32.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.41 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.22 150.92 35.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.131 0.491 . . . . 0.0 111.944 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.949 HD21 HD23 ' A' ' 164' ' ' LEU . 8.3 mp -118.34 139.81 50.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.723 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.483 ' OE1' ' HB1' ' A' ' 124' ' ' ALA . 0.1 OUTLIER -143.15 149.94 38.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 111.567 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.644 ' HE2' HD23 ' A' ' 162' ' ' LEU . 6.2 m-85 -121.21 157.25 30.67 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.91 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -120.45 137.46 54.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.964 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -89.38 113.0 24.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.823 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 23.0 m -102.81 146.99 27.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 11.4 t30 60.31 109.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -147.66 82.06 1.52 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.8 mp -133.4 124.17 48.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.175 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -99.65 111.74 4.28 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.395 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -170.85 -179.19 2.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.934 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.32 89.39 0.06 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -70.24 138.34 51.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 46.4 p -76.18 -59.17 2.88 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.823 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 2.7 tt -91.28 -30.85 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.069 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 67.85 87.95 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 10.9 m -118.41 128.03 54.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 0.0 110.908 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 2.9 ttp85 -109.46 97.89 29.37 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.898 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 135.21 52.4 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.469 2.112 . . . . 0.0 112.388 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.88 -51.09 20.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.897 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -145.93 127.06 14.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.893 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -67.08 -100.85 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.486 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.485 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 2.1 mtm -108.6 140.75 41.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.68 0.276 . . . . 0.0 110.888 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.644 HD23 ' HE2' ' A' ' 141' ' ' TYR . 0.8 OUTLIER -121.97 117.41 26.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.089 179.293 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.441 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 85.2 p -132.7 155.54 48.63 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.331 0.586 . . . . 0.0 111.885 -179.244 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' LEU . . . . . 0.949 HD23 HD21 ' A' ' 139' ' ' LEU . 0.1 OUTLIER -142.76 125.2 15.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.692 179.125 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.4 163.7 27.45 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.477 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.788 HG12 HG22 ' A' ' 137' ' ' THR . 23.3 m -108.89 147.93 13.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.419 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 11.3 t -136.21 147.0 47.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.488 . . . . 0.0 111.852 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.746 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 3.0 ptm180 -108.2 119.13 38.6 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.103 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -82.16 154.75 25.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 159.11 -81.44 0.15 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.501 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 60.41 34.97 20.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.893 0.377 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -132.16 160.88 23.78 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.48 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 60.48 170.39 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.319 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -104.45 -34.26 8.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.141 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.108 -179.964 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 2.9 mtt . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.806 0.336 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.409 ' HA ' ' HD2' ' A' ' 2' ' ' PRO . . . -175.62 102.0 0.25 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.039 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 1' ' ' ALA . 41.4 Cg_endo -67.49 114.7 3.37 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.45 2.1 . . . . 0.0 112.242 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.5 tttp -108.05 -31.16 8.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.013 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -146.72 157.51 43.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.037 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 65.65 41.37 4.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.941 0.401 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -123.35 169.32 11.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.712 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.6 p-90 -124.52 163.87 20.96 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.523 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.42 ' CZ ' ' HA3' ' A' ' 42' ' ' GLY . 33.0 p90 -155.25 156.62 35.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.93 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 p -149.26 151.93 35.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.98 -160.73 21.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 119.904 -1.141 . . . . 0.0 113.32 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -127.11 154.45 44.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.524 -0.338 . . . . 0.0 110.512 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -142.21 146.08 34.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.083 0.468 . . . . 0.0 111.549 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 36' ' ' GLY . 1.4 mp -143.24 119.18 10.62 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.374 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.544 ' O ' ' HB2' ' A' ' 15' ' ' PHE . . . -149.52 168.56 29.77 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.012 -1.089 . . . . 0.0 113.914 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.544 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 0.3 OUTLIER 170.84 -92.53 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 122.979 0.512 . . . . 0.0 110.19 178.554 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.422 ' H ' ' HB3' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -177.58 128.28 0.14 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 110.985 179.662 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -151.18 84.14 1.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -127.24 145.8 50.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 60.1 -179.66 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.933 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -147.0 31.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 m 60.4 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.934 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -130.74 -128.27 2.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.558 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -108.49 35.58 3.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.867 0.365 . . . . 0.0 110.918 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.5 pt -103.98 -30.49 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -150.91 136.22 17.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -132.51 -67.05 0.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 32.1 m-20 -107.36 77.39 1.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.878 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -173.28 -148.97 6.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.467 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.57 123.61 12.56 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.597 2.198 . . . . 0.0 112.325 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -64.94 167.42 7.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -97.45 -176.31 3.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -148.73 100.59 3.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.937 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 31.1 m-20 -132.63 85.0 2.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.856 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.455 ' O ' ' HB3' ' A' ' 15' ' ' PHE . 8.9 mm100 -123.61 179.15 4.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.701 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.419 ' HA ' ' CB ' ' A' ' 15' ' ' PHE . 0.4 OUTLIER -148.99 136.45 20.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.47 -179.927 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.43 ' O ' ' HA ' ' A' ' 13' ' ' LEU . . . -123.79 149.37 16.88 Favored Glycine 0 C--N 1.331 0.264 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.189 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.38 153.02 46.75 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.999 0.428 . . . . 0.0 111.726 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.95 -173.29 42.37 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.606 -0.807 . . . . 0.0 113.295 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -130.55 154.22 48.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.876 -0.162 . . . . 0.0 110.57 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -159.23 161.65 36.09 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.281 0.562 . . . . 0.0 112.258 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -154.77 159.22 28.84 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.201 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CZ ' ' A' ' 8' ' ' TYR . . . -157.77 165.1 33.46 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.796 -1.192 . . . . 0.0 113.563 -179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.505 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.5 m-85 -119.91 135.14 55.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.404 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -95.13 125.96 40.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.27 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.1 t -92.88 -37.57 8.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.874 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.437 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -153.6 179.32 1.32 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.125 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.437 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 35.2 Cg_exo -60.72 -26.1 82.3 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.689 2.259 . . . . 0.0 113.712 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.4 p90 -127.97 4.43 5.93 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 113.135 0.791 . . . . 0.0 113.135 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 49' ' ' VAL . 9.1 p -139.52 115.72 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.601 -0.44 . . . . 0.0 111.718 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.4 -175.7 17.76 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.653 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -127.15 149.45 49.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.569 0.224 . . . . 0.0 110.44 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -147.76 136.82 22.17 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.085 0.469 . . . . 0.0 111.578 -179.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -128.22 155.27 44.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.231 179.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.34 158.37 29.47 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.213 -0.994 . . . . 0.0 113.197 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -159.12 167.37 29.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.79 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.42 154.09 22.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.982 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -100.69 169.71 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.961 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.2 tt 60.48 92.56 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -155.74 -103.8 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.512 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.45 137.35 47.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.874 0.369 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -174.04 87.2 0.36 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.06 149.79 65.47 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.351 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -115.02 35.46 4.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.861 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.61 -53.74 20.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.919 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 153.07 -28.0 0.8 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.557 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 42.8 t 61.03 110.39 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.798 0.333 . . . . 0.0 110.925 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 29.4 m -124.36 31.01 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.142 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -134.66 116.87 15.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -86.07 126.8 34.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.36 -155.81 8.56 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.465 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -81.59 -44.27 17.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 111.079 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 1.6 t80 60.72 46.01 9.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -97.5 38.22 1.29 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.986 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -93.87 -167.49 1.7 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER 62.9 -169.01 0.19 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.841 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -112.07 132.8 11.03 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.532 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 78' ' ' GLN . 11.0 p -157.93 157.55 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.718 0.295 . . . . 0.0 111.044 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.511 ' CD ' HG11 ' A' ' 122' ' ' VAL . 6.1 tt0 -130.21 142.78 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.051 0.453 . . . . 0.0 111.08 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.7 131.34 43.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.84 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.41 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.4 p -151.46 173.0 15.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.495 0.664 . . . . 0.0 111.891 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -110.29 142.41 41.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.963 179.03 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.62 127.25 53.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.969 0.414 . . . . 0.0 111.453 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.6 mp -129.73 111.22 12.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.303 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.436 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -133.55 169.79 22.61 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.266 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.481 ' HB3' HD11 ' A' ' 93' ' ' ILE . 2.5 t80 -121.69 137.4 27.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.613 0.244 . . . . 0.0 110.591 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -83.14 97.55 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.687 2.258 . . . . 0.0 112.63 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.456 HD11 HG12 ' A' ' 93' ' ' ILE . 31.1 mt -80.67 -35.67 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.048 0.451 . . . . 0.0 110.462 179.462 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.434 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.4 m -148.27 164.81 32.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.112 179.677 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.434 ' N ' HG22 ' A' ' 88' ' ' THR . 1.6 t70 -60.51 -27.34 67.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.522 0.201 . . . . 0.0 111.479 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.442 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 73.8 m-20 -112.27 -34.9 5.77 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 15.1 tp -102.84 123.74 47.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.981 0.42 . . . . 0.0 111.688 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -135.39 164.19 28.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.348 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.037 HG22 HG12 ' A' ' 127' ' ' VAL . 1.3 pt -117.75 142.29 32.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.929 178.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.436 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 36.6 m-85 -144.72 159.14 43.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.686 0.755 . . . . 0.0 112.838 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.697 HG23 ' O ' ' A' ' 124' ' ' ALA . 91.1 m -140.87 137.02 32.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.191 178.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.588 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 54.8 mtm180 -118.17 137.44 52.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.883 0.373 . . . . 0.0 111.277 -179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.3 tt -141.9 121.21 13.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.853 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.41 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -165.11 -146.25 4.71 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.273 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.23 156.05 26.71 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.612 -0.804 . . . . 0.0 113.179 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.97 158.86 15.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.765 0.317 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.432 ' CG2' HG13 ' A' ' 77' ' ' VAL . 12.1 m -145.83 118.2 2.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -126.93 115.22 18.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.561 ' HB2' HG23 ' A' ' 117' ' ' THR . 4.6 tpt180 -131.43 127.13 36.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -131.62 126.61 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.092 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -104.25 152.05 22.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 6.5 m -144.88 -49.79 0.26 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.907 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.07 149.64 40.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 49.7 m -103.47 136.19 43.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -127.53 -45.28 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 18.3 t 69.02 -67.14 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.218 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -60.14 -31.21 69.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -103.0 125.79 8.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.484 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 8.5 mttp -104.21 105.37 15.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 19.6 m120 -104.78 136.91 43.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -104.59 90.76 3.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -119.14 36.53 4.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.874 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 103' ' ' ARG . 0.2 OUTLIER -94.88 118.55 31.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.9 179.975 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -77.78 126.02 7.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.553 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 20.7 t -146.69 139.34 19.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.776 0.322 . . . . 0.0 111.148 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -164.65 164.69 13.29 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.76 157.08 63.38 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.595 2.197 . . . . 0.0 112.253 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.511 HG11 ' CD ' ' A' ' 78' ' ' GLN . 21.5 t -145.42 97.56 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.225 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 124' ' ' ALA . 40.2 t80 -98.65 156.56 16.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.678 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.697 ' O ' HG23 ' A' ' 95' ' ' THR . . . -158.27 148.02 19.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.313 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.98 140.0 8.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.124 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 175.36 -151.75 12.48 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.306 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 1.037 HG12 HG22 ' A' ' 93' ' ' ILE . 29.7 m -140.26 149.24 21.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.126 0.488 . . . . 0.0 111.357 -179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -125.39 132.37 52.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.631 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.442 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 39.6 t80 -125.54 146.2 49.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.213 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.405 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -97.91 115.4 28.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.929 179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.4 tt -88.5 -35.04 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.958 0.409 . . . . 0.0 110.561 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.711 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -150.49 172.41 5.32 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.426 179.631 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.711 ' CD ' HG22 ' A' ' 132' ' ' THR . 52.8 Cg_exo -53.23 -57.06 2.2 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.473 2.115 . . . . 0.0 112.488 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -102.89 31.8 4.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.515 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.16 114.23 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 111.743 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.4 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -129.09 154.23 46.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.919 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.839 HG22 HG12 ' A' ' 166' ' ' VAL . 26.1 p -129.0 140.59 51.57 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.411 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.2 ttm105 -137.39 135.1 36.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.947 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.579 HD13 HD12 ' A' ' 164' ' ' LEU . 3.3 tp -124.98 132.51 53.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.432 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.77 165.58 32.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.255 0.55 . . . . 0.0 111.886 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.458 ' HA ' ' O ' ' A' ' 161' ' ' MET . 8.6 p90 -129.73 162.8 27.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.948 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -160.93 115.94 2.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -92.69 139.38 30.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 8.8 t -98.18 152.32 19.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -98.13 35.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -89.27 109.52 20.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 24.4 mt -133.69 -49.42 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -149.21 -46.86 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.457 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -133.23 -68.19 0.59 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.914 0.387 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . 59.92 169.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -67.04 115.67 7.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 60.47 162.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.879 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.434 ' C ' HD12 ' A' ' 153' ' ' ILE . 2.8 pp -152.73 174.0 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.192 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 171.96 -112.14 0.43 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.538 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 32.1 p -110.8 140.65 45.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.838 0.351 . . . . 0.0 110.959 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.8 mtt180 -70.7 147.02 94.25 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.59 151.61 52.84 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.547 2.165 . . . . 0.0 112.284 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -117.01 30.22 7.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.903 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -177.49 82.69 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.89 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -149.57 -156.22 7.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.484 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER 59.98 -84.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.425 0.155 . . . . 0.0 110.938 -179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -120.75 117.87 28.57 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.257 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.435 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 95.4 p -130.28 153.04 49.05 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.231 0.538 . . . . 0.0 111.9 -179.301 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' LEU . . . . . 0.579 HD12 HD13 ' A' ' 139' ' ' LEU . 3.0 tt -144.3 123.19 12.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.889 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.39 159.29 27.49 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.355 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.839 HG12 HG22 ' A' ' 137' ' ' THR . 26.7 m -103.72 147.05 10.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' SER . . . . . 0.4 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 78.6 p -134.81 145.51 48.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.1 0.476 . . . . 0.0 111.785 -179.335 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -112.19 132.06 55.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.675 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.51 116.25 31.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.009 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -108.75 134.18 51.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -174.47 59.65 0.12 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.453 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -112.48 96.37 5.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 64.45 -153.98 48.53 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.484 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -131.42 -54.74 1.02 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 110.935 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -107.54 33.41 4.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.076 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.996 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 3.0 tpt . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.808 0.337 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -146.28 152.95 47.77 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.119 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.78 116.47 4.58 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.547 2.165 . . . . 0.0 112.34 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.91 83.53 2.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -64.46 117.81 7.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -68.51 -124.95 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.482 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.8 m -119.47 155.27 32.38 Favored 'General case' 0 N--CA 1.461 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.674 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.544 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.1 p90 -126.8 164.45 21.34 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.623 -179.267 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.412 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 26.5 p90 -155.26 157.05 36.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.018 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 p -149.13 151.19 33.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.739 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.6 -163.35 24.48 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.05 -1.071 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.49 153.47 50.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.556 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.4 ptmt -138.0 149.74 46.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.169 0.509 . . . . 0.0 111.81 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 37' ' ' ALA . 9.1 tt -149.29 125.3 10.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.637 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.439 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.14 174.2 27.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.239 -0.982 . . . . 0.0 113.58 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.701 ' CZ ' HD12 ' A' ' 35' ' ' LEU . 3.1 m-85 -115.11 144.59 43.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.72 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -154.35 -168.3 2.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.9 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 61.79 84.76 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -113.79 85.72 2.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -104.22 174.0 6.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.992 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -93.46 127.49 39.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.8 p -113.39 -47.63 3.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.886 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.87 50.35 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -106.47 -176.73 3.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.787 0.327 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.442 HD12 ' N ' ' A' ' 24' ' ' ILE . 3.9 mp -126.81 -45.2 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -158.65 161.47 37.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -72.27 87.38 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.929 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -155.99 110.63 2.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.96 -150.0 17.44 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.517 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.62 97.17 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.527 2.151 . . . . 0.0 112.315 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.7 t -82.6 152.04 26.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.985 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -176.78 37.69 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.861 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -85.15 -40.83 16.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -93.18 164.68 13.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.58 124.04 45.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.701 HD12 ' CZ ' ' A' ' 15' ' ' PHE . 8.5 tt -85.63 132.61 34.13 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.979 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.81 138.17 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.545 ' HB2' HD12 ' A' ' 13' ' ' LEU . . . -118.18 159.22 23.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.815 0.34 . . . . 0.0 111.198 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.17 -174.24 40.86 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.281 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.14 154.29 47.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.761 -0.22 . . . . 0.0 110.549 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -159.14 156.96 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.317 0.58 . . . . 0.0 112.101 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -150.29 159.06 27.95 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.244 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.412 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -157.12 164.98 33.09 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 119.793 -1.194 . . . . 0.0 113.498 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.6 m-85 -118.53 134.17 55.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.445 -0.378 . . . . 0.0 110.384 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 14.7 tt0 -95.79 126.44 41.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.238 179.395 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.443 HG21 ' CE2' ' A' ' 51' ' ' PHE . 25.1 t -94.75 -35.77 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.837 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.51 ' HB2' HG23 ' A' ' 49' ' ' VAL . 0.6 OUTLIER -155.67 172.77 5.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.866 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.472 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 23.1 Cg_endo -62.23 -15.87 47.26 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.222 1.948 . . . . 0.0 113.449 -179.26 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CD1' ' HG2' ' A' ' 47' ' ' PRO . 39.9 m-85 -128.24 -4.03 5.57 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.51 HG23 ' HB2' ' A' ' 46' ' ' ASN . 4.0 m -139.45 116.93 11.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.566 -0.453 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.53 -175.65 16.83 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.456 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 45' ' ' VAL . 85.0 m-85 -128.97 149.56 50.76 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -148.85 138.03 21.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.127 0.489 . . . . 0.0 111.665 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 6.3 mtt -128.26 156.09 43.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.148 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.22 158.29 29.36 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.031 -1.081 . . . . 0.0 113.138 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -156.74 158.61 37.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.89 0.376 . . . . 0.0 110.821 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 25.3 p-10 -90.52 128.29 36.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -92.75 -38.38 11.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 12.3 tp 68.81 -67.22 0.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.047 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 166.26 93.41 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.469 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.31 103.2 9.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.892 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -139.86 88.36 12.12 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -68.99 131.21 21.81 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.544 2.163 . . . . 0.0 112.29 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -60.23 -72.6 0.11 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.929 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.91 35.99 0.07 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.91 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 140.67 162.81 9.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.418 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.6 m -107.32 154.04 21.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.881 0.372 . . . . 0.0 110.839 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.454 HG23 ' N ' ' A' ' 68' ' ' GLU . 13.9 m -135.5 -46.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.112 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.454 ' N ' HG23 ' A' ' 67' ' ' VAL . 4.8 tm-20 -134.24 93.02 3.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 8.5 m120 60.58 158.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 175.05 -56.64 0.12 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.05 114.47 4.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.135 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -65.25 125.67 25.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.928 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -78.16 -32.49 50.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -97.54 104.87 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.069 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -95.96 152.88 18.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.884 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -139.91 123.56 2.48 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.525 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 78' ' ' GLN . 21.4 t -140.56 156.24 23.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.732 0.301 . . . . 0.0 111.151 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.43 ' N ' HG12 ' A' ' 77' ' ' VAL . 46.0 mt-30 -129.8 141.27 50.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.057 0.456 . . . . 0.0 111.039 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.608 ' O ' HD12 ' A' ' 79' ' ' LEU . 4.0 pp -131.23 130.83 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.764 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.408 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.71 173.03 15.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.475 0.655 . . . . 0.0 111.964 -179.178 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.71 142.0 38.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.827 178.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -107.99 126.33 52.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.823 0.344 . . . . 0.0 111.554 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.4 tt -129.65 110.64 11.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.37 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.438 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.8 169.01 22.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.362 -0.923 . . . . 0.0 113.209 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.406 ' CD2' ' HD2' ' A' ' 86' ' ' PRO . 5.1 t80 -124.28 137.61 29.42 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.614 0.245 . . . . 0.0 110.65 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.406 ' HD2' ' CD2' ' A' ' 85' ' ' TYR . 98.5 Cg_endo -85.37 100.19 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.684 2.256 . . . . 0.0 112.633 -179.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.418 HG22 ' O ' ' A' ' 91' ' ' LEU . 1.0 OUTLIER -82.04 -34.2 12.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.053 0.454 . . . . 0.0 110.367 179.333 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.413 HG22 ' N ' ' A' ' 89' ' ' ASP . 23.6 m -148.59 163.83 36.07 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.26 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.413 ' N ' HG22 ' A' ' 88' ' ' THR . 1.0 OUTLIER -62.45 -24.96 67.73 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.418 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -111.42 -29.43 7.79 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.502 HD23 ' HB3' ' A' ' 129' ' ' TYR . 93.7 mt -108.12 124.72 50.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 111.696 -179.344 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -133.51 157.75 44.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.326 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 5.2 mt -117.04 141.71 34.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.888 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.438 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 16.8 m-85 -143.62 157.87 44.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.697 0.76 . . . . 0.0 112.721 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.6 p -141.83 137.05 31.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.52 -1.218 . . . . 0.0 108.987 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.883 ' CG ' ' HB3' ' A' ' 124' ' ' ALA . 0.4 OUTLIER -119.57 140.94 49.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.963 0.411 . . . . 0.0 111.467 -179.463 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.715 ' O ' HD12 ' A' ' 97' ' ' LEU . 1.4 pp -142.17 120.68 12.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.816 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.408 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -164.96 -144.85 4.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.278 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.47 163.14 28.96 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.553 -0.832 . . . . 0.0 113.261 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 6.4 ttt -101.97 144.74 30.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.901 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.412 HG22 ' O ' ' A' ' 77' ' ' VAL . 5.1 m -122.74 122.08 65.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.135 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -109.75 125.32 52.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -109.87 106.84 16.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -106.73 128.4 54.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.088 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.84 124.73 28.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.852 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.586 HG21 ' NE2' ' A' ' 115' ' ' HIS . 4.4 t -88.8 156.6 18.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.89 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 11.0 mtpp -150.65 -49.35 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 60.0 m -110.66 115.67 29.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -127.77 89.24 2.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.447 HG23 ' N ' ' A' ' 111' ' ' TYR . 12.3 m -138.34 -46.98 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.171 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.447 ' N ' HG23 ' A' ' 110' ' ' VAL . 5.7 m-85 -101.0 -35.9 9.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 144.31 132.48 2.56 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -157.5 -174.37 4.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 110.862 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -80.25 135.25 36.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' HIS . . . . . 0.586 ' NE2' HG21 ' A' ' 106' ' ' THR . 3.6 t-160 -142.22 -47.56 0.35 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.899 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.44 167.07 15.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.875 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.1 p -82.34 139.19 34.26 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.998 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.95 129.66 9.28 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.66 159.98 12.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.858 0.361 . . . . 0.0 111.105 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.1 m -176.92 88.62 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.04 132.19 23.92 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.627 2.218 . . . . 0.0 112.327 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 15.5 m -148.31 175.33 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.062 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 9.7 p90 -146.71 164.05 33.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.967 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.883 ' HB3' ' CG ' ' A' ' 96' ' ' ARG . . . -141.38 162.15 36.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.235 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.31 141.98 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.078 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 139' ' ' LEU . . . 177.27 -154.86 16.59 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 119.926 -1.131 . . . . 0.0 113.331 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 16.2 m -140.38 148.22 22.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.045 0.45 . . . . 0.0 111.441 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.402 ' CB ' ' HB3' ' A' ' 138' ' ' ARG . 0.0 OUTLIER -127.52 132.6 49.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.649 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.502 ' HB3' HD23 ' A' ' 91' ' ' LEU . 30.8 p90 -129.92 151.61 50.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.361 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -102.3 117.31 34.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.835 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.537 ' O ' HG23 ' A' ' 132' ' ' THR . 20.5 pt -88.96 -36.1 8.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.04 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.537 HG23 ' O ' ' A' ' 131' ' ' ILE . 0.8 OUTLIER -162.47 162.12 19.53 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.965 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.26 140.79 41.35 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.558 2.172 . . . . 0.0 112.222 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.54 19.53 6.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.587 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 32.2 mt -149.08 111.76 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.047 0.451 . . . . 0.0 111.633 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.54 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -129.11 151.1 50.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.797 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.1 m -133.46 140.36 47.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.449 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.402 ' HB3' ' CB ' ' A' ' 128' ' ' GLU . 3.6 ptm180 -146.92 145.0 29.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.158 0.504 . . . . 0.0 111.886 -179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.403 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 4.0 pp -120.21 140.61 50.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.575 179.053 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -146.45 157.37 43.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.147 0.499 . . . . 0.0 111.63 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.466 ' HA ' ' O ' ' A' ' 161' ' ' MET . 2.7 p90 -137.84 164.84 27.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.001 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -128.9 143.99 51.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -106.75 153.8 21.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.895 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 20.5 m 60.48 94.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -133.27 -52.74 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -131.69 86.56 2.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.623 ' O ' HD12 ' A' ' 147' ' ' ILE . 2.8 pp -143.65 153.68 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.095 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -78.9 -81.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.473 ' O ' HD13 ' A' ' 147' ' ' ILE . 8.8 p-10 -62.56 138.75 58.55 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 0.0 110.88 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.94 -51.94 9.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.063 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -86.31 135.68 33.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.447 HG22 ' OD2' ' A' ' 149' ' ' ASP . 38.5 p -134.47 165.78 24.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.891 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 24.5 mt -134.9 111.31 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 114.98 -173.65 14.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.46 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -130.9 109.67 10.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.89 149.12 65.02 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -52.44 145.74 35.64 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.603 2.202 . . . . 0.0 112.319 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -168.37 -57.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.4 m120 60.59 91.05 0.06 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -59.33 -91.83 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 8.8 mtm -119.73 132.82 55.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.663 0.268 . . . . 0.0 110.876 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 5.5 tp -122.25 118.97 29.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.085 179.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.439 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 4.9 t -136.9 157.99 45.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.365 0.602 . . . . 0.0 112.132 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 1.1 tt -143.33 128.05 18.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.694 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.96 162.84 27.78 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.443 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 136' ' ' ALA . 22.0 t -105.39 146.6 12.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.381 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.7 m -134.59 145.42 48.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.137 0.494 . . . . 0.0 111.614 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -113.83 131.53 56.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -108.66 117.73 34.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.976 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -102.04 172.2 7.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 119.32 170.31 14.54 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.484 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.5 mm-40 60.62 35.61 19.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -69.96 -47.18 48.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.545 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -85.98 138.97 31.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.928 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -106.15 31.24 5.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.098 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -179.996 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.809 0.337 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -113.9 87.64 12.95 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.104 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.84 99.09 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.601 2.2 . . . . 0.0 112.29 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.88 160.74 14.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -130.26 -174.68 3.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.901 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.434 ' HA ' ' CE1' ' A' ' 43' ' ' TYR . 2.0 m120 65.31 41.67 4.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.961 0.41 . . . . 0.0 110.812 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 45.4 p -121.97 168.86 11.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.72 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 25.9 p-90 -128.38 162.81 26.24 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.667 -179.294 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.45 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 1.4 p90 -155.28 157.28 36.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.717 179.356 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.1 p -149.15 151.78 34.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.665 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.429 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.1 -165.65 27.79 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.392 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -128.79 152.45 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.539 -0.33 . . . . 0.0 110.252 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.447 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -139.05 150.47 45.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.327 0.585 . . . . 0.0 112.058 -179.208 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.447 HD12 ' O ' ' A' ' 12' ' ' LYS . 1.7 mp -139.05 116.91 11.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.675 178.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.54 ' O ' ' HB2' ' A' ' 15' ' ' PHE . . . -149.45 165.5 29.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 119.734 -1.222 . . . . 0.0 114.375 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.54 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 0.7 OUTLIER 171.11 -90.82 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.022 0.529 . . . . 0.0 110.272 178.495 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.41 ' O ' ' N ' ' A' ' 34' ' ' GLN . 1.4 m -177.54 125.75 0.13 Allowed 'General case' 0 C--N 1.335 -0.045 0 CA-C-O 120.845 0.355 . . . . 0.0 110.946 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -135.34 -52.92 0.78 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -173.36 162.6 4.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.9 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -123.49 128.26 49.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.05 -66.91 0.7 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 102.56 2.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.868 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -134.67 -67.88 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.43 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -133.36 143.71 49.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.816 0.341 . . . . 0.0 110.895 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.7 mt -67.52 90.91 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.052 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -107.62 123.96 49.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -130.41 36.54 3.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -121.03 31.18 6.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.64 91.53 0.44 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.16 -38.26 70.84 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.258 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -145.81 100.02 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.841 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -97.81 -36.23 10.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -154.11 137.84 16.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.903 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 59.6 m-20 -136.92 92.59 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.91 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.453 ' O ' ' HB3' ' A' ' 15' ' ' PHE . 1.1 mm100 -125.03 -179.9 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.547 ' O ' HD12 ' A' ' 35' ' ' LEU . 3.6 pp -147.41 137.28 22.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.364 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.431 ' N ' ' HB2' ' A' ' 15' ' ' PHE . . . -124.27 155.76 18.19 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.961 -0.637 . . . . 0.0 112.252 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -130.74 149.58 52.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.032 0.444 . . . . 0.0 111.73 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.68 179.65 44.04 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.28 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.26 153.24 47.17 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.55 -0.167 . . . . 0.0 110.55 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -159.38 165.69 32.71 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.349 0.595 . . . . 0.0 112.226 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -155.05 161.35 30.31 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.401 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.45 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -152.23 163.8 30.32 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 119.794 -1.193 . . . . 0.0 113.616 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.2 t80 -132.44 132.56 42.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.531 -0.335 . . . . 0.0 110.493 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -92.93 123.69 36.37 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.68 -43.83 12.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.813 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.539 ' ND2' ' HB ' ' A' ' 49' ' ' VAL . 3.1 p-10 -152.06 165.19 18.01 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.411 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.534 ' HD2' ' HB2' ' A' ' 46' ' ' ASN . 65.9 Cg_exo -40.12 123.09 1.28 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.904 2.403 . . . . 0.0 113.79 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 48' ' ' TYR . 0.8 OUTLIER 59.17 17.68 5.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.419 178.871 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.539 ' HB ' ' ND2' ' A' ' 46' ' ' ASN . 24.5 t -136.68 114.02 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.451 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.24 -177.35 19.96 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.568 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -124.89 152.11 44.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -147.12 134.85 21.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.059 0.456 . . . . 0.0 111.527 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' MET . . . . . 0.409 ' CE ' HD21 ' A' ' 79' ' ' LEU . 16.4 ttm -126.84 151.79 47.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.182 179.433 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -157.44 157.43 28.12 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.247 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -156.52 167.14 31.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.348 . . . . 0.0 110.73 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.26 145.37 26.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -94.47 87.98 5.33 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.804 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.5 mt -104.5 33.13 3.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 96.77 91.95 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 13.1 ttm180 -123.01 -49.68 1.95 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.828 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 5.9 ttt -143.83 84.8 9.54 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.02 164.26 35.46 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.609 2.206 . . . . 0.0 112.309 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -95.08 101.66 13.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -148.49 31.24 0.82 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.881 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.81 -82.04 1.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 m -146.1 93.19 2.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -112.82 153.66 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -121.29 80.72 1.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -96.46 -175.66 3.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 174.48 -151.33 12.49 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.503 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -174.39 152.1 1.7 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.868 0.366 . . . . 0.0 111.043 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -137.95 -56.96 0.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.8 mtmt -105.28 154.02 20.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . 60.15 85.67 0.1 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.111 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.59 144.43 35.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.432 ' HA3' ' CE2' ' A' ' 102' ' ' PHE . . . -132.65 122.69 3.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.503 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 78' ' ' GLN . 21.4 t -137.93 159.28 33.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.078 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.489 ' N ' HG12 ' A' ' 77' ' ' VAL . 3.0 tt0 -129.29 138.76 51.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.03 0.443 . . . . 0.0 111.029 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.409 HD21 ' CE ' ' A' ' 53' ' ' MET . 6.1 mt -129.44 130.68 46.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.852 179.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.9 p -151.56 173.09 15.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.445 0.64 . . . . 0.0 111.997 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -108.28 142.18 38.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.85 -1.068 . . . . 0.0 109.896 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -108.6 126.15 52.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.879 0.371 . . . . 0.0 111.488 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 5.2 mt -129.96 113.12 14.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.332 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.471 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -136.4 171.59 22.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.371 -0.918 . . . . 0.0 113.494 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -128.94 136.94 29.96 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 110.476 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -83.95 104.26 1.07 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.651 2.234 . . . . 0.0 112.946 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 1.063 HD11 HG23 ' A' ' 93' ' ' ILE . 1.1 mp -78.33 -36.52 20.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 121.173 0.511 . . . . 0.0 110.183 179.172 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.733 HG23 ' H ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -150.91 169.64 21.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.957 179.119 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.1 -22.37 66.81 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -112.11 -29.05 7.74 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.733 ' H ' HG23 ' A' ' 88' ' ' THR . 0.3 OUTLIER -109.68 125.53 52.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.099 0.476 . . . . 0.0 112.031 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.518 ' HA ' HD12 ' A' ' 87' ' ' ILE . 4.3 m-20 -133.01 155.42 49.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.186 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.063 HG23 HD11 ' A' ' 87' ' ' ILE . 11.5 pt -117.47 141.25 37.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.933 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.471 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 24.5 m-85 -144.27 161.28 39.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 112.628 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -141.63 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.218 178.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.76 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 75.7 mtp180 -117.34 136.23 53.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.893 0.378 . . . . 0.0 111.287 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.7 tt -140.42 119.38 12.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.95 -143.96 3.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.349 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -149.9 152.58 24.49 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.299 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 7.3 ttm -102.16 126.85 49.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.701 0.286 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 101' ' ' VAL . 29.5 m -107.05 122.11 60.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.432 ' CE2' ' HA3' ' A' ' 76' ' ' GLY . 1.4 t80 -125.39 133.16 52.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.892 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.99 109.14 6.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.907 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -142.98 122.75 13.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.125 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -107.65 124.51 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.883 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 m -98.83 31.73 2.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 60.32 31.59 20.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.915 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.5 p -114.65 149.55 36.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 7.2 m-20 -102.55 35.56 2.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.886 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 21.5 t 62.64 101.3 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -97.59 24.14 7.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.76 28.48 42.41 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.507 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 5.5 mtpp -145.24 -48.34 0.23 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.788 0.328 . . . . 0.0 110.939 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 38.3 t30 -65.85 104.73 1.14 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.855 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -69.27 -45.92 68.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.921 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 5.1 t0 60.48 172.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p 53.59 78.34 0.15 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -82.63 103.65 2.45 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.513 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 m -138.05 118.0 15.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.81 0.338 . . . . 0.0 111.105 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -156.99 155.2 27.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.882 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 158.19 57.45 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.581 2.187 . . . . 0.0 112.303 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 21.6 t -152.01 125.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.171 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -106.88 155.56 19.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.76 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -150.63 146.79 26.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.176 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.79 139.44 7.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.24 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.74 -158.02 22.05 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.112 -1.042 . . . . 0.0 113.238 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 1.034 HG12 HG22 ' A' ' 93' ' ' ILE . 31.0 m -138.45 146.39 26.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.058 0.456 . . . . 0.0 111.241 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.429 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.2 OUTLIER -126.03 131.7 52.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.739 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 129' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 129' ' ' TYR . 3.5 p90 -127.48 149.28 50.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.179 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.49 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.898 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.438 HD11 ' OG1' ' A' ' 137' ' ' THR . 39.1 mt -88.91 -34.75 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.008 0.433 . . . . 0.0 110.744 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.704 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -148.88 174.56 3.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.675 179.835 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.704 ' CD ' HG22 ' A' ' 132' ' ' THR . 51.2 Cg_exo -53.8 -61.61 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.657 2.238 . . . . 0.0 112.75 -179.609 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLU . . . . . 0.597 ' C ' HD12 ' A' ' 135' ' ' ILE . 2.4 mt-10 -101.17 30.17 4.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.643 -179.31 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.597 HD12 ' C ' ' A' ' 134' ' ' GLU . 4.4 mp -146.66 114.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.44 . . . . 0.0 111.609 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -127.05 156.34 41.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.994 179.739 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' THR . . . . . 1.076 HG22 HG12 ' A' ' 166' ' ' VAL . 3.5 p -141.77 139.07 32.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.474 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.41 ' HB3' ' CB ' ' A' ' 128' ' ' GLU . 4.4 ptp85 -148.94 148.32 29.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.178 0.514 . . . . 0.0 111.931 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.498 HD23 HD12 ' A' ' 164' ' ' LEU . 0.3 OUTLIER -117.55 140.8 49.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.602 -0.726 . . . . 0.0 109.753 179.202 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -144.55 151.78 39.59 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.044 0.45 . . . . 0.0 111.561 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.452 ' HA ' ' O ' ' A' ' 161' ' ' MET . 8.1 p90 -124.95 161.83 25.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.979 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -138.63 176.08 9.0 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -124.08 135.63 53.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.3 m -95.35 -31.4 13.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -102.49 159.37 15.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.895 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -176.53 -40.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.433 HG23 ' N ' ' A' ' 148' ' ' GLY . 3.8 tt -120.05 -41.64 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.091 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.433 ' N ' HG23 ' A' ' 147' ' ' ILE . . . 67.12 98.85 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.461 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -107.14 79.45 1.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.827 0.346 . . . . 0.0 110.902 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -172.92 109.7 0.19 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 20.9 m170 60.58 -176.28 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 51.5 p -98.95 31.61 2.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.933 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 23.8 mt -118.78 -51.0 3.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.31 158.82 6.12 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.503 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 2.9 t -106.07 145.47 31.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.896 0.379 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -102.54 138.53 19.68 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.93 113.1 3.45 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.472 2.115 . . . . 0.0 112.303 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -82.97 -31.74 27.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -166.07 112.99 0.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -59.73 166.27 9.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.415 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.452 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER -60.84 136.18 58.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.612 0.244 . . . . 0.0 110.91 -179.938 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 6.4 tp -118.81 118.57 31.94 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.419 ' CB ' ' HA3' ' A' ' 14' ' ' GLY . 10.3 t -130.51 154.37 47.86 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 121.255 0.55 . . . . 0.0 112.03 -179.151 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' LEU . . . . . 0.597 HD23 ' N ' ' A' ' 165' ' ' GLY . 4.7 tt -145.25 123.98 12.59 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.771 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' GLY . . . . . 0.597 ' N ' HD23 ' A' ' 164' ' ' LEU . . . -144.88 163.4 28.01 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.573 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 1.076 HG12 HG22 ' A' ' 137' ' ' THR . 29.3 m -105.29 146.99 11.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.38 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 2.8 m -134.96 147.21 49.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.204 0.526 . . . . 0.0 111.776 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -114.63 131.89 56.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.732 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 50.0 mtp180 -108.18 118.26 36.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.038 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -98.95 173.56 6.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -145.57 -142.08 3.75 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.515 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -162.04 -168.36 1.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 110.785 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 129.09 73.96 0.16 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.559 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -91.02 152.26 20.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.847 0.356 . . . . 0.0 110.878 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -88.88 -54.14 4.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.1 -179.977 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 5.3 ttt . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 120.844 0.354 . . . . 0.0 111.182 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -175.1 89.05 0.31 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.11 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.53 -61.35 0.54 Allowed 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.591 2.194 . . . . 0.0 112.293 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.5 mmtm -153.46 -76.38 0.12 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.65 -83.23 0.06 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.756 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.2 t30 67.41 42.8 2.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.809 0.337 . . . . 0.0 110.954 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 43' ' ' TYR . 74.5 p -123.49 160.69 26.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.752 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.0 t90 -119.09 137.49 53.54 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.286 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.429 ' CD1' ' HA ' ' A' ' 169' ' ' ARG . 3.9 m-85 -124.32 155.92 37.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.831 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.441 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 71.4 p -149.01 147.03 28.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.05 -163.06 23.45 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.174 -1.012 . . . . 0.0 113.364 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.48 153.99 50.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.647 -0.276 . . . . 0.0 110.611 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.43 ' HB2' ' CD1' ' A' ' 40' ' ' PHE . 0.1 OUTLIER -137.12 149.88 47.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.157 0.503 . . . . 0.0 111.863 -179.401 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 tt -149.1 124.06 10.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.678 179.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.2 174.26 27.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.171 -1.014 . . . . 0.0 113.577 -179.196 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 3.7 m-85 -116.73 145.84 43.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.796 0.331 . . . . 0.0 110.638 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.5 p -139.15 -167.95 2.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 62.28 117.27 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.979 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -138.15 -52.19 0.61 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 60.13 170.51 0.08 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -141.08 -48.44 0.41 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.84 172.69 6.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.924 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.31 -160.07 24.04 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -102.62 85.41 2.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.6 mt -120.1 137.27 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.042 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -64.62 119.03 9.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.931 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 60.61 166.67 0.08 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.87 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -95.97 155.91 16.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.7 73.09 1.26 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.545 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.21 -35.01 61.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.588 2.192 . . . . 0.0 112.306 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 60.64 82.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 60.42 102.74 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -149.99 86.71 1.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.1 p30 -137.36 176.39 8.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.956 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -118.67 118.74 32.45 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.797 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.53 ' H ' HD23 ' A' ' 35' ' ' LEU . 0.5 OUTLIER -83.32 131.9 35.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.922 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.18 142.7 13.97 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.449 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.2 158.55 25.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 111.173 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.35 -173.12 40.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.284 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.04 153.4 48.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.813 -0.193 . . . . 0.0 110.694 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.43 ' CD1' ' HB2' ' A' ' 12' ' ' LYS . 23.6 p90 -159.42 169.02 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.186 0.517 . . . . 0.0 111.867 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -145.68 160.9 28.2 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.756 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 52' ' ' GLU . . . -148.46 124.65 1.9 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.043 -1.075 . . . . 0.0 113.222 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.4 t80 -104.53 129.51 52.57 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -94.51 124.81 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.776 0.322 . . . . 0.0 110.548 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.11 -38.1 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.453 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 0.8 OUTLIER -147.06 -179.92 1.04 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.073 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.453 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.5 Cg_exo -59.96 -35.77 92.25 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.476 2.117 . . . . 0.0 112.923 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -123.74 11.11 9.06 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.2 t -135.55 112.95 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.573 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.25 178.03 21.14 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.489 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -127.1 150.01 49.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.573 0.225 . . . . 0.0 110.533 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.433 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 0.9 OUTLIER -146.9 133.73 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.031 0.443 . . . . 0.0 111.429 -179.654 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' MET . . . . . 0.804 ' HG3' HD12 ' A' ' 79' ' ' LEU . 8.5 ttp -126.49 151.95 47.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.352 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -158.26 157.54 28.4 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.272 -0.966 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -156.49 158.68 37.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.769 0.319 . . . . 0.0 110.811 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 22.2 p-10 -100.29 128.73 46.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -148.23 95.86 2.53 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.937 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.547 HD23 ' N ' ' A' ' 59' ' ' GLY . 1.1 tt -112.21 153.4 27.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.547 ' N ' HD23 ' A' ' 58' ' ' LEU . . . 91.91 65.01 1.13 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.43 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -87.74 -31.41 19.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.722 0.296 . . . . 0.0 110.848 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.6 148.1 87.26 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.6 164.0 37.12 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.455 2.103 . . . . 0.0 112.321 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -176.95 -66.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.954 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.7 mttt -75.91 161.87 28.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -62.95 175.96 7.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 5.0 m -98.59 35.48 1.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 0.0 110.873 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.1 m -99.84 176.57 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.075 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -144.93 33.3 1.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.956 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.2 m-20 -95.16 117.64 30.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 137.85 -158.46 24.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.531 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -129.46 141.1 51.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.832 0.348 . . . . 0.0 111.081 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -169.48 90.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 21.8 ttmt -100.64 107.61 19.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -150.97 106.31 3.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.073 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -118.79 141.33 48.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -155.16 114.32 0.61 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.547 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.48 HG12 HG23 ' A' ' 101' ' ' VAL . 11.1 p -148.64 140.59 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.687 0.279 . . . . 0.0 110.951 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 100' ' ' MET . 4.5 mt-30 -126.22 132.06 51.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.976 0.417 . . . . 0.0 110.985 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.804 HD12 ' HG3' ' A' ' 53' ' ' MET . 0.3 OUTLIER -133.83 129.98 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.624 179.266 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -152.07 173.1 15.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.518 0.675 . . . . 0.0 111.979 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -103.37 142.37 34.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.862 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' LYS . . . . . 0.511 ' C ' HD12 ' A' ' 83' ' ' LEU . 3.4 tttm -109.14 124.59 51.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 111.389 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.511 HD12 ' C ' ' A' ' 82' ' ' LYS . 9.1 mp -130.7 110.14 11.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.464 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.451 ' HA3' ' CD2' ' A' ' 94' ' ' TYR . . . -133.46 172.09 21.68 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.383 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -126.74 137.59 30.78 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.665 0.269 . . . . 0.0 110.509 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.4 102.05 0.73 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.721 2.281 . . . . 0.0 112.716 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 91' ' ' LEU . 7.0 tp -82.46 -33.33 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.029 0.442 . . . . 0.0 110.312 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.35 165.24 32.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.222 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -66.08 -21.98 66.39 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.522 0.193 . . . . 0.0 111.522 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -111.34 -27.82 8.48 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.407 ' O ' HG22 ' A' ' 87' ' ' ILE . 3.0 mt -115.97 127.73 55.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.952 0.406 . . . . 0.0 111.677 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -134.96 161.83 34.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.147 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.998 HG22 HG12 ' A' ' 127' ' ' VAL . 29.4 pt -119.62 142.06 36.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.033 179.117 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.451 ' CD2' ' HA3' ' A' ' 84' ' ' GLY . 39.5 m-85 -143.92 158.99 43.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.621 0.724 . . . . 0.0 112.662 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -139.03 136.47 35.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.111 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.436 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 1.3 mtp85 -116.35 136.86 52.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.034 0.445 . . . . 0.0 111.183 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.482 HD23 ' CB ' ' A' ' 123' ' ' PHE . 8.8 mt -139.38 117.43 11.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.748 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -168.48 -142.38 3.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.327 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.517 ' HA2' ' O ' ' A' ' 120' ' ' SER . . . -144.27 145.23 14.59 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.054 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.614 ' SD ' HG11 ' A' ' 122' ' ' VAL . 9.6 ptm -128.03 117.96 22.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.207 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.48 HG23 HG12 ' A' ' 77' ' ' VAL . 3.9 m -93.16 117.31 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.006 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -132.02 111.03 11.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.84 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.6 124.12 19.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -136.4 156.15 49.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.057 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -132.95 133.04 42.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.848 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.2 p -146.53 114.36 6.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.912 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.59 -177.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 m -60.33 132.79 55.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.872 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.76 -179.91 3.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.583 HG12 ' O ' ' A' ' 110' ' ' VAL . 15.3 t 59.84 29.18 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -115.54 -36.06 4.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 166.1 41.66 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.538 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -99.58 134.16 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.847 0.356 . . . . 0.0 110.903 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -105.17 31.35 4.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 14.2 m80 -67.59 -177.44 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.843 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -149.67 122.95 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.043 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.3 -176.54 3.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.871 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.88 106.12 1.0 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 45.3 t -57.08 -74.86 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.654 0.264 . . . . 0.0 110.985 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' SER . . . . . 0.527 ' O ' HG22 ' A' ' 122' ' ' VAL . 0.6 OUTLIER 177.08 -67.8 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.37 179.553 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.477 ' CD ' ' CB ' ' A' ' 120' ' ' SER . 77.3 Cg_exo -38.03 112.13 0.11 Allowed 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.889 2.393 . . . . 0.0 113.192 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.614 HG11 ' SD ' ' A' ' 100' ' ' MET . 6.8 m -153.04 151.44 11.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 0.0 111.318 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.482 ' CB ' HD23 ' A' ' 97' ' ' LEU . 18.8 p90 -137.7 164.09 29.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.761 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.436 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -148.52 153.19 38.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.299 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.41 140.97 8.68 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.102 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 176.96 -154.2 15.49 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.402 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.998 HG12 HG22 ' A' ' 93' ' ' ILE . 31.0 m -139.59 146.98 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.07 0.462 . . . . 0.0 111.377 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.417 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.7 OUTLIER -126.19 131.04 52.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.531 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 129' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -128.84 150.81 50.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.478 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.79 116.03 31.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.769 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 32.7 mt -86.69 -38.42 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.874 0.368 . . . . 0.0 110.948 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.778 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -162.19 166.34 14.3 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.894 -179.978 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.778 ' HD2' HG22 ' A' ' 132' ' ' THR . 49.8 Cg_exo -55.87 140.21 85.1 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.617 2.211 . . . . 0.0 112.53 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 63.78 10.42 5.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.441 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.522 HD11 ' HB ' ' A' ' 132' ' ' THR . 13.4 pt -149.32 117.01 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.117 0.484 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.563 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -128.57 157.0 42.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.855 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.9 m -136.36 140.84 43.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.58 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -149.0 149.43 31.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.154 0.502 . . . . 0.0 111.788 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.423 ' O ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -120.11 141.83 49.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -145.06 152.78 40.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.538 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' TYR . . . . . 0.47 ' HA ' ' O ' ' A' ' 161' ' ' MET . 26.8 p90 -130.48 164.66 24.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.014 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -135.71 125.2 25.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -95.2 162.6 13.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.854 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.1 p -114.9 -38.65 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 51.4 m-80 -110.54 115.06 28.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.92 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -146.0 125.84 13.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 18.8 pt -112.41 -39.67 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 177.67 -50.42 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -73.34 141.83 47.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.805 0.336 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -157.03 146.71 20.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.035 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 28.4 m-70 -105.27 165.74 10.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.6 m -131.18 -46.26 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.7 mt -72.71 -51.34 28.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.1 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -105.38 93.06 0.87 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.577 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 8.4 m -130.99 105.6 7.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.796 0.331 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -99.43 149.04 35.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.93 88.64 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.587 2.191 . . . . 0.0 112.323 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -101.44 -40.73 6.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -167.92 92.77 0.37 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -175.19 -149.26 7.18 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.529 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER -133.56 132.44 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.639 0.257 . . . . 0.0 110.916 179.983 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 2.8 mt -122.28 118.57 28.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.122 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.468 ' C ' HD12 ' A' ' 164' ' ' LEU . 8.5 t -137.35 157.96 45.46 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 121.351 0.596 . . . . 0.0 112.093 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' LEU . . . . . 0.468 HD12 ' C ' ' A' ' 163' ' ' SER . 5.6 mp -143.33 128.57 18.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.716 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -144.12 163.57 27.73 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.471 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.563 HG13 ' O ' ' A' ' 136' ' ' ALA . 21.5 t -105.09 146.04 12.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' SER . . . . . 0.402 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 2.0 m -134.67 143.8 47.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.078 0.466 . . . . 0.0 111.657 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -111.23 131.72 54.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.699 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.429 ' HA ' ' CD1' ' A' ' 8' ' ' TYR . 0.0 OUTLIER -107.19 118.8 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.149 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -85.88 165.07 17.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -139.1 110.72 0.73 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.516 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -60.22 -36.32 77.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 0.0 110.904 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 148.5 59.52 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.478 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -121.89 145.88 47.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.901 0.382 . . . . 0.0 110.845 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -108.32 -35.76 6.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.106 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 179.968 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 p . . . . . 0 N--CA 1.461 0.089 0 CA-C-O 120.919 0.39 . . . . 0.0 110.664 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 18.6 p90 -125.44 164.22 20.92 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.577 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.424 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 22.5 p90 -155.2 156.6 35.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.77 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 44.4 p -149.13 150.51 32.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.737 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.0 -162.98 23.26 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.245 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.99 153.5 51.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.543 -0.329 . . . . 0.0 110.584 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.97 149.41 47.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.181 0.515 . . . . 0.0 111.739 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.734 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.872 0.368 . . . . 0.0 111.193 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -173.91 -174.74 41.04 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.374 -0.917 . . . . 0.0 113.325 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.67 154.15 48.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.836 -0.182 . . . . 0.0 110.612 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -159.24 163.75 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.326 0.584 . . . . 0.0 112.112 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.25 161.16 30.65 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.27 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.424 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -158.0 165.08 33.57 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.711 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -120.16 134.93 55.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.517 -0.342 . . . . 0.0 110.409 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -95.05 125.77 39.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.337 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -92.94 -38.42 9.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.418 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.0 OUTLIER -155.01 177.93 1.84 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.165 179.888 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.415 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.2 Cg_exo -60.14 -23.53 73.94 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.707 2.271 . . . . 0.0 113.644 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.415 ' CD1' ' HB2' ' A' ' 47' ' ' PRO . 69.3 m-85 -127.59 2.31 6.17 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.517 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.9 m -137.77 115.94 13.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.844 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.44 179.83 19.9 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.51 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -129.03 151.41 49.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.522 0.201 . . . . 0.0 110.556 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -152.03 138.49 18.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.045 0.45 . . . . 0.0 111.789 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 1.3 ptm -126.72 156.8 40.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.919 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.37 159.78 30.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.593 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 12.4 t80 . . . . . 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.587 179.922 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 78' ' ' GLN . 25.4 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.731 0.3 . . . . 0.0 110.984 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.491 ' N ' HG12 ' A' ' 77' ' ' VAL . 6.5 tt0 -127.81 136.43 51.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.027 0.441 . . . . 0.0 110.844 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.611 ' O ' HD12 ' A' ' 79' ' ' LEU . 4.0 pp -131.22 130.87 43.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.843 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.414 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.6 p -151.74 173.13 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.464 0.65 . . . . 0.0 111.874 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.56 141.24 39.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.905 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.8 mttp -108.02 126.98 53.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.493 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 20.9 mt -129.8 110.68 11.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.402 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.44 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.96 169.36 22.56 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.41 -0.9 . . . . 0.0 113.109 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.729 ' HB2' HD11 ' A' ' 93' ' ' ILE . 35.0 m-85 -123.72 137.67 29.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 110.548 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -84.43 99.4 0.75 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.707 2.271 . . . . 0.0 112.613 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 33.5 mt -81.28 -34.63 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.057 0.456 . . . . 0.0 110.442 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.435 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.9 m -148.0 164.78 32.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.184 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.435 ' N ' HG22 ' A' ' 88' ' ' THR . 58.6 m-20 -60.13 -27.66 67.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.478 0.18 . . . . 0.0 111.485 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.434 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 1.6 m-20 -112.02 -33.78 6.17 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -178.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.1 tt -102.85 123.84 47.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.941 0.4 . . . . 0.0 111.716 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -135.69 164.14 28.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.261 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.981 HG22 HG12 ' A' ' 127' ' ' VAL . 1.7 pp -119.6 142.93 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.003 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.44 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 6.7 m-85 -143.4 157.49 44.42 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.706 0.765 . . . . 0.0 112.715 -178.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 124' ' ' ALA . 91.6 m -141.14 136.26 31.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 114.542 -1.208 . . . . 0.0 109.029 178.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.826 ' CG ' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -118.13 139.58 51.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.963 0.411 . . . . 0.0 111.384 -179.543 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.0 mp -140.82 119.18 12.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.736 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.414 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -166.13 -141.84 3.26 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.296 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.44 23.35 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.317 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.8 ttt . . . . . 0 C--N 1.328 -0.336 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.991 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.408 ' CD1' ' N ' ' A' ' 123' ' ' PHE . 3.5 p90 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.781 0.324 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.826 ' HB3' ' CG ' ' A' ' 96' ' ' ARG . . . -142.18 164.2 30.8 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.252 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -149.04 141.95 9.42 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.122 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.4 ' HA3' ' O ' ' A' ' 139' ' ' LEU . . . 177.25 -155.0 16.92 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 119.87 -1.157 . . . . 0.0 113.358 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.981 HG12 HG22 ' A' ' 93' ' ' ILE . 30.1 m -139.71 148.17 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.974 0.416 . . . . 0.0 111.25 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -124.51 132.2 53.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.642 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.434 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 45.0 t80 -128.27 148.33 50.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.418 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 116.37 32.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.818 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 7.8 tp -88.57 -36.58 9.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.467 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -162.36 165.09 16.14 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.854 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.467 ' HD2' HG22 ' A' ' 132' ' ' THR . 11.7 Cg_endo -55.2 141.59 80.08 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.596 2.197 . . . . 0.0 112.074 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 58.54 19.01 6.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.531 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 31.1 mt -149.13 111.95 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 121.018 0.437 . . . . 0.0 111.718 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.577 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -124.42 156.13 37.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.836 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.6 m -142.83 136.26 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.5 ptt85 -146.15 157.94 43.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.253 0.549 . . . . 0.0 112.038 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.839 HD12 HD13 ' A' ' 164' ' ' LEU . 1.9 tt -128.18 139.86 52.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.596 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.472 ' N ' HD23 ' A' ' 139' ' ' LEU . 38.6 mt-10 -147.35 158.18 43.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.177 0.513 . . . . 0.0 111.693 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.869 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.421 HD12 ' N ' ' A' ' 162' ' ' LEU . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.118 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 17.8 m -136.73 157.54 46.52 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.331 0.586 . . . . 0.0 112.015 -179.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . 0.839 HD13 HD12 ' A' ' 139' ' ' LEU . 10.9 tp -141.69 127.87 19.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.673 179.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.98 161.75 27.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.09 -1.052 . . . . 0.0 113.431 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.2 m -106.16 147.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . 0.577 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 22.4 p -134.54 146.11 49.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.159 0.504 . . . . 0.0 111.608 -179.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -113.61 131.63 56.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.786 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -108.54 117.12 33.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.955 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 4.0 t80 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.975 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 67.5 p . . . . . 0 N--CA 1.463 0.216 0 CA-C-O 120.868 0.366 . . . . 0.0 110.797 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 12.9 p90 -128.01 164.18 22.93 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.641 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.415 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 5.3 p90 -155.29 156.63 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.417 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 3.3 t -149.17 150.21 32.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.71 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.416 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.75 -161.94 22.24 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.465 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -130.46 159.38 37.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.537 -0.331 . . . . 0.0 110.608 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -142.26 150.05 40.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.216 0.532 . . . . 0.0 112.003 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.798 ' HG ' ' HB2' ' A' ' 37' ' ' ALA . 6.6 tt . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.548 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.798 ' HB2' ' HG ' ' A' ' 13' ' ' LEU . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.793 0.33 . . . . 0.0 111.027 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.18 -159.4 31.86 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.357 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -135.1 155.08 51.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.543 0.211 . . . . 0.0 110.668 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -159.29 163.66 35.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.289 0.566 . . . . 0.0 111.907 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -140.61 158.84 26.24 Favored Glycine 0 N--CA 1.448 -0.544 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.35 179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.415 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.67 150.13 21.75 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.509 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 6.9 m-85 -117.35 131.79 56.72 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 mt-30 -94.64 126.46 39.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.236 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.01 -36.9 7.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.769 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.453 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.0 OUTLIER -152.76 179.21 1.32 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.154 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.436 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 39.3 Cg_exo -61.47 -26.89 81.62 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.684 2.256 . . . . 0.0 113.692 -179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.79 ' O ' HD23 ' A' ' 83' ' ' LEU . 11.3 p90 -124.53 4.11 8.31 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 -178.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.453 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 3.7 m -137.74 116.11 13.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.862 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.35 179.41 19.56 Favored Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.439 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -130.23 152.38 49.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.62 0.248 . . . . 0.0 110.767 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.408 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 13.0 mt-10 -150.38 136.71 18.77 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.09 0.471 . . . . 0.0 111.528 -179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . 0.449 ' HG2' HD12 ' A' ' 79' ' ' LEU . 5.1 mpp? -132.35 114.39 14.32 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.327 179.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -119.09 164.02 13.23 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.431 -0.89 . . . . 0.0 113.39 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.636 ' HB3' HG12 ' A' ' 77' ' ' VAL . 17.9 p90 . . . . . 0 C--N 1.331 -0.221 0 CA-C-O 120.796 0.331 . . . . 0.0 110.828 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 55' ' ' TYR . 30.9 m . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.735 0.302 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.0 pm0 -131.72 139.33 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.449 HD12 ' HG2' ' A' ' 53' ' ' MET . 7.7 tt -127.11 132.13 50.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.803 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -151.62 173.06 15.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.44 0.638 . . . . 0.0 111.978 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.54 141.44 39.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.862 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -108.83 126.44 53.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.874 0.369 . . . . 0.0 111.447 -179.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.79 HD23 ' O ' ' A' ' 48' ' ' TYR . 2.4 mt -131.61 110.09 10.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.239 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.1 177.53 19.48 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.773 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 85' ' ' TYR . 3.4 m-85 -131.76 140.63 38.87 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.659 0.266 . . . . 0.0 110.475 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -87.56 106.72 0.61 Allowed 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.836 2.357 . . . . 0.0 112.826 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 1.003 HD11 HD22 ' A' ' 91' ' ' LEU . 26.4 pt -80.22 -33.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.23 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.749 HG22 HG13 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -150.65 169.68 21.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.05 178.914 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -64.17 -23.31 67.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.079 0.399 . . . . 0.0 112.079 -179.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.446 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -110.94 -28.22 8.45 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 -178.708 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 1.003 HD22 HD11 ' A' ' 87' ' ' ILE . 0.5 OUTLIER -109.34 126.37 53.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.138 0.494 . . . . 0.0 111.924 -179.086 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.24 152.52 50.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.001 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 12.0 tt -123.11 142.12 40.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.907 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.439 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 28.5 p90 -153.22 170.21 21.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.719 0.771 . . . . 0.0 113.021 -179.017 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 p -139.62 141.91 37.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.62 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.613 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 46.1 mtp180 -117.3 137.39 52.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.882 0.372 . . . . 0.0 111.067 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.636 HD23 ' N ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -139.86 120.03 13.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.856 -179.924 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -141.06 3.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.338 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.17 151.89 23.78 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.591 -0.814 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 2.4 ppp? . . . . . 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.955 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.841 0.353 . . . . 0.0 110.818 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.613 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -151.94 149.48 28.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.21 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.91 138.65 7.44 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.075 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.38 -158.5 22.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 119.996 -1.097 . . . . 0.0 113.264 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 18.8 m -141.89 149.78 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.134 0.492 . . . . 0.0 111.474 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -125.27 131.37 53.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.504 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.446 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 42.6 t80 -126.89 146.98 50.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.319 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.4 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.84 114.53 27.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.81 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -87.03 -39.18 12.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.009 0.433 . . . . 0.0 110.933 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.726 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -159.59 169.75 9.88 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.729 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.726 ' CD ' HG22 ' A' ' 132' ' ' THR . 32.0 Cg_exo -58.41 139.94 92.57 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.52 2.147 . . . . 0.0 112.214 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 59.71 17.72 6.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.842 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.45 ' O ' HG23 ' A' ' 135' ' ' ILE . 1.8 tt -149.21 113.93 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.114 0.483 . . . . 0.0 111.721 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.71 157.86 40.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.084 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 3.2 t -124.9 141.11 52.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.534 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 25.0 mtt180 -135.16 134.59 40.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.124 0.488 . . . . 0.0 111.815 -179.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.939 HD12 HD12 ' A' ' 164' ' ' LEU . 4.3 tt -130.06 130.78 45.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.543 179.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.526 ' N ' HD23 ' A' ' 139' ' ' LEU . 0.9 OUTLIER -153.53 169.42 23.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.392 0.615 . . . . 0.0 112.017 -179.08 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . 0.416 ' CZ ' ' HG ' ' A' ' 162' ' ' LEU . 4.1 m-85 . . . . . 0 C--N 1.327 -0.39 0 CA-C-N 115.21 -0.904 . . . . 0.0 110.847 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.523 HD23 ' C ' ' A' ' 162' ' ' LEU . 7.2 tt . . . . . 0 C--O 1.23 0.055 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 28.3 t -132.69 154.2 50.39 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.199 0.523 . . . . 0.0 111.78 -179.267 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . 0.939 HD12 HD12 ' A' ' 139' ' ' LEU . 8.0 tt -144.66 122.7 12.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.853 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.12 163.83 26.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.245 -0.978 . . . . 0.0 113.24 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.8 m -105.06 146.83 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . 0.416 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 0.9 OUTLIER -135.14 143.42 46.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.096 0.474 . . . . 0.0 111.67 -179.505 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -109.61 132.68 53.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.687 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.12 29.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.89 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.8 t80 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.893 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.8 p . . . . . 0 N--CA 1.462 0.166 0 CA-C-O 120.889 0.376 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 9.2 p-90 -126.68 164.58 20.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.561 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.425 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 2.8 p90 -155.34 158.35 38.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.966 179.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 t -149.14 149.54 31.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -169.68 -162.94 22.86 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.399 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.6 155.43 48.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.601 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.425 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 14.2 pttt -139.5 153.14 47.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.299 0.571 . . . . 0.0 112.276 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.011 HD13 ' HB2' ' A' ' 37' ' ' ALA . 48.3 tp . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.268 179.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 1.011 ' HB2' HD13 ' A' ' 13' ' ' LEU . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.851 0.358 . . . . 0.0 111.0 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.71 -162.78 35.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.306 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.86 155.1 45.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.717 -0.241 . . . . 0.0 110.7 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.425 ' CE1' ' HB3' ' A' ' 12' ' ' LYS . 27.3 p90 -159.13 157.72 31.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.304 0.573 . . . . 0.0 112.01 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -147.47 159.86 28.14 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.319 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.425 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -155.26 161.29 30.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 119.824 -1.179 . . . . 0.0 113.602 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 13.1 t80 -123.05 133.72 54.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.252 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -95.07 125.62 39.86 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.272 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 t -93.24 -37.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.961 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.474 ' HB2' HG23 ' A' ' 49' ' ' VAL . 1.1 t30 -153.92 178.32 1.66 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.424 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.4 Cg_exo -60.1 -25.97 81.24 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.679 2.252 . . . . 0.0 113.64 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CE1' ' HB2' ' A' ' 47' ' ' PRO . 17.9 m-85 -127.46 3.99 6.24 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.474 HG23 ' HB2' ' A' ' 46' ' ' ASN . 4.3 m -138.04 115.06 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.819 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.65 -177.23 18.4 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.466 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.59 150.04 49.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.559 0.219 . . . . 0.0 110.629 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -146.57 134.25 21.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.039 0.447 . . . . 0.0 111.375 -179.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -128.43 153.68 46.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.339 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.61 158.84 30.02 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.191 -1.004 . . . . 0.0 113.116 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 7.3 p90 . . . . . 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.863 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 31.3 m . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.684 0.278 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -130.22 140.43 50.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.048 0.451 . . . . 0.0 111.091 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -129.85 132.1 46.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.968 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.423 ' HB ' ' HA3' ' A' ' 98' ' ' GLY . 1.3 t -151.43 170.11 20.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.523 0.678 . . . . 0.0 112.09 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.94 144.22 35.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.946 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -110.14 125.26 52.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -130.89 108.15 9.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.209 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.479 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -134.99 176.89 19.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.232 -0.985 . . . . 0.0 113.658 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.564 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.5 m-85 -128.07 140.18 37.52 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.661 0.267 . . . . 0.0 110.606 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -87.87 103.72 0.51 Allowed 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.772 2.315 . . . . 0.0 112.634 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 41.6 pt -82.14 -30.64 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.042 0.448 . . . . 0.0 110.337 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.404 ' OG1' ' HB3' ' A' ' 91' ' ' LEU . 0.2 OUTLIER -150.47 167.31 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.177 179.297 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -64.94 -23.45 67.23 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.447 ' HB3' ' CE1' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -112.07 -37.31 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.02 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.404 ' HB3' ' OG1' ' A' ' 88' ' ' THR . 15.3 tp -102.94 125.73 49.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.984 0.421 . . . . 0.0 111.656 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -133.54 161.02 35.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.186 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.051 HG22 HG12 ' A' ' 127' ' ' VAL . 2.6 pp -125.66 143.23 39.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.035 179.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.479 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 10.2 p90 -155.1 170.27 22.2 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.723 0.773 . . . . 0.0 113.003 -178.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.3 p -139.39 143.05 37.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.714 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.67 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 68.5 mtm180 -118.69 139.06 52.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.012 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 6.7 tp -141.25 120.84 13.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.1 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.423 ' HA3' ' HB ' ' A' ' 80' ' ' THR . . . -164.8 -149.04 5.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.56 152.25 24.35 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.107 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.2 ptt? . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.829 0.347 . . . . 0.0 110.848 -179.889 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 t80 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.67 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -151.48 148.5 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.221 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.95 138.88 7.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.111 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.65 -156.96 20.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.002 -1.094 . . . . 0.0 113.299 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 1.051 HG12 HG22 ' A' ' 93' ' ' ILE . 28.9 m -141.54 147.9 21.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.043 0.449 . . . . 0.0 111.335 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.421 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 21.6 tt0 -124.05 132.11 53.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.703 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.447 ' CE1' ' HB3' ' A' ' 90' ' ' ASP . 70.9 t80 -126.09 146.4 49.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.176 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.39 116.15 31.68 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.808 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.598 HD11 HG22 ' A' ' 135' ' ' ILE . 2.2 pt -92.8 -30.99 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.611 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.816 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.2 OUTLIER -147.13 169.27 9.65 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.499 179.916 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.816 ' HD2' HG22 ' A' ' 132' ' ' THR . 53.1 Cg_exo -55.91 -60.95 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.575 2.183 . . . . 0.0 112.843 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . 0.608 ' C ' HD12 ' A' ' 135' ' ' ILE . 9.8 tt0 -98.05 23.85 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.708 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.608 HD12 ' C ' ' A' ' 134' ' ' GLU . 4.3 mp -146.46 117.6 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.053 0.454 . . . . 0.0 111.651 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.12 161.86 29.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.082 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.816 HG22 HG12 ' A' ' 166' ' ' VAL . 80.9 p -135.93 140.59 44.14 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.407 179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.65 144.04 32.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.237 0.542 . . . . 0.0 112.041 -179.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.621 HD12 ' CD1' ' A' ' 164' ' ' LEU . 2.6 tt -124.83 136.34 53.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.598 178.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.462 ' N ' HD23 ' A' ' 139' ' ' LEU . 16.8 mt-10 -146.0 156.44 43.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.227 0.537 . . . . 0.0 111.807 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.536 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 8.4 mp . . . . . 0 C--O 1.23 0.079 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 22.5 m -132.31 152.7 51.28 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.201 0.524 . . . . 0.0 111.627 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . 0.621 ' CD1' HD12 ' A' ' 139' ' ' LEU . 2.7 tt -143.81 123.86 13.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.775 179.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . 0.425 ' N ' HD23 ' A' ' 164' ' ' LEU . . . -143.55 164.75 27.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.24 -0.981 . . . . 0.0 113.456 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.816 HG12 HG22 ' A' ' 137' ' ' THR . 25.9 m -105.45 147.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . 0.414 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 30.0 p -134.78 145.91 48.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.125 0.488 . . . . 0.0 111.761 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -112.12 131.96 55.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.738 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -108.51 116.79 32.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.025 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 3.1 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 -179.955 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.462 0.127 0 CA-C-O 120.957 0.408 . . . . 0.0 110.811 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 7.2 t90 -113.1 161.07 17.53 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.317 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.467 ' CZ ' ' HB2' ' A' ' 169' ' ' ARG . 0.1 OUTLIER -145.12 141.62 28.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 m -147.56 144.42 28.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.698 0.285 . . . . 0.0 111.189 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -173.82 -157.58 15.82 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.295 -0.955 . . . . 0.0 113.256 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -134.02 155.44 49.98 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.659 -0.271 . . . . 0.0 110.746 179.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.467 ' C ' HD12 ' A' ' 13' ' ' LEU . 1.7 mmmm -139.16 153.15 47.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.147 0.498 . . . . 0.0 111.966 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HG ' ' HB1' ' A' ' 37' ' ' ALA . 2.7 mp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.516 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.603 ' HB1' ' HG ' ' A' ' 13' ' ' LEU . . . . . . . . 0 C--O 1.232 0.18 0 CA-C-O 120.79 0.329 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.01 -159.78 32.47 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.28 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.4 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -114.51 151.63 33.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.921 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.447 ' CD2' ' HA3' ' A' ' 54' ' ' GLY . 61.2 m-85 -151.23 149.88 29.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.03 0.443 . . . . 0.0 111.692 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.04 156.75 28.63 Favored Glycine 0 N--CA 1.45 -0.417 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -157.04 154.67 25.73 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 119.783 -1.199 . . . . 0.0 113.771 -179.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 24.9 t80 -107.21 133.63 51.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.5 -0.35 . . . . 0.0 110.086 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -96.13 125.91 40.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.453 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.0 t -94.78 -36.44 6.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.484 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.8 OUTLIER -156.6 173.37 5.03 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.688 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.484 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 25.9 Cg_endo -62.82 -15.31 46.21 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 122.227 1.952 . . . . 0.0 113.551 -179.085 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -126.86 -4.76 6.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.6 m -139.07 117.48 12.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.97 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.6 -179.37 18.67 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.369 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -128.87 149.59 50.7 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.636 0.255 . . . . 0.0 110.414 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -149.37 137.01 20.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.004 0.43 . . . . 0.0 111.616 -179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . 0.43 ' HG2' HD23 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -128.23 156.72 42.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.212 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.447 ' HA3' ' CD2' ' A' ' 40' ' ' PHE . . . -159.03 157.54 28.58 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.142 -1.028 . . . . 0.0 113.199 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.646 ' HD2' HG22 ' A' ' 77' ' ' VAL . 13.9 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-O 120.873 0.368 . . . . 0.0 110.841 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.646 HG22 ' HD2' ' A' ' 55' ' ' TYR . 24.8 t . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.709 0.29 . . . . 0.0 110.952 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.489 ' N ' HG12 ' A' ' 77' ' ' VAL . 6.7 tt0 -128.11 134.14 49.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.007 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.43 HD23 ' HG2' ' A' ' 53' ' ' MET . 2.4 mt -128.92 130.28 46.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.842 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.7 p -151.38 173.1 14.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.461 0.648 . . . . 0.0 111.99 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -109.0 142.91 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.001 179.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -109.07 126.17 52.89 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.877 0.37 . . . . 0.0 111.479 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.0 mp -129.15 112.17 13.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.248 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.72 170.85 22.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.217 -0.992 . . . . 0.0 113.474 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.745 ' HB2' HD11 ' A' ' 93' ' ' ILE . 3.1 m-85 -124.3 139.07 32.05 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.639 0.257 . . . . 0.0 110.517 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -85.31 100.04 0.68 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.708 2.272 . . . . 0.0 112.704 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 1.024 HD11 HG23 ' A' ' 93' ' ' ILE . 1.2 mp -80.36 -35.04 15.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.135 0.493 . . . . 0.0 110.309 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.438 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.8 m -148.62 164.88 32.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.164 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.438 ' N ' HG22 ' A' ' 88' ' ' THR . 1.9 t70 -60.71 -24.8 65.95 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.574 0.212 . . . . 0.0 111.574 -179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.441 ' CB ' ' CE2' ' A' ' 129' ' ' TYR . 10.8 m-20 -113.08 -33.52 6.0 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.087 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 6.8 tp -102.89 123.58 46.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.903 0.383 . . . . 0.0 111.793 -179.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.684 ' HA ' HD12 ' A' ' 87' ' ' ILE . 72.6 m-20 -134.03 160.81 36.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.297 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.036 HG22 HG12 ' A' ' 127' ' ' VAL . 1.0 OUTLIER -120.41 142.88 34.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.984 179.099 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.438 ' CE1' ' HB2' ' A' ' 128' ' ' GLU . 47.2 p90 -147.15 163.49 36.14 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.653 0.74 . . . . 0.0 112.872 -178.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -140.58 139.64 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.363 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.495 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -116.51 135.04 54.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.891 0.377 . . . . 0.0 111.003 -179.748 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.37 118.21 11.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.836 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.86 -144.19 3.99 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.298 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -150.03 151.09 23.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.205 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 p90 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.495 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -156.17 150.82 25.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.207 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.45 139.3 7.75 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.126 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.37 -156.57 19.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.248 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 1.036 HG12 HG22 ' A' ' 93' ' ' ILE . 29.4 m -138.88 148.25 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.161 0.505 . . . . 0.0 111.267 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.438 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 40.1 tt0 -124.62 131.93 53.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.715 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.441 ' CE2' ' CB ' ' A' ' 90' ' ' ASP . 48.8 t80 -127.9 147.59 50.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.239 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 117.0 34.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.859 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.834 HD11 ' CG2' ' A' ' 135' ' ' ILE . 29.6 pt -89.57 -33.59 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.069 0.462 . . . . 0.0 110.671 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.7 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -147.37 174.58 3.29 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.52 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.7 ' CD ' HG22 ' A' ' 132' ' ' THR . 50.7 Cg_exo -54.17 -62.08 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.586 2.191 . . . . 0.0 112.75 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . 0.478 ' C ' HD12 ' A' ' 135' ' ' ILE . 12.2 tt0 -100.15 31.52 3.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.629 -179.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.834 ' CG2' HD11 ' A' ' 131' ' ' ILE . 4.5 mp -145.99 115.52 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.952 0.406 . . . . 0.0 111.555 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.528 ' O ' HG23 ' A' ' 166' ' ' VAL . . . -131.07 150.13 52.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.924 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.31 141.66 51.95 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.641 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.404 ' HD2' ' HB2' ' A' ' 167' ' ' SER . 0.2 OUTLIER -134.2 140.48 46.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.104 0.478 . . . . 0.0 111.687 -179.515 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.5 pp -132.68 130.54 40.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.511 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -151.68 168.21 25.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.301 0.572 . . . . 0.0 111.933 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . 0.676 ' CE2' HD23 ' A' ' 162' ' ' LEU . 2.7 m-85 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.911 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.676 HD23 ' CE2' ' A' ' 141' ' ' TYR . 0.5 OUTLIER . . . . . 0 N--CA 1.463 0.215 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.8 m -132.44 154.12 50.17 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.292 0.568 . . . . 0.0 111.891 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 2.6 mp -145.3 122.52 11.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.865 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -141.88 165.18 26.62 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.25 -0.976 . . . . 0.0 113.465 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 136' ' ' ALA . 8.8 p -111.37 147.19 15.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . 0.438 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 5.3 t -136.33 151.54 49.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.294 0.568 . . . . 0.0 112.175 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -119.49 133.63 55.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.838 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 2.0 ttp180 -106.97 121.61 44.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.295 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 9.0 t80 . . . . . 0 C--N 1.33 -0.253 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.935 -179.961 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.704 HG23 ' HB2' ' A' ' 44' ' ' GLN . 4.1 t . . . . . 0 N--CA 1.46 0.061 0 CA-C-O 120.79 0.329 . . . . 0.0 110.455 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 35.7 p90 -127.92 164.16 22.89 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.798 -179.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.417 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 4.0 p90 -155.24 157.16 36.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.907 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.402 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 0.8 OUTLIER -149.02 150.86 33.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.741 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.89 -164.93 27.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.332 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.53 154.14 49.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.628 -0.286 . . . . 0.0 110.568 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.459 ' C ' HD12 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -138.32 150.48 46.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.186 0.517 . . . . 0.0 111.809 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.479 HD12 ' N ' ' A' ' 13' ' ' LEU . 1.9 mp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.628 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.821 0.343 . . . . 0.0 111.256 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.62 -173.26 42.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.385 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 153.45 52.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.716 -0.242 . . . . 0.0 110.598 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.413 ' CE1' ' HB2' ' A' ' 12' ' ' LYS . 6.2 p90 -159.42 166.33 31.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.225 0.536 . . . . 0.0 112.016 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -148.08 160.03 28.21 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.53 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.417 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.1 159.88 28.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.363 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -124.85 132.13 53.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.569 -0.315 . . . . 0.0 110.276 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.704 ' HB2' HG23 ' A' ' 6' ' ' THR . 1.7 mt-30 -95.48 126.22 40.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.119 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.8 t -96.24 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.0 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.496 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 3.3 m-20 -103.54 171.27 5.28 Favored Pre-proline 0 C--N 1.332 -0.185 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.192 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.496 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 10.1 Cg_endo -51.52 128.8 27.15 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.683 2.255 . . . . 0.0 113.085 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.419 ' CE1' ' HG3' ' A' ' 86' ' ' PRO . 1.4 m-85 59.88 16.32 5.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.407 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 47' ' ' PRO . 2.8 m -138.95 113.96 8.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.843 -0.343 . . . . 0.0 111.385 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.3 -172.86 14.48 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.777 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -130.3 154.31 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.561 0.22 . . . . 0.0 110.602 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -150.4 138.14 19.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.482 . . . . 0.0 111.733 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -130.46 113.53 14.41 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.261 179.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.03 159.65 14.14 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.406 -0.902 . . . . 0.0 113.189 -179.136 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.559 ' HB3' HG12 ' A' ' 77' ' ' VAL . 47.8 p90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 120.804 0.335 . . . . 0.0 110.846 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.559 HG12 ' HB3' ' A' ' 55' ' ' TYR . 31.1 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.706 0.289 . . . . 0.0 111.044 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -130.29 137.34 49.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.075 0.464 . . . . 0.0 111.028 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.433 HD23 ' N ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -125.34 130.16 51.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.702 179.315 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.408 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.7 p -151.35 173.01 15.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.492 0.663 . . . . 0.0 111.924 -179.101 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.0 141.98 37.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.922 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -108.26 125.57 51.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.82 0.343 . . . . 0.0 111.403 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.417 ' CD1' HG12 ' A' ' 49' ' ' VAL . 2.4 tp -130.31 112.44 13.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.397 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.449 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.49 171.17 22.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.434 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.487 ' HB2' HD11 ' A' ' 93' ' ' ILE . 29.4 m-85 -123.99 138.94 31.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.715 0.293 . . . . 0.0 110.598 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.419 ' HG3' ' CE1' ' A' ' 48' ' ' TYR . 95.1 Cg_endo -84.6 98.89 0.72 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.73 2.286 . . . . 0.0 112.675 -179.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 24.0 mm -79.06 -36.66 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.032 0.444 . . . . 0.0 110.365 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.51 164.45 34.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.177 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -60.61 -24.02 65.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.524 0.202 . . . . 0.0 111.314 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.447 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 2.7 m-20 -113.6 -35.06 5.34 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -102.86 123.48 46.59 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.944 0.402 . . . . 0.0 111.758 -179.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -133.69 161.25 35.19 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.292 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.035 HG22 HG12 ' A' ' 127' ' ' VAL . 2.7 pt -121.44 142.51 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.979 179.123 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.449 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 40.4 p90 -147.8 165.34 30.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.69 0.757 . . . . 0.0 112.895 -178.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -144.32 140.66 29.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.399 -1.273 . . . . 0.0 109.445 179.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.712 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 45.5 mtm-85 -118.81 137.44 53.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 111.18 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.42 ' HB3' ' CE1' ' A' ' 123' ' ' PHE . 0.5 OUTLIER -139.5 119.7 13.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.918 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.408 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -166.32 -141.6 3.19 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.352 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.34 150.58 22.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.55 -0.833 . . . . 0.0 113.251 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.8 ptp . . . . . 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.945 -179.917 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.42 ' CE1' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.715 0.293 . . . . 0.0 110.752 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.712 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -155.41 146.57 22.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.325 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.2 138.94 7.55 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.188 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.21 -155.77 18.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.044 -1.074 . . . . 0.0 113.243 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 1.035 HG12 HG22 ' A' ' 93' ' ' ILE . 29.8 m -138.71 147.97 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.008 0.432 . . . . 0.0 111.258 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -124.77 132.2 53.38 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.692 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.447 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 34.7 t80 -125.87 145.95 50.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.047 -179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.404 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.86 115.58 29.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.952 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.476 HD11 HG22 ' A' ' 135' ' ' ILE . 21.4 pt -89.88 -33.11 5.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.036 0.446 . . . . 0.0 110.408 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.698 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -149.25 165.16 18.34 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.187 179.682 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.698 ' HD2' HG22 ' A' ' 132' ' ' THR . 9.6 Cg_endo -53.17 -56.25 2.93 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -95.75 17.07 15.8 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.476 HG22 HD11 ' A' ' 131' ' ' ILE . 3.5 mp -144.3 120.61 4.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.061 0.458 . . . . 0.0 111.897 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.53 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -131.13 154.05 48.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.814 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.2 p -125.06 142.19 51.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.618 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.537 ' O ' HD12 ' A' ' 139' ' ' LEU . 24.9 mtt180 -138.66 135.23 34.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.067 0.46 . . . . 0.0 111.873 -179.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 138' ' ' ARG . 8.5 mp -124.67 133.89 53.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.574 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -151.76 167.63 27.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.307 0.575 . . . . 0.0 112.005 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . 0.589 ' HE2' HD23 ' A' ' 162' ' ' LEU . 2.9 m-85 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.851 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.589 HD23 ' HE2' ' A' ' 141' ' ' TYR . 1.7 mp . . . . . 0 C--O 1.232 0.178 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -131.77 152.54 50.88 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.315 0.579 . . . . 0.0 111.861 -179.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . 0.63 ' O ' HD12 ' A' ' 164' ' ' LEU . 3.9 pp -142.45 122.54 13.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.673 179.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.17 163.68 27.02 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.236 -0.983 . . . . 0.0 113.485 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.53 HG13 ' O ' ' A' ' 136' ' ' ALA . 21.8 t -106.14 146.94 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.5 p -134.87 145.73 48.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.469 . . . . 0.0 111.739 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.5 m-85 -114.64 131.39 56.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.773 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.55 118.64 37.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.021 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.882 -179.987 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.449 HG22 ' H ' ' A' ' 7' ' ' TRP . 0.2 OUTLIER . . . . . 0 N--CA 1.463 0.208 0 CA-C-O 121.076 0.465 . . . . 0.0 111.634 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.6 m-90 -125.19 166.67 16.04 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.562 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.487 ' N ' ' O ' ' A' ' 42' ' ' GLY . 1.5 p90 -155.62 163.03 40.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.16 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 m -149.22 152.75 36.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.519 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -171.49 -160.36 19.86 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 119.894 -1.146 . . . . 0.0 113.426 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.27 153.92 51.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.631 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.46 ' C ' HD12 ' A' ' 13' ' ' LEU . 1.6 mmmp? -137.58 149.8 46.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.119 0.485 . . . . 0.0 111.567 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.467 HD12 ' N ' ' A' ' 13' ' ' LEU . 2.1 mp . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.662 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.888 0.375 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.21 -167.54 38.26 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.301 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.408 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -119.02 153.03 35.34 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.477 0.18 . . . . 0.0 110.75 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 54' ' ' GLY . 1.7 m-85 -154.72 142.69 20.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.158 0.504 . . . . 0.0 111.619 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -140.61 156.94 25.55 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.535 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -155.57 165.07 32.36 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.215 -0.993 . . . . 0.0 112.82 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 1.4 p90 -146.06 139.27 25.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.921 0.391 . . . . 0.0 111.373 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -94.96 124.67 39.14 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.533 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 10.9 m -98.49 -37.0 6.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.72 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.485 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.9 OUTLIER -149.39 170.11 8.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.359 -179.828 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.485 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 6.2 Cg_endo -48.64 120.5 5.3 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.826 2.351 . . . . 0.0 113.26 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.514 ' O ' HD12 ' A' ' 83' ' ' LEU . 0.9 OUTLIER 58.38 18.37 5.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.561 -0.745 . . . . 0.0 112.33 178.85 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.431 ' CG2' ' CB ' ' A' ' 46' ' ' ASN . 4.9 m -138.71 112.96 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.826 0.346 . . . . 0.0 111.451 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.45 -172.36 15.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . 0.439 ' HB2' ' CZ ' ' A' ' 43' ' ' TYR . 20.9 m-85 -128.38 151.43 49.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.662 0.268 . . . . 0.0 110.518 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -145.87 135.23 23.0 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.026 0.441 . . . . 0.0 111.47 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 15.1 ttp -129.73 154.71 46.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.331 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 40' ' ' PHE . . . -160.72 159.31 30.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.265 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.603 ' HD2' HG22 ' A' ' 77' ' ' VAL . 22.1 t80 . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.603 HG22 ' HD2' ' A' ' 55' ' ' TYR . 24.7 t . . . . . 0 N--CA 1.458 -0.071 0 CA-C-O 120.736 0.303 . . . . 0.0 111.051 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -128.23 135.27 49.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 111.047 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -130.85 130.76 44.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.888 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.409 ' HA ' ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.37 173.05 14.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.492 0.663 . . . . 0.0 111.989 -179.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.75 144.35 35.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.986 178.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . 0.411 ' HE2' ' CD2' ' A' ' 94' ' ' TYR . 0.3 OUTLIER -110.24 125.29 52.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.381 . . . . 0.0 111.479 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.514 HD12 ' O ' ' A' ' 48' ' ' TYR . 6.2 tp -130.64 110.06 11.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.263 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.466 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.02 175.29 20.95 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.71 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -129.09 139.87 36.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.694 0.283 . . . . 0.0 110.576 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -86.63 104.18 0.66 Allowed 'Trans proline' 0 N--CA 1.46 -0.465 0 C-N-CA 122.786 2.324 . . . . 0.0 112.736 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.436 HD11 ' HG ' ' A' ' 91' ' ' LEU . 40.3 pt -81.11 -33.75 13.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.162 0.506 . . . . 0.0 110.353 179.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.36 164.3 33.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.151 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -60.59 -25.09 65.96 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.451 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 1.0 OUTLIER -112.74 -30.85 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.104 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.436 ' HG ' HD11 ' A' ' 87' ' ' ILE . 13.4 tp -102.96 123.59 46.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.614 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -131.62 154.97 48.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.369 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.05 HG22 HG12 ' A' ' 127' ' ' VAL . 25.6 pt -123.07 142.62 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.873 179.043 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.466 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 19.3 p90 -152.83 170.15 21.05 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.752 0.786 . . . . 0.0 113.073 -178.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.4 p -141.5 142.5 33.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.295 -1.321 . . . . 0.0 109.53 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.474 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -118.14 137.49 52.93 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.964 0.412 . . . . 0.0 111.001 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.684 HD12 ' CE2' ' A' ' 123' ' ' PHE . 1.3 tt -139.77 119.25 13.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.814 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.409 ' HA3' ' HA ' ' A' ' 80' ' ' THR . . . -164.98 -144.52 4.08 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.233 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -152.9 152.6 24.24 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.491 -0.862 . . . . 0.0 113.292 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.3 ttt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.845 -179.904 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.684 ' CE2' HD12 ' A' ' 97' ' ' LEU . 9.6 t80 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.79 0.328 . . . . 0.0 110.816 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.483 ' HB1' ' OE1' ' A' ' 140' ' ' GLU . . . -152.14 147.1 26.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.249 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.6 138.82 7.62 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.14 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.1 -157.96 21.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.314 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 1.05 HG12 HG22 ' A' ' 93' ' ' ILE . 28.4 m -138.38 147.99 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.052 0.453 . . . . 0.0 111.255 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -125.35 131.1 53.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.777 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.451 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 38.0 t80 -126.86 146.59 50.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.408 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.89 115.65 29.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.807 HD11 HG22 ' A' ' 135' ' ' ILE . 19.8 pt -89.27 -34.82 7.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.958 0.408 . . . . 0.0 110.7 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.726 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -146.65 172.98 4.59 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.555 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.726 ' CD ' HG22 ' A' ' 132' ' ' THR . 50.5 Cg_exo -54.4 -61.86 0.36 Allowed 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.517 2.145 . . . . 0.0 112.757 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -99.84 25.44 7.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.777 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.807 HG22 HD11 ' A' ' 131' ' ' ILE . 4.0 mp -144.24 116.06 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.979 0.419 . . . . 0.0 111.565 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -127.35 158.48 37.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.972 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.788 HG22 HG12 ' A' ' 166' ' ' VAL . 26.0 p -141.49 138.42 32.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.41 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.22 150.92 35.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.131 0.491 . . . . 0.0 111.944 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.949 HD21 HD23 ' A' ' 164' ' ' LEU . 8.3 mp -118.34 139.81 50.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.723 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.483 ' OE1' ' HB1' ' A' ' 124' ' ' ALA . 0.1 OUTLIER -143.15 149.94 38.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 111.567 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . 0.644 ' HE2' HD23 ' A' ' 162' ' ' LEU . 6.2 m-85 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.91 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.644 HD23 ' HE2' ' A' ' 141' ' ' TYR . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.08 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 85.2 p -132.7 155.54 48.63 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.331 0.586 . . . . 0.0 111.885 -179.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . 0.949 HD23 HD21 ' A' ' 139' ' ' LEU . 0.1 OUTLIER -142.76 125.2 15.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.692 179.125 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.4 163.7 27.45 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.477 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.788 HG12 HG22 ' A' ' 137' ' ' THR . 23.3 m -108.89 147.93 13.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 11.3 t -136.21 147.0 47.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.488 . . . . 0.0 111.852 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.746 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 3.0 ptm180 -108.2 119.13 38.6 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.103 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 179.994 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 N--CA 1.461 0.086 0 CA-C-O 120.854 0.359 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.6 p-90 -124.52 163.87 20.96 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.523 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.42 ' CZ ' ' HA3' ' A' ' 42' ' ' GLY . 33.0 p90 -155.25 156.62 35.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.93 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 p -149.26 151.93 35.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.98 -160.73 21.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 119.904 -1.141 . . . . 0.0 113.32 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -127.11 154.45 44.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.524 -0.338 . . . . 0.0 110.512 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -142.21 146.08 34.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.083 0.468 . . . . 0.0 111.549 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.4 mp . . . . . 0 C--N 1.326 -0.429 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.374 178.96 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.999 0.428 . . . . 0.0 111.726 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.95 -173.29 42.37 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.606 -0.807 . . . . 0.0 113.295 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -130.55 154.22 48.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.876 -0.162 . . . . 0.0 110.57 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -159.23 161.65 36.09 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.281 0.562 . . . . 0.0 112.258 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -154.77 159.22 28.84 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.201 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CZ ' ' A' ' 8' ' ' TYR . . . -157.77 165.1 33.46 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.796 -1.192 . . . . 0.0 113.563 -179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.505 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.5 m-85 -119.91 135.14 55.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.404 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -95.13 125.96 40.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.27 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.1 t -92.88 -37.57 8.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.874 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.437 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -153.6 179.32 1.32 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.125 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.437 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 35.2 Cg_exo -60.72 -26.1 82.3 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.689 2.259 . . . . 0.0 113.712 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.4 p90 -127.97 4.43 5.93 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 113.135 0.791 . . . . 0.0 113.135 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 49' ' ' VAL . 9.1 p -139.52 115.72 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.601 -0.44 . . . . 0.0 111.718 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.4 -175.7 17.76 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.653 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -127.15 149.45 49.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.569 0.224 . . . . 0.0 110.44 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -147.76 136.82 22.17 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.085 0.469 . . . . 0.0 111.578 -179.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -128.22 155.27 44.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.231 179.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.34 158.37 29.47 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.213 -0.994 . . . . 0.0 113.197 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 30.5 p90 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.79 -179.978 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 78' ' ' GLN . 11.0 p . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.718 0.295 . . . . 0.0 111.044 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.466 ' N ' HG22 ' A' ' 77' ' ' VAL . 6.1 tt0 -130.21 142.78 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.051 0.453 . . . . 0.0 111.08 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.7 131.34 43.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.84 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.41 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.4 p -151.46 173.0 15.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.495 0.664 . . . . 0.0 111.891 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -110.29 142.41 41.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.963 179.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.62 127.25 53.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.969 0.414 . . . . 0.0 111.453 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.6 mp -129.73 111.22 12.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.303 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.436 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -133.55 169.79 22.61 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.266 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.481 ' HB3' HD11 ' A' ' 93' ' ' ILE . 2.5 t80 -121.69 137.4 27.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.613 0.244 . . . . 0.0 110.591 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -83.14 97.55 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.687 2.258 . . . . 0.0 112.63 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.456 HD11 HG12 ' A' ' 93' ' ' ILE . 31.1 mt -80.67 -35.67 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.048 0.451 . . . . 0.0 110.462 179.462 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.434 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.4 m -148.27 164.81 32.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.112 179.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.434 ' N ' HG22 ' A' ' 88' ' ' THR . 1.6 t70 -60.51 -27.34 67.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.522 0.201 . . . . 0.0 111.479 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.442 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 73.8 m-20 -112.27 -34.9 5.77 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 15.1 tp -102.84 123.74 47.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.981 0.42 . . . . 0.0 111.688 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -135.39 164.19 28.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.348 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.037 HG22 HG12 ' A' ' 127' ' ' VAL . 1.3 pt -117.75 142.29 32.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.929 178.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.436 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 36.6 m-85 -144.72 159.14 43.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.686 0.755 . . . . 0.0 112.838 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.697 HG23 ' O ' ' A' ' 124' ' ' ALA . 91.1 m -140.87 137.02 32.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.191 178.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.588 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 54.8 mtm180 -118.17 137.44 52.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.883 0.373 . . . . 0.0 111.277 -179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.3 tt -141.9 121.21 13.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.853 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.41 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -165.11 -146.25 4.71 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.273 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.23 156.05 26.71 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.612 -0.804 . . . . 0.0 113.179 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.765 0.317 . . . . 0.0 110.857 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 124' ' ' ALA . 40.2 t80 . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.79 0.328 . . . . 0.0 110.678 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.697 ' O ' HG23 ' A' ' 95' ' ' THR . . . -158.27 148.02 19.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.313 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.98 140.0 8.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.124 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 175.36 -151.75 12.48 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.306 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 1.037 HG12 HG22 ' A' ' 93' ' ' ILE . 29.7 m -140.26 149.24 21.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.126 0.488 . . . . 0.0 111.357 -179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -125.39 132.37 52.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.631 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.442 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 39.6 t80 -125.54 146.2 49.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.213 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.405 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -97.91 115.4 28.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.929 179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.4 tt -88.5 -35.04 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.958 0.409 . . . . 0.0 110.561 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.711 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -150.49 172.41 5.32 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.426 179.631 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.711 ' CD ' HG22 ' A' ' 132' ' ' THR . 52.8 Cg_exo -53.23 -57.06 2.2 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.473 2.115 . . . . 0.0 112.488 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -102.89 31.8 4.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.515 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.16 114.23 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 111.743 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.4 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -129.09 154.23 46.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.919 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.839 HG22 HG12 ' A' ' 166' ' ' VAL . 26.1 p -129.0 140.59 51.57 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.411 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.2 ttm105 -137.39 135.1 36.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.947 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.579 HD13 HD12 ' A' ' 164' ' ' LEU . 3.3 tp -124.98 132.51 53.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.432 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.77 165.58 32.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.255 0.55 . . . . 0.0 111.886 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 8.6 p90 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.948 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . 0.423 ' O ' HD12 ' A' ' 139' ' ' LEU . 95.4 p -130.28 153.04 49.05 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.231 0.538 . . . . 0.0 111.9 -179.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . 0.579 HD12 HD13 ' A' ' 139' ' ' LEU . 3.0 tt -144.3 123.19 12.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.889 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.39 159.29 27.49 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.355 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.839 HG12 HG22 ' A' ' 137' ' ' THR . 26.7 m -103.72 147.05 10.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . 0.4 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 78.6 p -134.81 145.51 48.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.1 0.476 . . . . 0.0 111.785 -179.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -112.19 132.06 55.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.675 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.51 116.25 31.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.009 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.95 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 N--CA 1.461 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.674 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.544 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.1 p90 -126.8 164.45 21.34 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.623 -179.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.412 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 26.5 p90 -155.26 157.05 36.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.018 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 p -149.13 151.19 33.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.739 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.6 -163.35 24.48 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.05 -1.071 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.49 153.47 50.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.556 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.4 ptmt -138.0 149.74 46.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.169 0.509 . . . . 0.0 111.81 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 37' ' ' ALA . 9.1 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.637 179.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.545 ' HB2' HD12 ' A' ' 13' ' ' LEU . . . . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.815 0.34 . . . . 0.0 111.198 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.17 -174.24 40.86 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.281 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.14 154.29 47.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.761 -0.22 . . . . 0.0 110.549 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -159.14 156.96 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.317 0.58 . . . . 0.0 112.101 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -150.29 159.06 27.95 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.244 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.412 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -157.12 164.98 33.09 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 119.793 -1.194 . . . . 0.0 113.498 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.6 m-85 -118.53 134.17 55.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.445 -0.378 . . . . 0.0 110.384 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 14.7 tt0 -95.79 126.44 41.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.238 179.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.443 HG21 ' CE2' ' A' ' 51' ' ' PHE . 25.1 t -94.75 -35.77 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.837 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.51 ' HB2' HG23 ' A' ' 49' ' ' VAL . 0.9 OUTLIER -155.67 172.77 5.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.866 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.472 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 23.1 Cg_endo -62.23 -15.87 47.26 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.222 1.948 . . . . 0.0 113.449 -179.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CD1' ' HG2' ' A' ' 47' ' ' PRO . 39.9 m-85 -128.24 -4.03 5.57 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.51 HG23 ' HB2' ' A' ' 46' ' ' ASN . 4.0 m -139.45 116.93 11.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.566 -0.453 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.53 -175.65 16.83 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.456 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 45' ' ' VAL . 85.0 m-85 -128.97 149.56 50.76 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -148.85 138.03 21.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.127 0.489 . . . . 0.0 111.665 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 6.3 mtt -128.26 156.09 43.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.148 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.22 158.29 29.36 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.031 -1.081 . . . . 0.0 113.138 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 4.0 p90 . . . . . 0 C--N 1.331 -0.219 0 CA-C-O 120.89 0.376 . . . . 0.0 110.821 -179.994 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 78' ' ' GLN . 21.4 t . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.732 0.301 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.43 ' N ' HG12 ' A' ' 77' ' ' VAL . 46.0 mt-30 -129.8 141.27 50.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.057 0.456 . . . . 0.0 111.039 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.608 ' O ' HD12 ' A' ' 79' ' ' LEU . 4.0 pp -131.23 130.83 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.764 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.408 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.71 173.03 15.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.475 0.655 . . . . 0.0 111.964 -179.178 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.71 142.0 38.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.827 178.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -107.99 126.33 52.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.823 0.344 . . . . 0.0 111.554 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.4 tt -129.65 110.64 11.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.37 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.438 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.8 169.01 22.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.362 -0.923 . . . . 0.0 113.209 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.406 ' CD2' ' HD2' ' A' ' 86' ' ' PRO . 5.1 t80 -124.28 137.61 29.42 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.614 0.245 . . . . 0.0 110.65 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.406 ' HD2' ' CD2' ' A' ' 85' ' ' TYR . 98.5 Cg_endo -85.37 100.19 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.684 2.256 . . . . 0.0 112.633 -179.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.418 HG22 ' O ' ' A' ' 91' ' ' LEU . 1.0 OUTLIER -82.04 -34.2 12.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.053 0.454 . . . . 0.0 110.367 179.333 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.413 HG22 ' N ' ' A' ' 89' ' ' ASP . 23.6 m -148.59 163.83 36.07 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.26 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.413 ' N ' HG22 ' A' ' 88' ' ' THR . 1.0 OUTLIER -62.45 -24.96 67.73 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.418 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -111.42 -29.43 7.79 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.502 HD23 ' HB3' ' A' ' 129' ' ' TYR . 93.7 mt -108.12 124.72 50.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 111.696 -179.344 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -133.51 157.75 44.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.326 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 5.2 mt -117.04 141.71 34.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.888 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.438 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 16.8 m-85 -143.62 157.87 44.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.697 0.76 . . . . 0.0 112.721 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.6 p -141.83 137.05 31.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.52 -1.218 . . . . 0.0 108.987 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.883 ' CG ' ' HB3' ' A' ' 124' ' ' ALA . 0.4 OUTLIER -119.57 140.94 49.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.963 0.411 . . . . 0.0 111.467 -179.463 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.715 ' O ' HD12 ' A' ' 97' ' ' LEU . 1.4 pp -142.17 120.68 12.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.816 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.408 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -164.96 -144.85 4.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.278 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.47 163.14 28.96 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.553 -0.832 . . . . 0.0 113.261 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 6.4 ttt . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.901 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 9.7 p90 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.796 0.332 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.883 ' HB3' ' CG ' ' A' ' 96' ' ' ARG . . . -141.38 162.15 36.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.235 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.31 141.98 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.078 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 139' ' ' LEU . . . 177.27 -154.86 16.59 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 119.926 -1.131 . . . . 0.0 113.331 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 16.2 m -140.38 148.22 22.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.045 0.45 . . . . 0.0 111.441 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.402 ' CB ' ' HB3' ' A' ' 138' ' ' ARG . 0.0 OUTLIER -127.52 132.6 49.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.649 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.502 ' HB3' HD23 ' A' ' 91' ' ' LEU . 30.8 p90 -129.92 151.61 50.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.361 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -102.3 117.31 34.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.835 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.537 ' O ' HG23 ' A' ' 132' ' ' THR . 20.5 pt -88.96 -36.1 8.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.04 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.537 HG23 ' O ' ' A' ' 131' ' ' ILE . 0.8 OUTLIER -162.47 162.12 19.53 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.965 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.26 140.79 41.35 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.558 2.172 . . . . 0.0 112.222 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.54 19.53 6.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.587 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 32.2 mt -149.08 111.76 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.047 0.451 . . . . 0.0 111.633 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.54 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -129.11 151.1 50.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.797 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.1 m -133.46 140.36 47.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.449 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.402 ' HB3' ' CB ' ' A' ' 128' ' ' GLU . 3.6 ptm180 -146.92 145.0 29.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.158 0.504 . . . . 0.0 111.886 -179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.403 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 4.0 pp -120.21 140.61 50.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.575 179.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -146.45 157.37 43.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.147 0.499 . . . . 0.0 111.63 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 2.7 p90 . . . . . 0 C--N 1.327 -0.374 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.001 179.932 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 5.5 tp . . . . . 0 C--O 1.231 0.13 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 4.9 t -136.9 157.99 45.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.365 0.602 . . . . 0.0 112.132 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 1.1 tt -143.33 128.05 18.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.694 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.96 162.84 27.78 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.443 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 136' ' ' ALA . 22.0 t -105.39 146.6 12.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.7 m -134.59 145.42 48.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.137 0.494 . . . . 0.0 111.614 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -113.83 131.53 56.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -108.66 117.73 34.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.976 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 45.4 p . . . . . 0 N--CA 1.462 0.156 0 CA-C-O 120.892 0.377 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 25.9 p-90 -128.38 162.81 26.24 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.667 -179.294 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.45 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 1.4 p90 -155.28 157.28 36.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.717 179.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.1 p -149.15 151.78 34.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.665 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.429 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.1 -165.65 27.79 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.392 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -128.79 152.45 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.539 -0.33 . . . . 0.0 110.252 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.447 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -139.05 150.47 45.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.327 0.585 . . . . 0.0 112.058 -179.208 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.447 HD12 ' O ' ' A' ' 12' ' ' LYS . 1.7 mp . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.675 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.075 0 CA-C-O 121.032 0.444 . . . . 0.0 111.73 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.68 179.65 44.04 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.28 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.26 153.24 47.17 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.55 -0.167 . . . . 0.0 110.55 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -159.38 165.69 32.71 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.349 0.595 . . . . 0.0 112.226 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -155.05 161.35 30.31 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.401 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.45 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -152.23 163.8 30.32 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 119.794 -1.193 . . . . 0.0 113.616 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.2 t80 -132.44 132.56 42.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.531 -0.335 . . . . 0.0 110.493 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -92.93 123.69 36.37 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.68 -43.83 12.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.813 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.534 ' HB2' ' HD2' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -152.06 165.19 18.01 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.411 -179.873 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.534 ' HD2' ' HB2' ' A' ' 46' ' ' ASN . 65.9 Cg_exo -40.12 123.09 1.28 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.904 2.403 . . . . 0.0 113.79 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 48' ' ' TYR . 0.8 OUTLIER 59.17 17.68 5.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.419 178.871 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 47' ' ' PRO . 24.5 t -136.68 114.02 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.451 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.24 -177.35 19.96 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.568 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -124.89 152.11 44.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -147.12 134.85 21.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.059 0.456 . . . . 0.0 111.527 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . 0.409 ' CE ' HD21 ' A' ' 79' ' ' LEU . 16.4 ttm -126.84 151.79 47.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.182 179.433 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -157.44 157.43 28.12 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.247 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 13.9 p90 . . . . . 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.348 . . . . 0.0 110.73 179.946 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 78' ' ' GLN . 21.4 t . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.726 0.298 . . . . 0.0 111.078 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.489 ' N ' HG12 ' A' ' 77' ' ' VAL . 3.0 tt0 -129.29 138.76 51.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.03 0.443 . . . . 0.0 111.029 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.409 HD21 ' CE ' ' A' ' 53' ' ' MET . 6.1 mt -129.44 130.68 46.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.852 179.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.9 p -151.56 173.09 15.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.445 0.64 . . . . 0.0 111.997 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -108.28 142.18 38.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.85 -1.068 . . . . 0.0 109.896 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -108.6 126.15 52.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.879 0.371 . . . . 0.0 111.488 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 5.2 mt -129.96 113.12 14.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.332 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.471 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -136.4 171.59 22.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.371 -0.918 . . . . 0.0 113.494 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -128.94 136.94 29.96 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 110.476 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -83.95 104.26 1.07 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.651 2.234 . . . . 0.0 112.946 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 1.063 HD11 HG23 ' A' ' 93' ' ' ILE . 1.1 mp -78.33 -36.52 20.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 121.173 0.511 . . . . 0.0 110.183 179.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.733 HG23 ' H ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -150.91 169.64 21.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.957 179.119 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.1 -22.37 66.81 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -112.11 -29.05 7.74 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.733 ' H ' HG23 ' A' ' 88' ' ' THR . 0.3 OUTLIER -109.68 125.53 52.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.099 0.476 . . . . 0.0 112.031 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.518 ' HA ' HD12 ' A' ' 87' ' ' ILE . 4.3 m-20 -133.01 155.42 49.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.186 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.063 HG23 HD11 ' A' ' 87' ' ' ILE . 11.5 pt -117.47 141.25 37.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.933 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.471 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 24.5 m-85 -144.27 161.28 39.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 112.628 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -141.63 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.218 178.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.76 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 75.7 mtp180 -117.34 136.23 53.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.893 0.378 . . . . 0.0 111.287 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.7 tt -140.42 119.38 12.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.95 -143.96 3.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.349 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -149.9 152.58 24.49 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.299 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 7.3 ttm . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.701 0.286 . . . . 0.0 110.965 -179.962 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 t80 . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.77 0.319 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.76 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -150.63 146.79 26.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.176 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.79 139.44 7.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.24 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.74 -158.02 22.05 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.112 -1.042 . . . . 0.0 113.238 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 1.034 HG12 HG22 ' A' ' 93' ' ' ILE . 31.0 m -138.45 146.39 26.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.058 0.456 . . . . 0.0 111.241 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.429 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.2 OUTLIER -126.03 131.7 52.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.739 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 129' ' ' TYR . 3.5 p90 -127.48 149.28 50.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.179 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.49 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.898 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.438 HD11 ' OG1' ' A' ' 137' ' ' THR . 39.1 mt -88.91 -34.75 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.008 0.433 . . . . 0.0 110.744 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.704 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -148.88 174.56 3.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.675 179.835 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.704 ' CD ' HG22 ' A' ' 132' ' ' THR . 51.2 Cg_exo -53.8 -61.61 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.657 2.238 . . . . 0.0 112.75 -179.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . 0.597 ' C ' HD12 ' A' ' 135' ' ' ILE . 2.4 mt-10 -101.17 30.17 4.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.643 -179.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.597 HD12 ' C ' ' A' ' 134' ' ' GLU . 4.4 mp -146.66 114.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.44 . . . . 0.0 111.609 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -127.05 156.34 41.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.994 179.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 1.076 HG22 HG12 ' A' ' 166' ' ' VAL . 3.5 p -141.77 139.07 32.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.474 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.41 ' HB3' ' CB ' ' A' ' 128' ' ' GLU . 4.4 ptp85 -148.94 148.32 29.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.178 0.514 . . . . 0.0 111.931 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.498 HD23 HD12 ' A' ' 164' ' ' LEU . 0.3 OUTLIER -117.55 140.8 49.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.602 -0.726 . . . . 0.0 109.753 179.202 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -144.55 151.78 39.59 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.044 0.45 . . . . 0.0 111.561 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 8.1 p90 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.979 179.955 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 6.4 tp . . . . . 0 N--CA 1.462 0.148 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 10.3 t -130.51 154.37 47.86 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 121.255 0.55 . . . . 0.0 112.03 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . 0.597 HD23 ' N ' ' A' ' 165' ' ' GLY . 4.7 tt -145.25 123.98 12.59 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.771 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . 0.597 ' N ' HD23 ' A' ' 164' ' ' LEU . . . -144.88 163.4 28.01 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.573 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 1.076 HG12 HG22 ' A' ' 137' ' ' THR . 29.3 m -105.29 146.99 11.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 2.8 m -134.96 147.21 49.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.204 0.526 . . . . 0.0 111.776 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -114.63 131.89 56.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.732 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 50.0 mtp180 -108.18 118.26 36.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.038 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.839 179.983 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 43' ' ' TYR . 74.5 p . . . . . 0 N--CA 1.461 0.116 0 CA-C-O 120.916 0.389 . . . . 0.0 110.752 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.0 t90 -119.09 137.49 53.54 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.286 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.429 ' CD1' ' HA ' ' A' ' 169' ' ' ARG . 3.9 m-85 -124.32 155.92 37.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.831 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.441 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 71.4 p -149.01 147.03 28.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.05 -163.06 23.45 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.174 -1.012 . . . . 0.0 113.364 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.48 153.99 50.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.647 -0.276 . . . . 0.0 110.611 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.43 ' HB2' ' CD1' ' A' ' 40' ' ' PHE . 0.1 OUTLIER -137.12 149.88 47.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.157 0.503 . . . . 0.0 111.863 -179.401 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 tt . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.678 179.216 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.111 0 CA-C-O 120.87 0.367 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.35 -173.12 40.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.284 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.04 153.4 48.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.813 -0.193 . . . . 0.0 110.694 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.43 ' CD1' ' HB2' ' A' ' 12' ' ' LYS . 23.6 p90 -159.42 169.02 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.186 0.517 . . . . 0.0 111.867 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -145.68 160.9 28.2 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.756 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 52' ' ' GLU . . . -148.46 124.65 1.9 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.043 -1.075 . . . . 0.0 113.222 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.4 t80 -104.53 129.51 52.57 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -94.51 124.81 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.776 0.322 . . . . 0.0 110.548 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.11 -38.1 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.453 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 0.8 OUTLIER -147.06 -179.92 1.04 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.073 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.453 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.5 Cg_exo -59.96 -35.77 92.25 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.476 2.117 . . . . 0.0 112.923 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -123.74 11.11 9.06 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.2 t -135.55 112.95 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.573 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.25 178.03 21.14 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.489 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -127.1 150.01 49.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.573 0.225 . . . . 0.0 110.533 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.433 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 0.9 OUTLIER -146.9 133.73 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.031 0.443 . . . . 0.0 111.429 -179.654 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' MET . . . . . 0.804 ' HG3' HD12 ' A' ' 79' ' ' LEU . 8.5 ttp -126.49 151.95 47.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.352 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -158.26 157.54 28.4 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.272 -0.966 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.2 p90 . . . . . 0 C--N 1.33 -0.269 0 CA-C-O 120.769 0.319 . . . . 0.0 110.811 -179.963 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 11.1 p . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.687 0.279 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 100' ' ' MET . 4.5 mt-30 -126.22 132.06 51.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.976 0.417 . . . . 0.0 110.985 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.804 HD12 ' HG3' ' A' ' 53' ' ' MET . 0.3 OUTLIER -133.83 129.98 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.624 179.266 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -152.07 173.1 15.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.518 0.675 . . . . 0.0 111.979 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -103.37 142.37 34.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.862 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . 0.511 ' C ' HD12 ' A' ' 83' ' ' LEU . 3.4 tttm -109.14 124.59 51.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 111.389 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.511 HD12 ' C ' ' A' ' 82' ' ' LYS . 9.1 mp -130.7 110.14 11.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.464 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.451 ' HA3' ' CD2' ' A' ' 94' ' ' TYR . . . -133.46 172.09 21.68 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.383 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -126.74 137.59 30.78 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.665 0.269 . . . . 0.0 110.509 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.4 102.05 0.73 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.721 2.281 . . . . 0.0 112.716 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 91' ' ' LEU . 7.0 tp -82.46 -33.33 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.029 0.442 . . . . 0.0 110.312 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.35 165.24 32.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.222 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -66.08 -21.98 66.39 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.522 0.193 . . . . 0.0 111.522 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -111.34 -27.82 8.48 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.407 ' O ' HG22 ' A' ' 87' ' ' ILE . 3.0 mt -115.97 127.73 55.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.952 0.406 . . . . 0.0 111.677 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -134.96 161.83 34.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.147 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.998 HG22 HG12 ' A' ' 127' ' ' VAL . 29.4 pt -119.62 142.06 36.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.033 179.117 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.451 ' CD2' ' HA3' ' A' ' 84' ' ' GLY . 39.5 m-85 -143.92 158.99 43.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.621 0.724 . . . . 0.0 112.662 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -139.03 136.47 35.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.111 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.436 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 1.3 mtp85 -116.35 136.86 52.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.034 0.445 . . . . 0.0 111.183 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.482 HD23 ' CB ' ' A' ' 123' ' ' PHE . 8.8 mt -139.38 117.43 11.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.748 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -168.48 -142.38 3.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.327 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -144.27 145.23 14.59 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.054 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.42 ' HA ' ' HA ' ' A' ' 78' ' ' GLN . 9.6 ptm . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.207 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.482 ' CB ' HD23 ' A' ' 97' ' ' LEU . 18.8 p90 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.786 0.327 . . . . 0.0 110.761 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.436 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -148.52 153.19 38.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.299 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.41 140.97 8.68 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.102 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 176.96 -154.2 15.49 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.402 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.998 HG12 HG22 ' A' ' 93' ' ' ILE . 31.0 m -139.59 146.98 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.07 0.462 . . . . 0.0 111.377 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.417 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.7 OUTLIER -126.19 131.04 52.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.531 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -128.84 150.81 50.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.478 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.79 116.03 31.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.769 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 32.7 mt -86.69 -38.42 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.874 0.368 . . . . 0.0 110.948 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.778 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -162.19 166.34 14.3 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.894 -179.978 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.778 ' HD2' HG22 ' A' ' 132' ' ' THR . 49.8 Cg_exo -55.87 140.21 85.1 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.617 2.211 . . . . 0.0 112.53 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 63.78 10.42 5.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.441 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.522 HD11 ' HB ' ' A' ' 132' ' ' THR . 13.4 pt -149.32 117.01 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.117 0.484 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.563 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -128.57 157.0 42.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.855 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.9 m -136.36 140.84 43.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.58 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -149.0 149.43 31.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.154 0.502 . . . . 0.0 111.788 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.423 ' O ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -120.11 141.83 49.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -145.06 152.78 40.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.538 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' TYR . . . . . . . . . . . . . 26.8 p90 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.014 -179.976 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 C--O 1.231 0.099 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . 0.468 ' C ' HD12 ' A' ' 164' ' ' LEU . 8.5 t -137.35 157.96 45.46 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 121.351 0.596 . . . . 0.0 112.093 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' LEU . . . . . 0.468 HD12 ' C ' ' A' ' 163' ' ' SER . 5.6 mp -143.33 128.57 18.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.716 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -144.12 163.57 27.73 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.471 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.563 HG13 ' O ' ' A' ' 136' ' ' ALA . 21.5 t -105.09 146.04 12.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' SER . . . . . 0.402 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 2.0 m -134.67 143.8 47.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.078 0.466 . . . . 0.0 111.657 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -111.23 131.72 54.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.699 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.429 ' HA ' ' CD1' ' A' ' 8' ' ' TYR . 0.0 OUTLIER -107.19 118.8 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.149 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.944 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 20.7 ttt . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.857 0.36 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -74.04 152.14 88.51 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.83 175.67 7.85 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.555 2.17 . . . . 0.0 112.35 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -118.73 167.45 11.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -149.67 157.26 43.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.847 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.9 t30 66.25 41.56 3.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.7 p -123.9 171.67 9.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.664 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 18.6 p90 -125.44 164.22 20.92 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.577 -179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.424 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 22.5 p90 -155.2 156.6 35.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.77 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 44.4 p -149.13 150.51 32.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.737 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.0 -162.98 23.26 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.245 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.99 153.5 51.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.543 -0.329 . . . . 0.0 110.584 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.97 149.41 47.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.181 0.515 . . . . 0.0 111.739 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.21 124.31 10.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.734 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.25 174.18 28.02 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.093 -1.051 . . . . 0.0 113.463 -179.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.765 ' CE2' HD13 ' A' ' 162' ' ' LEU . 12.1 p90 -121.4 147.54 45.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.8 0.333 . . . . 0.0 110.71 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.18 143.56 50.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.8 tm0? -66.38 -58.55 5.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.911 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.9 t80 -143.03 137.58 29.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.54 ' HD2' HG23 ' A' ' 21' ' ' THR . 19.0 t60 -94.99 169.71 9.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.953 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -98.3 36.05 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.871 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.54 HG23 ' HD2' ' A' ' 19' ' ' HIS . 0.8 OUTLIER -74.23 156.25 37.43 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -105.59 -30.87 4.46 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -94.19 97.22 10.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.811 0.338 . . . . 0.0 110.954 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.7 mt -110.24 127.67 67.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.064 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 m-80 -153.29 35.85 0.47 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.904 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -135.88 148.8 48.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.898 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.29 -31.58 26.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.952 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.82 149.89 15.29 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.69 -45.17 1.16 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.509 2.139 . . . . 0.0 112.295 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.8 p -127.48 -71.99 0.65 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.3 t-160 -147.89 -68.26 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -156.73 96.57 1.64 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -177.2 116.05 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -120.3 115.79 24.26 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.738 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 6.3 mt -84.0 133.78 34.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.46 148.72 19.73 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.421 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -123.18 158.4 30.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.872 0.368 . . . . 0.0 111.193 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -173.91 -174.74 41.04 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.374 -0.917 . . . . 0.0 113.325 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.67 154.15 48.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.836 -0.182 . . . . 0.0 110.612 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -159.24 163.75 35.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.326 0.584 . . . . 0.0 112.112 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.25 161.16 30.65 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.27 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.424 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -158.0 165.08 33.57 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.711 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -120.16 134.93 55.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.517 -0.342 . . . . 0.0 110.409 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -95.05 125.77 39.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.337 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -92.94 -38.42 9.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.009 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.418 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.0 OUTLIER -155.01 177.93 1.84 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.165 179.888 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.415 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.2 Cg_exo -60.14 -23.53 73.94 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.707 2.271 . . . . 0.0 113.644 -179.088 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.415 ' CD1' ' HB2' ' A' ' 47' ' ' PRO . 69.3 m-85 -127.59 2.31 6.17 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.517 ' O ' HG23 ' A' ' 49' ' ' VAL . 26.9 m -137.77 115.94 13.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.844 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.44 179.83 19.9 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.51 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -129.03 151.41 49.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.522 0.201 . . . . 0.0 110.556 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -152.03 138.49 18.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.045 0.45 . . . . 0.0 111.789 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 1.3 ptm -126.72 156.8 40.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.919 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.37 159.78 30.77 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.593 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.404 ' CE1' ' O ' ' A' ' 76' ' ' GLY . 12.4 t80 -154.53 140.54 18.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.793 0.33 . . . . 0.0 110.587 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -84.98 112.2 20.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.47 ' O ' HD12 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -67.15 -170.05 0.11 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 57' ' ' PHE . 2.7 mp -149.81 147.77 28.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.894 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -131.74 123.61 3.74 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.467 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.8 mtm180 -105.44 177.09 4.95 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.851 0.358 . . . . 0.0 110.972 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 2.4 mmt -123.0 93.99 47.75 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.871 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -49.51 -27.11 13.56 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.582 2.188 . . . . 0.0 112.382 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -93.41 70.25 4.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.45 129.14 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.9 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -110.43 54.91 0.52 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 m -117.01 138.35 51.63 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.806 0.336 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.474 ' O ' HG23 ' A' ' 67' ' ' VAL . 30.5 m -65.55 118.97 9.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.187 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -142.06 109.65 5.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.898 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -142.01 170.78 15.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.86 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.32 -48.35 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.53 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.45 -179.19 5.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.833 0.349 . . . . 0.0 111.05 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 9.8 m-85 -142.98 113.23 7.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER 60.29 31.5 20.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -87.86 152.98 21.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.066 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -144.31 157.96 43.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.404 ' O ' ' CE1' ' A' ' 55' ' ' TYR . . . -154.94 143.57 10.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.592 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 78' ' ' GLN . 25.4 t -154.78 159.12 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.731 0.3 . . . . 0.0 110.984 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.491 ' N ' HG12 ' A' ' 77' ' ' VAL . 6.5 tt0 -127.81 136.43 51.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.027 0.441 . . . . 0.0 110.844 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.611 ' O ' HD12 ' A' ' 79' ' ' LEU . 4.0 pp -131.22 130.87 43.48 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.843 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.414 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.6 p -151.74 173.13 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.464 0.65 . . . . 0.0 111.874 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.56 141.24 39.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 114.88 -1.055 . . . . 0.0 109.905 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.8 mttp -108.02 126.98 53.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.493 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 20.9 mt -129.8 110.68 11.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.402 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.44 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.96 169.36 22.56 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.41 -0.9 . . . . 0.0 113.109 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.729 ' HB2' HD11 ' A' ' 93' ' ' ILE . 35.0 m-85 -123.72 137.67 29.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 110.548 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -84.43 99.4 0.75 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.707 2.271 . . . . 0.0 112.613 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 33.5 mt -81.28 -34.63 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 121.057 0.456 . . . . 0.0 110.442 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.435 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.9 m -148.0 164.78 32.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.184 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.435 ' N ' HG22 ' A' ' 88' ' ' THR . 58.6 m-20 -60.13 -27.66 67.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.478 0.18 . . . . 0.0 111.485 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.434 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 1.6 m-20 -112.02 -33.78 6.17 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -178.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 7.1 tt -102.85 123.84 47.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.941 0.4 . . . . 0.0 111.716 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -135.69 164.14 28.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.261 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.981 HG22 HG12 ' A' ' 127' ' ' VAL . 1.7 pp -119.6 142.93 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.003 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.44 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 6.7 m-85 -143.4 157.49 44.42 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.706 0.765 . . . . 0.0 112.715 -178.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 124' ' ' ALA . 91.6 m -141.14 136.26 31.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 114.542 -1.208 . . . . 0.0 109.029 178.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.826 ' CG ' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -118.13 139.58 51.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.963 0.411 . . . . 0.0 111.384 -179.543 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 5.0 mp -140.82 119.18 12.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.736 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.414 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -166.13 -141.84 3.26 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.296 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.83 151.44 23.35 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.507 -0.854 . . . . 0.0 113.317 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.8 ttt -103.79 122.87 46.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 77' ' ' VAL . 7.4 m -96.88 128.86 47.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.128 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -132.7 133.88 44.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.93 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 7.9 ttm-85 -140.27 147.69 40.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.826 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -142.1 162.2 36.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.122 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -110.74 130.61 55.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.986 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.8 92.45 1.74 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 20.7 mttp 60.26 105.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -138.54 125.5 21.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.848 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.41 30.8 3.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.585 HG12 ' O ' ' A' ' 110' ' ' VAL . 15.9 t 59.39 31.28 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.086 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.9 -32.64 12.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.971 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 94.28 72.18 1.16 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.489 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 6.5 mmtm -139.99 161.05 38.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.859 0.361 . . . . 0.0 110.863 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -128.42 158.5 38.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.899 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -117.74 -40.67 2.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.922 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.17 118.73 2.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.942 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.82 152.18 34.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.888 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -100.5 113.26 4.65 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.504 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.4 t -146.08 62.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.982 0.42 . . . . 0.0 111.076 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . 0.505 ' O ' HG23 ' A' ' 122' ' ' VAL . 1.8 m -105.87 102.18 37.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.69 139.11 32.0 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.508 2.139 . . . . 0.0 112.382 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 120' ' ' SER . 21.5 t -141.24 159.0 22.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.119 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.484 ' N ' HG12 ' A' ' 122' ' ' VAL . 3.5 p90 -137.18 164.02 29.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.826 ' HB3' ' CG ' ' A' ' 96' ' ' ARG . . . -142.18 164.2 30.8 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.252 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -149.04 141.95 9.42 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.122 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.4 ' HA3' ' O ' ' A' ' 139' ' ' LEU . . . 177.25 -155.0 16.92 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 119.87 -1.157 . . . . 0.0 113.358 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.981 HG12 HG22 ' A' ' 93' ' ' ILE . 30.1 m -139.71 148.17 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 120.974 0.416 . . . . 0.0 111.25 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -124.51 132.2 53.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.642 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.434 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 45.0 t80 -128.27 148.33 50.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.418 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 116.37 32.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.818 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 7.8 tp -88.57 -36.58 9.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.89 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.467 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -162.36 165.09 16.14 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.854 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.467 ' HD2' HG22 ' A' ' 132' ' ' THR . 11.7 Cg_endo -55.2 141.59 80.08 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.596 2.197 . . . . 0.0 112.074 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 58.54 19.01 6.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.531 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 31.1 mt -149.13 111.95 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 121.018 0.437 . . . . 0.0 111.718 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.577 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -124.42 156.13 37.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.836 179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 32.6 m -142.83 136.26 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.5 ptt85 -146.15 157.94 43.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.253 0.549 . . . . 0.0 112.038 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.839 HD12 HD13 ' A' ' 164' ' ' LEU . 1.9 tt -128.18 139.86 52.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.596 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.472 ' N ' HD23 ' A' ' 139' ' ' LEU . 38.6 mt-10 -147.35 158.18 43.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.177 0.513 . . . . 0.0 111.693 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 161' ' ' MET . 19.3 m-85 -125.05 158.59 33.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.869 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . 0.435 ' OE1' HG11 ' A' ' 122' ' ' VAL . 21.6 mt-30 -126.61 154.11 44.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -104.91 125.97 51.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.831 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 58.9 p -100.06 -31.43 11.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 70.9 m-80 -95.43 78.54 3.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -175.82 37.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.851 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.6 pt -152.88 172.93 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 74.06 -76.46 1.05 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.444 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 35.1 t0 -141.1 135.88 31.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.869 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.57 125.92 30.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.07 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 -85.19 141.15 30.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.62 -59.7 2.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.899 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 3.1 pt -146.35 165.64 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.119 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 139.65 -123.37 2.47 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.562 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 39.8 p -71.07 143.92 50.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.857 0.36 . . . . 0.0 110.887 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -93.06 139.11 23.0 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.855 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.25 85.68 0.83 Allowed 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.507 2.138 . . . . 0.0 112.275 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -145.46 35.9 1.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.816 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -174.76 128.04 0.31 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.887 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -151.08 -129.39 1.58 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.491 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 1.7 ttm -91.55 139.22 30.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.657 0.265 . . . . 0.0 110.934 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.765 HD13 ' CE2' ' A' ' 15' ' ' PHE . 0.8 OUTLIER -121.94 118.43 28.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.073 179.252 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.433 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 17.8 m -136.73 157.54 46.52 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.331 0.586 . . . . 0.0 112.015 -179.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . 0.839 HD13 HD12 ' A' ' 139' ' ' LEU . 10.9 tp -141.69 127.87 19.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.673 179.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.98 161.75 27.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.09 -1.052 . . . . 0.0 113.431 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 16.2 m -106.16 147.08 12.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . 0.577 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 22.4 p -134.54 146.11 49.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.159 0.504 . . . . 0.0 111.608 -179.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -113.61 131.63 56.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.786 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -108.54 117.12 33.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.955 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -107.66 131.4 54.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 136.5 57.15 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.543 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -83.83 -56.95 3.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.798 0.332 . . . . 0.0 110.89 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 66.08 -164.17 40.49 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.526 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -140.9 -51.39 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -106.92 -64.11 1.22 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.066 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.136 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 4.3 mtm . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.861 0.362 . . . . 0.0 111.202 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -76.73 143.5 71.58 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.07 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.32 132.32 14.88 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.574 2.183 . . . . 0.0 112.37 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.67 -38.67 3.93 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.787 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.466 ' O ' ' N ' ' A' ' 6' ' ' THR . 1.3 t70 -140.06 28.78 2.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.875 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -64.12 67.05 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.848 0.356 . . . . 0.0 111.777 -179.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.466 ' N ' ' O ' ' A' ' 4' ' ' ASP . 67.5 p -126.13 173.02 9.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.797 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 12.9 p90 -128.01 164.18 22.93 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.641 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.415 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 5.3 p90 -155.29 156.63 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.417 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 3.3 t -149.17 150.21 32.28 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.71 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.416 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.75 -161.94 22.24 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.465 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -130.46 159.38 37.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.537 -0.331 . . . . 0.0 110.608 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -142.26 150.05 40.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.216 0.532 . . . . 0.0 112.003 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.798 ' HG ' ' HB2' ' A' ' 37' ' ' ALA . 6.6 tt -149.24 125.98 11.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.548 179.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.455 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.2 174.36 27.92 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.011 -1.09 . . . . 0.0 113.745 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 2.9 m-85 -134.39 154.23 51.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.272 179.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.592 ' HB2' HD12 ' A' ' 35' ' ' LEU . 10.3 t -148.38 -169.23 3.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.836 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -74.57 151.57 39.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -107.7 91.55 3.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 13.3 m170 -104.09 103.14 12.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.878 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -161.29 132.39 5.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.895 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.0 157.72 17.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.974 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.403 ' O ' ' CD2' ' A' ' 23' ' ' PHE . . . 162.3 51.53 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.474 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' A' ' 22' ' ' GLY . 0.8 OUTLIER -174.75 137.97 0.47 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.806 0.336 . . . . 0.0 110.851 -179.971 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.7 pt -74.91 -30.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -125.21 150.55 46.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -138.37 179.64 6.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.88 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -101.22 -31.33 11.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.885 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 153.24 177.78 27.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.564 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.32 162.28 2.22 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.593 2.195 . . . . 0.0 112.285 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 p -105.21 178.67 4.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -167.23 33.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -119.57 -176.81 3.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -134.88 171.35 14.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.0 mt-30 166.2 142.31 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.676 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.592 HD12 ' HB2' ' A' ' 16' ' ' SER . 3.8 tt -156.47 -70.47 0.11 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.592 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 144.81 176.9 19.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.643 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.798 ' HB2' ' HG ' ' A' ' 13' ' ' LEU . . . -128.24 -176.9 3.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.793 0.33 . . . . 0.0 111.027 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.18 -159.4 31.86 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.357 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -135.1 155.08 51.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.543 0.211 . . . . 0.0 110.668 179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -159.29 163.66 35.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.289 0.566 . . . . 0.0 111.907 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -140.61 158.84 26.24 Favored Glycine 0 N--CA 1.448 -0.544 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.35 179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.415 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.67 150.13 21.75 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.509 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 6.9 m-85 -117.35 131.79 56.72 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' A' ' 4' ' ' ASP . 11.3 mt-30 -94.64 126.46 39.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.552 -0.295 . . . . 0.0 110.236 179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.01 -36.9 7.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.769 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.453 ' HB2' ' CG2' ' A' ' 49' ' ' VAL . 1.0 OUTLIER -152.76 179.21 1.32 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.154 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.436 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 39.3 Cg_exo -61.47 -26.89 81.62 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.684 2.256 . . . . 0.0 113.692 -179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.79 ' O ' HD23 ' A' ' 83' ' ' LEU . 11.3 p90 -124.53 4.11 8.31 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.97 0.73 . . . . 0.0 112.97 -178.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.453 ' CG2' ' HB2' ' A' ' 46' ' ' ASN . 3.7 m -137.74 116.11 13.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.862 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.35 179.41 19.56 Favored Glycine 0 C--N 1.332 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.439 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -130.23 152.38 49.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.62 0.248 . . . . 0.0 110.767 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.408 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 13.0 mt-10 -150.38 136.71 18.77 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.09 0.471 . . . . 0.0 111.528 -179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . 0.449 ' HG2' HD12 ' A' ' 79' ' ' LEU . 5.1 mpp? -132.35 114.39 14.32 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.327 179.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -119.09 164.02 13.23 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.431 -0.89 . . . . 0.0 113.39 -179.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.636 ' HB3' HG12 ' A' ' 77' ' ' VAL . 17.9 p90 -152.43 156.19 39.0 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.796 0.331 . . . . 0.0 110.828 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.675 ' HB3' HD13 ' A' ' 58' ' ' LEU . 8.2 m-20 -85.0 153.88 22.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -86.28 -71.87 0.52 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.825 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.675 HD13 ' HB3' ' A' ' 56' ' ' ASP . 9.5 mp 60.49 32.93 20.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.874 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 129.13 -99.11 0.46 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.444 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.0 mtt180 -139.23 168.58 19.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.752 0.31 . . . . 0.0 110.928 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -157.36 88.28 2.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.925 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.6 -175.62 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.541 2.16 . . . . 0.0 112.227 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -159.57 -45.15 0.05 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.913 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? -58.62 -30.82 67.56 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.966 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.68 141.79 9.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.496 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -176.98 172.77 1.95 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.821 0.343 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 12.2 m -90.01 144.68 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.135 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -153.17 -176.0 5.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.843 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -135.1 167.51 20.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.878 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.37 28.25 10.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.488 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . 59.81 177.99 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -93.56 154.38 17.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.7 mmtm -101.32 154.0 19.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.86 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.91 120.71 13.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.149 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -98.31 135.14 40.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -131.73 121.4 3.08 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.428 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 55' ' ' TYR . 30.9 m -136.0 154.15 33.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.735 0.302 . . . . 0.0 111.151 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.0 pm0 -131.72 139.33 48.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.449 HD12 ' HG2' ' A' ' 53' ' ' MET . 7.7 tt -127.11 132.13 50.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.803 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -151.62 173.06 15.11 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.44 0.638 . . . . 0.0 111.978 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.54 141.44 39.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.862 178.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -108.83 126.44 53.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.874 0.369 . . . . 0.0 111.447 -179.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.79 HD23 ' O ' ' A' ' 48' ' ' TYR . 2.4 mt -131.61 110.09 10.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.239 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.439 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.1 177.53 19.48 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.1 -1.048 . . . . 0.0 113.773 -179.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 85' ' ' TYR . 3.4 m-85 -131.76 140.63 38.87 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.659 0.266 . . . . 0.0 110.475 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -87.56 106.72 0.61 Allowed 'Trans proline' 0 N--CA 1.459 -0.518 0 C-N-CA 122.836 2.357 . . . . 0.0 112.826 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 1.003 HD11 HD22 ' A' ' 91' ' ' LEU . 26.4 pt -80.22 -33.78 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.23 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.749 HG22 HG13 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -150.65 169.68 21.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.05 178.914 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -64.17 -23.31 67.27 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.079 0.399 . . . . 0.0 112.079 -179.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.446 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -110.94 -28.22 8.45 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.401 0.519 . . . . 0.0 112.401 -178.708 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 1.003 HD22 HD11 ' A' ' 87' ' ' ILE . 0.5 OUTLIER -109.34 126.37 53.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.138 0.494 . . . . 0.0 111.924 -179.086 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.24 152.52 50.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.001 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 12.0 tt -123.11 142.12 40.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.907 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.439 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 28.5 p90 -153.22 170.21 21.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.719 0.771 . . . . 0.0 113.021 -179.017 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 p -139.62 141.91 37.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.62 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.613 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 46.1 mtp180 -117.3 137.39 52.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.882 0.372 . . . . 0.0 111.067 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.636 HD23 ' N ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -139.86 120.03 13.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.856 -179.924 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -141.06 3.06 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.338 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -151.17 151.89 23.78 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.591 -0.814 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 2.4 ppp? -101.98 132.51 47.77 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.35 124.92 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.07 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.407 ' HE1' ' HB2' ' A' ' 104' ' ' ALA . 6.8 t80 -117.26 125.75 51.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.891 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -129.3 122.21 29.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . 0.407 ' HB2' ' HE1' ' A' ' 102' ' ' PHE . . . -138.21 125.72 22.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.121 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -83.92 136.37 34.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.878 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -103.35 125.33 49.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.914 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 6.2 mtmp? -70.96 -46.07 63.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.9 p -166.15 32.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -74.4 -63.96 1.13 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.892 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 29.8 m -100.72 146.2 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.145 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -95.54 -33.38 12.43 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.881 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -76.32 -158.64 8.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.499 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -153.56 104.84 2.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.799 0.333 . . . . 0.0 110.929 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -139.13 83.93 1.98 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.827 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 60.3 178.29 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.796 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -168.83 33.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.4 m -146.15 109.17 4.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -84.21 123.64 6.31 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.548 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.6 m -131.07 150.0 34.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 111.119 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 2.7 m -171.56 149.22 2.41 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.847 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.539 ' O ' HG13 ' A' ' 122' ' ' VAL . 55.5 Cg_endo -70.06 158.94 54.93 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.543 2.162 . . . . 0.0 112.348 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.539 HG13 ' O ' ' A' ' 121' ' ' PRO . 6.0 m -159.02 141.71 5.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.138 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -117.65 158.88 23.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.818 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.613 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -151.94 149.48 28.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.21 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.91 138.65 7.44 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.075 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.38 -158.5 22.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 119.996 -1.097 . . . . 0.0 113.264 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 18.8 m -141.89 149.78 19.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.134 0.492 . . . . 0.0 111.474 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -125.27 131.37 53.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.504 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.446 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 42.6 t80 -126.89 146.98 50.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.319 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.4 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.84 114.53 27.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.81 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -87.03 -39.18 12.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.009 0.433 . . . . 0.0 110.933 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.726 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -159.59 169.75 9.88 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.729 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.726 ' CD ' HG22 ' A' ' 132' ' ' THR . 32.0 Cg_exo -58.41 139.94 92.57 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.52 2.147 . . . . 0.0 112.214 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 59.71 17.72 6.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.842 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.45 ' O ' HG23 ' A' ' 135' ' ' ILE . 1.8 tt -149.21 113.93 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.114 0.483 . . . . 0.0 111.721 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.71 157.86 40.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.084 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 3.2 t -124.9 141.11 52.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.534 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 25.0 mtt180 -135.16 134.59 40.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.124 0.488 . . . . 0.0 111.815 -179.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.939 HD12 HD12 ' A' ' 164' ' ' LEU . 4.3 tt -130.06 130.78 45.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.543 179.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.526 ' N ' HD23 ' A' ' 139' ' ' LEU . 0.9 OUTLIER -153.53 169.42 23.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.392 0.615 . . . . 0.0 112.017 -179.08 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.477 ' HA ' ' O ' ' A' ' 161' ' ' MET . 4.1 m-85 -122.2 161.98 22.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.21 -0.904 . . . . 0.0 110.847 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -129.49 151.34 50.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -119.75 150.77 39.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -160.88 78.47 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.87 102.12 13.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.942 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 13.9 m-80 -127.58 78.93 1.86 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.882 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 5.9 pt -76.94 -30.74 18.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.055 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 69.07 -85.67 0.22 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.55 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -162.94 83.79 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.828 0.347 . . . . 0.0 110.908 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -162.17 -170.18 2.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.082 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 2.7 t-160 -102.99 34.18 2.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.883 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.0 t -106.84 31.05 5.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 1.7 pt -67.14 116.24 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.084 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -166.16 104.78 0.23 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.507 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 3.4 t -112.7 128.7 56.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.59 146.34 32.31 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.876 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.46 -61.91 0.39 Allowed 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.545 2.163 . . . . 0.0 112.214 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -152.17 77.82 1.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -151.58 35.71 0.56 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -96.12 -104.22 2.09 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.504 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.477 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 39.2 mtt -93.79 130.91 39.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.627 0.251 . . . . 0.0 110.902 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.523 HD23 ' C ' ' A' ' 162' ' ' LEU . 7.2 tt -120.95 119.1 31.61 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.455 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 28.3 t -132.69 154.2 50.39 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.199 0.523 . . . . 0.0 111.78 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . 0.939 HD12 HD12 ' A' ' 139' ' ' LEU . 8.0 tt -144.66 122.7 12.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.853 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.12 163.83 26.98 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.245 -0.978 . . . . 0.0 113.24 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 23.8 m -105.06 146.83 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . 0.416 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 0.9 OUTLIER -135.14 143.42 46.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.096 0.474 . . . . 0.0 111.67 -179.505 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -109.61 132.68 53.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.687 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 115.12 29.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.89 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -84.43 133.08 34.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.893 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.7 149.87 23.58 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.548 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 -83.76 -51.72 6.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.833 0.349 . . . . 0.0 110.895 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 84.41 165.14 38.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.448 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -148.56 96.9 2.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.86 0.362 . . . . 0.0 110.867 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -139.93 131.84 27.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.073 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.112 179.952 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 7.8 mtm . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 120.817 0.342 . . . . 0.0 111.218 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.741 ' HB3' ' HD3' ' A' ' 2' ' ' PRO . . . -72.79 -61.21 1.67 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.118 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.741 ' HD3' ' HB3' ' A' ' 1' ' ' ALA . 58.5 Cg_endo -71.64 173.71 12.14 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.533 2.155 . . . . 0.0 112.387 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.6 tptp -176.89 -40.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.929 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -148.06 164.05 35.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.955 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m120 65.38 41.87 4.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.978 0.418 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.8 p -124.06 172.2 9.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.734 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 9.2 p-90 -126.68 164.58 20.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.561 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.425 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 2.8 p90 -155.34 158.35 38.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.966 179.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 t -149.14 149.54 31.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -169.68 -162.94 22.86 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.399 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.6 155.43 48.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.554 -0.323 . . . . 0.0 110.601 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.425 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 14.2 pttt -139.5 153.14 47.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.299 0.571 . . . . 0.0 112.276 -179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.011 HD13 ' HB2' ' A' ' 37' ' ' ALA . 48.3 tp -147.32 127.42 13.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.268 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.462 ' O ' ' HB3' ' A' ' 35' ' ' LEU . . . -148.15 174.5 27.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.743 -178.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.425 ' HA ' ' CB ' ' A' ' 35' ' ' LEU . 19.2 m-85 -143.52 149.75 37.93 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.268 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.8 t -144.28 -172.34 3.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.823 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -117.55 109.91 17.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -124.98 140.8 52.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.887 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -95.13 129.03 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.866 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -106.22 176.88 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.78 161.58 41.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.837 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.58 -28.63 2.85 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -131.14 123.85 29.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.844 0.354 . . . . 0.0 110.906 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.6 pp -59.79 156.95 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.135 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.6 m-20 -162.53 -45.15 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.0 m120 60.67 35.62 19.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.957 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -105.79 159.73 15.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -132.12 63.71 0.62 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.504 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.75 -175.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.6 2.2 . . . . 0.0 112.314 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.42 -59.2 2.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.898 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 -161.99 -178.96 6.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.935 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -131.34 -178.15 4.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.929 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.463 ' O ' ' HB2' ' A' ' 34' ' ' GLN . 56.4 t30 -171.84 118.85 0.42 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.927 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 33' ' ' ASN . 42.5 tt0 167.56 144.68 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.477 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.462 ' HB3' ' O ' ' A' ' 14' ' ' GLY . 10.5 tt -158.08 -71.75 0.09 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.513 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 144.89 -179.69 21.86 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.397 -0.906 . . . . 0.0 112.624 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 1.011 ' HB2' HD13 ' A' ' 13' ' ' LEU . . . -123.61 -176.97 3.59 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.851 0.358 . . . . 0.0 111.0 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.71 -162.78 35.85 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.306 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.86 155.1 45.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.717 -0.241 . . . . 0.0 110.7 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.425 ' CE1' ' HB3' ' A' ' 12' ' ' LYS . 27.3 p90 -159.13 157.72 31.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.304 0.573 . . . . 0.0 112.01 -179.557 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -147.47 159.86 28.14 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.319 179.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.425 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -155.26 161.29 30.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 119.824 -1.179 . . . . 0.0 113.602 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 13.1 t80 -123.05 133.72 54.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.252 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.2 mm100 -95.07 125.62 39.86 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.272 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.7 t -93.24 -37.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.961 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.474 ' HB2' HG23 ' A' ' 49' ' ' VAL . 1.1 t30 -153.92 178.32 1.66 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.21 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.424 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.4 Cg_exo -60.1 -25.97 81.24 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.679 2.252 . . . . 0.0 113.64 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CE1' ' HB2' ' A' ' 47' ' ' PRO . 17.9 m-85 -127.46 3.99 6.24 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -178.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.474 HG23 ' HB2' ' A' ' 46' ' ' ASN . 4.3 m -138.04 115.06 11.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.819 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.65 -177.23 18.4 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.466 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.59 150.04 49.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.559 0.219 . . . . 0.0 110.629 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -146.57 134.25 21.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.039 0.447 . . . . 0.0 111.375 -179.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -128.43 153.68 46.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.339 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.61 158.84 30.02 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.191 -1.004 . . . . 0.0 113.116 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 7.3 p90 -159.17 161.81 36.27 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.863 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.4 t0 -93.21 124.62 37.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.98 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -108.37 128.59 54.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mt -94.01 -66.48 0.92 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.906 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 143.56 146.04 4.49 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.573 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 83.4 mtt180 -151.32 157.6 42.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.85 0.357 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . 0.408 ' CB ' ' CD ' ' A' ' 62' ' ' PRO . 0.0 OUTLIER -64.74 -60.9 7.25 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.942 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.408 ' CD ' ' CB ' ' A' ' 61' ' ' MET . 58.3 Cg_endo -71.77 145.6 46.42 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.425 2.083 . . . . 0.0 112.294 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -67.63 -53.79 25.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -78.13 -47.65 17.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.887 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 126.49 41.56 0.32 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.446 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.5 m 60.2 175.9 0.09 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.834 0.349 . . . . 0.0 110.834 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.6 -47.24 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.126 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -102.1 31.58 3.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.95 -54.7 2.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.839 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 73.15 82.79 0.32 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.552 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.92 90.77 1.31 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 111.057 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 2.5 m-85 -103.45 165.17 11.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tttt -131.05 -60.99 0.95 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -175.27 148.07 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.108 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 7.4 tt0 -117.95 117.22 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.916 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.43 ' HA3' ' CE2' ' A' ' 102' ' ' PHE . . . -134.19 124.01 3.43 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.476 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 31.3 m -142.83 162.78 17.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.684 0.278 . . . . 0.0 111.137 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -130.22 140.43 50.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.048 0.451 . . . . 0.0 111.091 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -129.85 132.1 46.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.968 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.423 ' HB ' ' HA3' ' A' ' 98' ' ' GLY . 1.3 t -151.43 170.11 20.38 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.523 0.678 . . . . 0.0 112.09 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.94 144.22 35.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.946 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 2.7 ttpp -110.14 125.26 52.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.913 0.387 . . . . 0.0 111.433 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -130.89 108.15 9.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.209 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.479 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -134.99 176.89 19.72 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.232 -0.985 . . . . 0.0 113.658 -179.186 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.564 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.5 m-85 -128.07 140.18 37.52 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.661 0.267 . . . . 0.0 110.606 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -87.87 103.72 0.51 Allowed 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.772 2.315 . . . . 0.0 112.634 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 41.6 pt -82.14 -30.64 9.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 121.042 0.448 . . . . 0.0 110.337 179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.404 ' OG1' ' HB3' ' A' ' 91' ' ' LEU . 0.2 OUTLIER -150.47 167.31 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.177 179.297 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -64.94 -23.45 67.23 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.447 ' HB3' ' CE1' ' A' ' 129' ' ' TYR . 0.8 OUTLIER -112.07 -37.31 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -179.02 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.404 ' HB3' ' OG1' ' A' ' 88' ' ' THR . 15.3 tp -102.94 125.73 49.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.984 0.421 . . . . 0.0 111.656 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -133.54 161.02 35.75 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.186 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.051 HG22 HG12 ' A' ' 127' ' ' VAL . 2.6 pp -125.66 143.23 39.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.035 179.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.479 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 10.2 p90 -155.1 170.27 22.2 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.723 0.773 . . . . 0.0 113.003 -178.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.3 p -139.39 143.05 37.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.714 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.67 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 68.5 mtm180 -118.69 139.06 52.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.012 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 6.7 tp -141.25 120.84 13.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.1 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.423 ' HA3' ' HB ' ' A' ' 80' ' ' THR . . . -164.8 -149.04 5.67 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.347 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.56 152.25 24.35 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.107 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 1.2 ptt? -106.52 141.19 38.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.829 0.347 . . . . 0.0 110.848 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 5.0 m -126.01 108.52 19.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.12 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.43 ' CE2' ' HA3' ' A' ' 76' ' ' GLY . 4.5 m-85 -118.2 111.9 19.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.848 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 -114.36 124.73 52.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -109.56 140.93 42.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.109 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.37 156.79 20.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.64 129.06 22.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.855 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -163.47 31.44 0.09 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.883 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 5.4 m -142.08 -54.66 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.2 t30 -154.6 147.02 23.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.908 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 21.4 t -123.56 106.5 17.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -67.73 -35.97 79.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.861 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -114.47 -120.13 3.45 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.459 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -156.78 -65.18 0.1 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.782 0.325 . . . . 0.0 110.953 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -73.78 147.75 43.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -122.06 124.21 43.42 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.841 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -106.82 139.79 40.69 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.896 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 47.2 p -107.46 154.57 21.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.86 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -91.06 111.86 4.03 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.473 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 21.5 t -152.13 113.17 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.808 0.337 . . . . 0.0 111.191 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.3 m -177.21 163.24 1.48 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.536 ' O ' HG13 ' A' ' 122' ' ' VAL . 54.4 Cg_endo -69.59 168.44 21.33 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.636 2.224 . . . . 0.0 112.316 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.536 HG13 ' O ' ' A' ' 121' ' ' PRO . 5.8 m -158.93 121.81 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.222 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -102.13 156.48 17.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.823 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.67 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -151.48 148.5 28.14 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.221 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.95 138.88 7.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.111 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.65 -156.96 20.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.002 -1.094 . . . . 0.0 113.299 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 1.051 HG12 HG22 ' A' ' 93' ' ' ILE . 28.9 m -141.54 147.9 21.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.043 0.449 . . . . 0.0 111.335 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.421 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 21.6 tt0 -124.05 132.11 53.63 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.703 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.447 ' CE1' ' HB3' ' A' ' 90' ' ' ASP . 70.9 t80 -126.09 146.4 49.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.176 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.39 116.15 31.68 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.808 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.598 HD11 HG22 ' A' ' 135' ' ' ILE . 2.2 pt -92.8 -30.99 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.611 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.816 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.2 OUTLIER -147.13 169.27 9.65 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.499 179.916 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.816 ' HD2' HG22 ' A' ' 132' ' ' THR . 53.1 Cg_exo -55.91 -60.95 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.575 2.183 . . . . 0.0 112.843 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . 0.608 ' C ' HD12 ' A' ' 135' ' ' ILE . 9.8 tt0 -98.05 23.85 7.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.708 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.608 HD12 ' C ' ' A' ' 134' ' ' GLU . 4.3 mp -146.46 117.6 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.053 0.454 . . . . 0.0 111.651 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -129.12 161.86 29.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.082 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.816 HG22 HG12 ' A' ' 166' ' ' VAL . 80.9 p -135.93 140.59 44.14 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.407 179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.65 144.04 32.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.237 0.542 . . . . 0.0 112.041 -179.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.621 HD12 ' CD1' ' A' ' 164' ' ' LEU . 2.6 tt -124.83 136.34 53.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.598 178.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.462 ' N ' HD23 ' A' ' 139' ' ' LEU . 16.8 mt-10 -146.0 156.44 43.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.227 0.537 . . . . 0.0 111.807 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.486 ' HA ' ' O ' ' A' ' 161' ' ' MET . 3.1 m-85 -121.17 143.06 49.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.536 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.06 145.48 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -104.31 142.93 33.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.945 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -109.7 -30.66 7.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.885 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 53.3 t30 62.04 152.2 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -168.98 -43.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.527 ' H ' HD12 ' A' ' 147' ' ' ILE . 3.4 mp -61.24 -43.65 96.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.161 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 158.53 -111.08 0.47 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.538 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -124.74 102.32 7.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.77 0.319 . . . . 0.0 110.876 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 160.96 15.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.123 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 8.9 m80 -127.55 80.68 1.97 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.909 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 38.9 p -137.45 132.39 33.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.874 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 2.7 tt -79.28 -30.86 14.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.078 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -111.71 133.2 11.31 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.51 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 20.8 p -77.32 157.0 30.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.791 0.329 . . . . 0.0 110.872 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.9 mmt85 -87.18 145.77 38.72 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -74.58 128.22 11.65 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.62 2.213 . . . . 0.0 112.377 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 58.98 45.72 14.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.953 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -112.88 -43.62 3.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -118.32 -110.78 2.48 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.514 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 2.4 mtp -102.38 130.84 49.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.596 0.236 . . . . 0.0 110.892 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 8.4 mp -120.8 118.98 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.12 179.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.411 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 22.5 m -132.31 152.7 51.28 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.201 0.524 . . . . 0.0 111.627 -179.354 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . 0.621 ' CD1' HD12 ' A' ' 139' ' ' LEU . 2.7 tt -143.81 123.86 13.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.775 179.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . 0.425 ' N ' HD23 ' A' ' 164' ' ' LEU . . . -143.55 164.75 27.31 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.24 -0.981 . . . . 0.0 113.456 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.816 HG12 HG22 ' A' ' 137' ' ' THR . 25.9 m -105.45 147.0 11.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . 0.414 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 30.0 p -134.78 145.91 48.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.125 0.488 . . . . 0.0 111.761 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -112.12 131.96 55.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.738 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -108.51 116.79 32.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.025 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -84.36 150.2 25.52 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.88 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -148.01 52.12 0.55 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.24 79.7 1.59 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 135.07 140.15 4.17 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.485 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -151.62 -50.93 0.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.873 0.368 . . . . 0.0 110.877 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -149.22 -67.56 0.22 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.07 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.1 -179.974 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 5.0 ptp . . . . . 0 N--CA 1.488 1.441 0 CA-C-O 120.856 0.36 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -98.37 150.13 36.42 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.041 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.8 68.6 1.71 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.528 2.152 . . . . 0.0 112.297 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 30.1 mtmt -149.36 166.35 29.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -87.88 -79.21 0.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 67.23 42.09 2.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.8 p -123.48 165.66 16.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.811 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 7.2 t90 -113.1 161.07 17.53 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.317 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.467 ' CZ ' ' HB2' ' A' ' 169' ' ' ARG . 0.1 OUTLIER -145.12 141.62 28.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -179.741 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 m -147.56 144.42 28.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.698 0.285 . . . . 0.0 111.189 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -173.82 -157.58 15.82 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.295 -0.955 . . . . 0.0 113.256 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -134.02 155.44 49.98 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.659 -0.271 . . . . 0.0 110.746 179.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.467 ' C ' HD12 ' A' ' 13' ' ' LEU . 1.7 mmmm -139.16 153.15 47.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.147 0.498 . . . . 0.0 111.966 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HG ' ' HB1' ' A' ' 37' ' ' ALA . 2.7 mp -148.9 128.21 12.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.516 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 35' ' ' LEU . . . -148.24 174.48 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.024 -1.084 . . . . 0.0 113.694 -178.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.43 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 3.8 m-85 -134.1 156.83 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.852 ' HB2' HD13 ' A' ' 35' ' ' LEU . 2.5 t -131.21 164.9 24.54 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.86 0.362 . . . . 0.0 110.915 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 62.87 73.69 0.45 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -83.18 168.15 17.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.822 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -173.11 93.37 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.867 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -127.31 -48.77 1.43 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 26.9 m -80.98 146.52 30.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.893 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 70.24 -157.07 53.52 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.506 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -176.15 88.6 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.804 0.335 . . . . 0.0 110.824 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.9 mp -128.26 113.39 30.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.157 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 11.2 m-20 -169.83 151.6 4.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.875 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -132.08 31.58 4.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.887 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -136.38 -47.03 0.63 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.898 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.9 -152.29 18.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.455 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.94 109.03 2.25 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.146 . . . . 0.0 112.308 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 49.4 m -153.35 -54.7 0.11 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 35.7 p-80 -126.58 115.42 19.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.929 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -143.46 88.22 1.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.929 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 11.3 m-20 63.59 130.76 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.948 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 166.6 142.66 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.852 HD13 ' HB2' ' A' ' 16' ' ' SER . 14.7 tp -156.51 -72.14 0.1 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.5 179.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 145.57 177.65 20.48 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 120.319 -0.943 . . . . 0.0 112.621 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.603 ' HB1' ' HG ' ' A' ' 13' ' ' LEU . . . -127.04 -176.94 3.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.79 0.329 . . . . 0.0 110.974 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.01 -159.78 32.47 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.353 -0.927 . . . . 0.0 113.28 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.4 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -114.51 151.63 33.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.65 0.262 . . . . 0.0 110.921 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.447 ' CD2' ' HA3' ' A' ' 54' ' ' GLY . 61.2 m-85 -151.23 149.88 29.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.03 0.443 . . . . 0.0 111.692 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.04 156.75 28.63 Favored Glycine 0 N--CA 1.45 -0.417 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -157.04 154.67 25.73 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 119.783 -1.199 . . . . 0.0 113.771 -179.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 24.9 t80 -107.21 133.63 51.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.5 -0.35 . . . . 0.0 110.086 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -96.13 125.91 40.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.453 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 29.0 t -94.78 -36.44 6.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.484 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.8 OUTLIER -156.6 173.37 5.03 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.688 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.484 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 25.9 Cg_endo -62.82 -15.31 46.21 Favored 'Trans proline' 0 CA--C 1.53 0.293 0 C-N-CA 122.227 1.952 . . . . 0.0 113.551 -179.085 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -126.86 -4.76 6.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.6 m -139.07 117.48 12.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.97 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -141.6 -179.37 18.67 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.369 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -128.87 149.59 50.7 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.636 0.255 . . . . 0.0 110.414 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -149.37 137.01 20.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.004 0.43 . . . . 0.0 111.616 -179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . 0.43 ' HG2' HD23 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -128.23 156.72 42.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.212 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.447 ' HA3' ' CD2' ' A' ' 40' ' ' PHE . . . -159.03 157.54 28.58 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.142 -1.028 . . . . 0.0 113.199 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.646 ' HD2' HG22 ' A' ' 77' ' ' VAL . 13.9 t80 -138.73 141.3 38.9 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.873 0.368 . . . . 0.0 110.841 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -129.01 129.0 44.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.927 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -95.07 116.6 28.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 10.9 mt -122.98 158.51 30.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.971 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -92.12 -88.47 1.49 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.469 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 12.7 ttm180 -101.48 147.75 26.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 0.0 110.842 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 1.1 mmt -85.25 160.57 54.23 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.903 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -36.12 11.62 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.513 2.142 . . . . 0.0 112.371 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 51.2 t80 -92.48 79.73 4.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.914 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.45 137.57 58.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.88 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -164.21 -42.3 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.435 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.1 t -171.36 111.91 0.34 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.876 0.37 . . . . 0.0 110.936 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.594 HG12 HD22 ' A' ' 69' ' ' ASN . 21.5 t -130.81 106.49 12.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.111 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -106.27 90.85 3.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.865 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.594 HD22 HG12 ' A' ' 67' ' ' VAL . 8.0 m-80 -90.7 149.45 22.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -141.95 -115.99 1.18 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.484 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -99.2 31.23 3.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.857 0.36 . . . . 0.0 111.097 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -175.78 -169.45 0.34 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 2.4 tmtt? -144.24 159.92 41.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.31 135.16 57.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 45.3 mt-30 -94.78 100.03 12.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.817 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.405 ' O ' ' CD2' ' A' ' 55' ' ' TYR . . . -113.86 107.43 1.89 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.508 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.646 HG22 ' HD2' ' A' ' 55' ' ' TYR . 24.8 t -111.53 159.13 11.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.709 0.29 . . . . 0.0 110.952 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.489 ' N ' HG12 ' A' ' 77' ' ' VAL . 6.7 tt0 -128.11 134.14 49.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.011 0.434 . . . . 0.0 111.007 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.43 HD23 ' HG2' ' A' ' 53' ' ' MET . 2.4 mt -128.92 130.28 46.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.842 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.7 p -151.38 173.1 14.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.461 0.648 . . . . 0.0 111.99 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -109.0 142.91 38.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.001 179.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 49.5 tttt -109.07 126.17 52.89 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.877 0.37 . . . . 0.0 111.479 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.0 mp -129.15 112.17 13.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.248 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.417 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.72 170.85 22.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.217 -0.992 . . . . 0.0 113.474 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.745 ' HB2' HD11 ' A' ' 93' ' ' ILE . 3.1 m-85 -124.3 139.07 32.05 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.639 0.257 . . . . 0.0 110.517 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -85.31 100.04 0.68 Allowed 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.708 2.272 . . . . 0.0 112.704 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 1.024 HD11 HG23 ' A' ' 93' ' ' ILE . 1.2 mp -80.36 -35.04 15.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.135 0.493 . . . . 0.0 110.309 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.438 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.8 m -148.62 164.88 32.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.164 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.438 ' N ' HG22 ' A' ' 88' ' ' THR . 1.9 t70 -60.71 -24.8 65.95 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.574 0.212 . . . . 0.0 111.574 -179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.441 ' CB ' ' CE2' ' A' ' 129' ' ' TYR . 10.8 m-20 -113.08 -33.52 6.0 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.087 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 6.8 tp -102.89 123.58 46.79 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.903 0.383 . . . . 0.0 111.793 -179.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.684 ' HA ' HD12 ' A' ' 87' ' ' ILE . 72.6 m-20 -134.03 160.81 36.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.297 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.036 HG22 HG12 ' A' ' 127' ' ' VAL . 1.0 OUTLIER -120.41 142.88 34.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.984 179.099 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.438 ' CE1' ' HB2' ' A' ' 128' ' ' GLU . 47.2 p90 -147.15 163.49 36.14 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.653 0.74 . . . . 0.0 112.872 -178.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -140.58 139.64 35.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.363 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.495 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -116.51 135.04 54.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.891 0.377 . . . . 0.0 111.003 -179.748 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -140.37 118.21 11.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.836 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.86 -144.19 3.99 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.298 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -150.03 151.09 23.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.701 -0.762 . . . . 0.0 113.205 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -102.54 128.61 49.11 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.853 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 11.9 p -104.52 129.87 56.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.034 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -116.55 115.57 26.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 6.7 mtp85 -105.56 126.29 51.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -125.43 135.59 52.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.085 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -81.95 155.15 25.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -163.51 151.87 13.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.833 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 4.6 mttm -96.75 80.23 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.883 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.03 -71.87 0.54 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -107.25 140.2 40.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.7 m -98.9 31.07 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.052 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -75.25 -35.97 61.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.924 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 98.67 -33.48 6.04 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.497 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 33.9 mttt -134.95 110.26 8.99 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.836 0.35 . . . . 0.0 110.873 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -115.72 175.78 5.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 10.6 m170 -107.43 36.54 2.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -119.35 98.69 6.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -152.53 150.29 29.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.476 ' O ' HG13 ' A' ' 119' ' ' VAL . . . -76.44 142.11 27.63 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.531 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.476 HG13 ' O ' ' A' ' 118' ' ' GLY . 8.4 m -157.28 139.36 5.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.84 0.352 . . . . 0.0 111.122 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . 0.404 ' HA ' ' HD3' ' A' ' 121' ' ' PRO . 0.3 OUTLIER -163.67 137.0 4.28 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.927 -180.0 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.486 ' O ' HG13 ' A' ' 122' ' ' VAL . 52.8 Cg_exo -54.68 159.77 8.36 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.502 2.135 . . . . 0.0 112.336 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 ' O ' ' A' ' 121' ' ' PRO . 15.3 m -158.06 134.77 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.095 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.404 ' CZ ' ' O ' ' A' ' 143' ' ' PHE . 5.0 p90 -121.25 162.44 20.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.495 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -156.17 150.82 25.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.207 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.45 139.3 7.75 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.126 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.37 -156.57 19.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 119.992 -1.099 . . . . 0.0 113.248 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 1.036 HG12 HG22 ' A' ' 93' ' ' ILE . 29.4 m -138.88 148.25 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.161 0.505 . . . . 0.0 111.267 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.438 ' HB2' ' CE1' ' A' ' 94' ' ' TYR . 40.1 tt0 -124.62 131.93 53.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.715 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.441 ' CE2' ' CB ' ' A' ' 90' ' ' ASP . 48.8 t80 -127.9 147.59 50.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.239 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -101.1 117.0 34.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.859 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.834 HD11 ' CG2' ' A' ' 135' ' ' ILE . 29.6 pt -89.57 -33.59 6.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.069 0.462 . . . . 0.0 110.671 179.561 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.7 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -147.37 174.58 3.29 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.52 179.821 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.7 ' CD ' HG22 ' A' ' 132' ' ' THR . 50.7 Cg_exo -54.17 -62.08 0.35 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.586 2.191 . . . . 0.0 112.75 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . 0.478 ' C ' HD12 ' A' ' 135' ' ' ILE . 12.2 tt0 -100.15 31.52 3.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.629 -179.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.834 ' CG2' HD11 ' A' ' 131' ' ' ILE . 4.5 mp -145.99 115.52 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.952 0.406 . . . . 0.0 111.555 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.528 ' O ' HG23 ' A' ' 166' ' ' VAL . . . -131.07 150.13 52.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.924 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.31 141.66 51.95 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.641 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.404 ' HD2' ' HB2' ' A' ' 167' ' ' SER . 0.2 OUTLIER -134.2 140.48 46.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.104 0.478 . . . . 0.0 111.687 -179.515 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.5 pp -132.68 130.54 40.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.511 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -151.68 168.21 25.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.301 0.572 . . . . 0.0 111.933 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.676 ' CE2' HD23 ' A' ' 162' ' ' LEU . 2.7 m-85 -131.8 159.28 38.97 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.911 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -141.57 165.06 28.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.404 ' O ' ' CZ ' ' A' ' 123' ' ' PHE . 0.7 OUTLIER -132.21 163.0 29.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 14.3 p -105.87 -178.53 3.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.1 121.61 33.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.967 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -128.57 173.74 10.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 4.6 mt 62.9 147.16 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.085 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -88.01 145.47 19.26 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.494 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -63.77 129.66 41.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.809 0.338 . . . . 0.0 110.957 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -172.39 -63.88 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.14 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -131.01 -60.26 0.97 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 48.6 p -73.71 116.38 14.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.877 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.1 pt -134.26 31.0 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.115 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -95.56 -177.35 37.05 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.453 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 62.7 p -96.91 125.78 41.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.808 0.337 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 1.8 mtt180 -122.15 135.77 25.74 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.915 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.19 108.82 2.8 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.487 2.125 . . . . 0.0 112.307 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -136.51 -60.43 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 21.3 t-20 -129.98 108.96 10.5 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.0 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -100.93 124.83 8.38 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.415 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.507 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.5 OUTLIER -94.1 115.91 28.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.622 0.249 . . . . 0.0 110.947 -179.957 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.676 HD23 ' CE2' ' A' ' 141' ' ' TYR . 0.5 OUTLIER -121.41 120.44 35.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.006 179.196 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.422 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 1.8 m -132.44 154.12 50.17 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-O 121.292 0.568 . . . . 0.0 111.891 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 2.6 mp -145.3 122.52 11.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.865 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -141.88 165.18 26.62 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.25 -0.976 . . . . 0.0 113.465 -179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 136' ' ' ALA . 8.8 p -111.37 147.19 15.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . 0.438 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 5.3 t -136.33 151.54 49.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.294 0.568 . . . . 0.0 112.175 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -119.49 133.63 55.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.838 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 2.0 ttp180 -106.97 121.61 44.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.295 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -69.06 154.86 41.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.935 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -135.6 -140.27 4.16 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.446 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -111.83 86.49 2.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.883 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -138.31 60.44 0.59 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.461 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -150.23 116.61 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . 60.52 106.44 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.043 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.105 179.962 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 1.6 mtt . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 120.867 0.365 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . 59.97 84.43 0.2 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 149.31 64.32 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.563 2.176 . . . . 0.0 112.269 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -110.7 113.61 26.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.897 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -173.42 100.25 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.855 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 24.4 m-80 59.31 -135.06 0.86 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.61 -0.268 . . . . 0.0 110.327 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.704 HG23 ' HB2' ' A' ' 44' ' ' GLN . 4.1 t -117.35 150.95 37.99 Favored 'General case' 0 N--CA 1.46 0.061 0 CA-C-O 120.79 0.329 . . . . 0.0 110.455 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 35.7 p90 -127.92 164.16 22.89 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.798 -179.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.417 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 4.0 p90 -155.24 157.16 36.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.907 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.402 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 0.8 OUTLIER -149.02 150.86 33.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.741 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.89 -164.93 27.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.332 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.53 154.14 49.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.628 -0.286 . . . . 0.0 110.568 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.459 ' C ' HD12 ' A' ' 13' ' ' LEU . 0.9 OUTLIER -138.32 150.48 46.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.186 0.517 . . . . 0.0 111.809 -179.461 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.479 HD12 ' N ' ' A' ' 13' ' ' LEU . 1.9 mp -148.63 127.08 12.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.628 179.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.15 174.11 27.95 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.197 -1.002 . . . . 0.0 113.481 -179.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.547 ' CE1' HD13 ' A' ' 162' ' ' LEU . 21.0 p90 -129.8 157.88 40.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 110.643 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.17 124.75 15.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.991 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -118.1 128.01 54.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.845 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -122.12 161.61 22.78 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.882 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -112.99 -169.55 1.5 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -123.41 111.63 16.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.0 p -78.54 106.59 10.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.941 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.63 129.23 4.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.49 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 60.56 98.83 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.872 0.368 . . . . 0.0 110.92 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 33.0 mt -108.41 135.21 47.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -142.46 165.08 28.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.869 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -136.77 82.53 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -75.56 -35.53 60.62 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.884 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 131.77 -81.3 0.32 Allowed Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.515 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.12 63.19 2.0 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.566 2.177 . . . . 0.0 112.334 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.5 m -100.74 143.02 31.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.905 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -105.63 101.48 10.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.854 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -96.63 -68.65 0.79 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 45.3 t30 -91.0 129.04 37.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.854 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -121.17 125.16 46.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.693 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.424 HD12 ' HB3' ' A' ' 15' ' ' PHE . 13.2 tp -96.04 136.36 36.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.147 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.46 156.8 23.26 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.378 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -130.67 162.44 29.4 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.821 0.343 . . . . 0.0 111.256 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.62 -173.26 42.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.33 -0.938 . . . . 0.0 113.385 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 153.45 52.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.716 -0.242 . . . . 0.0 110.598 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.413 ' CE1' ' HB2' ' A' ' 12' ' ' LYS . 6.2 p90 -159.42 166.33 31.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.225 0.536 . . . . 0.0 112.016 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -148.08 160.03 28.21 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.53 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.417 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -153.1 159.88 28.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 119.959 -1.115 . . . . 0.0 113.363 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 4.5 m-85 -124.85 132.13 53.36 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.569 -0.315 . . . . 0.0 110.276 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.704 ' HB2' HG23 ' A' ' 6' ' ' THR . 1.7 mt-30 -95.48 126.22 40.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.119 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 77.8 t -96.24 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.0 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.496 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 3.3 m-20 -103.54 171.27 5.28 Favored Pre-proline 0 C--N 1.332 -0.185 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.192 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.496 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 10.1 Cg_endo -51.52 128.8 27.15 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.683 2.255 . . . . 0.0 113.085 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.419 ' CE1' ' HG3' ' A' ' 86' ' ' PRO . 1.4 m-85 59.88 16.32 5.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.407 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 47' ' ' PRO . 2.8 m -138.95 113.96 8.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 C-N-CA 120.843 -0.343 . . . . 0.0 111.385 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.3 -172.86 14.48 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.777 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -130.3 154.31 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.561 0.22 . . . . 0.0 110.602 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -150.4 138.14 19.92 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.482 . . . . 0.0 111.733 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -130.46 113.53 14.41 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.261 179.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.03 159.65 14.14 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.406 -0.902 . . . . 0.0 113.189 -179.136 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.559 ' HB3' HG12 ' A' ' 77' ' ' VAL . 47.8 p90 -153.11 150.31 28.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.804 0.335 . . . . 0.0 110.846 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -103.81 144.34 31.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.936 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -155.2 127.35 7.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.8 tp -124.85 141.13 52.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.813 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -105.99 -170.57 23.31 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.582 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 5.7 mtp85 -142.92 -68.14 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.888 0.375 . . . . 0.0 110.912 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 5.8 tpt -146.3 81.43 9.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.03 63.55 1.95 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.493 2.129 . . . . 0.0 112.293 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -168.15 96.72 0.42 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.905 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.33 -61.39 0.6 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.877 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 105.17 142.67 11.42 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.545 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.14 79.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.774 0.321 . . . . 0.0 110.956 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 19.3 m -130.85 129.35 63.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.155 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -99.08 -40.86 7.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.915 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.4 m-20 -123.39 175.84 6.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.955 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.66 80.25 0.12 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.466 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.58 76.9 1.54 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.822 0.344 . . . . 0.0 111.127 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -104.67 -48.93 3.65 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.902 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.5 mmmt -75.83 176.31 7.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.06 152.03 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.071 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -105.84 107.39 18.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.918 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.419 ' HA3' ' CD1' ' A' ' 102' ' ' PHE . . . -142.69 145.96 16.44 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.559 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.559 HG12 ' HB3' ' A' ' 55' ' ' TYR . 31.1 m -144.12 163.99 14.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.706 0.289 . . . . 0.0 111.044 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 -130.29 137.34 49.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.075 0.464 . . . . 0.0 111.028 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.433 HD23 ' N ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -125.34 130.16 51.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.702 179.315 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.408 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.7 p -151.35 173.01 15.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.492 0.663 . . . . 0.0 111.924 -179.101 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.0 141.98 37.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.922 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -108.26 125.57 51.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.82 0.343 . . . . 0.0 111.403 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.417 ' CD1' HG12 ' A' ' 49' ' ' VAL . 2.4 tp -130.31 112.44 13.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.397 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.449 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -135.49 171.17 22.71 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.434 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.487 ' HB2' HD11 ' A' ' 93' ' ' ILE . 29.4 m-85 -123.99 138.94 31.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 120.715 0.293 . . . . 0.0 110.598 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.419 ' HG3' ' CE1' ' A' ' 48' ' ' TYR . 95.1 Cg_endo -84.6 98.89 0.72 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.73 2.286 . . . . 0.0 112.675 -179.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 24.0 mm -79.06 -36.66 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.032 0.444 . . . . 0.0 110.365 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.51 164.45 34.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.177 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -60.61 -24.02 65.16 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.524 0.202 . . . . 0.0 111.314 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.447 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 2.7 m-20 -113.6 -35.06 5.34 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -102.86 123.48 46.59 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.944 0.402 . . . . 0.0 111.758 -179.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -133.69 161.25 35.19 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.292 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.035 HG22 HG12 ' A' ' 127' ' ' VAL . 2.7 pt -121.44 142.51 37.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.979 179.123 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.449 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 40.4 p90 -147.8 165.34 30.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.69 0.757 . . . . 0.0 112.895 -178.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -144.32 140.66 29.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.399 -1.273 . . . . 0.0 109.445 179.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.712 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 45.5 mtm-85 -118.81 137.44 53.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 111.18 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.42 ' HB3' ' CE1' ' A' ' 123' ' ' PHE . 0.5 OUTLIER -139.5 119.7 13.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.918 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.408 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -166.32 -141.6 3.19 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.352 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.505 ' HA2' HG23 ' A' ' 122' ' ' VAL . . . -151.34 150.58 22.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.55 -0.833 . . . . 0.0 113.251 -179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.8 ptp -101.86 157.33 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.814 0.34 . . . . 0.0 110.945 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.712 HG12 HG12 ' A' ' 119' ' ' VAL . 3.4 m -141.38 101.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.419 ' CD1' ' HA3' ' A' ' 76' ' ' GLY . 1.2 t80 -96.33 124.52 40.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.958 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 25.0 mtt85 -122.15 131.08 53.77 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -126.89 142.16 51.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.055 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -91.37 120.55 32.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.1 m 60.29 93.82 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.948 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -157.55 158.08 34.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.941 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.88 145.45 45.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 23.5 t30 -128.87 170.74 13.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.884 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.13 158.04 41.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.108 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -74.5 -31.61 62.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.887 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.67 -30.23 68.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.483 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 11.1 mmtp -110.73 130.75 55.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.34 . . . . 0.0 110.891 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -101.21 31.3 3.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.906 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -160.4 120.39 2.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -60.36 -31.28 70.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 t -74.16 126.42 30.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -89.33 135.05 12.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.712 HG12 HG12 ' A' ' 101' ' ' VAL . 17.1 m -139.52 155.49 25.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.886 0.374 . . . . 0.0 111.189 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.3 m -177.31 153.9 1.05 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.862 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -52.59 147.05 31.81 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.547 2.165 . . . . 0.0 112.346 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.505 HG23 ' HA2' ' A' ' 99' ' ' GLY . 21.9 t -140.71 116.31 7.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.204 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.42 ' CE1' ' HB3' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -115.2 157.91 23.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.752 179.832 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.712 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -155.41 146.57 22.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.325 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.2 138.94 7.55 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.188 179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 177.21 -155.77 18.71 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.044 -1.074 . . . . 0.0 113.243 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 1.035 HG12 HG22 ' A' ' 93' ' ' ILE . 29.8 m -138.71 147.97 24.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.008 0.432 . . . . 0.0 111.258 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -124.77 132.2 53.38 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.692 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.447 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 34.7 t80 -125.87 145.95 50.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.047 -179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.404 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.86 115.58 29.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.952 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.476 HD11 HG22 ' A' ' 135' ' ' ILE . 21.4 pt -89.88 -33.11 5.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.036 0.446 . . . . 0.0 110.408 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.698 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -149.25 165.16 18.34 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.187 179.682 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.698 ' HD2' HG22 ' A' ' 132' ' ' THR . 9.6 Cg_endo -53.17 -56.25 2.93 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -95.75 17.07 15.8 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.348 0.499 . . . . 0.0 112.348 -178.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.476 HG22 HD11 ' A' ' 131' ' ' ILE . 3.5 mp -144.3 120.61 4.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.061 0.458 . . . . 0.0 111.897 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.53 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -131.13 154.05 48.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.814 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 43.2 p -125.06 142.19 51.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.618 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.537 ' O ' HD12 ' A' ' 139' ' ' LEU . 24.9 mtt180 -138.66 135.23 34.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.067 0.46 . . . . 0.0 111.873 -179.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 138' ' ' ARG . 8.5 mp -124.67 133.89 53.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.574 178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -151.76 167.63 27.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.307 0.575 . . . . 0.0 112.005 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.589 ' HE2' HD23 ' A' ' 162' ' ' LEU . 2.9 m-85 -122.57 159.5 27.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.851 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -159.98 115.93 2.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.984 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -92.42 162.62 14.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.901 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 62.5 m -92.75 108.36 19.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 25.2 m-20 -77.66 168.84 19.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -161.78 32.37 0.13 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.46 ' O ' HD12 ' A' ' 147' ' ' ILE . 1.6 pp -98.13 31.7 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.114 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -128.19 -101.71 1.08 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.451 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -73.58 120.1 18.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.835 0.35 . . . . 0.0 110.856 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.96 9.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.162 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 3.1 t-160 60.55 35.26 20.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.41 160.54 21.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.949 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.7 mt -71.32 -38.72 70.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.058 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 100.06 93.2 2.1 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.521 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 81.5 p -75.87 157.02 33.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.781 0.324 . . . . 0.0 110.944 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -100.88 97.98 7.73 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.24 104.1 1.34 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.489 2.126 . . . . 0.0 112.298 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -98.72 31.8 2.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -175.26 96.76 0.07 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 173.9 -154.9 20.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.791 ' HB3' HD12 ' A' ' 162' ' ' LEU . 10.3 mmm 61.96 -82.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.537 0.208 . . . . 0.0 110.932 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.791 HD12 ' HB3' ' A' ' 161' ' ' MET . 1.7 mp -120.65 118.18 29.47 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.475 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 0.3 OUTLIER -131.77 152.54 50.88 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-O 121.315 0.579 . . . . 0.0 111.861 -179.288 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . 0.63 ' O ' HD12 ' A' ' 164' ' ' LEU . 3.9 pp -142.45 122.54 13.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.673 179.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -142.17 163.68 27.02 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.236 -0.983 . . . . 0.0 113.485 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.53 HG13 ' O ' ' A' ' 136' ' ' ALA . 21.8 t -106.14 146.94 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.5 p -134.87 145.73 48.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.469 . . . . 0.0 111.739 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.5 m-85 -114.64 131.39 56.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.773 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.55 118.64 37.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.021 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -100.84 120.29 39.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.882 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.34 -74.2 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -78.87 85.46 4.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.815 0.341 . . . . 0.0 110.91 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -144.89 54.94 0.56 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.503 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -95.91 155.07 16.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.833 0.349 . . . . 0.0 110.932 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -60.0 127.39 31.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.136 179.966 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 12.8 mtp . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.72 0.295 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -175.35 89.05 0.3 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.43 138.0 41.21 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.599 2.199 . . . . 0.0 112.308 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.56 141.58 31.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.93 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -166.55 32.71 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -121.0 59.23 0.94 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.911 0.386 . . . . 0.0 110.399 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.449 HG22 ' H ' ' A' ' 7' ' ' TRP . 0.2 OUTLIER -132.1 173.26 11.41 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.634 -178.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.6 m-90 -125.19 166.67 16.04 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.562 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.487 ' N ' ' O ' ' A' ' 42' ' ' GLY . 1.5 p90 -155.62 163.03 40.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.16 179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 m -149.22 152.75 36.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.519 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -171.49 -160.36 19.86 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 119.894 -1.146 . . . . 0.0 113.426 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.27 153.92 51.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.631 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.46 ' C ' HD12 ' A' ' 13' ' ' LEU . 1.6 mmmp? -137.58 149.8 46.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.119 0.485 . . . . 0.0 111.567 -179.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.467 HD12 ' N ' ' A' ' 13' ' ' LEU . 2.1 mp -148.56 126.36 11.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.662 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.441 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.14 174.12 27.94 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.445 -179.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.8 ' HB3' HD12 ' A' ' 35' ' ' LEU . 18.2 p90 -128.63 156.47 43.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.856 0.36 . . . . 0.0 110.763 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -129.28 158.93 37.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.851 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 61.55 44.69 8.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 9.0 t80 -98.94 97.14 8.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.875 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -115.47 143.35 45.44 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.843 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -167.86 33.6 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.89 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.1 t -107.87 -31.92 7.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.904 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.52 -71.87 1.05 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.553 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.8 160.85 14.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 0.0 110.858 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 31.5 pt -92.57 165.07 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.088 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 11.8 t30 60.63 166.62 0.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.902 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -73.52 100.11 3.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.8 t30 -158.82 123.52 4.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -104.63 150.44 17.18 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.454 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.32 -45.59 1.24 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.577 2.185 . . . . 0.0 112.319 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 39.0 p -145.07 -58.54 0.35 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.902 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -106.89 131.25 54.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.877 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -95.66 -177.52 4.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 17.8 p-10 -78.16 146.51 35.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.835 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -119.65 127.3 52.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.723 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.8 HD12 ' HB3' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -94.27 135.2 35.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.07 -179.868 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.97 157.4 23.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.335 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -138.64 164.94 28.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.888 0.375 . . . . 0.0 111.32 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.21 -167.54 38.26 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.301 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.408 ' O ' ' CD1' ' A' ' 40' ' ' PHE . . . -119.02 153.03 35.34 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.477 0.18 . . . . 0.0 110.75 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.426 ' CZ ' ' HA3' ' A' ' 54' ' ' GLY . 1.7 m-85 -154.72 142.69 20.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.158 0.504 . . . . 0.0 111.619 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -140.61 156.94 25.55 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.535 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 8' ' ' TYR . . . -155.57 165.07 32.36 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.215 -0.993 . . . . 0.0 112.82 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 1.4 p90 -146.06 139.27 25.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.921 0.391 . . . . 0.0 111.373 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -94.96 124.67 39.14 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.533 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 10.9 m -98.49 -37.0 6.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.72 -179.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.485 ' CB ' ' HD2' ' A' ' 47' ' ' PRO . 0.9 OUTLIER -149.39 170.11 8.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.359 -179.828 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.485 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 6.2 Cg_endo -48.64 120.5 5.3 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.826 2.351 . . . . 0.0 113.26 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.514 ' O ' HD12 ' A' ' 83' ' ' LEU . 0.9 OUTLIER 58.38 18.37 5.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.561 -0.745 . . . . 0.0 112.33 178.85 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.431 ' CG2' ' CB ' ' A' ' 46' ' ' ASN . 4.9 m -138.71 112.96 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.826 0.346 . . . . 0.0 111.451 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.45 -172.36 15.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.565 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.439 ' HB2' ' CZ ' ' A' ' 43' ' ' TYR . 20.9 m-85 -128.38 151.43 49.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.662 0.268 . . . . 0.0 110.518 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -145.87 135.23 23.0 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.026 0.441 . . . . 0.0 111.47 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 15.1 ttp -129.73 154.71 46.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.331 179.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.426 ' HA3' ' CZ ' ' A' ' 40' ' ' PHE . . . -160.72 159.31 30.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.265 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.603 ' HD2' HG22 ' A' ' 77' ' ' VAL . 22.1 t80 -140.76 148.89 41.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.814 0.34 . . . . 0.0 110.897 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -113.54 119.33 37.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -122.53 -66.25 1.04 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.847 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.6 178.5 1.26 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.816 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -165.99 -49.39 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.449 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 20.6 mtt85 -130.24 136.48 49.24 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.842 0.353 . . . . 0.0 110.901 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 1.9 mtm -72.65 -60.69 1.92 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.882 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.66 109.89 2.88 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.537 2.158 . . . . 0.0 112.319 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -69.82 -55.74 9.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.856 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.55 31.34 20.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.879 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 135.57 122.74 2.24 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.533 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 33.8 p -109.9 105.9 15.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.816 0.341 . . . . 0.0 110.928 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.6 m -109.96 31.06 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.135 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -83.3 101.96 11.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.906 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -75.4 -36.5 60.84 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.77 52.14 1.22 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -101.42 -59.7 1.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.815 0.341 . . . . 0.0 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -129.73 -175.32 3.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.925 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 2.2 tmtm? -174.38 -41.26 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . 60.47 173.83 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.08 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -137.42 124.14 21.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.964 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -121.71 101.02 0.75 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.516 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.603 HG22 ' HD2' ' A' ' 55' ' ' TYR . 24.7 t -106.93 153.96 7.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.736 0.303 . . . . 0.0 111.051 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . . . . . . . . . 11.1 tt0 -128.23 135.27 49.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.981 0.419 . . . . 0.0 111.047 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -130.85 130.76 44.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.888 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.409 ' HA ' ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.37 173.05 14.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.492 0.663 . . . . 0.0 111.989 -179.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.75 144.35 35.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.986 178.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . 0.411 ' HE2' ' CD2' ' A' ' 94' ' ' TYR . 0.3 OUTLIER -110.24 125.29 52.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.381 . . . . 0.0 111.479 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.514 HD12 ' O ' ' A' ' 48' ' ' TYR . 6.2 tp -130.64 110.06 11.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.263 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.466 ' HA2' ' HA ' ' A' ' 94' ' ' TYR . . . -136.02 175.29 20.95 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.71 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -129.09 139.87 36.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.694 0.283 . . . . 0.0 110.576 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -86.63 104.18 0.66 Allowed 'Trans proline' 0 N--CA 1.46 -0.465 0 C-N-CA 122.786 2.324 . . . . 0.0 112.736 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.436 HD11 ' HG ' ' A' ' 91' ' ' LEU . 40.3 pt -81.11 -33.75 13.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.162 0.506 . . . . 0.0 110.353 179.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.36 164.3 33.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.151 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -60.59 -25.09 65.96 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.451 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 1.0 OUTLIER -112.74 -30.85 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.104 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.436 ' HG ' HD11 ' A' ' 87' ' ' ILE . 13.4 tp -102.96 123.59 46.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.614 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -131.62 154.97 48.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.369 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.05 HG22 HG12 ' A' ' 127' ' ' VAL . 25.6 pt -123.07 142.62 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.873 179.043 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.466 ' HA ' ' HA2' ' A' ' 84' ' ' GLY . 19.3 p90 -152.83 170.15 21.05 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.752 0.786 . . . . 0.0 113.073 -178.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.4 p -141.5 142.5 33.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.295 -1.321 . . . . 0.0 109.53 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.474 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 0.0 OUTLIER -118.14 137.49 52.93 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.964 0.412 . . . . 0.0 111.001 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.684 HD12 ' CE2' ' A' ' 123' ' ' PHE . 1.3 tt -139.77 119.25 13.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.814 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.469 ' O ' HG22 ' A' ' 122' ' ' VAL . . . -164.98 -144.52 4.08 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.233 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -152.9 152.6 24.24 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.491 -0.862 . . . . 0.0 113.292 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 3.3 ttt -101.99 157.78 16.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.544 -0.328 . . . . 0.0 110.845 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.428 ' O ' HG13 ' A' ' 101' ' ' VAL . 11.2 p -139.01 124.4 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.062 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -125.52 125.22 42.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -124.13 146.8 48.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.849 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.99 147.76 24.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.132 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -101.04 105.01 16.17 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.894 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.8 p -72.66 143.09 48.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 -44.71 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.837 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 6.8 t -139.16 -49.32 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.859 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -166.57 143.39 4.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.745 HG23 ' O ' ' A' ' 112' ' ' GLY . 5.6 m -147.81 174.59 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 16.2 t80 -68.57 -35.96 78.11 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.944 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.745 ' O ' HG23 ' A' ' 110' ' ' VAL . . . -113.5 -174.48 18.91 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.473 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 2.6 tttt -169.47 35.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.816 0.341 . . . . 0.0 110.898 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -151.69 153.19 33.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 1.4 t-160 -61.37 85.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.94 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.38 -60.55 1.64 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.2 p 57.67 106.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.017 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.55 130.58 18.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.491 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.405 HG12 ' HA ' ' A' ' 101' ' ' VAL . 21.6 m -149.19 157.77 6.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.869 0.366 . . . . 0.0 111.206 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 26.9 t -177.5 143.91 0.53 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.74 161.52 4.44 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.493 2.129 . . . . 0.0 112.3 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 98' ' ' GLY . 27.8 m -155.65 140.73 9.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.091 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.684 ' CE2' HD12 ' A' ' 97' ' ' LEU . 9.6 t80 -121.49 156.41 32.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.816 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.483 ' HB1' ' OE1' ' A' ' 140' ' ' GLU . . . -152.14 147.1 26.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.249 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.6 138.82 7.62 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.14 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.1 -157.96 21.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.053 -1.07 . . . . 0.0 113.314 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 1.05 HG12 HG22 ' A' ' 93' ' ' ILE . 28.4 m -138.38 147.99 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.052 0.453 . . . . 0.0 111.255 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -125.35 131.1 53.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.777 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.451 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 38.0 t80 -126.86 146.59 50.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.044 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.408 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -98.89 115.65 29.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.807 HD11 HG22 ' A' ' 135' ' ' ILE . 19.8 pt -89.27 -34.82 7.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.958 0.408 . . . . 0.0 110.7 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.726 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -146.65 172.98 4.59 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.555 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.726 ' CD ' HG22 ' A' ' 132' ' ' THR . 50.5 Cg_exo -54.4 -61.86 0.36 Allowed 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.517 2.145 . . . . 0.0 112.757 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -99.84 25.44 7.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.777 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.807 HG22 HD11 ' A' ' 131' ' ' ILE . 4.0 mp -144.24 116.06 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.979 0.419 . . . . 0.0 111.565 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -127.35 158.48 37.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.972 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.788 HG22 HG12 ' A' ' 166' ' ' VAL . 26.0 p -141.49 138.42 32.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.41 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.22 150.92 35.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.131 0.491 . . . . 0.0 111.944 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.949 HD21 HD23 ' A' ' 164' ' ' LEU . 8.3 mp -118.34 139.81 50.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.723 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.483 ' OE1' ' HB1' ' A' ' 124' ' ' ALA . 0.1 OUTLIER -143.15 149.94 38.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 111.567 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.644 ' HE2' HD23 ' A' ' 162' ' ' LEU . 6.2 m-85 -121.21 157.25 30.67 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.91 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -120.45 137.46 54.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.964 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -89.38 113.0 24.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.823 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 23.0 m -102.81 146.99 27.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 11.4 t30 60.31 109.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -147.66 82.06 1.52 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.834 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.8 mp -133.4 124.17 48.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.175 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -99.65 111.74 4.28 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.395 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -170.85 -179.19 2.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.934 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.32 89.39 0.06 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -70.24 138.34 51.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 46.4 p -76.18 -59.17 2.88 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.823 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 2.7 tt -91.28 -30.85 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.069 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 67.85 87.95 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 10.9 m -118.41 128.03 54.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 0.0 110.908 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 2.9 ttp85 -109.46 97.89 29.37 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.898 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 135.21 52.4 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 122.469 2.112 . . . . 0.0 112.388 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.88 -51.09 20.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.897 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -145.93 127.06 14.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.893 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -67.08 -100.85 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.486 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.485 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 2.1 mtm -108.6 140.75 41.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.68 0.276 . . . . 0.0 110.888 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.644 HD23 ' HE2' ' A' ' 141' ' ' TYR . 0.8 OUTLIER -121.97 117.41 26.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.089 179.293 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.441 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 85.2 p -132.7 155.54 48.63 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.331 0.586 . . . . 0.0 111.885 -179.244 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . 0.949 HD23 HD21 ' A' ' 139' ' ' LEU . 0.1 OUTLIER -142.76 125.2 15.65 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.692 179.125 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.4 163.7 27.45 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.089 -1.053 . . . . 0.0 113.477 -179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.788 HG12 HG22 ' A' ' 137' ' ' THR . 23.3 m -108.89 147.93 13.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 179.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 11.3 t -136.21 147.0 47.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.124 0.488 . . . . 0.0 111.852 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.746 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 3.0 ptm180 -108.2 119.13 38.6 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.103 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -82.16 154.75 25.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 159.11 -81.44 0.15 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.501 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 60.41 34.97 20.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.893 0.377 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -132.16 160.88 23.78 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.48 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 60.48 170.39 0.09 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.319 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -104.45 -34.26 8.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.141 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.108 -179.964 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 2.9 mtt . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.806 0.336 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.409 ' HA ' ' HD2' ' A' ' 2' ' ' PRO . . . -175.62 102.0 0.25 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.039 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 1' ' ' ALA . 41.4 Cg_endo -67.49 114.7 3.37 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.45 2.1 . . . . 0.0 112.242 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.5 tttp -108.05 -31.16 8.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.013 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -146.72 157.51 43.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.037 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 65.65 41.37 4.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.941 0.401 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -123.35 169.32 11.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.712 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.6 p-90 -124.52 163.87 20.96 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.523 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.42 ' CZ ' ' HA3' ' A' ' 42' ' ' GLY . 33.0 p90 -155.25 156.62 35.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.93 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.2 p -149.26 151.93 35.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -171.98 -160.73 21.16 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 119.904 -1.141 . . . . 0.0 113.32 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 39' ' ' ALA . . . -127.11 154.45 44.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.524 -0.338 . . . . 0.0 110.512 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 19.8 tttt -142.21 146.08 34.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.083 0.468 . . . . 0.0 111.549 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 36' ' ' GLY . 1.4 mp -143.24 119.18 10.62 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.374 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.544 ' O ' ' HB2' ' A' ' 15' ' ' PHE . . . -149.52 168.56 29.77 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.012 -1.089 . . . . 0.0 113.914 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.544 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 0.3 OUTLIER 170.84 -92.53 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 122.979 0.512 . . . . 0.0 110.19 178.554 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.422 ' H ' ' HB3' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -177.58 128.28 0.14 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.81 0.338 . . . . 0.0 110.985 179.662 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -151.18 84.14 1.32 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -127.24 145.8 50.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 75.5 m-70 60.1 -179.66 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.933 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -147.0 31.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 m 60.4 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.934 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -130.74 -128.27 2.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.558 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -108.49 35.58 3.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.867 0.365 . . . . 0.0 110.918 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.5 pt -103.98 -30.49 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.111 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -150.91 136.22 17.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -132.51 -67.05 0.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.877 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 32.1 m-20 -107.36 77.39 1.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.878 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -173.28 -148.97 6.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.467 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_exo -51.57 123.61 12.56 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.597 2.198 . . . . 0.0 112.325 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 20.0 p -64.94 167.42 7.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 5.3 m-70 -97.45 -176.31 3.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -148.73 100.59 3.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.937 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 31.1 m-20 -132.63 85.0 2.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.856 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.455 ' O ' ' HB3' ' A' ' 15' ' ' PHE . 8.9 mm100 -123.61 179.15 4.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.701 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.419 ' HA ' ' CB ' ' A' ' 15' ' ' PHE . 0.4 OUTLIER -148.99 136.45 20.26 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.47 -179.927 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.43 ' O ' ' HA ' ' A' ' 13' ' ' LEU . . . -123.79 149.37 16.88 Favored Glycine 0 C--N 1.331 0.264 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.189 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.38 153.02 46.75 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.999 0.428 . . . . 0.0 111.726 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.95 -173.29 42.37 Favored Glycine 0 C--N 1.331 0.259 0 C-N-CA 120.606 -0.807 . . . . 0.0 113.295 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 11' ' ' ALA . . . -130.55 154.22 48.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.876 -0.162 . . . . 0.0 110.57 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -159.23 161.65 36.09 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.281 0.562 . . . . 0.0 112.258 -179.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -154.77 159.22 28.84 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.201 179.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CZ ' ' A' ' 8' ' ' TYR . . . -157.77 165.1 33.46 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 119.796 -1.192 . . . . 0.0 113.563 -179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.505 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.5 m-85 -119.91 135.14 55.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.41 -0.395 . . . . 0.0 110.404 179.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -95.13 125.96 40.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.27 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.1 t -92.88 -37.57 8.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.874 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.437 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 1.0 OUTLIER -153.6 179.32 1.32 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.125 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.437 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 35.2 Cg_exo -60.72 -26.1 82.3 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.689 2.259 . . . . 0.0 113.712 -179.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.4 p90 -127.97 4.43 5.93 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 113.135 0.791 . . . . 0.0 113.135 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.511 ' O ' HG13 ' A' ' 49' ' ' VAL . 9.1 p -139.52 115.72 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 C-N-CA 120.601 -0.44 . . . . 0.0 111.718 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.4 -175.7 17.76 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.653 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -127.15 149.45 49.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.569 0.224 . . . . 0.0 110.44 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -147.76 136.82 22.17 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.085 0.469 . . . . 0.0 111.578 -179.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 2.1 mpp? -128.22 155.27 44.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.231 179.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.34 158.37 29.47 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.213 -0.994 . . . . 0.0 113.197 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -159.12 167.37 29.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.848 0.356 . . . . 0.0 110.79 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.42 154.09 22.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.982 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -100.69 169.71 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.961 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 1.2 tt 60.48 92.56 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -155.74 -103.8 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.512 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.45 137.35 47.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.874 0.369 . . . . 0.0 110.848 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -174.04 87.2 0.36 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.06 149.79 65.47 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.568 2.179 . . . . 0.0 112.351 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -115.02 35.46 4.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.861 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.61 -53.74 20.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.919 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 153.07 -28.0 0.8 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.557 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 42.8 t 61.03 110.39 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.798 0.333 . . . . 0.0 110.925 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 29.4 m -124.36 31.01 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.142 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -134.66 116.87 15.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.5 m-80 -86.07 126.8 34.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.887 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -164.36 -155.81 8.56 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.465 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -81.59 -44.27 17.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.813 0.339 . . . . 0.0 111.079 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 1.6 t80 60.72 46.01 9.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -97.5 38.22 1.29 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.986 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -93.87 -167.49 1.7 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.099 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER 62.9 -169.01 0.19 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.841 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -112.07 132.8 11.03 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.532 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 78' ' ' GLN . 11.0 p -157.93 157.55 3.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.718 0.295 . . . . 0.0 111.044 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.511 ' CD ' HG11 ' A' ' 122' ' ' VAL . 6.1 tt0 -130.21 142.78 50.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.051 0.453 . . . . 0.0 111.08 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.7 131.34 43.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.84 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.41 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.4 p -151.46 173.0 15.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.495 0.664 . . . . 0.0 111.891 -179.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -110.29 142.41 41.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.963 179.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.62 127.25 53.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.969 0.414 . . . . 0.0 111.453 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.6 mp -129.73 111.22 12.43 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.303 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.436 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -133.55 169.79 22.61 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.266 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.481 ' HB3' HD11 ' A' ' 93' ' ' ILE . 2.5 t80 -121.69 137.4 27.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.613 0.244 . . . . 0.0 110.591 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -83.14 97.55 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.434 0 C-N-CA 122.687 2.258 . . . . 0.0 112.63 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.456 HD11 HG12 ' A' ' 93' ' ' ILE . 31.1 mt -80.67 -35.67 15.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.048 0.451 . . . . 0.0 110.462 179.462 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.434 HG22 ' N ' ' A' ' 89' ' ' ASP . 27.4 m -148.27 164.81 32.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.112 179.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.434 ' N ' HG22 ' A' ' 88' ' ' THR . 1.6 t70 -60.51 -27.34 67.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.522 0.201 . . . . 0.0 111.479 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.442 ' HB3' ' CE2' ' A' ' 129' ' ' TYR . 73.8 m-20 -112.27 -34.9 5.77 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 15.1 tp -102.84 123.74 47.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.981 0.42 . . . . 0.0 111.688 -179.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -135.39 164.19 28.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.348 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.037 HG22 HG12 ' A' ' 127' ' ' VAL . 1.3 pt -117.75 142.29 32.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.929 178.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.436 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 36.6 m-85 -144.72 159.14 43.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.686 0.755 . . . . 0.0 112.838 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.697 HG23 ' O ' ' A' ' 124' ' ' ALA . 91.1 m -140.87 137.02 32.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.191 178.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.588 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 54.8 mtm180 -118.17 137.44 52.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.883 0.373 . . . . 0.0 111.277 -179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 8.3 tt -141.9 121.21 13.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.853 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.41 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -165.11 -146.25 4.71 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.273 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.23 156.05 26.71 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.612 -0.804 . . . . 0.0 113.179 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.97 158.86 15.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.765 0.317 . . . . 0.0 110.857 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.432 ' CG2' HG13 ' A' ' 77' ' ' VAL . 12.1 m -145.83 118.2 2.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.136 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -126.93 115.22 18.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.561 ' HB2' HG23 ' A' ' 117' ' ' THR . 4.6 tpt180 -131.43 127.13 36.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -131.62 126.61 35.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.092 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -104.25 152.05 22.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.932 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 6.5 m -144.88 -49.79 0.26 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.907 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -118.07 149.64 40.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 49.7 m -103.47 136.19 43.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.872 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -127.53 -45.28 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 18.3 t 69.02 -67.14 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.218 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -60.14 -31.21 69.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -103.0 125.79 8.62 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.484 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 8.5 mttp -104.21 105.37 15.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 19.6 m120 -104.78 136.91 43.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.919 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -104.59 90.76 3.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -119.14 36.53 4.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.874 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.561 HG23 ' HB2' ' A' ' 103' ' ' ARG . 0.2 OUTLIER -94.88 118.55 31.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.9 179.975 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -77.78 126.02 7.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.553 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 20.7 t -146.69 139.34 19.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.776 0.322 . . . . 0.0 111.148 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -164.65 164.69 13.29 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.911 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.76 157.08 63.38 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.595 2.197 . . . . 0.0 112.253 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.511 HG11 ' CD ' ' A' ' 78' ' ' GLN . 21.5 t -145.42 97.56 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.225 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 124' ' ' ALA . 40.2 t80 -98.65 156.56 16.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.678 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.697 ' O ' HG23 ' A' ' 95' ' ' THR . . . -158.27 148.02 19.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.313 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -147.98 140.0 8.11 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.124 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 175.36 -151.75 12.48 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.306 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 1.037 HG12 HG22 ' A' ' 93' ' ' ILE . 29.7 m -140.26 149.24 21.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.126 0.488 . . . . 0.0 111.357 -179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 62.4 tt0 -125.39 132.37 52.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.631 179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.442 ' CE2' ' HB3' ' A' ' 90' ' ' ASP . 39.6 t80 -125.54 146.2 49.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.213 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.405 ' O ' ' CE1' ' A' ' 129' ' ' TYR . . . -97.91 115.4 28.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.929 179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.4 tt -88.5 -35.04 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.958 0.409 . . . . 0.0 110.561 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.711 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -150.49 172.41 5.32 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.426 179.631 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.711 ' CD ' HG22 ' A' ' 132' ' ' THR . 52.8 Cg_exo -53.23 -57.06 2.2 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.473 2.115 . . . . 0.0 112.488 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -102.89 31.8 4.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.515 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 19.1 mt -149.16 114.23 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 111.743 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.4 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -129.09 154.23 46.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.919 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.839 HG22 HG12 ' A' ' 166' ' ' VAL . 26.1 p -129.0 140.59 51.57 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.411 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 2.2 ttm105 -137.39 135.1 36.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.947 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.579 HD13 HD12 ' A' ' 164' ' ' LEU . 3.3 tp -124.98 132.51 53.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.432 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.77 165.58 32.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.255 0.55 . . . . 0.0 111.886 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.458 ' HA ' ' O ' ' A' ' 161' ' ' MET . 8.6 p90 -129.73 162.8 27.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.948 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.93 115.94 2.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -92.69 139.38 30.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 8.8 t -98.18 152.32 19.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -98.13 35.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -89.27 109.52 20.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.883 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 24.4 mt -133.69 -49.42 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -149.21 -46.86 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.457 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -133.23 -68.19 0.59 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.914 0.387 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . 59.92 169.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 3.4 m-70 -67.04 115.67 7.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 60.47 162.13 0.05 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.879 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.434 ' C ' HD12 ' A' ' 153' ' ' ILE . 2.8 pp -152.73 174.0 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.192 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 171.96 -112.14 0.43 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.538 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 32.1 p -110.8 140.65 45.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.838 0.351 . . . . 0.0 110.959 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.8 mtt180 -70.7 147.02 94.25 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.59 151.61 52.84 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.547 2.165 . . . . 0.0 112.284 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -117.01 30.22 7.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.903 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -177.49 82.69 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.89 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -149.57 -156.22 7.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.484 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER 59.98 -84.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.425 0.155 . . . . 0.0 110.938 -179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -120.75 117.87 28.57 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.257 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.435 ' HA ' ' CA ' ' A' ' 14' ' ' GLY . 95.4 p -130.28 153.04 49.05 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.231 0.538 . . . . 0.0 111.9 -179.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . 0.579 HD12 HD13 ' A' ' 139' ' ' LEU . 3.0 tt -144.3 123.19 12.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.889 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.39 159.29 27.49 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.304 -0.95 . . . . 0.0 113.355 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.839 HG12 HG22 ' A' ' 137' ' ' THR . 26.7 m -103.72 147.05 10.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . 0.4 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 78.6 p -134.81 145.51 48.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.1 0.476 . . . . 0.0 111.785 -179.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -112.19 132.06 55.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.675 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.51 116.25 31.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.009 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -108.75 134.18 51.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -174.47 59.65 0.12 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.453 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -112.48 96.37 5.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 64.45 -153.98 48.53 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.484 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -131.42 -54.74 1.02 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.842 0.353 . . . . 0.0 110.935 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -107.54 33.41 4.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.076 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.086 179.996 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 3.0 tpt . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.808 0.337 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -146.28 152.95 47.77 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.119 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.78 116.47 4.58 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.547 2.165 . . . . 0.0 112.34 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -136.91 83.53 2.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -64.46 117.81 7.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 33.2 m120 -68.51 -124.95 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.482 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.8 m -119.47 155.27 32.38 Favored 'General case' 0 N--CA 1.461 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.674 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.544 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 1.1 p90 -126.8 164.45 21.34 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.623 -179.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.412 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 26.5 p90 -155.26 157.05 36.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.018 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 p -149.13 151.19 33.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.739 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -170.6 -163.35 24.48 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.05 -1.071 . . . . 0.0 113.296 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.49 153.47 50.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.632 -0.284 . . . . 0.0 110.556 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 13.4 ptmt -138.0 149.74 46.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.169 0.509 . . . . 0.0 111.81 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 37' ' ' ALA . 9.1 tt -149.29 125.3 10.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.637 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.439 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.14 174.2 27.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.239 -0.982 . . . . 0.0 113.58 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.701 ' CZ ' HD12 ' A' ' 35' ' ' LEU . 3.1 m-85 -115.11 144.59 43.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.72 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -154.35 -168.3 2.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.9 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 61.79 84.76 0.13 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -113.79 85.72 2.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.925 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -104.22 174.0 6.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.992 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -93.46 127.49 39.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.8 p -113.39 -47.63 3.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.886 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.87 50.35 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -106.47 -176.73 3.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.787 0.327 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.442 HD12 ' N ' ' A' ' 24' ' ' ILE . 3.9 mp -126.81 -45.2 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.059 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -158.65 161.47 37.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -72.27 87.38 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.929 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -155.99 110.63 2.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 109.96 -150.0 17.44 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.517 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.62 97.17 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.527 2.151 . . . . 0.0 112.315 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.7 t -82.6 152.04 26.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.985 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -176.78 37.69 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.861 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -85.15 -40.83 16.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -93.18 164.68 13.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.863 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.58 124.04 45.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.701 HD12 ' CZ ' ' A' ' 15' ' ' PHE . 8.5 tt -85.63 132.61 34.13 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.979 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.81 138.17 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.545 ' HB2' HD12 ' A' ' 13' ' ' LEU . . . -118.18 159.22 23.67 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.815 0.34 . . . . 0.0 111.198 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.17 -174.24 40.86 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.401 -0.904 . . . . 0.0 113.281 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.14 154.29 47.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.761 -0.22 . . . . 0.0 110.549 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -159.14 156.96 29.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.317 0.58 . . . . 0.0 112.101 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -150.29 159.06 27.95 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.244 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.412 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -157.12 164.98 33.09 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 119.793 -1.194 . . . . 0.0 113.498 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 3.6 m-85 -118.53 134.17 55.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.445 -0.378 . . . . 0.0 110.384 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 14.7 tt0 -95.79 126.44 41.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.238 179.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.443 HG21 ' CE2' ' A' ' 51' ' ' PHE . 25.1 t -94.75 -35.77 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.837 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.51 ' HB2' HG23 ' A' ' 49' ' ' VAL . 0.9 OUTLIER -155.67 172.77 5.58 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.866 179.985 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.472 ' HD2' ' CB ' ' A' ' 46' ' ' ASN . 23.1 Cg_endo -62.23 -15.87 47.26 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.222 1.948 . . . . 0.0 113.449 -179.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.417 ' CD1' ' HG2' ' A' ' 47' ' ' PRO . 39.9 m-85 -128.24 -4.03 5.57 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.51 HG23 ' HB2' ' A' ' 46' ' ' ASN . 4.0 m -139.45 116.93 11.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 C-N-CA 120.566 -0.453 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.53 -175.65 16.83 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.456 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 45' ' ' VAL . 85.0 m-85 -128.97 149.56 50.76 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -148.85 138.03 21.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.127 0.489 . . . . 0.0 111.665 -179.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . . . . . . . . . 6.3 mtt -128.26 156.09 43.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.148 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -159.22 158.29 29.36 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.031 -1.081 . . . . 0.0 113.138 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -156.74 158.61 37.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.89 0.376 . . . . 0.0 110.821 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 25.3 p-10 -90.52 128.29 36.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -92.75 -38.38 11.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.866 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 12.3 tp 68.81 -67.22 0.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.047 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 166.26 93.41 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.469 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.31 103.2 9.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.892 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -139.86 88.36 12.12 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -68.99 131.21 21.81 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.544 2.163 . . . . 0.0 112.29 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -60.23 -72.6 0.11 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.929 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.91 35.99 0.07 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.91 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 140.67 162.81 9.26 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.418 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.6 m -107.32 154.04 21.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.881 0.372 . . . . 0.0 110.839 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.454 HG23 ' N ' ' A' ' 68' ' ' GLU . 13.9 m -135.5 -46.67 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.112 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.454 ' N ' HG23 ' A' ' 67' ' ' VAL . 4.8 tm-20 -134.24 93.02 3.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 60.58 158.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 175.05 -56.64 0.12 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.5 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.05 114.47 4.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.135 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -65.25 125.67 25.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.928 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -78.16 -32.49 50.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.886 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -97.54 104.87 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.069 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -95.96 152.88 18.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.884 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -139.91 123.56 2.48 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.525 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.43 HG12 ' N ' ' A' ' 78' ' ' GLN . 21.4 t -140.56 156.24 23.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.732 0.301 . . . . 0.0 111.151 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.43 ' N ' HG12 ' A' ' 77' ' ' VAL . 46.0 mt-30 -129.8 141.27 50.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.057 0.456 . . . . 0.0 111.039 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.608 ' O ' HD12 ' A' ' 79' ' ' LEU . 4.0 pp -131.23 130.83 43.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.764 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.408 HG22 ' HA3' ' A' ' 98' ' ' GLY . 2.5 p -151.71 173.03 15.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.475 0.655 . . . . 0.0 111.964 -179.178 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -107.71 142.0 38.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.827 178.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -107.99 126.33 52.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.823 0.344 . . . . 0.0 111.554 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 4.4 tt -129.65 110.64 11.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.37 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.438 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -132.8 169.01 22.63 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.362 -0.923 . . . . 0.0 113.209 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.406 ' CD2' ' HD2' ' A' ' 86' ' ' PRO . 5.1 t80 -124.28 137.61 29.42 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.614 0.245 . . . . 0.0 110.65 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.406 ' HD2' ' CD2' ' A' ' 85' ' ' TYR . 98.5 Cg_endo -85.37 100.19 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.684 2.256 . . . . 0.0 112.633 -179.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.418 HG22 ' O ' ' A' ' 91' ' ' LEU . 1.0 OUTLIER -82.04 -34.2 12.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 121.053 0.454 . . . . 0.0 110.367 179.333 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.413 HG22 ' N ' ' A' ' 89' ' ' ASP . 23.6 m -148.59 163.83 36.07 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.26 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.413 ' N ' HG22 ' A' ' 88' ' ' THR . 1.0 OUTLIER -62.45 -24.96 67.73 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 -179.418 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -111.42 -29.43 7.79 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.502 HD23 ' HB3' ' A' ' 129' ' ' TYR . 93.7 mt -108.12 124.72 50.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 111.696 -179.344 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -133.51 157.75 44.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.326 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 5.2 mt -117.04 141.71 34.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.888 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.438 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 16.8 m-85 -143.62 157.87 44.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.697 0.76 . . . . 0.0 112.721 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.6 p -141.83 137.05 31.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.52 -1.218 . . . . 0.0 108.987 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.883 ' CG ' ' HB3' ' A' ' 124' ' ' ALA . 0.4 OUTLIER -119.57 140.94 49.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.963 0.411 . . . . 0.0 111.467 -179.463 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.715 ' O ' HD12 ' A' ' 97' ' ' LEU . 1.4 pp -142.17 120.68 12.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.816 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.408 ' HA3' HG22 ' A' ' 80' ' ' THR . . . -164.96 -144.85 4.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.278 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -148.47 163.14 28.96 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.553 -0.832 . . . . 0.0 113.261 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 6.4 ttt -101.97 144.74 30.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 0.0 110.901 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.412 HG22 ' O ' ' A' ' 77' ' ' VAL . 5.1 m -122.74 122.08 65.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.135 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -109.75 125.32 52.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.868 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -109.87 106.84 16.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -106.73 128.4 54.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.088 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.84 124.73 28.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.852 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.782 HG21 ' CE1' ' A' ' 115' ' ' HIS . 4.4 t -88.8 156.6 18.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.89 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 11.0 mtpp -150.65 -49.35 0.13 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 60.0 m -110.66 115.67 29.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -127.77 89.24 2.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.447 HG23 ' N ' ' A' ' 111' ' ' TYR . 12.3 m -138.34 -46.98 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.171 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.447 ' N ' HG23 ' A' ' 110' ' ' VAL . 5.7 m-85 -101.0 -35.9 9.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 144.31 132.48 2.56 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -157.5 -174.37 4.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 110.862 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -80.25 135.25 36.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . 0.782 ' CE1' HG21 ' A' ' 106' ' ' THR . 3.4 t60 -142.22 -47.56 0.35 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.899 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.44 167.07 15.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.875 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.1 p -82.34 139.19 34.26 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.998 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.95 129.66 9.28 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.0 m -112.66 159.98 12.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.858 0.361 . . . . 0.0 111.105 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.1 m -176.92 88.62 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.86 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.04 132.19 23.92 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.627 2.218 . . . . 0.0 112.327 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 15.5 m -148.31 175.33 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.062 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 9.7 p90 -146.71 164.05 33.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.967 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.883 ' HB3' ' CG ' ' A' ' 96' ' ' ARG . . . -141.38 162.15 36.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.235 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.31 141.98 9.6 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.078 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 139' ' ' LEU . . . 177.27 -154.86 16.59 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 119.926 -1.131 . . . . 0.0 113.331 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 16.2 m -140.38 148.22 22.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.045 0.45 . . . . 0.0 111.441 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.402 ' CB ' ' HB3' ' A' ' 138' ' ' ARG . 0.0 OUTLIER -127.52 132.6 49.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.649 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.502 ' HB3' HD23 ' A' ' 91' ' ' LEU . 30.8 p90 -129.92 151.61 50.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.361 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -102.3 117.31 34.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.835 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.537 ' O ' HG23 ' A' ' 132' ' ' THR . 20.5 pt -88.96 -36.1 8.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.04 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.537 HG23 ' O ' ' A' ' 131' ' ' ILE . 0.8 OUTLIER -162.47 162.12 19.53 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.965 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.26 140.79 41.35 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.558 2.172 . . . . 0.0 112.222 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.54 19.53 6.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.587 179.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 32.2 mt -149.08 111.76 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.047 0.451 . . . . 0.0 111.633 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.54 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -129.11 151.1 50.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.797 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 4.1 m -133.46 140.36 47.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.449 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.402 ' HB3' ' CB ' ' A' ' 128' ' ' GLU . 3.6 ptm180 -146.92 145.0 29.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.158 0.504 . . . . 0.0 111.886 -179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.403 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 4.0 pp -120.21 140.61 50.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.575 179.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -146.45 157.37 43.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.147 0.499 . . . . 0.0 111.63 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.466 ' HA ' ' O ' ' A' ' 161' ' ' MET . 2.7 p90 -137.84 164.84 27.95 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.001 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -128.9 143.99 51.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -106.75 153.8 21.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.895 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 20.5 m 60.48 94.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -133.27 -52.74 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.891 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -131.69 86.56 2.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.623 ' O ' HD12 ' A' ' 147' ' ' ILE . 2.8 pp -143.65 153.68 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.095 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -78.9 -81.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.473 ' O ' HD13 ' A' ' 147' ' ' ILE . 8.8 p-10 -62.56 138.75 58.55 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.867 0.365 . . . . 0.0 110.88 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.94 -51.94 9.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.063 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -86.31 135.68 33.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.89 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.447 HG22 ' OD2' ' A' ' 149' ' ' ASP . 38.5 p -134.47 165.78 24.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.891 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 24.5 mt -134.9 111.31 13.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.148 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 114.98 -173.65 14.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.46 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -130.9 109.67 10.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.795 0.331 . . . . 0.0 110.894 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.89 149.12 65.02 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -52.44 145.74 35.64 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.603 2.202 . . . . 0.0 112.319 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -168.37 -57.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.4 m120 60.59 91.05 0.06 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.885 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -59.33 -91.83 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 8.8 mtm -119.73 132.82 55.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.663 0.268 . . . . 0.0 110.876 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 5.5 tp -122.25 118.97 29.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.085 179.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.439 ' HA ' ' HA3' ' A' ' 14' ' ' GLY . 4.9 t -136.9 157.99 45.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.365 0.602 . . . . 0.0 112.132 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . . . . . . . . . 1.1 tt -143.33 128.05 18.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.694 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -143.96 162.84 27.78 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.443 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 136' ' ' ALA . 22.0 t -105.39 146.6 12.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 179.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.7 m -134.59 145.42 48.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.137 0.494 . . . . 0.0 111.614 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -113.83 131.53 56.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 mtt180 -108.66 117.73 34.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.976 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -102.04 172.2 7.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 119.32 170.31 14.54 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.484 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.5 mm-40 60.62 35.61 19.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -69.96 -47.18 48.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.545 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -85.98 138.97 31.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.867 0.365 . . . . 0.0 110.928 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -106.15 31.24 5.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.098 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.109 -179.996 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.809 0.337 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -113.9 87.64 12.95 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.104 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.84 99.09 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.601 2.2 . . . . 0.0 112.29 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.88 160.74 14.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -130.26 -174.68 3.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.901 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.434 ' HA ' ' CE1' ' A' ' 43' ' ' TYR . 2.0 m120 65.31 41.67 4.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.961 0.41 . . . . 0.0 110.812 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 45.4 p -121.97 168.86 11.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.72 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 25.9 p-90 -128.38 162.81 26.24 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.667 -179.294 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.45 ' CE2' ' HA3' ' A' ' 42' ' ' GLY . 1.4 p90 -155.28 157.28 36.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.717 179.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.1 p -149.15 151.78 34.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.665 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.429 ' HA3' ' HA ' ' A' ' 167' ' ' SER . . . -170.1 -165.65 27.79 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.392 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -128.79 152.45 48.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.539 -0.33 . . . . 0.0 110.252 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.447 ' O ' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -139.05 150.47 45.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.327 0.585 . . . . 0.0 112.058 -179.208 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.447 HD12 ' O ' ' A' ' 12' ' ' LYS . 1.7 mp -139.05 116.91 11.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.092 -0.958 . . . . 0.0 108.675 178.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.54 ' O ' ' HB2' ' A' ' 15' ' ' PHE . . . -149.45 165.5 29.52 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 119.734 -1.222 . . . . 0.0 114.375 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.54 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 0.7 OUTLIER 171.11 -90.82 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.022 0.529 . . . . 0.0 110.272 178.495 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.41 ' O ' ' N ' ' A' ' 34' ' ' GLN . 1.4 m -177.54 125.75 0.13 Allowed 'General case' 0 C--N 1.335 -0.045 0 CA-C-O 120.845 0.355 . . . . 0.0 110.946 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -135.34 -52.92 0.78 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -173.36 162.6 4.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.9 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -123.49 128.26 49.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.05 -66.91 0.7 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.931 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -156.88 102.56 2.01 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.868 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -134.67 -67.88 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.43 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -133.36 143.71 49.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.816 0.341 . . . . 0.0 110.895 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.7 mt -67.52 90.91 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.052 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -107.62 123.96 49.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -130.41 36.54 3.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.882 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -121.03 31.18 6.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.92 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 133.64 91.53 0.44 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.16 -38.26 70.84 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.258 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -145.81 100.02 3.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.841 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -97.81 -36.23 10.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.866 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 14.8 tt0 -154.11 137.84 16.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.903 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 59.6 m-20 -136.92 92.59 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.91 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.453 ' O ' ' HB3' ' A' ' 15' ' ' PHE . 1.1 mm100 -125.03 -179.9 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.703 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.547 ' O ' HD12 ' A' ' 35' ' ' LEU . 3.6 pp -147.41 137.28 22.95 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.364 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.431 ' N ' ' HB2' ' A' ' 15' ' ' PHE . . . -124.27 155.76 18.19 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.961 -0.637 . . . . 0.0 112.252 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -130.74 149.58 52.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.032 0.444 . . . . 0.0 111.73 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.68 179.65 44.04 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.28 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -128.26 153.24 47.17 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 110.55 -0.167 . . . . 0.0 110.55 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -159.38 165.69 32.71 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.349 0.595 . . . . 0.0 112.226 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -155.05 161.35 30.31 Favored Glycine 0 N--CA 1.451 -0.357 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.401 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.45 ' HA3' ' CE2' ' A' ' 8' ' ' TYR . . . -152.23 163.8 30.32 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 119.794 -1.193 . . . . 0.0 113.616 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.2 t80 -132.44 132.56 42.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.531 -0.335 . . . . 0.0 110.493 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -92.93 123.69 36.37 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.68 -43.83 12.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.813 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.534 ' HB2' ' HD2' ' A' ' 47' ' ' PRO . 0.3 OUTLIER -152.06 165.19 18.01 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.411 -179.873 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.534 ' HD2' ' HB2' ' A' ' 46' ' ' ASN . 65.9 Cg_exo -40.12 123.09 1.28 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.904 2.403 . . . . 0.0 113.79 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 48' ' ' TYR . 0.8 OUTLIER 59.17 17.68 5.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.419 178.871 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 47' ' ' PRO . 24.5 t -136.68 114.02 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.451 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.24 -177.35 19.96 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.568 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -124.89 152.11 44.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -147.12 134.85 21.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.059 0.456 . . . . 0.0 111.527 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . 0.409 ' CE ' HD21 ' A' ' 79' ' ' LEU . 16.4 ttm -126.84 151.79 47.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.182 179.433 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -157.44 157.43 28.12 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.247 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -156.52 167.14 31.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.348 . . . . 0.0 110.73 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.26 145.37 26.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.891 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -94.47 87.98 5.33 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.804 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.5 mt -104.5 33.13 3.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.829 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 96.77 91.95 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 13.1 ttm180 -123.01 -49.68 1.95 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.839 0.352 . . . . 0.0 110.828 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 5.9 ttt -143.83 84.8 9.54 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.02 164.26 35.46 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.609 2.206 . . . . 0.0 112.309 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -95.08 101.66 13.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -148.49 31.24 0.82 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.881 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.81 -82.04 1.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 m -146.1 93.19 2.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -112.82 153.66 14.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 -121.29 80.72 1.69 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -96.46 -175.66 3.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 174.48 -151.33 12.49 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.503 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -174.39 152.1 1.7 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.868 0.366 . . . . 0.0 111.043 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -137.95 -56.96 0.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.91 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 9.8 mtmt -105.28 154.02 20.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . 60.15 85.67 0.1 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.111 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.59 144.43 35.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.936 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.432 ' HA3' ' CE2' ' A' ' 102' ' ' PHE . . . -132.65 122.69 3.3 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.503 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 78' ' ' GLN . 21.4 t -137.93 159.28 33.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.726 0.298 . . . . 0.0 111.078 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.489 ' N ' HG12 ' A' ' 77' ' ' VAL . 3.0 tt0 -129.29 138.76 51.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.03 0.443 . . . . 0.0 111.029 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.409 HD21 ' CE ' ' A' ' 53' ' ' MET . 6.1 mt -129.44 130.68 46.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.852 179.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.9 p -151.56 173.09 15.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.445 0.64 . . . . 0.0 111.997 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -108.28 142.18 38.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 114.85 -1.068 . . . . 0.0 109.896 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -108.6 126.15 52.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.879 0.371 . . . . 0.0 111.488 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 5.2 mt -129.96 113.12 14.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.332 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.471 ' HA3' ' CG ' ' A' ' 94' ' ' TYR . . . -136.4 171.59 22.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.371 -0.918 . . . . 0.0 113.494 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -128.94 136.94 29.96 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.64 0.257 . . . . 0.0 110.476 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -83.95 104.26 1.07 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.651 2.234 . . . . 0.0 112.946 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 1.063 HD11 HG23 ' A' ' 93' ' ' ILE . 1.1 mp -78.33 -36.52 20.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 121.173 0.511 . . . . 0.0 110.183 179.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.733 HG23 ' H ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -150.91 169.64 21.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.957 179.119 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -63.1 -22.37 66.81 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -112.11 -29.05 7.74 Favored 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.733 ' H ' HG23 ' A' ' 88' ' ' THR . 0.3 OUTLIER -109.68 125.53 52.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.099 0.476 . . . . 0.0 112.031 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.518 ' HA ' HD12 ' A' ' 87' ' ' ILE . 4.3 m-20 -133.01 155.42 49.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.186 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.063 HG23 HD11 ' A' ' 87' ' ' ILE . 11.5 pt -117.47 141.25 37.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.933 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.471 ' CG ' ' HA3' ' A' ' 84' ' ' GLY . 24.5 m-85 -144.27 161.28 39.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.679 0.752 . . . . 0.0 112.628 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -141.63 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.218 178.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.76 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 75.7 mtp180 -117.34 136.23 53.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.893 0.378 . . . . 0.0 111.287 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 2.7 tt -140.42 119.38 12.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.881 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.95 -143.96 3.92 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.349 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -149.9 152.58 24.49 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.586 -0.816 . . . . 0.0 113.299 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 7.3 ttm -102.16 126.85 49.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.701 0.286 . . . . 0.0 110.965 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 101' ' ' VAL . 29.5 m -107.05 122.11 60.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.432 ' CE2' ' HA3' ' A' ' 76' ' ' GLY . 1.4 t80 -125.39 133.16 52.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.892 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.99 109.14 6.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.907 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -142.98 122.75 13.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.125 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -107.65 124.51 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.883 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 m -98.83 31.73 2.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.861 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 60.32 31.59 20.46 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.915 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 19.5 p -114.65 149.55 36.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 7.2 m-20 -102.55 35.56 2.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.886 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 21.5 t 62.64 101.3 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -97.59 24.14 7.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.012 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.76 28.48 42.41 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.507 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 5.5 mtpp -145.24 -48.34 0.23 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.788 0.328 . . . . 0.0 110.939 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 38.3 t30 -65.85 104.73 1.14 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.855 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -69.27 -45.92 68.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.921 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 5.1 t0 60.48 172.68 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.925 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p 53.59 78.34 0.15 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.099 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -82.63 103.65 2.45 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.513 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.9 m -138.05 118.0 15.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.81 0.338 . . . . 0.0 111.105 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -156.99 155.2 27.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.882 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 158.19 57.45 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.581 2.187 . . . . 0.0 112.303 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 21.6 t -152.01 125.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.171 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -106.88 155.56 19.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.76 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -150.63 146.79 26.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.176 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -146.79 139.44 7.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.24 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 178.74 -158.02 22.05 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.112 -1.042 . . . . 0.0 113.238 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 1.034 HG12 HG22 ' A' ' 93' ' ' ILE . 31.0 m -138.45 146.39 26.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.058 0.456 . . . . 0.0 111.241 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.429 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.2 OUTLIER -126.03 131.7 52.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.739 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . 0.401 ' CD1' ' N ' ' A' ' 129' ' ' TYR . 3.5 p90 -127.48 149.28 50.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.179 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.49 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.898 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.438 HD11 ' OG1' ' A' ' 137' ' ' THR . 39.1 mt -88.91 -34.75 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.008 0.433 . . . . 0.0 110.744 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.704 HG22 ' CD ' ' A' ' 133' ' ' PRO . 0.0 OUTLIER -148.88 174.56 3.32 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.675 179.835 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.704 ' CD ' HG22 ' A' ' 132' ' ' THR . 51.2 Cg_exo -53.8 -61.61 0.42 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.657 2.238 . . . . 0.0 112.75 -179.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . 0.597 ' C ' HD12 ' A' ' 135' ' ' ILE . 2.4 mt-10 -101.17 30.17 4.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.643 -179.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.597 HD12 ' C ' ' A' ' 134' ' ' GLU . 4.4 mp -146.66 114.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.44 . . . . 0.0 111.609 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' A' ' 167' ' ' SER . . . -127.05 156.34 41.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.994 179.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 1.076 HG22 HG12 ' A' ' 166' ' ' VAL . 3.5 p -141.77 139.07 32.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.474 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.41 ' HB3' ' CB ' ' A' ' 128' ' ' GLU . 4.4 ptp85 -148.94 148.32 29.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.178 0.514 . . . . 0.0 111.931 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.498 HD23 HD12 ' A' ' 164' ' ' LEU . 0.3 OUTLIER -117.55 140.8 49.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.602 -0.726 . . . . 0.0 109.753 179.202 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -144.55 151.78 39.59 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.044 0.45 . . . . 0.0 111.561 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.452 ' HA ' ' O ' ' A' ' 161' ' ' MET . 8.1 p90 -124.95 161.83 25.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.979 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -138.63 176.08 9.0 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.903 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -124.08 135.63 53.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.3 m -95.35 -31.4 13.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -102.49 159.37 15.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.895 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 7.0 t-20 -176.53 -40.6 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.895 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.433 HG23 ' N ' ' A' ' 148' ' ' GLY . 3.8 tt -120.05 -41.64 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.091 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.433 ' N ' HG23 ' A' ' 147' ' ' ILE . . . 67.12 98.85 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.688 -0.767 . . . . 0.0 112.461 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -107.14 79.45 1.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.827 0.346 . . . . 0.0 110.902 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -172.92 109.7 0.19 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 20.9 m170 60.58 -176.28 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 51.5 p -98.95 31.61 2.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.933 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 23.8 mt -118.78 -51.0 3.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.072 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 74.31 158.82 6.12 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.503 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 2.9 t -106.07 145.47 31.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.896 0.379 . . . . 0.0 110.885 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 10.6 ttm180 -102.54 138.53 19.68 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.93 113.1 3.45 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.472 2.115 . . . . 0.0 112.303 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -82.97 -31.74 27.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.953 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 19.7 m-20 -166.07 112.99 0.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -59.73 166.27 9.95 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.415 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.452 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER -60.84 136.18 58.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.612 0.244 . . . . 0.0 110.91 -179.938 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 6.4 tp -118.81 118.57 31.94 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.419 ' CB ' ' HA3' ' A' ' 14' ' ' GLY . 10.3 t -130.51 154.37 47.86 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 121.255 0.55 . . . . 0.0 112.03 -179.151 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . 0.597 HD23 ' N ' ' A' ' 165' ' ' GLY . 4.7 tt -145.25 123.98 12.59 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.771 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . 0.597 ' N ' HD23 ' A' ' 164' ' ' LEU . . . -144.88 163.4 28.01 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.114 -1.041 . . . . 0.0 113.573 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 1.076 HG12 HG22 ' A' ' 137' ' ' THR . 29.3 m -105.29 146.99 11.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' A' ' 136' ' ' ALA . 2.8 m -134.96 147.21 49.69 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.204 0.526 . . . . 0.0 111.776 -179.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -114.63 131.89 56.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.732 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 50.0 mtp180 -108.18 118.26 36.29 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.038 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -98.95 173.56 6.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -145.57 -142.08 3.75 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.515 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -162.04 -168.36 1.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 110.785 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 129.09 73.96 0.16 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.559 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -91.02 152.26 20.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.847 0.356 . . . . 0.0 110.878 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -88.88 -54.14 4.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.069 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.1 -179.977 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 0' ' ' MET . . . . . . . . . . . . . 5.3 ttt . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 120.844 0.354 . . . . 0.0 111.182 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . -175.1 89.05 0.31 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.11 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.53 -61.35 0.54 Allowed 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.591 2.194 . . . . 0.0 112.293 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.5 mmtm -153.46 -76.38 0.12 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -75.65 -83.23 0.06 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.756 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.2 t30 67.41 42.8 2.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.809 0.337 . . . . 0.0 110.954 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.418 ' O ' ' CG ' ' A' ' 43' ' ' TYR . 74.5 p -123.49 160.69 26.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.752 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.419 ' HA ' ' HA ' ' A' ' 43' ' ' TYR . 8.0 t90 -119.09 137.49 53.54 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.286 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.429 ' CD1' ' HA ' ' A' ' 169' ' ' ARG . 3.9 m-85 -124.32 155.92 37.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.831 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.441 ' HA ' ' HA2' ' A' ' 41' ' ' GLY . 71.4 p -149.01 147.03 28.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 166' ' ' VAL . . . -170.05 -163.06 23.45 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.174 -1.012 . . . . 0.0 113.364 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -132.48 153.99 50.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.647 -0.276 . . . . 0.0 110.611 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.43 ' HB2' ' CD1' ' A' ' 40' ' ' PHE . 0.1 OUTLIER -137.12 149.88 47.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.157 0.503 . . . . 0.0 111.863 -179.401 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 tt -149.1 124.06 10.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.678 179.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 163' ' ' SER . . . -148.2 174.26 27.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.171 -1.014 . . . . 0.0 113.577 -179.196 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 3.7 m-85 -116.73 145.84 43.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.796 0.331 . . . . 0.0 110.638 179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.5 p -139.15 -167.95 2.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 62.28 117.27 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.979 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -138.15 -52.19 0.61 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.816 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 60.13 170.51 0.08 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -141.08 -48.44 0.41 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.84 172.69 6.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.924 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 134.31 -160.07 24.04 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -102.62 85.41 2.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.6 mt -120.1 137.27 54.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.042 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -64.62 119.03 9.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.931 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 60.61 166.67 0.08 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.87 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -95.97 155.91 16.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 83.7 73.09 1.26 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.545 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.21 -35.01 61.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.588 2.192 . . . . 0.0 112.306 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 60.64 82.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 60.42 102.74 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -149.99 86.71 1.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.1 p30 -137.36 176.39 8.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.956 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -118.67 118.74 32.45 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.797 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.53 ' H ' HD23 ' A' ' 35' ' ' LEU . 0.5 OUTLIER -83.32 131.9 35.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.922 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -136.18 142.7 13.97 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.449 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.2 158.55 25.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.87 0.367 . . . . 0.0 111.173 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.35 -173.12 40.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.367 -0.921 . . . . 0.0 113.284 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.04 153.4 48.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.813 -0.193 . . . . 0.0 110.694 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.43 ' CD1' ' HB2' ' A' ' 12' ' ' LYS . 23.6 p90 -159.42 169.02 24.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.186 0.517 . . . . 0.0 111.867 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.441 ' HA2' ' HA ' ' A' ' 9' ' ' THR . . . -145.68 160.9 28.2 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.756 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 52' ' ' GLU . . . -148.46 124.65 1.9 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.043 -1.075 . . . . 0.0 113.222 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 7' ' ' TRP . 8.4 t80 -104.53 129.51 52.57 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -94.51 124.81 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.776 0.322 . . . . 0.0 110.548 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.11 -38.1 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.875 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.453 ' CB ' ' CD ' ' A' ' 47' ' ' PRO . 0.8 OUTLIER -147.06 -179.92 1.04 Allowed Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.073 -179.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.453 ' CD ' ' CB ' ' A' ' 46' ' ' ASN . 31.5 Cg_exo -59.96 -35.77 92.25 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.476 2.117 . . . . 0.0 112.923 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -123.74 11.11 9.06 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.2 t -135.55 112.95 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.573 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.25 178.03 21.14 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.489 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -127.1 150.01 49.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.573 0.225 . . . . 0.0 110.533 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.433 ' HA ' ' HA2' ' A' ' 42' ' ' GLY . 0.9 OUTLIER -146.9 133.73 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.031 0.443 . . . . 0.0 111.429 -179.654 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' MET . . . . . 0.804 ' HG3' HD12 ' A' ' 79' ' ' LEU . 8.5 ttp -126.49 151.95 47.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.352 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -158.26 157.54 28.4 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.272 -0.966 . . . . 0.0 113.265 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -156.49 158.68 37.65 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.769 0.319 . . . . 0.0 110.811 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 22.2 p-10 -100.29 128.73 46.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -148.23 95.86 2.53 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.937 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.547 HD23 ' N ' ' A' ' 59' ' ' GLY . 1.1 tt -112.21 153.4 27.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.547 ' N ' HD23 ' A' ' 58' ' ' LEU . . . 91.91 65.01 1.13 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.43 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 21.0 ptt-85 -87.74 -31.41 19.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.722 0.296 . . . . 0.0 110.848 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.6 148.1 87.26 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.6 164.0 37.12 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.455 2.103 . . . . 0.0 112.321 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -176.95 -66.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.954 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 19.7 mttt -75.91 161.87 28.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.89 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -62.95 175.96 7.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 5.0 m -98.59 35.48 1.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 0.0 110.873 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.1 m -99.84 176.57 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.075 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -144.93 33.3 1.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.956 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.2 m-20 -95.16 117.64 30.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 137.85 -158.46 24.66 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.531 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -129.46 141.1 51.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.832 0.348 . . . . 0.0 111.081 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -169.48 90.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 21.8 ttmt -100.64 107.61 19.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.851 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -150.97 106.31 3.35 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.073 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -118.79 141.33 48.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -155.16 114.32 0.61 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.547 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.48 HG12 HG23 ' A' ' 101' ' ' VAL . 11.1 p -148.64 140.59 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.687 0.279 . . . . 0.0 110.951 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 100' ' ' MET . 4.5 mt-30 -126.22 132.06 51.83 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.976 0.417 . . . . 0.0 110.985 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.804 HD12 ' HG3' ' A' ' 53' ' ' MET . 0.3 OUTLIER -133.83 129.98 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.624 179.266 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.5 p -152.07 173.1 15.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.518 0.675 . . . . 0.0 111.979 -179.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -103.37 142.37 34.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.862 178.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . 0.511 ' C ' HD12 ' A' ' 83' ' ' LEU . 3.4 tttm -109.14 124.59 51.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 111.389 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.511 HD12 ' C ' ' A' ' 82' ' ' LYS . 9.1 mp -130.7 110.14 11.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.464 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.451 ' HA3' ' CD2' ' A' ' 94' ' ' TYR . . . -133.46 172.09 21.68 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.405 -0.902 . . . . 0.0 113.383 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -126.74 137.59 30.78 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.665 0.269 . . . . 0.0 110.509 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.4 102.05 0.73 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.721 2.281 . . . . 0.0 112.716 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 91' ' ' LEU . 7.0 tp -82.46 -33.33 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.029 0.442 . . . . 0.0 110.312 179.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -149.35 165.24 32.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.222 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -66.08 -21.98 66.39 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 111.522 0.193 . . . . 0.0 111.522 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -111.34 -27.82 8.48 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.407 ' O ' HG22 ' A' ' 87' ' ' ILE . 3.0 mt -115.97 127.73 55.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.952 0.406 . . . . 0.0 111.677 -179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -134.96 161.83 34.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.147 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.998 HG22 HG12 ' A' ' 127' ' ' VAL . 29.4 pt -119.62 142.06 36.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.033 179.117 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.451 ' CD2' ' HA3' ' A' ' 84' ' ' GLY . 39.5 m-85 -143.92 158.99 43.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.621 0.724 . . . . 0.0 112.662 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -139.03 136.47 35.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.111 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.436 ' HB2' ' HB3' ' A' ' 124' ' ' ALA . 1.3 mtp85 -116.35 136.86 52.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.034 0.445 . . . . 0.0 111.183 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.482 HD23 ' CB ' ' A' ' 123' ' ' PHE . 8.8 mt -139.38 117.43 11.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.748 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -168.48 -142.38 3.48 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.327 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.517 ' HA2' ' O ' ' A' ' 120' ' ' SER . . . -144.27 145.23 14.59 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.054 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.614 ' SD ' HG11 ' A' ' 122' ' ' VAL . 9.6 ptm -128.03 117.96 22.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.207 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.48 HG23 HG12 ' A' ' 77' ' ' VAL . 3.9 m -93.16 117.31 36.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.006 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -132.02 111.03 11.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.84 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.6 124.12 19.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -136.4 156.15 49.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.057 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -132.95 133.04 42.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.848 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.2 p -146.53 114.36 6.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.912 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.59 -177.88 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 2.1 m -60.33 132.79 55.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.872 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -112.76 -179.91 3.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.583 HG12 ' O ' ' A' ' 110' ' ' VAL . 15.3 t 59.84 29.18 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.1 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -115.54 -36.06 4.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 166.1 41.66 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.538 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -99.58 134.16 42.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.847 0.356 . . . . 0.0 110.903 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -105.17 31.35 4.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -67.59 -177.44 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.843 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -149.67 122.95 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.043 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.3 -176.54 3.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.871 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -122.88 106.12 1.0 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.525 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 45.3 t -57.08 -74.86 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.654 0.264 . . . . 0.0 110.985 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' SER . . . . . 0.527 ' O ' HG22 ' A' ' 122' ' ' VAL . 0.6 OUTLIER 177.08 -67.8 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.37 179.553 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.477 ' CD ' ' CB ' ' A' ' 120' ' ' SER . 77.3 Cg_exo -38.03 112.13 0.11 Allowed 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.889 2.393 . . . . 0.0 113.192 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.614 HG11 ' SD ' ' A' ' 100' ' ' MET . 6.8 m -153.04 151.44 11.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.944 0.402 . . . . 0.0 111.318 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.482 ' CB ' HD23 ' A' ' 97' ' ' LEU . 18.8 p90 -137.7 164.09 29.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.761 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.436 ' HB3' ' HB2' ' A' ' 96' ' ' ARG . . . -148.52 153.19 38.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.299 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -148.41 140.97 8.68 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.102 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 176.96 -154.2 15.49 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.402 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.998 HG12 HG22 ' A' ' 93' ' ' ILE . 31.0 m -139.59 146.98 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.07 0.462 . . . . 0.0 111.377 -179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.417 ' HG2' ' CD1' ' A' ' 94' ' ' TYR . 0.7 OUTLIER -126.19 131.04 52.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.531 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -128.84 150.81 50.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.478 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -100.79 116.03 31.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.769 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 32.7 mt -86.69 -38.42 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.874 0.368 . . . . 0.0 110.948 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.778 HG22 ' HD2' ' A' ' 133' ' ' PRO . 0.1 OUTLIER -162.19 166.34 14.3 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.894 -179.978 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.778 ' HD2' HG22 ' A' ' 132' ' ' THR . 49.8 Cg_exo -55.87 140.21 85.1 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.617 2.211 . . . . 0.0 112.53 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 63.78 10.42 5.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.441 179.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.522 HD11 ' HB ' ' A' ' 132' ' ' THR . 13.4 pt -149.32 117.01 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.117 0.484 . . . . 0.0 112.081 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.563 ' O ' HG13 ' A' ' 166' ' ' VAL . . . -128.57 157.0 42.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.855 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 1.9 m -136.36 140.84 43.56 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.58 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -149.0 149.43 31.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.154 0.502 . . . . 0.0 111.788 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.423 ' O ' HD12 ' A' ' 139' ' ' LEU . 4.4 pp -120.11 141.83 49.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -145.06 152.78 40.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.058 0.456 . . . . 0.0 111.538 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' TYR . . . . . 0.47 ' HA ' ' O ' ' A' ' 161' ' ' MET . 26.8 p90 -130.48 164.66 24.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.014 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 5.5 mp0 -135.71 125.2 25.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -95.2 162.6 13.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.854 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.1 p -114.9 -38.65 3.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.862 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 51.4 m-80 -110.54 115.06 28.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.92 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -146.0 125.84 13.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 18.8 pt -112.41 -39.67 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 177.67 -50.42 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -73.34 141.83 47.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.805 0.336 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -157.03 146.71 20.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.035 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' HIS . . . . . . . . . . . . . 28.4 m-70 -105.27 165.74 10.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.888 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.6 m -131.18 -46.26 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 4.7 mt -72.71 -51.34 28.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.1 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -105.38 93.06 0.87 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.577 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 8.4 m -130.99 105.6 7.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.796 0.331 . . . . 0.0 110.888 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -99.43 149.04 35.48 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.93 88.64 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.587 2.191 . . . . 0.0 112.323 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -101.44 -40.73 6.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -167.92 92.77 0.37 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -175.19 -149.26 7.18 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.529 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 141' ' ' TYR . 0.0 OUTLIER -133.56 132.44 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.639 0.257 . . . . 0.0 110.916 179.983 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 2.8 mt -122.28 118.57 28.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.122 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.468 ' C ' HD12 ' A' ' 164' ' ' LEU . 8.5 t -137.35 157.96 45.46 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-O 121.351 0.596 . . . . 0.0 112.093 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' LEU . . . . . 0.468 HD12 ' C ' ' A' ' 163' ' ' SER . 5.6 mp -143.33 128.57 18.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.716 179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -144.12 163.57 27.73 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.155 -1.022 . . . . 0.0 113.471 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.563 HG13 ' O ' ' A' ' 136' ' ' ALA . 21.5 t -105.09 146.04 12.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.354 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . 0.402 ' HA ' ' HA3' ' A' ' 10' ' ' GLY . 2.0 m -134.67 143.8 47.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.078 0.466 . . . . 0.0 111.657 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -111.23 131.72 54.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.699 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.429 ' HA ' ' CD1' ' A' ' 8' ' ' TYR . 0.0 OUTLIER -107.19 118.8 37.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.149 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -85.88 165.07 17.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -139.1 110.72 0.73 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.516 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -60.22 -36.32 77.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 0.0 110.904 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 148.5 59.52 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.478 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -121.89 145.88 47.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.901 0.382 . . . . 0.0 110.845 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' ALA . . . . . . . . . . . . . . . -108.32 -35.76 6.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.106 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.066 179.968 . . . . . . . . 0 0 . 1 stop_ save_